View recent copies of Biotech Daily with important stories on research and development (R&D), mergers and acquisitions (M&A), finance, government grants and regulation, share price movements, industry news and personnel appointments in Australian Stock Exchange listed biotechnology companies.

All articles include the company name, technology and indication and many have senior personnel in the headline. The easiest way to search is by opening a dialogue box by typing Control F or Command F.

 

 

Wednesday December 1, 2021

November BDI-40 Up 1%, ASX200 Down 1%
Big Caps Up 1%, NBI Down 4%

 

Nov 10, 2021

Immutep: IMP321 ‘Non-Significant’ Cancer Benefit; Sub-Groups; Correction: Rage Bio; Clarity Recruits Prostate Cancer Imaging Dosimetry; Immuron, US Navy Cow Colostrum Drug Development Resumes; Zucero Begins Phase IIa Pixatimod Trial; Imagion Pleads Schultz, ‘Enrolment’ To ASX 32.5% Query; Impedimed AGM 15% Oppose Placement Capacity; Avita 130k Directors’ Shares, 378k Options AGM; Arovella Appoints Dr Elizabeth Stoner Director

Nov 9, 2021

Redhill: Kukbo Invests Up-To $13.5m For Asian Rights; Rage $3.7m From IP Group, Monash - Dr Chris Wraight CEO; Pharmaxis: FDA Clears PXS-5505 Phase II Liver Cancer Trial; Actinogen: FDA Approves Xanamem For Fragile X Trial; Island Pays NY State University $914k For Dengue Fever Trial; Race: Wollongong Uni To Evaluate Zantrene Formulations; Artrya ‘Preferred Supplier’ To UK NHS Hospitals; Living Cell Receives $381k NZ R&D Tax Credit; Regal Takes 7.7% Of Medadvisor; Creso Loses 3-Day Consultant Dr Brian Walker MLC

Nov 8, 2021

Amplia $5.4m Placement, $7m Rights Issue; Next Science: TGA Approves Xperience Surgical Solution; Living Cell Drops $4m Rights Issue Price To 0.8c; Clinuvel Adds Neuracthel To Melanocortin Portfolio; Clinuvel Pleads Schultz, ‘Research Note’ To 17.2% Fall Query; Paradigm: ‘Zilosul For Knee Osteoarthritis To Cost $3k-$4k PA’; Corrections: Antisense Therapeutics; Uscom: 2 China Patents For Cardiac Monitor; Mach7: AI Visualize Alleges US Patent Infringement; Adalta Receives Net $894k Federal R&D Tax Incentive; Woke To Distribute O-T-C Havn Mushroom Products; Creso: Halucenex Psilocybin Testing For Phase II Trial; Platinum Takes 5.2% Of Antisense; Perennial Reduces To 8.85% Of Medadvisor; Alex Waislitz, Thorney-Tiga, Urban Land Below 5% In Zelira

Nov 5, 2021

Dr Boreham’s Crucible: Antisense; Prevatex Raises $2.2m; Proteomics: ‘Promarkerd Beats Standard-Of-Care Tests’; Pharmaust Rights Options Raise $514k; Visioneering: ‘Naturalvue Reduces Myopia Progression’; Visioneering Launches Naturalvue Enhanced Multifocal Lens; IQ3: 41%-Owned Oncotex Licences Gold Compounds For Cancer; Blackrock Takes 5.8% Of Avita; Vanguard Takes 5.2% Of Avita; Paradice Takes 8.4% Of Impedimed; JM Financial Reduces To 9.8% Of Universal Biosensors; Regal Funds Below 5% In Adherium; Quincy Street Takes 6.3% Of Zelira; Ausbiotech Appoints Geoffrey Kempler Chair; Polynovo Loses 7-Year CEO, M-D Paul Brennan - ‘Differences’; Visioneering Appoints Dr Ashley Tuan CMO

Nov 4, 2021

Vale Peter Turvey (10.10.1951 - 27.10.2021); Kazia Recruits 1st EVT801 Solid Tumor Patient; Avita: Medicare Expands Recell Reimbursement; Trajan $1.3m For Forth Female Hormone Mapping; Impedimed: Astrazeneca Extends Sozo Contract 3 Months; Invex Prepares For Phase III Presendin For IIH Trial; Noxopharm Recruits 1st Daart-2 Patient; Alterity: Studies Back ATH434 For Parkinson’s, In-Vitro, In Mice; Amplia: Cruk Extends AMP886 Milestone Deadline; US Patent For Medlab Nanocelle; Bioxyne Drops Proposed Acquisition; L1 Capital Takes 7.2% Of Anteris; Creso: WA Legalise Cannabis MLC Dr Brian Walker Advisor

Nov 3, 2021

FDA Clears Paradigm Phase III PPS For Knee OA Trial; MTP Connect $450k Backs $1m For 5 WA Companies; Medlab: DISER Approves $27m Offshore RDTI; Correction: Bard1 AGM; Memphasys Completes Felix Validation, Verification; Lumos: Canada Sars-Cov-2 Rapid Test Interim Approval; BCal: Sample Testing ‘Positive Results’, Trial Begins; Nuheara Federal Hearing Services Provider; Uscom Spirosonic Koneska Technical Agreement; Argenica: ARG-007 Reduces Hie Brain Death 50%, In Rats; Race, Newcastle Uni Zantrene Cancer Diagnostic; Zelira Marijuana Technology; $1.35m Upfront DRCN Deal; MGC Builds Malta Cimetra Factory, $4.8m Grant; Vanguard (Just) Below 5% In Cochlear

Nov 2, 2021

Telix: TGA 1st Illuccix For Prostate Cancer Imaging Approval; Medadvisor $4m US Pilot Sars-Cov-2 Vaccination Program; Israel Approves MGC Cimetra Dosing Study; Neuroscientific: Biospective To Run Emtinb MS Studies; Immutep: China Patent For IMP321 Combination; Osteopore: China Patent For Bone Scaffold Method; Hexima 2.8m Director Options AGM; Perennial Takes 7.5% Of Ecofibre

Nov 1, 2021

October BDI-40 Up 0.3%, ASX200 Down 0.1%, Big Caps Up 3%; Antisense Phase II/III DMD EU Okay; Raises $20m, Rights For $16.8m; Hexima Raises $10m, Share Plan For $1m; Patrys Raises $2.5m, Rights Offer For $5.3m; Eye Co: Dry AMD Fludrocortisone Acetate ‘No Adverse Events’; Austco $1.6m Singapore Tacera Maintenance Contract; Next Science, Tela Bio US ‘White Label’ Deal; Biotron Starts 2 Phase II BIT225 HIV Trials; Imugene, Eureka Join Oncolytic Virus, T-Cells For Tumors; Race Applies For Phase II Acute Myeloid Leukaemia Trial; Bionomics: ‘FDA Okays BNC210 Social Anxiety Disorder Trial’; Creso, Innuana To Grow Marijuana, Swiss Distribution; Paradigm Requests ‘FDA Response’ Trading Halt; Medadvisor Requests ‘Customer Agreement’ Trading Halt; Bard1 Name Change To Inoviq, 2m Director Options AGM; Bard1 Founder Dr Irminger-Finger Diluted Below 5%; Ausbiotech Draft ‘Decadal Blueprint’ For Consultation; Ausbiotech To Lose 9-Year Director, Chair Michelle Burke

Oct 29, 2021

Dr Boreham’s Crucible: Uscom; Resmed Record Q1 Revenue Up 20% To $1.2b, Profit Up 14% To $290m; LBT: FDA 501k Approval For APAS Independence; Immutep: EMA ‘Supports’ IMP321 For Breast Cancer; Cann Global Raises $1.8m; Medical Developments Remuneration 1st Strike: Philip Powell Goes; Adalta 6.7m Director Options AGM; Mesoblast 1.6m Chief Executive, 200k Director Options AGM; Starpharma 493k CEO Performance Rights AGM; Bioxyne Takes ‘Acquisition’ Trading Halt To Suspension; Stemcell Extends ‘Joint Venture’ Suspension; Cronos 80m Shares From ASX To Voluntary Escrow; Pacific Edge Appoints Dr Peter Meintjes CEO; 4D Loses Director Lusia Guthrie; Lost Director Heath Lee; Stefan Ross Replaces Patrys Co Sec Melanie Leydin; Claire Newstead-Sinclair Replaces Invion Co Sec Melanie Leydin

Oct 28, 2021

Ecofibre Claims Marijuana Cancer Results; 1.6 Quarters Cash; Invion: INV-043, Photosoft Kills TNBC, Immunity, In Mice; Up 139%; Incannex: Psilocybin Anxiety Trial Approved, FDA Meeting; Hexima 1.3 Quarters Cash; Requests ‘Capital Raising’ Halt; Anteris Less Than 1 Quarter Cash, Loans, Capital Raising; Resapp Has 2 Quarters Cash, RDTI Coming; Patrys Requests ‘Capital Raising’ Trading Halt; SG Hiscock Below 5% Of Atomo; One Funds, Saville Capital Take 12.5% Of Bluechiip; Victoria Appoints Grant Dooley Breakthrough Victoria CEO

Oct 27, 2021

Aroa H1 Revenue Up 37% To $13.2m; Impedimed Raises $35m, Share Plan For $5m More; Anteris: L1 Capital $5m Placement; Tali Receives $504k R&DTI Victoria Loan; Epsilon Extends $4m Loan Repayment; Universal Biosensors Recruits 1st Xprecia Prime Trial Patient; Oventus: Algorithm Accurate For Apnoea; FDA Exvent Trial; Rhinomed: Rhinoswab St Vincent’s Trial Approved; Race, Chaim Sheba Analyze Zantrene FTO Biomarkers; Adherium AGM 19% Oppose Remuneration Report; LBT Potential 2nd Strike Spill, 1.75m Directors Options AGM; Opthea: China Patent For OPT-302; Bioxyne Requests ‘Potential Acquisition’ Trading Halt; Perennial Reduces To 12.3% In Medadvisor; Loumea Diluted Below 5% In Rhythm; Regal Funds Below 5% In BCal; Black Rock Takes 11% Of Imricor; Oncology One: Peter Mac CEO Prof Shelley Dolan Director; Speedx, Onko-Innate, David Blake Win Ausbiotech Gongs; Ausbiotech: Regenerative Medicine Foundations Laid; Bio-Melbourne Addresses Freight Logistics, Delays

Oct 26, 2021

Ausbiotech Conference 2021, Biotech Invest Open; Victoria $16m For Brain Cancer Centre; Volpara H1 Receipts Up 40% To $13m; Nova Eye $1.42m US Paycheck Loan Forgiven; Atomo: TGA Broadens HIV Self-Test Sales, Advertising; Resapp Expands India Sars-Cov-2 Cough Diagnostic Trial; Bluechiip Signs Fujifilm Irvine IVF Contract; Noxopharm Doses 1st Patient In Veyonda, Nivolumab Tumor Study; Starpharma: Vietnam Viraleze Distributor; 100k Unit Order; Living Cell: NZeno Auckland Island Pigs For Parkinson’s Trial; Polynovo AGM Avoids Spill By 1.7%, 29% Oppose M-D Incentives; MGC Potential 2nd Strike Spill; 100% Directors’ Pay Pool Hike AGM; Hydrix 5.25m Gavin Coote Rights AGM, Paul Lewis Director; Immutep 3.6m CEO Marc Voigt Performance Rights AGM; Medadvisor: 1.5m M-D Robert Read Options AGM; Proteomics To Lose 7-Year Chair Terry Sweet; Anteotech Appoints Tim Pritchard CFO, Co Sec; 2 Executives; Amplia Appoints Dr José Iglesias Clinical Advisor

Oct 25, 2021

Genetic Signatures $12m Record Q1 Revenue; Universal Biosensors: Vinmetrica To Sell Sentia; $1m Sales; Recce Phase I R327 I-V Trial Approved; Creso $217k Scrip For Impactive Marijuana Joint Pain; Memphasys Receives $1.4m Federal R&D Tax Incentive; Optiscan Receives $770k Federal R&D Tax Incentive; Memphasys: China Sperm Separation Patent; Noxopharm: Australia, Europe Allow Veyonda Patent; Impedimed Requests Capital Raising Trading Halt; Invex 2.5m Performance Shares; 60% Pay Pool Hike AGM; Bluechiip 4.5m M-D Andrew McLellan Performance Rights AGM; Paul Hopper Takes 7% Of Imugene

Oct 22, 2021

Dr Boreham’s Crucible: Avita Medical; Chimeric ‘On The Path To CDH17 Car-T Trial’; Medadvisor Expands Walmart Deal; Clinuvel Doses 1st Xeroderma Pigmentosum DNA Repair Patient; Neurotech: ‘Marijuana NTI164 Beats CBD, THC For MS, In-Vitro’; Goodbye Suda, Hello Arovella Therapeutics; Pharmaust 14% Oppose Incentive Scheme Remuneration Report; Austco 2nd Strike, 80% Director Fee Pool Hike AGM; Mayne: $2m M-D Scott Richards ‘Performance’ Rights AGM; Acrux: 6m M-D Michael Kotsanis Rights AGM; BTC 6m Chair Dr Richard Treagus Options AGM; Vanguard Takes 5% Of Cochlear; Copia Takes 5.4% Of Probiotec; Allan Gray Reduces To 6.5% Of Impedimed

Oct 21, 2021

Federal $25m For Stem Cell Research; Hemideina Raises $10m For Cochlear Implants; Cann Group Plan Raises $8.7m, Total $18.7m; Dimerix: ‘1st Phase III Dmx-200 Approval For FSGS’; Neuren: 2nd FDA ‘Hold’ On NNZ-2591, For Phelan-McDermid; Suda: Chile Approves Teva Zolpimist Application; Avecho, Lambert Trial TPM-Marijuana For Arthritis Pain; Pharmaust Manufactures Trial Batches Of Monepantel; Cannim Hires Epsilon For Hummingbud Marijuana; Rhythm 5.3m Director Options AGM; Nova Eye: 2.25m Director Options AGM; Telix Releases 21m Voluntary Escrow Shares

Oct 20, 2021

Telix: ‘TLX101 Safe, Lengthens Glioblastoma Survival’; Zelira: Quincy Street Placement Raises $6.7m; 54% Premium; Pharmacare Pays $1.6m For Medlab Food Additive Business; Truscreen Claims Cervical Cancer Test Success; China Expansion; Imugene Doses 1st CF33 Checkvacc Breast Cancer Patient; Opthea Takes OPT-302 Wet AMD Trials To Asia-Pacific; Control Bionics: ‘Rent Neuronode For Immediate Use’; Incannex Hires Procaps For IHL-42X Manufacture; Oncosil 50% Deliver 2nd Strike; Spill Fails By 2%; Dr Roger Aston; Neurotech 100% Director Fee Pool Hike AGM; Vectus Pleads ‘Schultz, News’ To ASX 24% Query; Acorn Takes 5.3% Of Micro-X; Jason Carrol Takes 7% Of Island; Perennial Below 5% In Hydrix

Oct 19, 2021

CSL 2021 R&D Briefing: ‘Spending Up, Recombinant Focus’; Impedimed Trial: ‘L-Dex Significantly Reduces Lymphoedema’; Artrya $40m IPO For Salix Arterial Plaque Detection; Living Cell $3.5m For NTCell Parkinson’s Trial; Rights For $4m More; Woke, Monash Formulate Psilocybin For Depression Trial; Queensland Uni’s Jetra $1.3m For Fatty Liver Disease; Clarity Closes Sar-Bombesin C-Bobcat Trial Early; Emyria: Eurofins To Screen MDMA Analogs For CNS Activity; Race Wins 6th US Zantrene Patent; Osteopore, Singular Work On Cranial Implant Design Tool; Opthea AGM 20% Oppose Director Options; Dr Jeremy Levin; Nanosonics 353k CEO Rights AGM; Chimeric 7.5m Director Options AGM; Alterity Expands Biomuse ATH343 Multiple System Atrophy Study; Zelira Requests ‘Capital Raising’ Trading Halt; Oncosil Loses 8-Year Director Dr Roger Aston Before AGM; Adherium Appoints Robert Spurr Interim CFO

Oct 18, 2021

Pacific Edge ‘Oversubscribed’ Plan Raises $22m; Total $99.9m; Alcidion, Sydney Health $1.8m Tele-Health Contract; Heramed Notes Raise $2.4m; Mach7 Sales Orders Up 390% To $16.2m; Cynata: Fujifilm Pays $6.7m For New Deal; Patrys: Deoxymab Increases Breast Cancer Survival, In Mice; Mesoblast: ‘Remestemcell-L Improves Child GvHD Survival’; Neuroscientific Completes Emtinb Pharmacology Studies; Auscann Requests FDA CPAT-01 Meeting; Pharmaust: 24 Dogs, 1 Partial Response To Monepantel; Proteomics: ‘Clinical Utility Study Backs Promarkerd’; VGI: Japan Tocotrienol Patent; Anatara 1.8m Director Options AGM; One Week To Ausbiotech Invest 2021, Conference

Oct 15, 2021

Dr Boreham’s Crucible: A Trip Through Psychedelic Drugs; MTP Connect Covid-19-Related 3rd ‘Skills Gaps’ Report; Nuheara Begins 50-Patient Hearing Aid Clinical Trial; Dimerix Brings Phase III DMX-200 For Covid-19 Trial To Australia; MGC Tells ASX: ‘Director Hayes 3y Wrong, Share Trades OK’; Bod ASX Code Change To ‘Bod’; Living Cell ‘Placement, Rights Offer’ Trading Halt; Micro-X 133% Directors’ Fee Pool Hike AGM; Visioneering Q3 Receipts Up 4.2% To Record $2.7m; Cronos Record Q1 Marijuana Revenue $1.1m; Perennial Reduces To 13.6% Of Medadvisor; Perennial Reduces To 5.2% Of Hydrix; IDT To Lose Director Mary Sontrop At AGM

Oct 14, 2021

Federal $30m For Child Musculo-Skeletal Research; Amplia Receives $1.1m Federal R&D Tax Incentive; Heramed Requests ‘Capital Raising’ Trading Halt; Jason Carroll Takes 6% Of Island; Neurotech Tells ASX: ‘Patent Applications Material’; Nuheara AGM 19% Oppose Remuneration Report; Ausbiotech Invest, Partnering 2021 Registration

Oct 13, 2021

Protagonist Jumps 94% As FDA Lifts Rusfertide Hold; IDT, MIPS $2m Sars-Cov-2 mRNA Vaccine Manufacturing Deal; Pharmaxis Doses First Of 24 Patients In PXS-5505 Phase II Trial; Resonance: ‘Liversmart To Launch This Year’; Auscann: Marijuana Dermacann Safe In Dogs At 5mg/Kg; Paradigm PPS Reduces Ards Lung Inflammation, In Mice; Prescient In-Vitro Data Backs Omnicar; US Patent For Redhill’s Talicia For Helicobacter Pylori; Audeara Appoints Oaktree US Headphone Distributor; Actinogen Receives $1.4m Federal R&D Tax Incentive; Kazia 2.5m M-D Dr James Garner Options AGM; Bio-Melbourne, Cytiva Translation Funding

Oct 12, 2021

Alcidion Signs $630k Queen’s Hospital Burton Deal; Imricor: ‘Oversubscribed’ Plan Raises $1m; Total $17.5m; Imricor ICMR For Hungary’s Semmelweis University; Anteris Appoints Iqvia, CRF For Duravr Feasibility Study; CSL: 26% Oppose $10m Paul Perreault ‘Performance’ Shares; Anteo 100% Directors’ Fee Pool Hike AGM; Neurotech Requests ‘Patent Lodgment’ Trading Halt; Oncosil Appoints Prof Ricky Sharma Director

Oct 11, 2021

Acrux Terminates Harris EMLA Licence On Bankruptcy; Audeara, Amplifon Sign Headphone Supply Agreement; Resapp Files Sleepcheckrx FDA 510(K) Application; Universal Biosensors Receives $2.8m Federal R&D Tax Incentive; Creso: ‘Mernova Highest Legal THC In Canada’; USPTO Allows Neuren NNZ-2591 For Autism Patent; Medlab US NRGbiotic Depression Patent; Neuroscientific 8m Directors Options AGM; CMO Dr Sud Agarwal, Cannvalate Take 8.9% Of Incannex

Oct 8, 2021

Biotech Call To Arms: David Blake - Update; Dr Boreham’s Crucible: Somnomed; Cynata: DSMB Okays Stem Cell Covid-19 Trial Unchanged; Lumos Retracts Febridx $2.5b Economic Value Article; LBT: South Australia Extends Loan Repayment; Starpharma: Admenta Italia To Distribute Viraleze In Italy; Adherium CMS Submission On Remote Therapeutic Monitoring; Immuron IMM124E Increases T-Cells In-Vitro, Mice; Actinogen 53m CEO, Director Shares AGM; Clinuvel Potential 2nd Strike Board Spill AGM; Mach7 402k M-D Rights, 335k Director Options AGM; Daniel Ow Replaces Osteopore Directors Carmichael, Pocock; Resmed Pays Rajwant Sodhi $963k; Consultant

Oct 7, 2021

Ellume Recalls Sars-Cov-2 Home Tests On False Positives; Mayne: US FDA 2nd Nuvaring Rejection; National Facility, La Trobe Uni Develop Nanomslide; Medi-Cal To Reimburse Redhill Talicia (Sydney’s Heliconda); Adalta: BTB $760k Moved To Inhaled AD-214; Nova Eye 5-Year Itrack Results; Cardiex: Conneqt, Fenda Manufacturing Agreement; Emyria Joins Palantir Foundry Builders Program; Impedimed AGM: M-D Rights, Options; Chair Scott Ward Goes; MGC: AMC Orders $4m Of Cimetra; Australian Ethical Diluted To 4.9% Of Immutep; Peter Meurs, Skiptan Take 13.8% Of Dimerix; Honsue Cho Takes 26% Of Invion

Oct 6, 2021

Neuren ‘Over-Subscribed’ Plan Raises $3m, Total $23.3m; Aroa H1 Revenue Up 108% To $16.2m; Lumos: ‘Febridx Can Save US $2.5b PA’; Clarification Halt; Emvision: FDA Wants More Data For Portable Brain Scanner; VGI Takes IVB001 Trial To RMH, $1.5m Drawdown-Equity Facility; Race Granted 5th US Bisantrene (Zantrene) Patent; US Allows Medlab Nanocelle Patent; Patrys 25m M-D Options AGM; Island Releases 6.7m Voluntary Escrow Shares; Merchant Funds Takes 5.6% Of Dimerix; Leanne Ralph Replaces Hexima Co Sec Helen Molloy

Oct 5, 2021

CSIRO Eliminates Dengue, Yellow Fever, Zika Mosquito; Redhill Sub-Group Data Backs Opaganib For Covid-19; Volpara: $3m US Breast Software Contract; Rhythm Receives $2.4m Federal R&D Tax Incentive; Pharmaxis Approved For Phase II PXS-5505 Myelofibrosis Trials; Opthea Starts Euro Enrolment For OPT-302 Wet AMD Trials; Clinuvel Ready For Scenesse Xeroderma Pigmentosum Trial; Anteris Duravr Heart Valve ‘Fully-Functioning’ In Sheep; Atomo, Access Replace Rapid Sars-Cov-2 Self-Test Deal; Creso $809k Marijuana Orders; Goodbye Lifespot Health, Hello Inhalerx; Paul Sherman Replaces Palla CFO Brendan Middleton

Oct 4, 2021

Incannex Options Raise $17.7m; Vivelys To Distribute Universal Biosensors Sentia In France; IMCRC: Stryker, Queensland To Build R&D Facility; Avecho Starts Phase I TPM-Marijuana Absorption Trial; Atomo Requests ‘Access Bio’ Trading Halt; TDM Takes 26.8% Of Somnomed; Argenica To Release 1.3m ASX Escrow Shares; Antisense Appoints Dr Gil Price Director; Mayne Appoints Dr Carolyn Myers Director; Exopharm Appoints David Oxley, Johannes Mühl Executives; Troy Di Domenico Replaces Dorsavi CFO Damian Connellan

Oct 1, 2021

September BDI-40 Down 4%; ASX200 Down 3%; Big Caps Down 8%; Biotech Call To Arms: David Blake; Pro Medicus, Novant $40m, 7-Year Visage 7 Deal; Dimerix Share Plan Raises $4m, Total $24m; Pharmaust: Options Rights Offer For $792k; Report To TGA Cautious On MDMA, Psilocybin; Neuren: FDA ‘Hold’ On NNZ-2591 For Angelman IND; Medibio Launches Luca For Stress; Hamish George Replaces Amplia CFO Jeff Carter; David Franks Replaces Exopharm Co Sec Elizabeth McGregor

Sep 30, 2021

Dr Boreham’s Crucible: Aroa Biosurgery; ENA Trials INNA-051 Nasal Spray For Covid-19, Influenza; Adherium Receives $370k Federal R&D Tax Incentive; Cynata: Fujifilm Pays $6.9m In New Stem Cell Manufacture Deal; Paradigm Doses 1st Brazil PPS For MPS-VI Patient; Recce Ready For R327 Phase I Trial; Amplia: Garvan Backs FAK For Pancreatic Cancer; Clarity: Evergreen To Manufacture Copper Isotope Products; Impedimed: Icon To Install 13 Sozo Units; Volpara, Natera Combine For US Cancer Screening; Race: ‘Zantrene Kills FTO-Producing Melanoma, In-Vitro’; Argenica Appoints Linear For Perth ARG-007 Safety Trial; Antisense: EMA Committee Supports ATL1102 For DMD Plan; MGC: AMC Orders 1,000 Cimetra Units; Regal Funds Reduces To 7.8% In Micro-X; Michelle Wing Increases, Diluted To 9% Of Rhythm

Sep 29, 2021

Victoria $4m Backs Neo-Bionica For Medical Devices; Micro-X Wins 2 US Airport Security Contracts; Up To $5.7m; WEHI: ‘Antibody Combo Blocks Sars-Cov-2 In Mice, Hamsters’; PYC: ‘VP-001 Penetrates Rabbit Retina’; Immutep: $3.4m French R&D Tax Incentive; Mayne Appoints Upsher-Smith US Isotretinoin Distributor; Botanix Trials Cannabinoid BTX1204A For Dog Eczema; Stemcell Takes ‘Joint Venture’ Trading Halt To Suspension; Regal Funds Reduces To 5.8% Of Adherium; Veronique Morgan-Smith Replaces Mach7 Co Sec Jenni Pilcher

Sep 28, 2021

Federal Government: Home Covid Testing From November; Mach7: Trinity Orders $7.4m Software, Services; TGA Issues IDT Sterile Licence For mRNA Production; Imricor To Sell Mirtle 12-Lead ECG System; Telix: $12m Federal R&D Tax Incentive; $139m Offshore OK; 4D Medical 702k CEO Options, 50% Directors Pay Pool Hike AGM; Adherium 149m CEO Rights AGM; SG Hiscock Reduces To 6.6% Of Resonance; LBT Appoints Brian O’Dwyer Director

Sep 27, 2021

Pacific Edge Up 22.5% On ASX IPO For Bladder Cancer Tests; Impedimed: Advocate Health Adopts Sozo Heart Program; LBT Appoints Thermo Fisher US APAS Independence Distributor; Federal $12m For Glioblastoma Agile Trial; Kazia; Adalta: ‘AD-214 Reduces Kidney Fibrosis, In Mice’; Eye Co: ‘FA Effective For Macular Atrophy, In Mice’; Invex Partners With Peptron For Presendin; Paradigm: FDA Trial Concern On Mouse Adrenal Gland Function; Noxopharm: US Patent For ‘Veyonda Abscopal Responses’; Exopharm Pleads US Patent News To ASX 24.5% Price Query; Stemcell United Requests ‘Joint Venture’ Trading Halt; Oncosil Receives $1.1m Federal R&D Tax Incentive; Oventus Pleads Schultz To ASX 30% Query; M&G Below 5% In Medical Developments; TDM Takes 26.7% Of Somnomed
 
Dr Boreham’s Crucible: Testing The Covid Assay Developers; Federal, MTP Connect $9m For Diabetes, C-V; Technologies; Cochlear: University Of Pittsburg Files Patent Infringement; Adherium: Astrazeneca $891k Hailie Deal; Immuron Loses Covid Vaccine Bid, Director Peter Anastasiou; Dimerix: India Recommends DMX-200 Covid-19 Trial; Antisense: ‘ATL1102 Significantly Modifies DMD Biomarkers’; Paradigm Ethics OK For Knee Osteoarthritis Pain Trial; Invex Requests ‘Exenatide Deal’ Trading Halt; HSBC Increases, Diluted To 6.8% Of Pharmaxis, In April; Perennial Reduces To 6.7% Of Nuheara; Botanix Appoints Dr Jack Hoblitzell Drug Development Head
 
Atmo Raises $9.6m For Gut Gas Monitor Capsule; Telix: US FDA Extends Illucix Review 3 Months; Micro-X $8m Stroke Alliance Deal; Anteo: Eugeni TGA Application; Romanian Distributor; Osprey: GE Healthcare Resumes Dyevert Euro Promotion; Uscom: BP+ ‘94% Effective For AF Screening’; Zelira’s Ilera Launches Marijuana Acne Product Line; Chimeric: Euro Patent For Car-CLTX, CHM1101; Visioneering: USPTO Allows Multifocal Lens Patent; Polynovo Potential 2nd Strike Board Spill AGM; Cogstate 1.4m O’Connor Family Incentive Options AGM; FMR Takes 5% Of Somnomed; Medibio Appoints Dr Elizabeth Lombardo Adviser
 
Victoria, Monash Uni ‘1st Cardiovascular Centre’; Rhythm Recruits Colostat Trial; Lumos: US FDA ‘Deprioritizes’ Covidx Emergency Use; Imugene: Japan Patent For HER-Vaxx Immunotherapy; Bod, Woolcock Trial S3 Marijuana For Insomnia; Emyria: Preliminary Analysis Of 1st MDMA Analogue; Harbour Takes 10% Of Volpara; Dorsavi Chair Greg Tweedly To Retire At AGM; Clarity Joins Corar
FDA Hold On Protagonist’s Rusfertide (PTG-300); 62% Fall; Federal $6.5m For Rapid Hepatitis C Test; Federal Industry Ministers: Christian Porter Out, Angus Taylor In; Victoria, Burnet, Doherty Rapid Covid-19 Antibody Test; Biomuse Study Readies Alterity For Phase II Parkinson’s MSA Trial; Universal Biosensors Adds 2 Centres For Tn Antigen Cancer Test; Bionomics Prepares For BNC210 Social Anxiety Disorder Trial; Adalta: Victoria $4m RDTI Loan; Resapp Expands Covid-19 Trial To India; Memphasys On-Track For Samson Horse Semen Test; Island: Curia Replaces Cerrx For ISLA-101 Supply; Cronos Pleads Schultz, $61m Marijuana Deal To ASX 30% Query; Oncosil Potential 2nd Strike Board Spill AGM; Epsilon: Valens 1st Marijuana Order For $540k; Zelira Appoints Adjupharm Germany Marijuana Distributor; Creso, Halucenex, Acadia Uni Work On Psilocybin, CBD Gel Capsules
 
Emvision $8m Stroke Alliance Deal; Volpara, Revealdx Combine For Lung Screen; $341k Note; Anteo: Ramma For Greece, Cyprus Eugeni, Sars-Cov-2 Tests; Neuren: Brazil Trofinetide For Rett, Autism Spectrum Patent; MGC: Germany Approves Natural Artemic; Cochlear $2.4m CEO Options, Rights AGM; Dr Greg Rice Replaces Bard1 CSO Dr Peter French; VGI Appoints Prof Darrell Crawford Adviser; Emyria Appoints Dr Jeremy Tannenbaum Psychedelic Adviser
 
Redhill: Opaganib Phase II/III Misses Covid-19 Endpoints; IDT: $11.5m For Federal Sterile Drug Manufacture Plant; Amplia 1st Line AMP945 Combination Pancreatic Cancer Trial; Telix Supplies Illuccix To Amgen For PSMA Therapy Trial; Patrys: ‘PAT-DX3- MMAE Reduces Breast Cancer Growth, In Mice’; Nuheara: Registration-Directed Hearing Aid Trial; Avecho Recruits 1st Phase I TPM-Marijuana Trial Patient; Orthocell: ‘Celgro Rope Improves ACL Reconstruction, In Rabbits’; Imricor Pleads Schultz To ASX Listing Rule 15.7 Leak Query; Starpharma: US Patent For DEP-Cabazitaxel; Cynata: 2 Russian Patents For Cymerus Stem Cells; Argenica ARG-007 For Stroke Scale-Up, Purity; Suda Name Change To Arovella, 8m Dr Michael Baker Options EGM; Regal Funds Reduces To 7.4% Of Adherium; Atomo Appoints Deborah Neff Director; Adherium Loses CFO Anne Bell, Melbourne CFO Wanted; Chimeric Appoints 3 ‘Cellular Immunotherapy’ Advisers 
 
TGA Approves Micro-X Rover; Telix Files US IND For TLX250 Kidney Cancer Trial; Telix: US Guidelines Include PSMA-PET Imaging; Cronos Takes CDA For $61m Scrip In Marijuana Merger; Universal Biosensors, Peter Mac Work On Tn Antigen Test; VGI Appoints Gallipoli For IVB001 Nash Trial; DISER Approves Resapp Overseas R&D; Expects $820k; Cann Group Tests Gelpell Equipment; Harvest One Payment; MGC: UK Approves Import, Use Of Cannepil+ For Epilepsy; Total Brain: $600k ARR As IBM Signs US Veterans Affairs; Rhythm Files Colostat Manufacturer File To TGA; Opthea 1.6m CEO Rights, 4m Director Options AGM; SG Hiscock Takes 5% Of Atomo; Jencay Reduces To 9.6% Of Universal Biosensors; Regal Reduces To 8.8% Of Adherium; Shimano, Ex-M-D Peter Griffiths Below 5% Of Neurotech; One Funds, Saville Take 5% Of Imricor; Lumos Appoints Trump S-G Dr Jerome Adams Adviser
 
Neuren Raises $20m, Share Plan For $2m More; Telix Appoints Radius Illuccix Italy Distributor; Impedimed: 2 Abstracts Back Sozo For Heart Failure; Heramed: ‘Pilot Program Women Approve Foetal Monitoring’; Acrux: US FDA Accepts Dapsone Gel Application; Paradigm: ‘PPS Improves Grip In Mice With Chikungunya’; VGI NE1-Elite Muscle Soreness, Swelling Trial; Creso: MHG Orders $338k Marijuana Products; Universal Biosensors 7.5m CEO, CFO, Staff Performance Rights; Paul Hopper Takes 5.4% Of Imugene
 
Dr Boreham’s Crucible: IDT Australia; Rhinomed: Victoria Orders 1m Rhinoswabs; Distributors; QRX Hopes To Return To The ASX; Correction: Epsilon; Neuren Requests Capital Raising Trading Halt; Sun Hung Kai Increases, Diluted In Total Brain; Consolidation; Polynovo Loses Coo Dr Anthony Kaye; Oventus Appoints Michael Sisk Head Of Finance
 
Haemalogix Raises 10m For Multiple Myeloma; Adherium: FDA Approves ‘Next Generation’ Hailie Sensor; Telix Images Last Patient In Japan TLX591-CDx Trial; Epsilon, Valens Facility Deal; Buys Alternamed For $4.3m Scrip; Auscann Appoints Knoell CPAT-01 Advisor; Clime Takes 10.5% Of Mach7; Australian Ethical Takes 10.2% Of Mach7; Director Andrew Kroger Diluted To 41.5% In Cryosite; Steve Parkes Replaces Mach7 CFO Jenni Pilcher
 
Imricor Raises $16.5m, Plan For $1m More; Volpara, Riverain Deal For Lung Cancer Screening; IDT Tells 2nd ASX Aware Query ‘Federal Deal Not Material’; Showa Denko Evaluates Exopharm Leap Technology; Epsilon Takes ‘Partnership’ Trading Halt To Suspension; FIL Reduces To 5.8% In Cogstate
 
Vale Dr Kevin Healey (May 26, 1952 – Sep 3, 2021); Rhythm Raises $4.3m, Placement For $1.275m More; Vectus Completes Second VB0004 Cohort; Ecofibre, Southern Cross Uni Start Marijuana Sleep Trial; Orthocell: Canada, Hong Kong Patents For Celgro; Little Green WA Psilocybin Licence, Stephen Bright Advisor; Imricor Requests ‘Capital Raising’ Trading Halt
 
S&P ASX Indices: 2 Biotechs Up, 2 Down; Queensland Grant For Analytica Pericoach Manufacture; Anteo: Pera Medikal Turkey Eugeni Covid Test Distributor; Little Green Danish Marijuana; Morten Snede, Tony Roberts; Epsilon Requests ‘Partnership’ Trading Halt; CMO Dr Matthew Myntti Reduces To 7.1% Of Next Science; Perennial Takes 6.5% Of Ecofibre; Anteris Appoints Dr Chris Meduri CMO; Radiopharm Appoints Riccardo Canevari CEO, M-D; Creso Appoints Dr Miri Halperin Wernli, William Lay
 
Dr Boreham’s Crucible: Nanosonics; BTC Revenue Up 17% To $7m, Loss Down 53% To $464m; Neuren: FDA Orphan Status For Nnz-2591 For Prader-Willi; BCal: Sydney Breast Clinic Collects Blood For Cancer Test; Federal DISER Approves Neuroscientific Overseas R&D; Osprey EGM Approves 100-To-1 Consolidation; Nova Eye Buys Back 388k Unmarketable Parcel Shares; CSL $9.8m CEO Performance Rights AGM; MGC: India Approves Cimetra Import; Peter Meurs Increases, Diluted To 10.7% Of Dimerix; Regal Funds Management Takes 7.5% Of Althea; Suda Appoints Dr John Maher Scientific Advisor 
 
Kazia: France Approves Phase I EVT801 For Cancer Trial; Chimeric, Oncobay Partner To Develop CHM1101; Audeara Revenue Up 24% To $1.1m, Loss Up 176% To $1.25m; Immutep Doses Last 2nd-Line NSCLC IMP321-Keytruda Patient; FIL Reduces To 6% Of Telix; TDM Takes 26% Of Somnomed; Australian Ethical Takes 8.7% Of Mach7; Ausbiotech: Regenerative Medicine Manufacture, Trials; Lung Health Initiative: Theodora Elia-Adams Director
 
Imugene: HER-Vaxx Misses Gastric Cancer Secondary Endpoint; Palla Pharma H1 Revenue Down 43% To $7m, Loss Up 267% To $33m; Hydrix Revenue Down 50% To $7.4m, Loss Up 204% To $9.8m; Epsilon H1 Revenue Down 7% To $3.2m, Loss Down 26% To $4.1m; Creso H1 Revenue Up 109% To $3m, Loss Up 9% To $19m; Cardiex Revenue Up 14% To $5.3m, Loss Up 67% To $5.5m; MGC Revenue Up 43% To $3m, Loss Down 28% To $14m; Emyria Revenue Up 95% To $2m, Loss Down 6% To $4.9m; Cann Global Revenue Down 17% To $1.5m, Loss Down 41% To $5m; 4D Medical Continues I-Med Radiology Program; Neuren: Acadia Trofinetide Under-5 Rett Trial; Angelman Ind; Resapp: Indonesia Approves Resappdx; Memphasys: Hydrix To Pay $500k, 1m Shares For Felix Flaw; Althea: Boston Beer Deal For Canadian Marijuana Drinks; Hexima Appoints Jake Nunn Director; Medibio M-D Claude Solitario Pay Rise To $200k: Co-Sec Change
 
Althea Record Revenue Up 128% To $11.5m, Loss Up 1.9% To $15m; Mesoblast Revenue Down 77% To $10.2m, Loss Up 27% To $135m; Stemcell Revenue Up 11-Fold To $8.5m, Loss Up 107% To $3m; Regeneus Revenue Up 325% To $7.1m, Loss To $2.15m Profit; Little Green Revenue Up 218% To $7m, Loss To $24.6m Profit; Medlab Revenue Down 3.7% To $5.2m, Loss Down 7.9% To $12.4m; Bioxyne Revenue Down 6.6% To $2.1m, Loss Down 28% To $426k; Incannex Revenue Up 211% To $1.9m, Loss Up 74% To $8.2m; Proteomics Revenue Down 8% To $1.3m, Loss Up 64% To $2.9m; Oventus Revenue Up 160% To $1.1m, Loss Down 2.9% To $9.8m; Orthocell Completes Ortho-ATI Rotator Cuff Follow-Up; Pharmaxis: PXS‐6302 For Burns Scars ‘Safe, Well-Tolerated’; Neuroscientific: Emtinb ‘Significantly Reduces Ms Biomarkers’; Immutep: China’s EOC Plans IMP321, PD-1 Trial; Pharmaust: Epichem Repays Lab Expansion Loans; Cynata: Canada Patent For Cymerus Stem Cells; Creso, Red Light Holland End Merger; Aims At Nasdaq; Movac Fund 3 Below 5% In Aroa; Exopharm Appoints Dr Jennifer King Director
 
Medadvisor Revenue Up 304% To $39m, Loss Up 49% To $15.4m; Austco Revenue Down 1% To $31m, Profit Up 37% To $3m; Lumos Revenue Up 198% To $25m, Loss Up 50% To $20m; Next Science H1 Revenue Up 272% To $5.4m, Loss Down 37% To $4m; Imex H1 Revenue Up 15% To $5.2m, Loss Up 18% To $3m; Resonance Revenue Up 3% To $3.8m, Loss To $586k Profit; IQ3 Revenue Down 58% To $3m, Loss Up 156% To $6m; Orthocell Revenue Up 48% To $1m, Loss Up 47% To $9m; Federal Diser Approves Neuren Overseas R&D; Expects $6.5m; Anteris Extends Lemaitre Manufacturing Deal; Althea Pleads Schultz To ASX Listing Rule 15.7 Leak Query; Imricor To Sell Nordicneurolab Monitors; ASX Removes TBG From Official List; Credit Suisse Below 5% Of IDT; Merchant Reduces, Diluted To 12.6% Of Bard1; SG Hiscock Takes 9.6% Of Bod; Chimeric Appoints Jennifer Chow CEO, M-D; Starts On $754k; David Austin Replaces Cann Global Chair Pnina Feldman 
 
Dr Boreham’s Crucible: Clarity Pharmaceuticals; Mayne Revenue Down 12% To $401m, Loss Up 125% To $208m; Redhill H1 Revenue Up 92% To $58m, Loss Up 57% To $72m; Clinuvel Revenue Up 43% To $48m, Profit Up 68% To $24.7m; Avita Revenue Up 66% To $43m, Loss Down 37% To $36.5m; Atomo Revenue Up 25% To $6.7m, Loss Down 35% To $6m; Anteris H1 Revenue Down 20% To $3.2m, Loss Up 74% To $10m; Allegra Revenue Down 10.2% To $4.5m, Loss Down 50% To $579k; Micro-X Revenue Down 11% To $3.8m, Loss Up 46% To $14.7m; Total Brain Revenue Down 4.7% To $3.7m, Loss Up 9% To $8.3m; Cronos Revenue Up 14-Fold To $1.7m, Loss Up 3% To $4m; Imugene Dosing 3rd PD1-Vaxx Cohort; Rhinomed: Royal Children’s Hospital Trials Rhinoswab Junior; Osteopore Sponsors 2 PCL-TCP Reconstruction Trials; Immutep: China Patent For LAG525; Painchek Disputes $1.4m NSW Tax Assessment; Next Science: Irrimax Xperience Surgical Wash Legal Action; Emyria: Calvert For EMD-003 Synthetic Cannabidiol Studies; MGC Claims $33m AMC Marijuana, Cimetra Deal; Frank Condella Replaces Mayne Chair Roger Corbett
 
Compumedics Revenue Up 2% To $36m, Loss To $1m Profit; Polynovo Revenue Up 32% To $29m, Loss Up 10% To $5m; Kazia Revenue $15m, Loss Down 32% To $8m; Control Bionics Revenue Up 28% To $4m, Loss Up 253% To $3.5m; Rhinomed Revenue Up 9% To $3.9m, Loss Up 18% To $8m; Starpharma Revenue Down 67% To $2m, Loss Up 34% To $19.7m; Dorsavi Revenue Down 7% To $1.8m, Loss Down 73% To $2m; LBT Revenue Down 5% To $1.4m, Loss Up 28% To $7m; Oncology One, Children’s Cancer Institute Work On Solid Tumors; Dash Launches Acrux Generic Testosterone In The US; Nova Eye Pays $2.8m For US Glaucoma Patents; USPTO Allows Cynata Cymerus Stem Cell Patent; Suda Appoints Dr Reuben Benjamin Advisor
 
Clarity Opens Up 18% For Cancer Radio-Pharmaceuticals; Althea Raises $10.6m; Probiotec Revenue Up 12% To $121m, Profit Down 21% To $5m; Trajan Revenue Up 7% To $77m, Profit Down 28% To $2m; Cogstate Revenue Up 44% To $45m, Loss To $7.2m Profit; Genetic Signatures Revenue Up 151% To 28m, Loss To $1.8m Profit; Medical Developments Revenue Up 9% To $26m, Profit To $13m Loss; IDT Revenue Up 19.5% To $17m, Loss To $2m Profit; Cryosite Revenue Up 12% To $10m, Profit Down 56% To $653k; Impedimed Revenue Up 47% To $8m, Loss Down 3% To $21m; Acrux Revenue Up 7% To $1.3m, Loss Up 33% To $13m; Medlab: TGA Okays Nanabis Marijuana Cancer Pain Trial; Dimerix Files Phase III DMX-200 FSGS Study Ethics Application; Bayer Increases Cardiex Trial Contract $682k; Chimeric Releases 19m Shares From Escrow; Credit Suisse Takes 6% Of IDT; Perennial Takes 15% Of Medadvisor; Deborah Ambrosini Replaces Cann Group CFO Greg Bullock
 
Nanosonics Revenue Up 3% To $103m, Profit Down 15% To $8.6m; Somnomed Revenue Up 9% To $63m, Loss Up 147% To $1.2m; Alcidion Revenue Up 39% To $26m, Loss Down 27% To $2m; Impedimed Receives $1.8m Federal R&D Tax Incentive; Adalta, Carina Work On I-Body, Car-T-Cell For Cancer; Suda: ‘Stada Zolpimist Licence For Insomnia In Australia’; Invion EGM For Cho Deal, 138m Thian Chew Options; Imugene Pleads Schultz To ASX Listing Rule 15.7 Leak Query; Perennial Takes 8% Of 4D Medical; Health Management Sells Medadvisor Shares To Cotiviti; China Patent For Hexima Pezadeftide (HXP124) For Toe Fungus; Antisense Dr Gil Price Joins US Duchenne Advocacy Board; Neuroscientific: Dr Peter Hnik, Dr Frank Bonner Advisors
 
Mach 7 Revenue Up 1% To $19m, Profit To $9m Loss; Cyclopharm H1 Revenue Up 47% To $8.5m, Loss Down 31% To $4m; IDT: Victoria Buys $1m mRNA Nanoassemblr - Federal Facility; Bod Revenue Up 25% To $7.5m, Loss Up 12% To $4m; Cann Group Revenue Up 369% To $4m, Loss Up 48% To $25m; Bard1 ‘Oversubscribed’ Plan Raises $3.4m; Total $18.4m; Polynovo Starts Novosorb Syntrel Hernia Repair Trial; Impedimed: FDA Sozo Breakthrough Status For Kidney Failure; Telix, Lightpoint Work On Radiation-Guided Surgery; Island, Griffith Uni Repurpose Anti-Virals; Noxopharm: NOX66/Idronoxil/Veyonda Benefit For Covid-19; Lumos Releases 10m Escrow Shares; Actinogen: Brazil Patent Completes Xanamem Protection; Mitsubishi Tanabe Pharma Korea Ends Suda Zolpimist Licence; Vectus Doses 1st VB0004 Blood-Pressure Cohort; Starpharma: ‘Viraleze Kills Sars-Cov-2 More Than 99.9% In Mice’; Althea, Canopy Growth Marijuana Manufacturing Deal; Suspended TBG Suspended For Non-Payment Of Listing Fees; Co-Founder Dr William Garner Takes 27% Of Island; Cotiviti Tales 11.7% Of Medadvisor; Pro Medicus Appoints Alice Williams Director; Anteo Loses CFO Gail Jukes; Duncan Cornish Interim CFO
 
Dr Boreham’s Crucible: Rhinomed; Cochlear Revenue Up 10% To $1.5b, Loss To $327m Profit; SDI Revenue Up 21% To $82m, Profit Up 111% To $9m; Cellmid Revenue Down 14% To $7m, Loss Down 31% To $3m; Visioneering H1 Revenue Up 53% To $4m, Loss Down 71% To $2m; Imugene ‘Oversubscribed’ Share Plan Raises $5m; Total $95m; IDT Tells ASX: Good mRNA News May Have Pushed Price 49%; Federal $79m For New Technologies; Fellowships; Osprey 100-To-1 Consolidation, Director Options EGM; Chimeric: FDA Approves CHM1101 Glioblastoma IND; Imricor Releases 13m Escrow Shares; Anatara Launches IBS-D Trial Recruitment Website; Alcidion Appoints Victoria Weekes, Daniel Sharp Directors; Emyria Appoints Dr Mat Martin-Iverson MDMA Advisor
 
Nova Eye Revenue Up 5% To $13m, Profit To $4.4m Loss; Uscom Revenue Up 11% To $3.9m, Loss Down 31% To $924k; Telix H1 Revenue Up 81% To $2.9m, Loss Up 78% To $32.5m; Oncosil: 1st Pancreatic Cancer Device Revenue $213k; Telix Adds Phase I, Phase II Trials To Phase III Prostact Trial; Rhythm Starts Filing Colostat Blood Test To TGA; Dimerix Tells ASX: ‘No Leak, Try Broker Or Investors’; Biotech Daily Editorial: Confidential Means Confidential; Neuroscientific: Emtinb ‘Reduces Covid-19 Biomarkers In-Vitro’, Halt; Epsilon, Tetra, Terry White Melbourne Marijuana Clinic; Noxopharm Requests ‘Veyonda Covid’ Trading Halt; Incannex Nasdaq IPO EGM; Robins Super Fund Takes 5.9% Of Cryosite; Niv Dagan, 10 Bolivianos Take 9% Of Lifespot; Volpara Appoints Ann Custin Director; Prescient Appoints Prof Donald O’Rourke Advisor 
 
CSL Revenue Up 7.2% To $12.6b, Profit Up 9.6% To $2.9b; Pro Medicus Revenue Up 20% To $68m, Profit Up 34% To $31m; Editorial: Your R&D Tax Incentive Is Not Revenue; Nuheara Revenue Up 374% To $10.7m, Loss Down 38% To $7.2m; Pharmaust Revenue Down 33% To $2.1m, Loss Down 2% To $1.3m; Total Brain $1.9m Of $4m Rights Applications; Total $6.5m; Australian Patent For Island ISLA-101 For Dengue Fever; Telix, Merck KGaA Work On Cancer; 2 Breast Cancer Trials; Tali: ‘Akili Up To $51m ADHD Deal’; Incannex Files US SEC Registration For Nasdaq IPO; Volpara AGM 32% Dissent; Loses Director Dr Monica Saini; Lifespot EGM To Become Inhalerx Marijuana Vape Company
 
Burnet Sells 360 Biolabs To Bioagilytix; Baymatob: ‘FDA Approves Oli For Postpartum Haemorrhage’; Queensland Uni Looks For Sport Concussion Biomarkers; South Australia Uni Nano-Polymer Micelles For C Albicans; Elixinol H1 Revenue Down 39% To $4.8m, Loss Down 87% To $11m; Osprey H1 Revenue Up 33% To $1.5m, Loss Down 30% To $7.1m; Telix: Great Ormond Street Trials TlLX66 For Paediatric Leukaemia; Avita: FDA Approves Recell For Vitiligo IDE Amendment; Pharmaxis $3.8m Aptar Option To Develop Orbital Inhaler; Starpharma: Nasal Viraleze, SPL7013 Safe, Not Systemic; Bard1: Proof-Of-Concept Sub-B2M Elisa Ovarian Cancer Test; Nuheara Plans Hearing Aid Clinical Trial; CSL: Melbourne Uni V-C Prof Duncan Maskell Director; PYC Ophthalmology Clinical Advisory Board
 
Dimerix Placement Raises $20m, Share Plan For $2m More; Radiopharm Raises $20m Seed Capital For Nuclear Medicine; Correction: Painchek; Genetic Technologies Completes Easydna Acquisition; Creso: Halucenex Wins Canada Psychedelics Dealer Licence; Tali Requests ‘Licence’ Trading Halt; Suda, Imperial College Inkt Deal; Prof Karadimitris Sab Chair; Invex: Europe Exanatide Patent For ICP Treatment; Living Cell Cuts Costs, Loses COO Dr Janice Lam; Founder Dr Graham Melrose Reduces To 22% Of Recce
 
 
Pharmaxis Revenue Up 207% To $22.7m, Loss Down 79% To $3m; Antisense: FDA Wants More Data For ATL1102 DMD Application; Proteomics Hires Biotem For Promarkerd Kidney Disease Kits; Imagion, GCT Work On Nano-Scintillator For Breast Cancer; Australia Allows Eye Co Patent For Geographic Atrophy; VGI: Informed Sport Certifies NE1-Elite ‘No Banned Substances’; Dimerix Requests ‘Capital Raising’ Trading Halt; Creso Requests ‘Canada Health Licence’ Trading Halt; Factor To Hold 10-To-1 Consolidation; Jason Carroll Takes 5% Of Island; Osprey Appoints Martin Emerson Director
 
Rhinomed: ‘NSW Orders 1m Rhinoswab Sars-Cov-2 Tests’; Venstra Raises $2m For ‘Next Gen Miniature Heart Pump’; Noxopharm Adds Detail To US NCI Collaboration; Recce Wins 2nd R327 Federal Grant Of $50,000; Uscom: China Awards 5 BP+ Software Copyrights; Creso: Canada Approves Medical Marijuana Licence; Doherty’s Prof Sharon Lewin To Open Ausbiotech 2021; Perennial Below 5% Of Atomo; BCCL Reduces To 6.9% Of Tali 
Mach7 Up-To $2.4m Eunity Imaging Licence To Idaho’s St Luke’s; Aroa: ‘Myriad Matrix’s Efficacy For Pilonidal Sinus Disease’; Ecofibre Revenue Down 43% To $29m, Profit To $7m Loss; TBG H1 Receipts Up 2.7% To $3m; Mayne To Defend ‘Misleading, Deceptive Conduct’ Class Action; Paradigm: FDA Requires Further Ind Clarification; Patrys: Covid-19 Delays PAT-DX1 Manufacture, Trial 6 Months; Pharmaust’s Epichem Waste-To-Fuel Reactor ‘Operational’; Perennial Takes 13.5% Of Micro-X; Regal Funds Reduces To 9% Of Micro-X; Race Founder Dr William Garner Reduces To 6%; Perennial Takes 9% Of Lumos; Zoltan Varga Increases, Diluted To 18.5% In Total Brain; Anteotech: CEO Derek Thomson Extended On $395k; Mike Tonroe Replaces Genetic Tech Co Sec Justyn Stedwell; Elizabeth Spooner Replaces Stemcell Co Sec Chow Yee Koh
 
BDI-40 Down 6%; Big Caps Up 4%, ASX200 Up 1%, NBI Down 0.2%; Orthocell ‘Celgro Helps Develop Lymphatic Tissue’; Anteris To Raise $9m; Anteris H1 Receipts Down 6% To $3.5m; Stemcell United Receipts $7.7m; Epsilon H1 Receipts Down 2% To $3m; Creso H1 Receipts Down 21% To $2m; Resonance Receipts Up 2.2% To $3.7m; Dimerix: Remap-Cap Covid-19 Pneumonia Trial On-Track; Biocurate Funds Monash Early Breast Cancer Research; Bionomics ‘Possible Nasdaq IPO’, Merck Royalty Return; Resapp Requests ‘Licencing Agreement’ Trading Halt; Lifespot AGM Up-To 97% Block 7m Director Options; Hydrix: Angel Medical Implants 1st US Guardian Patient; Thorney, Tiga Take 19.9% Of Oventus; Mark Leong Replaces Osteopore Chair Brett Sandercock; Epsilon Appoints Dr Rob Jenny, Simon Rowe Directors; Adrian Sturrock Replaces Bod CFO Alan Dworkin; Suda Appoints Dr Sandhya Buchanan Manufacturing, Quality
 
Bard1 Raises $15m, Share Plan For $2m More; Rhythm 1-For-40 Rights Offer For $4.3m; Dr Boreham’s Crucible: Alcidion Group; Psychae: Unnamed Company $40m For Psychedelic Research; Medadvisor Receipts Up 306% To $38m; Kazia Posts Licencing Receipts Of $12.7m; Imex H1 Receipts Up 1.5% To $4.5m; Mesoblast Receipts Down 20% To $6m; Medlab Receipts Down 22.5% To $5m; Total Brain Receipts Down 22% To $3.9m; Rhinomed Receipts Down 7% To $3m; Universal Biosensors H1 Receipts Up 441% To $1.3m; Starpharma Receipts Down 66% To $2.4m; Incannex Receipts Up 56% To $2.2m; Dorsavi Receipts Down 32% To $1.6m; Proteomics Receipts Down 17% To $1.5m; Oventus Receipts Up 168% To $1.05m; Telix: Shuts Belgian Cyclotrons, To Build New Cyclotrons; Medadvisor API Deal Adds 250 Pharmacies, Revenue; Paradigm Requests ‘FDA Response’ Trading Halt; TBG AGM 24% Oppose Remuneration Report; Nyrada: US Patent For Pcsk9 Cholesterol Program; 4D Releases 1.7m ASX Escrow, 38.6m Voluntary Escrow Shares; Starpharma Loses Director Peter Turvey
 
Imugene Placement Raises $90m; Share Plan For $5m More; Aroa ‘Oversubscribed’ Placement Raises $47m; $5m Plan; Clinuvel Receipts Up 32% To $39m; Genetic Signatures Receipts Up 241% To $30m; Pharmaxis Expects Revenue Up 82% To $24m, Loss Down 79% To $3m; Hydrix Receipts Down 39% To $9.7m; Atomo Receipts Up 202% To $8m; Regeneus Receipts $7.7m; Osprey H1 Receipts Down 3% To $1.5m; Cronos Receipts Up 970% To $1.2m; Queensland Uni Develops Intranasal Spray-To-Gel; Volpara: US FDA Clears VIS 3.2 Algorithm, Architecture; Epsilon 64% Vote Off Directors Alan Beasley, Lou Cattelan; Anteris Requests Capital Raising Trading Halt; Australian Ethical Takes 19% Of Nova Eye; Mason Stevens Takes 6% Of Patrys; Karen Borg Replaces Optiscan Director Graeme Mutton
 
Little Green Pharma Receipts Up 271% To $6m; Micro-X Receipts Up 104% To $5m; IQ3 Receipts Down 56% To $3.2m; Pharmaust Receipts Down 30% To $2.5m; Emyria Receipts Up 110% To $2m; Bluechiip Receipts Up 42% To $1.2m; Acrux: US FDA Approves Generic EMLA Local Anaesthetic; Clarity Starts Cu-64/Cu-67 Sar-BIS-PSMA Prostate Cancer Trial; Anteo Appoints Apacor UK Eugeni Distributor; Regeneus, Kolling Work On Progenza For Osteo-Arthritis, In Mice; Bard1: Queensland Uni Uses Exo-Net For Ovarian Cancer Test; Chimeric Licences Pennsylvania Uni Car-T For Solid Tumors; Rhythm Requests ‘Capital Raising’ Halt; Dr Charmaine Gittleson To Replace Antisense Chair Bob Moses; Starpharma Appoints Lynda Cheng Director; Resonance Appoints Ajay Nair Sales, Marketing G-M
 
Prescient: Safety Takes PTX-100 To Cancer Expansion Study; Somnomed Receipts Down 3% To $60m; Alcidion Receipts Up 54% To $32m; Althea Receipts Up 126% To $10.3m; Impedimed Receipts Up 44% To $8m; Control Bionics Posts $3.3m; MGC Receipts Up 26.5% To $2.7m; Audeara Posts $1.2m Receipts; Control Bionics Appoints DNR Wheels Singapore Reseller; US Allows Medlab Nrgbiotic For Depression Patent; Incannex Starts Phase I IHL-675A Safety Trial; Patent; Starpharma: ‘SPL7013 Kills 99.9% Of Delta, Kappa Sars-Cov-2’; Aroa Requests ‘Capital Raising’ Trading Halt; Imugene Requests ‘Capital Raising’ Trading Halt; CTXone Renames Itself Oncology One; Factor To Buy Powerlime, Become Dominion Minerals; Dr Alan Finkel, Nebula, Howitt Below 5% Of Cogstate; Sean Williams Replaces Lifespot Chair Rodney Hannington 
 
Cann Group Placement, Share Plan For $20m; Nuheara Receipts Up 162% To $8.85m; Cardiex Receipts Down 12.5% To $4.5m; Cann Group Receipts Down 20% To $1.4m; Imex Pays $8.5m For ‘Related Party’ Rimab; Visioneering To Distribute Innovatus Lenses In North America; Patrys: ‘PAT-DX1 Slows Pancreatic Tumor Growth 26%, In Mice’; Pharmaust: 3 Labs Back Monepantel For Sars-Cov-2, In-Vitro; Hexima Completes Hxp124 Nail Fungus Trial Enrolment; Australian Patent For Anteris Sterilization System; One Funds Takes 11.7% Of IDT; Dr David Brookes Replaces Anatara Chair Sue MacLeman; Cynata Appoints CSL’s Dr Jolanta Airey CMO
 
Dr Boreham’s Crucible: The Life Sciences IPO Olympiad; Bard1 Placement Raises $15m; Share Plan For $2m More; Creso: Landing Strong To Provide PTSD Trial Support; Richmond Hill Below 5% Of Universal Biosensors; Regal Takes 6% Of BCal; Mercer Street Below 5% Of Anteris
 
Omniscient Raises $40m; FDA Clears Quicktome Brain Mapper; Cogstate Receipts Up 46% To $58m; Next Science H1 Receipts Up 83% To $6.3m; Elixinol H1 Receipts Down 28% To $5m; Telix H1 Receipts Down 6% To $2m; Invion Receipts Down 26% To $2.6m; Bioxyne Receipts Down 26% To $2.1m; Proteomics: Abcam To Manufacture Promarkerd Reagents; Island: Cerrx, Curia Manufacturing Agreements; US Patent For Recce R327, R529; Incannex Patent Application; IHL-42X Trial Extension Approved; Pharmaust Applies For Monepantel Patent For Viral Diseases; Cann Group Requests ‘Placement’ Trading Halt; FIL (Fidelity) Takes 6% Of Medical Developments; Browns Island Below 5% In Truscreen; BCal: Jayne Shaw 13%, Ronald Phillips 13%, Merchant 8%, Mera Vale 6%
 
BCal Climbs 10% On $10m IPO For Breast Cancer Screening; Immutep ‘Over-Subscribed’ Plan Raises $7.2m; Total $67.2m; Total Brain $6.5m Placement, Rights Offer; Amplia: ‘AMP945 Safe, Well-Tolerated, Appropriate For FAK’; Ecofibre Receipts Down 24% To $23m; Micro-X New Generator: ‘Half The Price, 4 Times The Power’; Hydrix Takes Guardian Cardiac Arrest Device To TGA; Argenica’s Prof Bruno Meloni Wins $290k Grant For Rat Study; MGC Tells ASX: ‘June 23 Slovenian Patent Material At Jul 15’; Bard1 Requests ‘Capital Raising’ Trading Halt; Australian Ethical Takes 7.55% Of Mach7; Milano Topco, HMS Increase, Diluted To 11.7% Of Medadvisor; Hanno Cappon Replaces Bod Director Patrice Malard; Stemcell United Appoints Francesco Cannavo Director
 
Clarity $92m IPO For Cancer Radio-Pharmaceuticals; Mach7 Receipts Up 23% To $21m; Redhill Completes Opaganib For Covid-19 Pneumonia Trial; ENA Starts INNA-051 Nasal Spray Covid-19 Prevention Trial; Nova Eye Unaudited Revenue Up 6% To $13.5m; Cellmid Receipts Down 32% To $5.6m; Osprey: Dyevert Canada Approval, GE Healthcare Distributor; Emvision Prepares Commercial Portable Brain Scanner; Telix: On-Track For TLX250-CDx FDA Biologics Application; China Patent For Recce R327, R529; Auscann Starts Marijuana Dermacann For Dogs Application; Incannex Requests ‘Patent, Ethics Approval’ Trading Halt; Correction: Adalta; Cochlear Loses Director Abbas Hussain; Otto Buttula Replaces Oncosil’s Chris Roberts, Michael Bassett; MTP Connect Appoints Dr Amanda Ruth ‘Guest Of The Chair’; Lifespot: Saich, Davies In; Stedwell, Cannavo Out
 
Compumedics: Revenue Up 1.4% To $36m; Vaccines The Key; Mesoblast: ‘Remestemcel-L Cuts Under 65s ARDS Mortality 48%’; Recce: R327 Kills ‘Flesh-Eating’ Bacteria, In-Vitro; Mach7 Licences Eunity To Advocate Aurora For $4.3m; Volpara Distributes Invitae Genetic Breast Cancer Test; Genetic Technologies Buys Easydna For $5.4m; Dimerix: FDA Confirms Phase III DMX-200 FSGS Trial Design; Adalta Closes Phase I Trial, To Take Inhaled AD-214 To Phase II; Anteo: Australia, SE Asia Eugeni Sars-Cov-2 Distributors; Heramed: Obstetrix Heracare Foetal Heart Pilot Study; Medlab: WEP To Run UK Marijuana Distribution Programs; Respiri: Adherium Offer Lapses; Total Brain Requests ‘Capital Raising’ Trading Halt; Rain Maker Reduces To 9% In Osteopore
 
Dr Boreham’s Crucible: Lumos Diagnostics; Medical Developments Expects 2020-’21 Loss Up To $5.2m; Visioneering H1 Receipts Up 36% To $4.3m; Nova Eye Unmarketable Parcel Facility; Proteomics: Janssen Drug ‘Significantly Reduces’ Test Scores; Incannex: Procaps To Manufacture Soft-Gel Ihl-675a; MGC Applies For Slovenian Marijuana Delivery Patent; Creso Launches 2 Marijuana Sport Products In Switzerland; Aroa To Release 118m Voluntary Escrow Shares; Living Cell Chair Bernie Tuch Replaces CEO Ken Taylor
 
Victoria $643k Extends J&J Monash Office 2 Years; Volpara: Euro Patent For Breast Care Platform; Actinogen Enrols 1st Xanamia Trial Patient; Bod Marijuana Customer Receipts Up 82% To $6.6m; Total Brain, Eastman $250k Mental Health Contract; Creso Completes Halucenex Acquisition; Anteris AGM 12% Oppose Director Dr Wenyi Gu; Rhythm Director David White Joins US Subsidiary Ichordx
 
Doherty, Peter Mac Stop Sars-Cov-2 Replication, In-Vitro; Planet Innovation Opens $1m Clean-Room; Uscom Receipts Up 20% To $5m; Nuheara Welcomes US President Biden O-T-C Hearing Aid Order; Proteomics Requests ‘Promarkerd Study’ Trading Halt; PYC Trials VP-001 For Retinitis Pigmentosa, In Rabbits; Hexima Expects Euro Patent For Pezadeftide For Toe Fungus; I’rom Below 5% Of IDT; Azure (Invictus) Changes Name To VGI
 
Polynovo Increases US Sales Staff; Expects Record Revenue; Uniquest, CSL Develop ‘Molecule’ For Blood Vessel Damage; WEHI: Immune Boost Kills TB, In Mice; Orthocell: Samson Striate+ (Celgro Dental) Distributor; MGC Starts Phase III Cimetra (Artemic) Covid-19 Trial; Copia, IOOF Take 5% Of BTC Health; BCCL Reduces To 8.45% Of Tali; Lifespot Appoints Elizabeth Spooner Co-Co Sec
 
Recce Doses 1st Patients In R327 Topical Burns Trial; Argenica: ARG-007 Stable With Stroke Drugs; Cronos Expects Marijuana Revenue Of $1.2m; Medlab: Australian Approval For Phase III Nanabis Pain Trial; Patrys: ‘PAT-DX3 Crosses Blood-Brain Barrier, In Mice’; Pharmaust, WEHI Study Monepantel For HTLV-1, In Vitro; Zelira US ‘Observational’ Marijuana Pain Study Approved; Anteris Machines Cow Heart Tissue For Valves; Thorney, Tiga Take 18% Of Oventus; Telix Appoints Kyahn Williamson Comms, Investor Relations
 
Dr Boreham’s Crucible: Polynovo; LBT Presents Data From 5 Studies At European Meeting; Cann Group Recovers $1.2m Of $3.5m ‘Cyber Security Incident’; Althea’s Peak $1.3m 48north Marijuana Manufacture Deal; Creso Completes Anibidiol Uruguay Import Procedures; MGC 64.2m Director Rights EGM; Imugene Issues 119m Vaxinia Milestone Shares; Life Biosciences Diluted To 11.2% In Alterity; Ellerston Capital Takes 5.4% Of Lumos; Invion Executive Chair Thian Chew On $399k pa
 
Australia Approves Qbiotics Stelfonta For Dog Cancer; Brandon $13m For Amaroq Long Non-Coding RNA Cancer Trial; Imex Expects H1 Annual Recurring Revenue Up 12% To $1.1m; Immuron Acquisition Suspension; Chair Adam Blumenthal Reduces To 10% Of Creso; Ausbiotech Talks Patent Box
 
Cogstate Sales Contracts Up 14.5% To $47m; Russia Approves Uscom 1a; Eureka Report Interviews Biotech Daily; Medadvisor’s Adheris To Work With Ehealth Inc; Pharmaust Monepantel Tablets ‘Stable At 24 Months’; Neurotech Dolce Marijuana Beats CBD For Cox-2, In-Vitro; Elixxer Diluted To 12% Of Little Green; Madhukar Bhalla Replaces Incannex Co Sec Glenn Fowles; Polynovo M-D Paul Brennan LTIs Up 20%, Pending Hurdles
 
US Fast Track Status For Opthea Opt-302 For Wet AMD; Cartherics Swaps Collaboration From Hudson To ARMI, CCRM; US FDA Approves Immutep Phase IIb Tacti-003 HNSCC Trial; Bionomics Begins Phase IIb BNC210 PTSD US Trial; Creso: Red Light Holland Orders $219k Netherlands Marijuana; Fil Reduces To 8% In Telix; Planet Innovation Takes 27% Of Lumos; RPS Diagnostics Takes 10% Of Lumos; Perennial Takes 8% Of Lumos; Acorn Capital Takes 6% Of Lumos; CEO Fleta Solomon Increases, Diluted To 8.7% Of Little Green; Bianca Rinehart (Hancock Trust) Takes 11.5% Of Little Green
 
Lumos Opens Up 20% For P-O-C Diagnostics; Correction: Argenica Therapeutics; Proteomics Retracts Promarkerd ‘$506b Savings’ News; TGA: Starpharma Fined $93k For Viraleze ‘Illegal Advertising’; Living Cell Pleads Schultz To ASX 46% Query; Respiri Tells ASX: ‘Lawyers Investigating News, M-D Shares’; Prescient: ‘Immunogenicity Tests De-Risk Omnicar’; Medlab: ‘NRG Biotic Boosts Anti-Depressant Activity’; Nova Eye Files US 2RT For Macular Degeneration Trial IDE; Austco, KTPH $3.3m Supply Deal For Tacera Nurse Call; Recce Receives $177k Canadian R&D Tax Incentive; Resapp: Resappdx, Sleepcheck For Doctors On Demand; Zelira: Finclear Takes Pershing; Lifts Marijuana Investment Ban; Cann Global Receives 2 Canntab Marijuana Products; Thorney, Tiga Take 7% Of Little Green Pharma; Chimeric Appoints Ex-Celgene Dr George Matcham Director; Memphasys Appoints Prof John Aitken Research Director
 
Dr Boreham’s Crucible: Argenica Therapeutics; FDA Approves Imugene CF33 ‘Checkvacc’ Breast Cancer Trial; Cyclopharm H1 Revenue Up 45% To $8.1m; BTC Raises $2.5m For Pharmaxis Bronchitol, Aridol Acquisition; Ellume, Azova, Alaska Airlines Sars-Cov-2 Test Partnership; US Patent For Alterity Excess Iron Redistribution; Creso: ‘H1 Marijuana Revenue Up 113% To $3.1m’; Proteomics Extends ‘Presentation’ Suspension; Esense ASX-Delisting AGM; Allianz Takes 9% Of Starpharma; Gina Rinehart, Hancock Take 11.5% Of Little Green; Perennial Takes 7.6% Of Atomo; Visioneering Appoints Dr Dwight Akerman Director
 
15-Year BDI-40 Up 633% To Record $26b; Big Caps Up 1031%, ASX200 Up 44%; BTC Pays $2m To Distribute Pharmaxis Bronchitol, Aridol; Halt; Mesoblast To Meet FDA For Rexlemestrocel-L For Back Pain; Micro-X Launches Veterinary Rover Mobile Dr; Auscann Marijuana For Tasmania Department Of Health; Argenica ‘ARG-007 Safe, Well Tolerated, In Rats’; Neuroscientific: Emtinb Safe In Monkeys; FDA Approves Noxopharm Darrt-2 Cancer Trial Ind; Truscreen: Serbia Orders Cervical Cancer Screening Device; Memphasys Completes Verification, Validation To Go; Resonance Increases Acuity Facility To $7.75m; Bellwether Super Below 5% Of Bluechiip; Regal Funds Below 5% Of Hydrix; Joanne Moss To Replace LBT Chair Kate Costello; Osprey Appoints Steven Brandt Director; Hang Ling Leung Replaces Regeneus Co Sec Sandra Mcintosh; Miles Davis Replaces Bionomics Dr Rao; Dr Errol De Souza On $702k
 
Cynata Readies For Diabetic Foot Ulcer Stem Cell Trial; Paradigm Responds To FDA PPS Osteo-Arthritis Questions; Avita In US Russell 3000 Index; Universal Biosensors 23% AGM Dissent; Neuroscientific Requests ‘Study Results’ Trading Halt; Vanguard Below 5% Of Cochlear; APG Asset Takes 5.5% Of Cochlear; Adam Leitzes, Karst Peak Take 11% Of Pharmaxis; Australian Ethical Diluted To 5.6% Of Immutep; Perennial Takes 14% Of Medadvisor; Noxopharm Diluted To 24% Of Nyrada; Nyrada Director Dr Ian Dixon Increases, Diluted To 6.5%; Alcidion Loses Co-Founder Ray Blight
 
Federal $19m For Stem Cell Research; Gilead $300k Fellowship Grants For 5 Projects; 4D Medical: Johns Hopkins Joins XV Lung Trial; Pharmaxis: Low Dose PXS-5505 Safe, Inhibits Lox, Loxl2 Enzymes; Biotech Daily Editorial Policy: Respiri’s Adherium Bid; Genetic Technologies Tells ASX: ‘Late May Launch Expected’; Elixinol Terminates Cannacare Acquisition; Nyrada: NYX-PCSK9I Reduces LDL 46%, In Mice; Noxopharm Wins European Patent For Veyonda; Lifespot 7m In-The-Money Director Options, Potential Spill AGM; Proteomics Takes ‘Presentation’ Halt To Suspension; Creso Takes ‘Sales, Revenue Update’ Halt To Suspension; Emyria Appoints Dr Eli Kotler For MDMA-PTSD Trial
 
Cyclopharm: FDA Letter Delays Technegas ‘9 Months’; Qbiotics Raises $35m For Cancer, Wound Drugs; Total $85m; Atomo: Access Bio Covid-19 Antibody Test US Emergency Use; WEHI, Boehringer Ingelheim Partner On Cancer Proteins; Brandon $10m For Currus Car-T-Cell Solid Tumor Drugs; Cartherics Licences Toolgen Crispr/Cas9 For Gene-Editing; Hydrix: Angelmed FDA Approval For Guardian Battery; Amplia, Garvan Trial AMP945, Gemcitabine In Pancreatic Cancer; Nanosonics To Launch Auditpro Digital Data Flow; Antisense, MCRI Work On ATL1102 For Multiple Muscle Diseases; Cynata Appoints Datapharm For MSC Diabetic Foot Ulcer Trial; Pharmaust: 1 Of 15 Dogs MPL Tumor Regression; 6 ‘Stable’; Probiotec Completes $4m H&H Acquisition; Painchek Receives $1.25m Federal Milestone; Elixinol Requests ‘Proposed Acquisition’ Trading Halt; Visioneering Completes 100-To-1 CDI Consolidation; Probiotec Appoints Simon Gray Director; Resonance Appoints Exec Director Mitchell Wells M-D; Ecofibre Appoints Vanessa Wallace Director
 
Dr Boreham’s Crucible: Imugene; Proteomics: ‘Promarkerd Test Could Save $51b Per Year’; Halt; J&J, Navbit Launch Sprint Navigation For Hip Replacement; Ellume, Delta Air Lines Deal For Sars-Cov-2 Test Kits; Cronos: Saiph Marijuana Skin Products For Japan, Hong Kong; Total Brain $1.8m Loan; Adalta Takes $1.7m Radium RDTI Loan; Hydrix Requests ‘Angelmed Distribution’ Trading Halt; Creso Requests ‘Material Sales, Revenue Update’ Halt; State Street Takes 5% Of Cochlear; Dr Alan Finkel, Nebula, Howitt Reduce To 5% Of Cogstate; Esense Considers ASX Delisting; CSL Loses Director Abbas Hussain; Biocurate Appoints Dr Lindner Director; Ms Wu Investment; Chimeric Appoints Dr Li Ren For Technical Operations; Medibio Appoints R&CPMK For Marketing 
 
Patrys Tells ASX: ‘Journal Embargoed Despite 21% Price Jump’; Labcon Pays Bluechiip $2.1m For Resolution; New Deal; Next Science, Zimmer Talks On Xperience Distribution; Prescient: Omnicar Parts Manufacture Completed; Kazia Wins US, India Paxalisib Composition Patents; Trajan $1.3m US Paycheck Loan Forgiven; Jencay Capital Takes 5.3% Of Bluechiip; Perennial Takes 12% Of Medadvisor
 
CMRI, Gyroscope Work On Capsids For Gene Therapies; Telix Doses 1st TLX250-CDx Bladder Cancer Patient; Actinogen: FDA Okays Xanafx Phase II Fragile X Study Plan; Alterity: EMA Backs ATH434 MSA Trial Biomarkers, Design; Neuroscientific Appoints Linear Clinical For Emtinb Trial; Europe, Canada Patents For Medlab Nanocelle; Palla Completes Ireland, Germany Co-Codamol Submissions; Althea Ships Marijuana To South Africa; Respiri: Sigma To Sell Wheezo Asthma Monitors; Invex To Release 21m ASX Escrow Shares; Regal Funds Takes 17% Of Opthea; Richmond Hill Reduces To 6% Of Universal Biosensors
 
Zucero: FDA Cancer Trial Approval Delays $30m IPO; IDT: Talks With mRNA Victoria, State Government, MIPS; FDA Approves Acrux Generic Jublia; Little Green Raises $27m For Denmark Marijuana Facility; Suda Raises $3.7m For T-Cell Platform; ‘Potential’ Clarity IPO For Cancer Diagnostics, Therapies; Micro-X Appoints Roesys EMEA Rover Distributor; Cardiex, Lifeq Deal For Wearable Band; IDT, Clever Leaves Marijuana THC Flower Supply Deal; Antisense: EMA Requires Additional DMD Trial Information; Baker Brothers Reduces To 8.5% Of Opthea; Chair Dr Michael Monsour Takes 23.7% Of Analytica; Neuroscientific Appoints Paradigm CEO Paul Rennie Chair; Nuheara Appoints Nick O'Loughlin, Kathryn Penno Executives
 
Immutep Raises $60m, Plan For $5m; Triple Combination Trial; Victoria: MIPS, Doherty mRNA Vaccine Trial ‘This Year’; Telix: Early Data Takes TLX101 To 1st-Line Glioblastoma Trial; Orthocell: ‘Celgro Early Data Shows Nerve Regeneration’; Starpharma: UK Sars-Cov-2 Questions Halt Viraleze Sales; St Vincent’s Institute, Pfizer Cancer Collaboration; Actinogen Appoints 2 CROs, Cogstate For Xanamia; Emvision, MSH Research, Innovation Deal; Mayne Licences Solaraze, Actkerall; US Nextstellis Launch; Palla Appoints Alloga UK Pre-Wholesale Co-Codamol Supplier; Incannex: Vectura To Formulate IHL-216A For TBI; Little Green Requests ‘Acquisition, Capital Raising’ Halt; Unisuper Below 5% Of Kazia; Cryosite Director Andrew Kroger Holds 43.3%; Joanna Johnson Replaces Acrux CFO, Co Sec Deborah Ambrosini; Epsilon: Louisa Ho In, Philip Leighfield Out, Nicholas Marshall CFO
 
Dr Boreham’s Crucible: Actinogen Medical; Suda To Raise $3m For Imperial College T-Cell Cancer Therapy; Starpharma: ‘SPL7013 Kills Sars-Cov-2 Variants, In-Vitro’; Brazil Okays Paradigm PPS For MPS VI Trial; Zelira, Curtin Uni Improve Marijuana Brain Delivery, In Mice; Clime Takes 9% Of Mach7; Nicholas Marshall Replaces Cardiex Co-Sec Philip Leighfield
 
Brandon, Minderoo, Uniseed $32.5m For ENA Sars-Cov-2 Spray; Telix FDA Meeting For Illucix: ‘No Substantive Issues’; 4D Medical: Michigan Uni Buys $787k Permetium Scanner; Creso, Red Light Holland Marijuana Merger For Highbrid Lab; Victoria: All-Star mRNA Advisory Group; Auscann Leases R&D Facility To Source Certain; Cellmid: Record $1.4m Japan TV Hair Loss Sales; Bod: 2 UK Online Retailers To Distribute Marijuana CBII; Little Green 4.6m ‘Rights’ EGM; Little Green Appoints Medezin Polish Marijuana Distributor; Immutep Requests ‘Capital Raising’ Trading Halt; One Funds Takes 11% Of IDT; Jencay Reduces To 10.6% Of Universal Biosensors; Bio-Melbourne AI Medical Technology Forum; CMRI Wins NHMRC Ideas 2020
 
Patrys: ‘PAT-DX1 Reduces Brain Metastases 93% In Mice’; Avita Q4 Guidance Up 14% To $12.5m; CSIRO Appoints Prof Bronwyn Fox Chief Scientist; Bionics Queensland Prizes; Orthocell: China, NZ Celgro Patents; Rhythm: Sonic Healthcare Joins Colostat Trial; Creso Requests ‘Material Acquisition’ Trading Halt; CSL Appoints Alison Watkins Director
 
Invex: US FDA, EMA Differ On Presendin IIH Trial Endpoints; Kazia, Cornell Trial Paxalisib, Ketogenesis For Glioblastoma; Oventus Rights Raise $4.9m; Total $10m; Cogstate $3.2m US Paycheck Loan Forgiven; Nyrada Selects NYR-Bio1 For Traumatic Brain Injury Study; Anteris: Adapt Carotid Artery Conduit Works In Sheep; Respiri Withdraws $6m-$8m Revenue Guidance; Genetic Technologies US Patent For Genomic Analysis; Azure Food Additives NE1-Elite, NE1-Heart Ready For US Sale; MGC: Cannepil On Irish Reimbursement Scheme; Zelira: Health House Marijuana Toothpaste UK Distributor; Australian Ethical Reduces To 16% Of Cogstate; PYC US Office At J&J San Diego; Neuren Appoints CEO Jon Pilcher Managing-Director; Opthea Appoints Karen Adams Co Sec; MGC Loses Co Sec Nadine Barry
 
Dr Boreham’s Crucible: Trajan Group Holdings; Argenica IPO Opens Up 35%; Next Science H1 Revenue $4.5m To $5.2m, Beats Last Full Year; Avita: FDA Expands Recell To Children, Extensive Burns; India Approves Starpharma Viraleze Nasal Spray; Respiri: UK Approves Wheezo; Cellmid To Release 4.5m Voluntary Escrow Shares; Creso US O-T-C Dual Listing; Australian Super Takes 6% Of Trajan; Thorney, Tiga Take 5% Of Little Green
 
Argenica $7m IPO For ARG-007 For Stroke; Medadvisor: 9-Month Revenue Up 40%; Pharmaxis: 1st PXS-5505 Myelofibrosis Dose-Escalation Cohort; Patrys Receives $626k R&D Tax Incentive; Austco Pleads Schultz To ASX 30% Query; Noxopharm ‘Clarifies’ Darrt-2 Trial; Proteomics Appoints Jacqueline Gray CFO, Vik Malik CCO; Imugene Appoints Dr Monil Shah CBO
 
Lumos $63m IPO For Point-Of-Care Diagnostics; Epsilon To Supply CBD For Youth Severe Behavior Trial; Probiotec Guidance: Revenue Up 12% To $120m, Ebitda $21.5m; Elixinol Appoints Health House Distributor, Pharmacann Out; Cryosite Director Andrew Kroger Takes 43%; Probiotec Jonathan Wenig Replaces Chair Sandy Beard; MGC Appoints David Lim Joint Co Sec
 
Cogstate Earns $26m On Esai, Biogen FDA Alzheimer’s Approval; Redhill Opaganib Phase II/III Covid-19 Study Enrolled; Immuron Acquisition Suspension; ASX Activities Questions; Immutep, Cardiff Work On Cheaper, Oral Cancer Drugs; Almirall Challenges Acrux Generic Aczone; Race Contracts Trialog For Israel AML Combination Trial; Clarity: Dallas Joins Cu64-67 Paediatric Neuroblastoma Trial; Visioneering Loses 10% Capacity, Tom Dooley; Consolidation; Creso, Halucenex Expand Mushroom Psylocibin PTSD Trial; Avecho: ‘TPM Increases Cannabidiol Absorption Up To 5.4 Times’; Cellmid Supply, Collaboration Agreement With Pump Haircare; PYC 2nd Drug Candidate Works For ADAO, In-Vitro
 
Trajan Climbs 20% On $90m IPO; Emyria: ‘Marijuana Reduces Opioid Use, Significantly’; Telix, ATS $1.6m Eurostars Anti-Cancer Alpha Grant; Immutep: ‘Encouraging’ Insight-004 IMP321 Combo Tumor Data; Immutep: ‘Positive’ Tacti-002 IMP321, Keytruda Cancer Data; Dimerix: UK Innovation Passport, ILAP Status For DMX-200; Clinuvel Doses 1st Afamelanotide Stroke Patient; Kazia Enrols 1st Phase II Paxalisib Lymphoma Patient; Universal Biosensors 1st European Sentia Wine Test Sales; Azure Appoints Altipure Manufacturer; Helen Fouras, Velocimetry ‘Reduce’, Diluted To 43% In 4D; 4D Founder, CEO Prof Andreas Fouras Diluted To 22%; TBG Sells 5% Of TBG Inc To Beijing’s Dong Yuan For $1.1m; Tali: Detect Has 20k India Downloads; PYC Requests ‘Pre-Clinical Results’ Trading Halt; Veritas Below 5% In Cochlear; Trajan Appoints Mark Licciardo Joint Co-Sec; Mach7 Appoints David Madaffri Head Of Sales
 
Dr Boreham’s Crucible: Universal Biosensors; Russian Patent For Exopharm Leap Technology; Creso Appoints Route2 Ecuador Marijuana Distributor; Resonance Loses CEO Alison Laws; Mitchell Wells Executive; Polynovo Appoints Andrew Lumsden Director; Don Brumley Replaces Acrux Director Norman Gray; Oventus: John Cox COO; Jim Hunter Acting CFO, Dan Parry Out
 
Pro Medicus, Mayo Work On AI Visage Imaging; Qbiotics Raises $22.5m; 1st Patient In EB46, Merck Cancer Trial; Correction: Trajan; Painchek Takes 60% Of Local Market; Cynata, Tekcyte Diabetic Foot Ulcer Trial; Telix, Eckert Ziegler US Co-Promotion Deal; Dimerix: EMA Confirms Phase III Dmx-200 FSGS Trial Design; Resapp, Medgate Resappdx Trial Extended 2 Months; Zelira Licences Marijuana ZTL-106 To Levin For Pain Trial; Up To 19% Oppose $2 Somnomed Director Options EGM; Anteris Receives $1.5m Federal R&D Tax Incentive; Respiri Rebuts Adherium Rejection Claims; Cronos Launches Marijuana Gel Cleanser, Moisturiser; Prescient Pleads Schultz To ASX 23% Query; Sally McDow Replaces Painchek Co Sec Ian Hobson
 
Trajan To List On ASX On Monday; 300+ Staff Investors; Amplia: AMP945 Improves Pancreatic Cancer Chemo, In Mice; Oncosil Withdraws TGA Application On Data; Race Appoints Parexel For Phase I/II Bisantrene AML Trial; Invion, RMW Cho $4.5m Placement, Photosoft Deal; Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved; Pharmaust Phase I Monepantel MND Trial Approved; European Patent For Immutep Cancer Combinations; Regal Below 5% Of Genetic Signatures; Cryosite Director Andrew Kroger Takes 42%; Mercer Street Takes 5.5% Of Anteris; Opthea: Prof Julia Haller, Judith Robertson Directors; Avita Appoints James Corbett, Jan Stern Reed Directors
 
Imugene 117% Jump Takes May BDI-40 Up 4%; ASX200 Up 2%, Big Caps 5%; Applications Open For $2.5m CSL Centenary Fellowships; Immutep, Merck IMP321-M7824 Phase I/IIa Solid Tumor Trial; Antisense: ‘FDA Expects 9-Month ATL1102 Monkey Tox Trial’; Imagion Receives $2.6m Federal R&D Tax Incentive; Neuren: FDA ‘Minor Modifications’ For 3 Phase II Trials; Starpharma: ‘Viraleze Active Against UK Sars-Cov-2 Strain’; Adherium: US Hailie FDA Submission; Genetic Technologies, Infinity Launch Covid-19 Test; Avecho AGM 17% Oppose 14m Director Options; Medadvisor Loses Joint Co-Sec Carlo Campiciano; Epsilon Appoints Edward Jones Marijuana Manager
 
Truscreen Revenue Down 12% To $1m, Loss Down 33% To $3m; Correction: Audeara; Avecho, Ab Vista Partner On TPM For Pigs; Bard1 Receives $644k Federal R&D Tax Incentive; Neuroscientific Receives $584k Federal R&D Tax Incentive; Acrux Receives Further $175k Federal R&D Tax Incentive; Invion Requests ‘Placement, Technology’ Trading Halt; Immuron Takes ‘Acquisition’ Trading Halt To Suspension; Allan Gray Reduces To 9% Of Impedimed; TDM Takes 26% Of Somnomed; Eleanore Goodridge Takes 5.3% Of Noxopharm; Alison Deans To Replace Cochlear Chair Rick Holliday-Smith; Audeara Appoints Finlay ‘Fin’ Robb US Sales Manager; Respiri Appoints Theo Antonopoulos Chief Commercial Officer; Micro-X Opens Seattle Facility
 
Dr Boreham’s Crucible: Audeara; Respiri Files Replacement Adherium Bidder’s Statement; Austco Expects Profit Up 12%-32% To $2.8m-$3.3m; Cann Group Halves 2020-’21 Revenue Forecast To $4m-$5m; Azure Opens Up 25% At 25c On NSX; Imagion AGM 23% Dissent, Avoids Rem Report 1st Strike; Genetic Technologies Requests ‘Covid-19 Risk Test’ Halt; Perennial Reduces To 6.6% Of Hydrix; Alcidion Appoints Matthew Gepp CFO
 
Victoria Appoints Michael Kapel mRNA CEO; Bluechiip Boxtracker Wins Isber Gong; Volpara Revenue Up 57% To $19m, Net Loss Down 14% To $16.5m; Dimerix: ‘FDA Travere FSFG Knock-Back No Change To Program’; TGA Approves 2 Uscom Monitors; TGA Approves Next Science Blastx Anti-Microbial Wound Gel; Mayne: FDA Grants Nextstellis 5-Year Exclusivity; MTP Connect: Biointelect, Cicada For Redi Industry Training; Recce: ‘R327 Efficacy Against E Coli, In-Vitro’; Little Green $2.5m Demecan Marijuana Order; Invion To Release 1.1b Voluntary Escrow Shares; Immuron Requests ‘Acquisition’ Trading Halt; Imugene’s Paul Hopper, Leslie Chong Sell Shares, Exercise Options; Vanguard Below 5% Of Polynovo; Smart Top, Xianhui Meng Increase, Diluted To 21% Of Uscom; Pokies Bruce Mathieson Increases, Diluted To 9.2% Of Respiri
 
Havah $53m T+AI Deal With Clarus For Mastitis, Breast Cancer; Imagion Enrols 1st Patient In Magsense Breast Cancer Trial; Micro-X: 2nd US FDA Approval For Rover Bedside X-Ray; Epsilon Receives $1m Federal R&D Tax Incentive; Memphasys Notes Raise $3m; Avecho, TGA To Meet On O-T-C Soft-Gel CBD For Insomnia; Antisense ATL1102 Manufactured For DMD Trial; Immutep: China Patent For IMP321, Chemo Combination; Chinese, Hong Kong Patents For Orthocell Celgro; Palla Appoints GW Executive Giles Moss CEO, On $536k
 
Vivazome, Renerve Work On Exosome Spinal Cord Repair; Anteris Placement To Raise $2.3m; Paradigm: FDA Questions PPS For Osteoarthritis Trial; Telix: ‘TLX66 Amyloidosis Trial Meets Endpoints’; Telix Doses 1st Patient In Japan TLX591-CDx Prostate Imaging Trial; Invion: INV-043 Effective Against Multiple Cancers, In Mice; Clarity Signs Cu-67 Supply Deal With Northstar; Aroa Revenue Down 11% To $21m; Loss Up 222% To $18m; Imugene Chair Paul Hopper, M-D Leslie Chong Exercise $2.6m Options; Chimeric Doses 1st Patient In Glioblastoma 2nd Cohort; Visioneering 100-To-1 Consolidation AGM; Bard1: Preliminary Sub-B2M Test Shows ‘Feasibility’ For Cancer; Neurotech Dolce Beats CBD For MS Neuro-Markers, In Vitro; Actinogen Pleads Schultz To ASX 54% Query; Impedimed Releases Sozo Version 4; Memphasys Requests ‘Capital Raising’ Trading Halt; Mercer Street Below 5% In Anteris
 
Cynata: 1st Patient Enrolled In Cymerus Lung Trial; CE Mark For Uscom Spirosonic Air; Adalta, GE Work On Pre-Clinical Granzyme B Imaging; Emvision Improves Brain Scanner; Anteo Adds Brisbane Eugeni Test Strip Manufacturing; Resonance Applies For Antisense Oligonucleotides Patent; Bard1 Applies For Exo-Net, Sub-B2M Patents; Creso 15m Director, Staff, Everblu Shares; Halucenex AGM; TDM Takes 25% Of Somnomed

May 21, 2021; Dr Boreham’s Crucible: Genetic Signatures; MTP: Clinical Trials Worth $1.4b To Australia & Growing; Avecho Completes Marijuana Soft-Gel Design; Creso Polvet Poland Anibidiol For Livestock Distributor; Anteris Requests ‘Capital Raising’ Trading Halt; Veritas Below 5% In Cochlear
 
Anteo Plan: $32m Applications, Raises $8m; Total $20m; 4D Recruits 1st VQ Lung Imaging Cohort; Painchek Wins CE Mark, UK MHRA Approval; Rhinomed Wins CE Mark For Rhinoswab; Azure To List As VGI On NSX; Medlab Move To Synthetic Nanabis For Cancer Pain Trial; Cronos: Marijuana Sales Up, ECS Terpene Distribution; Hexima Renames HXP124 ‘Pezadeftide’; Race Appoints Prof Michael Kelso Principal Scientist; Neurotech Appoints Prof Allan Cripps Director
 
Victoria $245m For Institute Of Infectious Disease; Paradigm Claims 1st ‘Modest’ PPS (Zilosul) Revenue; Bard1: ‘Exo-Net High-Yield Pure Exosomes For Tests, Therapies’; Japan Patent For Adalta; US Patent For Island ISLA-101 Program; Recce: R327 ‘Effective, Not Highly Toxic For Sars-Cov-2, In-Vitro’; Neuroscientific Loses Chair Brian Leedman
 
LBT Sells 2 APAS Independence Units To UK; Audeara Opens Down 5% On $7m Specialist Headphones IPO; Imugene, City Of Hope Deal For CD19 Car-T-Cell Tumor Therapy; Biocurate, Monash Launch Pio For Cancer Immunotherapy; Proteomics, Avance PK Testing Contract; Telix Appoints Eckert Ziegler German Illucix Distributor; Bard1 Launches Exonet At Extracellular Vesicles Meeting; PYC: Unnamed Drug Candidate 2nd For ADOA; Bod Launches Marijuana Cannabigerol CBG50 In UK; MGC Applies For ‘Cimetra’ Slovenian Patent; Emyria 1.5m Consultant Options, Placement EGM; CEO Kate Quirke Below 5% In Alcidion; Cole Mackinnon, Isle Of Wight Diluted To 5.6% Of Alcidion; Resapp Re-Appoints Brian Leedman Exec Director On $187k
 
Immvirx $22m For IVX037, Targeted Oncolytic RNA Viruses; Correction: Island Pharmaceuticals; GSK $80k Australian Research Excellence Awards Open; Anteo Appoints Operon Eugeni Sars-Cov-3 Test Manufacturer; Resonance Selects Lead Component AS3 For Hepatitis B; Botanix: BTX1204A ‘Encouraging Efficacy’ For Eczema, In Dogs; Resapp Enrols 1st Covid-19 Cough Study Participant; Cardiex Launches Conneqt Consumer Brand; Elixinol 23% Oppose 43% Directors’ Fees Pool Hike; Analytica 50m Director Options, Placement EGM; Veritas Takes 5% Of Cochlear, Again; Mithra, Estetra Take 9.6% Of Mayne; Thorney, Tiga Take 17% Of Oventus
 
Dr Boreham’s Crucible: Island Pharmaceuticals; Queensland Uni Dengue Vaccine ‘Immune Response In Mice’; Perennial Takes 11% Of Medadvisor; BCCL Worldwide Takes 9.8% In Tali; Creso: Halucenex Secures More Synthetic Psilocybin; Rhinomed Appoints Prof John McBain Director; Pharmaust Dr Kim Agnew To Lead Monepantel Dog Trial
 
Pro Medicus, Vermont Uni $14m Visage 7 Deal; MTP Connect: $400k For WA Medical Product Manufacturing; Rhinomed: Rhinoswab Beats Standard-Of-Care For Sars-Cov-2; Proteomics Seeks US CPT-PLA Code For Promarkerd; Immuron: ‘IMM-124E Shows Novel Inhibition Of Sars-Cov-2’; Heramed, Obstetrix 100-Subject Herabeat Pilot Study; Imex AGM: 17% Oppose Director Options; Adherium Rick Legleiter, George Baran In; Mike Motion Out; Medlab Appoints Kerem Kaya CFO, Co Sec; Immuron Appoints Dr Dan Peres CMO
 
Budget 2021: Comment & Response - Biotech Daily, Ausbiotech, CSL; Bio-Melbourne Women In Leadership 2021 Gongs; Dimerix: India DMX-200 Covid-19 Trial Delayed By Covid-19; MTP Connect: Dr Staudacher, Dr Kulis Win $250k Redi Grants; Noxopharm Enrols Part 2 Veyonda Covid-19 Trial; Cardiex: US Sphygmocor Patent; Australian Patent For Hexima HXP124 For Toe Fungus; Emyria: ‘TGA Approves Smartphone Heartrate Monitor’; Creso Requests ‘Halucenex Acquisition Update’ Trading Halt; Regal Takes 10.5% Of Adherium
 
Funds For Patent Box Tax Cut, R&D, ANSTO
 
Trajan $90m IPO Oversubscribed; Speedx Wins Carb-X $1.8m For STD Diagnostic; Starpharma: Viraleze For UK Harlequins Rugby Team; Ellume: Sars-Cov-2 Home Test US Facility, US Executives; Emyria Requests ‘Openly Registration’ Trading Halt; Heramed Requests ‘Commercial Partnership’ Trading Halt; Incannex Adds UWA To IHL-42x Marijuana Sleep Apnoea Trial; Australian Super Takes 5.2% Of Micro-X; Blueflag Increases, Diluted To 7% Of Amplia; One Funds Diluted Below 5% In Adherium; Medical Developments Appoints Richard Betts Director; Clarity Appoints Shaemus Gleason Head Of US Operations
 
Audeara $7m IPO For Specialist Headphones; TGA Okays Telix Prostact TLX591-CDx Prostate Cancer Trial; Adherium Rejects Respiri Offer; Oventus Placement To Raise $5m, 1-For-4.4 Rights For $5m; Prescient, Peter Mac Research Omnicar For Cancers; Nuheara Ships 1st Hewlett Packard Elite Earbuds; Bionomics Adds Social Anxiety Disorder To BNC210 Trials; Race: Bisantrene Combinations For AML, In-Vitro; Osteopore: Product Variants CE Mark; Shelf-Life Extended; TDM Takes 25% Of Somnomed; Clime Reduces To 8% In Mach7; Peters Investments Takes 11.4% Of Optiscan; Phillip (Bioscience Managers) Takes 23.5% Of Adherium; Viburnum Takes 11% Of Adherium; FIL (Fidelity) Takes 10% Of Adherium
 
Dr Boreham’s Crucible: Control Bionics; Regeneus Placement To Raise Up-To $4.5m; Noxopharm Veyonda Sarcoma Trial To Enrol 40 Patients; Oventus Takes ‘Capital Raising’ Trading Halt To Suspension; Polynovo Appoints Dr Joshua Cheetham Head Of R&D 
 
CSL $583m Uniqure Deal For AMT-061 For Haemophilia-B; Medadvisor Raises $5.25m; $11.7m Loan; Nyrada Receives $976k R&D Tax Incentive; Mach7 $730k Vermont Uni Medical Centre Eunity Deal; Starpharma: Viraleze Online In Europe; Zelira Launches Marijuana Hope For Autism In US; Rhythm Improves Colostat With Lifestyle Risk Factors; Clarity: US Sar-BIS-PSMA For Prostate Cancer Patent; Creso: Halucenex, Nucro-Technics Psilocybin R&D Deal; MGC Requests ‘Further Artemic Findings’ Trading Halt; Optiscan Appoints Orchid’s Prof Camile Farah Director
 
SDI Expects Revenue Up 18% To $80m, Profit Up 77% To 101%; Alcidion ‘Over-Subscribed’ Share Plan Raises $3m, Total $18.4m; Race ‘Over-Subscribed’ Placement Raises $5.4m; Oventus Requests ‘Capital Raising’ Trading Halt; Hong Kong Approves Oncosil Pancreatic Cancer Device; Memphasys: New IVF Products Include Stallion Sperm Test; Neurotech Starts Phase I/II Marijuana For Autism Trial; Emyria Ecstasy Program For PTSD; Neuroscientific: Emtinb Dose Found In Rabbit Eyes To 14 Days; Nyrada: New Compounds Improve NYX-PCSK9I, In-Vitro; Regeneus Grants CEO Karolis Rosickas 25m Incentive Options; Avecho Loses Director David Segal
 
Amplia Placement Raises $3.8m; Clarity: US FDA Approves Phase I/IIa Prostate Trial; Recce: ‘R327 Kills 99.9% Of Six Pathogens, In-Vitro’; Impedimed: ‘Sozo Measures Heart Readmission Risk’; Uscom Develops Uscom-O2, Basic; Botanix Plans BTX1801 Dialysis Trial; Palla, M&A Legal Issues Settled, Production Begins, Launch; MGC Receives $996k Artemic Rescue Order; Total Brain, Hamptons Life $6m Agreement; Resapp Appoints Ilara Resappdx Kenya Distributor; Medadvisor Requests ‘Funding Facility’ Trading Halt; Medibio: US Patent For Mental State Assessment; Memphasys Prof John Aitken Wins Andrologist Gong; Nuheara Appoints John Luna Business Development Manager; Ron Hollands Replaces IQ3 4-Month Co Sec Aysha Hollingdale
 
Imagion, Patrys Collaborate On Brain Cancer Imaging; Pharmaxis: Teo $187k For Pre-Clinical PXS-5505 GBM Study; WEHI: Natural Antibodies Block Malaria Parasites; Bionomics Repays $6m Equipment, Bank Loan Early; Race Requests ‘Capital Raising’ Trading Halt; Total Brain Requests ‘Commercial Contract’ Trading Halt; Veritas Below 5% In Cochlear; Perennial Takes 15% Of Genetic Signatures; Inov8 Increases, Diluted To 7.8% Of Analytica; Chair Dr Michael Monsour Diluted To 19.99% Of Analytica; Telix Promotes, Appoints Executives For APAC, EMEA
 
Dr Boreham’s Crucible: Anteotech; Epidyolex For Epilepsy - 1st Marijuana On Pbs; Respiri Offers $19m, 1-For-7 Share Takeover Of Adherium; Mesoblast: ‘Remestemcel-L Cuts Subgroup Ards Mortality 46%’; Nova Eye Enrols 1st Patient In Itrack‘Magic’ Glaucoma Trial; Auscann (Cannpal) ‘CPAT-01 Improves Osteoarthritis In Dogs’; Analytica US Patent For Pericoach Vaginal Muscle Strength; Amplia Requests ‘Capital Raising’ Trading Halt; Acrux Receives $406k Overseas R&D Tax Incentive; Micro-X Repays $3m South Australian Government Loan; Cellmid Chinese Import Permit For Jo-Ju, Lexilis Shampoo; Cann Group Sends 20k Bottles Of Marijuana Oil To Iuvo; Avecho 18m Director Options AGM; Australian Ethical Takes 17.5% Of Nova Eye; Exopharm CEO Dr Ian Dixon Increases, Diluted To 18%; Atomo Appoints Joe Hockey, Bondi Partners Advisors; Medadvisor Loses Director Jeff Sherman
 
Federal $2.2m For Queensland Uni mRNA Vaccines, Cancer Drugs; Cellmid To Sell Lyramid For $500k Plus Royalties; Cann Recalls 250 Units Of 50ml Marijuana Oil; Atomo, Unitaid, Viatris Partner For Lower-Cost HIV Tests; Proteomics Files FDA 513(G) Applications For Promarkerd; Regeneus $300k Department Of Defence Grant For Sygenus; Bard1 Assays + CA125: Higher Accuracy For Ovarian Cancer; IQ3: Oncotex Manufacturing Deal With Sterling Pharma; Canada Patent For Neuren Trofinetide For Rett, Autism; Memphasys: 2 US Patents For Felix Sperm Separation Device; Biotron Receives $1.4m Federal R&D Tax Incentive; Universal Biosensors: Grapeworks Sentia NZ Distributor; Medibio To Meet FDA For Mebsleep 510(K) Re-Submission; Australian Super Takes 5% Of Alcidion; Oventus Has Less Than 2 Quarters Cash; Staff Cuts
 
Piper Alderman: Pharmalex Acquires Brandwood CKC; Allegra $2m Loan For Bone Substitute Research; Respiratory Compromise Institute Trials 4d Medical XV LVAS; Anteo Raises $12m For Eugeni Covid-19 Test; Plan For $4m; Emvision: Potential Stroke Detection Analysis Techniques; Amplia Plans Amp945 Combination Pancreatic Cancer Trial; Respiri: Terry White Chemmart To Stock Wheezo; Orthocell: ‘Celgro Nerve Repair Beats Market Leader’ In Rats; Race, Newcastle Uni Study Bisantrene Cardiac Impact; MGC Submits Artemic To Health Canada
 
Victoria: ‘Funding Returns 366% GSP, 454% Income In 10 Years’; Telix: GMS To Manufacture, Supply Radiation Unit Doses; Euro Patent For Osteopore Magnesium Composite Filler; Invion Selects INV-043 For Photo-Dynamic Therapy For Cancer; Anteris Completes ‘Commissural Alignment’ Design Concept; Memphasys Felix Sperm Separator Fix On-Track; Pharmaust Monepantel Dog Plasma Levels ‘Supportive’; Genetic Technologies Files US Covid-19 Risk Test Application; Blackrock Takes 7% Of Cochlear; Cann Group Appoints John Sharman Director
 
FDA Approves Next Science Xperience No Rinse Anti-Microbial; Paradigm: Further US FDA PPS Osteoarthritis Trial Questions; Universal Biosensors: Vicard Sentia South Africa Distributor; Anteo Battery Link Commercialization; Capital Raise Halt; Mackinnon, Isle Of Wight Diluted To 6.8% Of Alcidion; Caledonia, MKMS Below 5% Of Alcidion; Race Founder Dr William Garner Reduces To 7.4%; Regal Below 5% Of Alterity
 
Dr Boreham’s Crucible: Pharmaxis; WEHI, J&J Collaborate On New Malaria Drugs; Analytica Placement For $3.8m; Proteomics Wins ISO 13485 Quality Certification; Prescient: ‘No PTX-200 Dose-Limiting Toxicities’; Dimerix: Remap-Cap Recruits 1st DMX-200 Covid-19 Patients; Antisense: FDA Meeting ‘Constructive’ For ALT1102 For DMD; Auscann Receives $1.6m Federal R&D Tax Incentive; Somnomed 2.2m Director Options, 100% Pool Hike EGM; Regal Reduces To 6% Of Genetic Signatures; Somnomed CEO Neil Verdal-Austin 5-Year Extension On $530k; Auscann CEO Layton Mills Starts On $275k; Anteotech Loses Director Matt Sanderson 
 
Actinogen Plans 3 Phase II Cognition Trials For 2022; Chimeric: ‘No CLTX-CAR-T Dose-Limiting Toxicities’; Patrys: PAT-DX1, PAT-DX3 ‘Favorable’ P-K Profile; Impedimed: US FDA Okays Sozo Heart Failure Index; Oventus: Sleep Metrics To Promote O2vent; Noxopharm Claims ‘Positive’ Interim Noxcovid Results; Incannex: FDA Talks Lead To 3 IHL-675A Applications; Invex: FDA Meeting For Presendin For IIH; Heramed, Joondalup Heracare Pilot Program; MGC Buys Israel’s Medicanl CRO For $6m In Shares; Medibio Begins 2nd Mental Health Application Test; FIL Takes 10% Of Resapp
 
Victoria $50m For mRNA Research, Manufacture; Emyria Raises $5m; Nuheara Starts Elite Earbud Hewlett Packard Production; Factor Therapeutics: From Wounds To Limestone Mining; Incisive Wins Federal $1m For Bluecheck For Tooth Caries; Telix Phase I Japan Trial: TLX250-CDx Safe, Tolerable; Bioxyne Pleads Schultz To ASX 50% Query; Imugene: PFS Endpoint Met In Phase II HER-Vaxx Trial; Ecofibre: Hemp Research Completed 15 Months Early; Analytica Requests ‘Capital Raising’ Trading Halt; Investors Mutual Reduces To 7.5% In Mayne; Founder Dr Mel Bridges, Parma Reduces To 7% Of Anatara; Freeman Road Below 5% Of Resapp
 
Austin: Marijuana ‘No Low Back Pain Benefit With Oxycodone’; Genieus ‘Discovers ALS Biomarker; Potential Treatment’; Exopharm Raises $12m; Azure Raises $2.5m; Name Change To VGI; Ellume: CVS Stocks Sars-Cov-2 Rapid Test Kit; Kazia Potential $478m Evotec Licence For EVT801; Amplia: FAK Inhibitors Reduce Nash Fibrosis, In Mice; Anatara: Ethics Approval For CSIRO 3FDC Psychology Trial; Analytica Appoints Marwa Middle East Infusion Distributor; Little Green Appoints Balancial Danish Marijuana Distributor; Heramed Requests ‘Commercial Partnership’ Trading Halt; Osprey 111m CEO, Director Options AGM; Ausbiotech: Patrys CEO Dr James Campbell Director; Race Appoints Dr David Fuller CMO; Karst Peak Takes 9% Of Pharmaxis
 
Trajan Potential IPO For Precision Manufacturing, Chemistry; China Approves Uscom BP+; Telix Launches TLX599-CDx ‘Noble’ Registry; Adalta Begins Part B Of AD-214 Phase I Study; Ecofibre Marijuana Sleep Trial Approved; Creso: Halucenex, Sixth Wave Psilocybin Extraction Deal; Immutep Receives $1.2m R&D Tax Incentive; Emyria Requests ‘Placement’ Trading Halt; Mitsubishi, Morgan Stanley Below 5% In Cyclopharm; Optiscan: Robert Cooke Chair, Darren Lurie M-D On $375k; Allegra Appoints Robert Bell Technology, Innovation Head
 
Dr Boreham’s Crucible: Volpara Health Technologies; WEHI Discovers How Cancer-Fighting Immune Cells Develop; FDA Approves Mayne, Mirtha Nextstellis Contraceptive; Australian Patent For Anatara Detach For Animal Diarrhoea; Stemcell United Placement Raises $3.8m; Kazia Requests ‘In-Licencing Transaction’ Trading Halt; Exopharm Requests ‘Capital Raising’ Halt; Thorney, Tiga Increase, Diluted To 25% Of Visioneering; Race Appoints Prof Jianju Chen Advisor 
 
Alcidion Raising $18m For $9.6m Extramed; $21m Defence Deal; Amplia Completes Phase I AMP945 Dosing; Race: Bisantrene Inhibits FTO Cancer - Independent Study; Clarity Doses 1st Patient In Phase II Cu64-Sartate Trial; Victoria $2.4m For Bone Marrow Syndrome Research; Acrux Files Dapsone For Acne Anda To FDA; Recce: R327 For Burns Added To Trial Registry; Universal Bio: Wine & Beer Sentia Wine Test US Distributor; Total Brain Adds Heart Variability To Mental Health Monitor; Elixinol Name Change, 43% Directors Fee Hike AGM; Mitsubishi, Morgan Stanley Take 5% Of Cyclopharm; Credit Suisse Takes 5% In IDT; Mercer Street Reduces To 5% In Anteris
 
RMIT: Black Phosphorus Kills Bacteria, Fungi; Pharmaxis $4.4m Placement; GEN Pays Pharmaxis $2m For Russian Bronchitol Rights; Paradigm Doses 1st Phase IIb PPS Osteoarthritis Patient; Telix: TGA Starts Illuccix (TLX591-CDx) Priority Review; Universal Bio: Singularity Sentia Wine Test Chile Distributor; Imex 142k Free CEO, Directors’ Options AGM; Alcidion Requests ‘Acquisition, Capital Raising’ Trading Halt; Stemcell United Requests ‘Placement’ Trading Halt; Creso, Cannabis Queen Bilateral Distribution Deal; Dr Tracey Mynott, Myeng Reduce To 5% Of Anatara; Apeiron, Christian Angermayer Takes 12% Of Bionomics; Peter Mercouris To Replace IQ3 Director Monika Pawel
 
Island Opens Up 100% At 50c, Climbs To 67c; Bard1 Licences Liverpool Uni Type 3C Diabetes Biomarkers; Rhythm: Clinitrials Joins Colostat Trial; Universal Biosensors, Deakin, Swinburne Tn Antigen Deals; Rhinomed Receives $185k Federal R&D Tax Incentive; Avecho Approval For Phase I Marijuana Trial; Pharmaxis Requests ‘Capital Raising’ Trading Halt
 
Resapp Placement To Raise $5.5m; Redhill DSMB 4th Okay For Opaganib For Covid-19; Medlab: ‘Nanabis Reduces Cancer Pain 55%’; CE Mark For Anteotech Sars-Cov-2 Antigen Rapid Test; Imugene Data Back HER-Vaxx Combo, CF33 For Cancer; Tali, Indian Times Group Partnership Commenced; Creso: Halucenex, GTR Mushroom Genome Sequencing Deal; Telix 40% Directors Pool Hike, $100m Revenue CEO Options AGM; PYC: ‘PPMO Delivers RNA Therapeutic To Mouse Brains’; Anteris Takes New $2.7m Mercer Draw-Down Equity Facility; Allan Gray Increases To 10% Of Impedimed; Paradice Diluted To 7% Of Impedimed; Thorney, Tiga Take 15% Of Oventus; Mark Lampert, BVF Take 15.5% Of Bionomics; Amplia Appoints Jane Bell Director; Bod Appoints Medlab’s Alan Dworkin CFO; Genetic Technologies Appoints Opthea’s Michael Tonroe CFO
 
Dr Boreham’s Crucible: 4D Medical; Universal Biosensors Tn Test For Most Cancers; Lubris Deal; Kazia PK Data Confirms Paxalisib Dose; Next Science To Release 73m ASX Escrow Shares; Australian Ethical Takes 5.8% Of Impedimed; Platinum Reduces To 5.6% In Kazia; Anteo Joins Battery CRC Super Anode Project; Genetic Technologies Finalizes US Covid-19 Risk Test Launch; MGC Appoints Nadine Barry Co-Co Sec; 70m ‘Performance’ Rights
 
Impedimed: Sozo BIS Indicates Heart Risk; Visioneering ‘Oversubscribed’ Share Plan Raises $1.2m; FDA Grants Immutep Imp321 Fast-Track Status For HNSCC; Pharmaust Receives $756k R&D Tax Incentive; Resapp Requests ‘Capital Raising’ Halt; Universal Biosensors Requests ‘Agreements’ Halt; Credit Suisse Below 5% In IDT; Nick Allan Replaces Resonance CFO, Co Sec Agha Shahzad; Bionomics Appoints Suzanne Irwin Co Sec
 
Varonis Warns Of Healthcare Cyber Attacks; Island: $44m Bids For $7.5m IPO; Impedimed Options Raise $17.9m; Control Bionics Appoints Numotion US Trilogy Distributor; Imugene Begins 3rd Cohort PD1-Vaxx Dosing; Mayo Joins Trial; Recce ‘R327 Clears Drug-Resistant Infection’; US Patent For Volpara Enterprize, Live Software; Immutep Euro Patent For IMP701 Combination Therapy; Medlab Euro Patent For Nanocelle Drug Delivery; Pharmaust: Monepantel Anti-Viral Against Sars-Cov-2, In-Vitro; Bod: H&H Orders $312k Marijuana Oil For US; MGC Receives $425k Artemic Rescue Order; Perennial Reduces To 7.7% Of Hydrix; Suda Appoints Prof Gunnar Birgegård Scientific Advisor
 
CSL Covid-19 Hyperimmune Immunoglobulin Misses Endpoints; Bionomics Rights Raise $20.4m; Total $22.9m; Exopharm ‘Positive’ Phase I Plexaris Trial Results; Aroa: Myriad Morcells Wound Treatment FDA 510(K) Approval; Noxopharm Veyonda Patent Application; Allegra: Sr-Ht-Gahnite Spinal Cage Sheep Study ‘Successful’; Total Brain Receives $1.4m US ‘Paycheck’ Funding; Control Bionics To Release 7k ASX Escrow Shares; Cann Global Trials Marijuana For Multiple Sclerosis; Pharmaust Requests ‘Monepantel Sars-Cov-2 Results’ Halt; Genetic Signatures Appoints Dr Neil Gunn Director; Opthea Loses Co Sec, CFO Mike Tonroe; Creso Appoints John Griese US Business Development Head; Neurotech Appoints Krista Bates Director
 
March BDI-40 Up 0.2% - Record $18.5b, ASX200 Up 2%, Big Caps Down 1%; 4D Share Plan $32m Applications, Raises $6m; Total $46m; Perron: 3rd US-Approved Drug For Duchenne MD; Recce: ‘R327, R111 Kills Streptococcus Pneumoniae In Mice’; Exopharm Plexaris, Cevaris Safe In Rats, Efficacy Unknown; Universal Bio: Canada Distributor For Sentia Wine Test; Adherium 7.1m Directors Shares In Lieu Of Fees EGM; Creso Launches Marijuana Tea In Switzerland; Cronos FCTR Marijuana Gels For Japan, Hong Kong
 
Pharmaxis, Prof Fiona Wood Trial Pxs-6302 For Scar Inhibition; Opthea: FDA Opt-302 For Wet AMD Paediatric Waiver; Cellmid Rights Raise $4.5m; Medibio ‘Over-Subscribed’ Plan Raises $1m; Total $4m; Telix Appoints Grand River Illuccix (TLX591-CDx) Manufacturer; Memphasys Tests Felix Engineering Fix; Paradigm, Bene Agree New PPS Indications; Invex, FDA Meeting For Phase III Presendin IIH Trial; US Patent For Patrys Deoxymab Combination For Cancer; Creso Pays $70k For Mushroom Psilocybin Extraction; Pharmaust Monepantel Dog Cancer Trial Underway; Phillip Increases, Diluted To 19.6% Of Adherium; Summatix Diluted Below 5% In Adherium; Medlab Loses CFO, Co Sec Alan Dworkin; 4 Appointments; Anteotech Appoints CFO Gail Jukes; Neuroscientific Appoints Dougal Thring, Dr Alexandra Heaton
 
Kazia $382m+ Simcere Paxalisib Brain Cancer China Deal; Dorsavi, Medtronic $432k Wearable Sensors Extension; Swanson Reed: RDTI Registration Closes April 30; Analytica China Pericoach J-V; Race Trials Bisantrene For Extra-Medullary AML; Botanix Btx1702 For Inflammatory Rosacea Trial Approval; Dimerix Takes $5m Peter Meurs Loan; Avita: 15 Recell Abstracts At American Burn Meeting; Recce Granted European R327, R529 Patent; Cann Global: Canntab Marijuana Export Licence; Noxopharm Diluted To 24% Of Nyrada; Altnia Diluted To 7% Of Nyrada; Eleanore Goodridge Below 5% In Nyrada; Trudell Takes 19% Of Adherium; One Funds Diluted To 6% Of Adherium
 
Christian Porter Minister For Industry, Science, Technology; Cann Group, Er Ya Trade In Hong Kong Court For $3.5m; Cynata Expands Stem Cell Ards Trial Beyond Covid-19; Anteris: ‘Adapt Tissue Beats Medtronic For Calcification’; Uscom: Bp+ In China’s Final Review Phase; Living Cell Ends Peptide Research, Pays Auckland Uni $366k; Oventus Signs Inhome As 1st VGM Apnoea Contract; Cann Group, Emyria Plan Fast TGA O-T-C Marijuana; Pharmaust’s Epichem Joins WA Business Program; Respiri, Kevin Chan Trial Asthma Telehealth Program; Althea Launches Cheaper 20ml ‘Flexi’ Marijuana Oil Products; CEO Dr Sean Hall Diluted To 18% Of Medlab; Chair Michael Hall Diluted Below 5% Of Medlab; Director Drew Townsend Below 5% Of Medlab; Regal Takes 6% Of Adherium; Mesoblast Appoints Surgcenter Philip Facchina Director; PYC Appoints Jason Haddock Director; Mark Compton Replaces Next Science Chair George Savvides; Suda Appoints Prof Anil Sood Advisor
 
Dr Boreham’s Crucible: Cynata Therapeutics; Paradigm Files Ind For PPS Knee Osteoarthritis Trial; Immutep: BMS Trial Data Backs Lag3; Creso Placement Raises $18m; LBT Directors Take 25% Of Fees In Shares; Kazia Requests ‘Regional Licence’ Trading Halt; Cann Global Requests ‘Regulatory Milestone’ Trading Halt; Credit Suisse Takes 6% Of IDT; Regal Funds Takes 19.8% Of Visioneering; PYC Loses Director Dr Bernard Hockings
 
4D Access To US Defense, Veterans Contracts; TGA Okays Resapp Wearable Cough Monitor; Palla Retail Rights Raise $5.8m, Total $18m; Race, Newcastle Uni Study Bisantrene For Kidney Cancer; Dimerix: Nasogastric Dmx-200 For Remap-Cap Covid-19 Trial; Medadvisor $6.2m US Vaccine Adherence Contract Extension; Polynovo Appoints Premier Novosorb BTM US Distributor; Starpharma Appoints Lloyds UK Viraleze Distributor; Incannex, FDA Meet On Ihl-675a For Ards, Saards; Cellmid Receives $646k Federal R&D Tax Incentive; Elixinol Hemp Products Ok In UK; Toxicology Study Pending; Jencay Takes 5% Of Medadvisor; Eleanore Goodridge Reduces To 5.4% In Nyrada; Respiri Appoints Dr Andrew Weekes, Dr Mark Levy Advisors
 
Federal $3.2m For Medical Devices; Clinuvel Expands Scenesse To Xeroderma Pigmentosa-Variant; Alcidion $2.2m East Lancashire Nhs Patientrack Deal; Dimerix: Dmx-200 Combination Inhibits Inflammation In-Vitro; Truscreen Cervical Cancer Screening ‘Covid-19 Safe’; Creso Requests ‘Capital Raising’ Trading Halt; One Funds Takes 6% Of Idt; Actinogen CEO Dr Steven Gourlay Appointed M-D; Vale Bionomics Jack Moschakis; Adrian Hinton Interim Co Sec
 
Redhill Opaganib For Swiss Covid-19 ‘Compassionate Use’; Respiri: US FDA O-T-C Approval For Wheezo Asthma Monitor; Pharmaust’s Epichem, Thermaquatica Waste-To-Fuel Deal; MGC Cimetra (Artemic) Phase III Covid-19 Trial Approval; Creso US O-T-C Listing; More Psilocybin; Tdm Takes 24% Of Somnomed; Thorney, Tiga Increase, Diluted Below 5% Of Little Green; Bing-Cheng Liu Replaces TBG Director His-Kai Wang
 
Nyrada Commitments For $11m; Anteo: ‘Rapid Sars-Cov-2 Test 97.3% Sensitive, 99.6% Specific’; Medadvisor Repays Syneos $6.5m Convertible Note In Cash; Auscann $648k Instalment For Chile J-V Dayacann; Antisense Appoints Dr Charmaine Gittleson Director; Avita Appoints Michael Holder CFO 
 
Dr Boreham’s Crucible: Compumedics; Redhill Revenue Up 923% To $83m, Loss Up 80% To $98.5m; Medlab Raises $15m, Appoints Cheryl Maley Director; Pharmaxis Begins US Bronchitol Distribution; Race, Newcastle Uni Study Bisantrene For Melanoma; Noxopharm Begins Veyonda, Nivolumab Cancer Study; Palla: 1st UK Order For Codeine-Paracetamol Pills; IDT: Federal Assessment For Covid-19 Vaccine Production; Creso Launches Marijuana ‘Ritual Sticks’, $73k First Order; Medibio To Supply Ilumen To 1000 UK Compass Employees; Respiri Requests ‘Wheezo FDA Application’ Trading Halt; Ecofibre To Release 192m ASX Escrow Shares; Merchant Funds Takes 13% Of Auscann
 
Monash, Et Al Embryo Models For Pregnancy Studies; Volpara Density ‘Reduces Breast Cancer False Positives’; Amplia, Garvan Work On AMP945 For Pancreatic Cancer; Adherium Placement Raises $18m; Visioneering $1m Share Plan; ITM To Supply Telix Radio-Isotopes; Chimeric Doses 1st Glioblastoma Trial Patients; Osprey: 3 More US Distribution Deals; Bod, Drug Science Study Medicabilis For ‘Long Covid’; Oventus Appoints Connect DME, Circadian Distributors; Nyrada Requests ‘Capital Raising’ Trading Halt; ASIC Restricts TBG Capital Raising; Goodbye Cannpal; Auscann Expands, Board Changes
 
TDM Invests $50m In Qbiotics, Takes 12%; WEHI: Genetic Defect Linked To Mactel Eye Disease; UQ: ‘Anakinra Reduces Worst Chemotherapy Side-Effects’; Federal $15m For Psychedelics, PTSD, Mental Illness; Creso Phase II Psilocybin Trial For PTSD; Amplia Completes Ascending Dose AMP945 Trial; Painchek Wins CE Mark, TGA Approval; Bionomics Additional $3m Placement; Medlab Requests ‘Placement’ Trading Halt; Medadvisor To Release 15m Voluntary Escrow Shares; Universal Biosensors Loses Director Marshall Heinberg; Bill Fleming To Replace Creso’s Dr Miri Halperin Wernli; PYC Appoints Dr Michael Rosenblatt Director
 
Bard1, Minomic Work On Pancreatic Cancer Blood Test; Starpharma: ‘DEP-HER2-Lu Beats Herceptin For Breast Cancer In Mice’; Micro-X Terminates Thales IED Deal; Immutep Starts IMP321-Keytruda Head, Neck Cancer Trial; Azure Manufactures NE1-Elite, NE1-Heart Food Additives; Rhythm Colostat Blood Test 84% Sensitivity, 95% Specificity; Incannex: IHL-675A Beats CBD, HCQ For Arthritis In Rats; Imex: 54 Aquila Deals, $1.2m Annual Recurring Revenue; Imagion Receives Federal $50k Grant; Bluechiip Receives $1.6m R&D Tax Incentive; Adherium Requests ‘Placement’ Trading Halt; European Patent For Regeneus Progenza Stem Cells; Brandon, MRCF, Hesta Hold 27% Of Osprey; Naos Takes 29.5% Of BTC; FIL Reduces To 8.4% Of Resapp; Regal Reduces To 6.6% Of Alterity; Elixinol Appoints Kim Bradley-Ware Co-Co Sec
 
Victoria $17m For La Trobe Uni ‘Digital, Bio Innovation Hubs’; Opthea Treats 1st Phase III Wet AMD Patient, 1979 To Go; S&P ASX Indices: 11 Biotechs Up, 8 Down; Bard1 Granted hTERT Australian Patent; Recce: Pew Adds R327 To Its ‘Non-Traditional’ List; Elixinol To Pay Up To $37m For Germany’s Cannacare; Little Green $7.5m Land Purchase; Marijuana Order; Creso To Pay $500k, 47m Shares For Psychedelic Halucenex; Perennial Takes 5.35% Of 4D Medical; Race Founder Dr William Garner Reduces To 8.45%; Merchant Reduces To 6.4% Of Race; DMX Takes 6% Of Cryosite; Actinogen Appoints Dr Steven Gourlay CEO On $400k
 
 
 
 
  
  
  
  
  
Mesoblast Raises $142m; Emvision Wins $8m Of MRFF Stroke Funding; Palla $4m Placement, $8m Institutional Rights Issue; Neurotech To Raise $3.6m; Expands Dolce Cann Licence; Oasmia Licences Kazia’s Cantrixil For Cancer For $59m; Alcidion Wins $600k NZ Contracts; Nova Eye Starts Itrack Ab-Interno Glaucoma Study; Cynata Cymerus Idiopathic Pulmonary Fibrosis Mouse Study; PYC Claims VP-001 Pre-Clinical ‘Success For RP11’; Osprey Expands US Sales; Noxopharm Receives $4.6m Federal R&D Tax Incentive; CE Mark For Resapp Wearable Respiratory Test; 4D Takes ‘Capital Raising’ Halt To Suspension; Genetic Technologies Requests ‘Material Distribution’ Halt; Creso Appoints Ceres US Anibidiol Distributor; Merchant Funds Takes 14% Of Bard1; Jeffrey Emmanuel Below 5% In Bard1; M-D Fleta Solomon Diluted To 11% Of Little Green; Elixxer Reduces, Diluted To 16% Of Little Green
 
Feb BDI-40 Up 1.5% - Record $18.5b, ASX200 Up 1%, Big Caps Down 0.6%; $99m For Melb Uni-Micro-X Stroke, 4D Lung, Florey Epilepsy; Island $7.5m IPO For ISLA-101 For Mosquito-Borne Viruses; Kyocera Takes Regeneus H1 Revenue To $7m, Loss To $4m Profit; Mesoblast H1 Revenue Down 82% To $4.6m, Loss Up 67% To $65m; Cardiex H1 Revenue Up 16% To $2.7m, Loss Up 6% To $2m; TBG Revenue Up 38% To $4.6m, Profit To $3.5m Loss; Creso Revenue Down 33% To $2.4m, Loss Up 101% To $31m; Pharmaust H1 Revenue Down 37% To $1m, Loss Up 72% To $832k; Osteopore Revenue Up 266% To $1.5m, Loss Down 18% To $2m; Cynata, Tekcyte Work On Stem Cells For Diabetic Ulcers; ASX Delists Invitrocue For Reports, Medigard For Fees; JM Financial, No Plan B Reduce To 12% Of Universal Biosensors; Regal Funds Reduces To 7.5% Of Alterity; Dr Graham Kelly, Milligene Increase To 7.5% Of Noxopharm; Botanix ‘Terminates’ Dr Michael Thurn, Hires 3 Executives
  
Dr Boreham’s Crucible: Neuren Pharmaceuticals; Avita Hopes To Raise $88m In US; Austco H1 Revenue Down 17% To $14m, Profit Up 2% To $826k; Medical Dev H1 Revenue Up 15% To $12.6m, Profit To $1.1m Loss; Palla Revenue Down 60% To $22m, Loss Up 355% To $35m; Palla Trading Halt For $18m Placement, Rights; Elixinol Revenue Down 51% To $15m, Loss Up 26% To $104m; Imex Revenue Up 41% To $11m, Loss Down 40% $3.6m; Hydrix H1 Revenue Down 38% To $5.1m, Loss Up 188% $4.8m; Cryosite H1 Revenue Up 18.5% To $5m, Profit Down 77% To $285k; Telix Revenue Up 50% To $5.2m, Loss Up 61% To $45m; Resonance H1 Revenue Up 8% To $2m, Loss To $770k Profit; Incannex H1 Revenue $1.2m, Loss Up 31% $2.9m; Osprey Revenue Down 54% To $2.1m, Loss Down 26% To $17m; Polynovo Novosorb Synpath Ulcer Study Approved; 4D Requests ‘Material Grant’ Trading Halt; Emvision Requests ‘Funding Application’ Trading Halt; Mesoblast Requests ‘Private Placement’ Trading Halt; Micro-X Requests ‘Funding Application’ Trading Halt; Neurotech Requests ‘Financing Transaction’ Trading Halt; LBT Receives $826k R&D Tax Incentive; Invex Wins US Trademark For Presendin; Resapp, WMA Medetective Launch Delayed; Suda Contracts Medpharm To Improve Anagrelide Oral Spray; Cogstate Appoints David Franks Co-Sec; Resapp Loses 3-Month Co-Co Sec Stephen Hewitt-Dutton
  
Probiotec H1 Revenue Down 3.5% To $43m, Profit Up 79% To $1.2m; Cogstate H1 Revenue Up 59% To $17m, Loss Down 84% To $563k; Medadvisor H1 Revenue Up 192% To $13m, Loss Up 80% To $9.5m; Alcidion H1 Revenue Up 36% To $11m, Loss Down 23% To $1.4m; Cyclopharm Revenue Up 4% To $14.7m, Loss Up 107% To $6m; Nova Eye H1 Revenue Down 11% To $6.6m, Loss Down 45% To $1.6m; Althea H1 Revenue Up 175% To $5.1m, Loss Down 1% To $8.3m; Bod H1 Revenue Up 114% To $2.5m, Loss Down 8% To $1.3m; Micro-X H1 Revenue Up 190% To $2.4m, Loss Up 15% To $4.8m; Control Bionics H1 Revenue Up 22% To $2m, Loss Up 101% To $1m; Total Brain H1 Revenue Down 9% To $2m, Loss Up 3.5% To $4m; Invion H1 Revenue Down 33% To $1.2m, Loss Down 28% To $852k; Bioxyne H1 Revenue Down 10% To $1.2m, Loss Up 11% To $285k; Antisense Files ATL1102 Duchenne Plan To EMA; CSIRO Medicinal Marijuana Manufacturing Licence; Polynovo Appoints Medinamedical Nordic Novosorb Distributor; Avita Requests US Capital Raising Trading Halt; LHC Reduces To 9% In BTC; SIO Reduces To 19.96% In Anteris; Regeneus Loses Director Dr Alan Dunton; Antisense Appoints Alicia Mellors Co-Co Sec
  
Mayne H1 Revenue Down 8% To $209m, Loss Up 842% To $182m; Nanosonics H1 Revenue Down 11% To $43m, Profit Down 74% To $1.5m; Compumedics H1 Revenue Down 1% To $18m, Profit Up 717% To $1.3m; Clinuvel H1 Revenue Up 58% To $16m, Profit Up 420% To $6m; Little Green H1 Revenue Up 427% To $3.8m, Loss To $484k Profit; Medlab H1 Revenue Down 9% To $2.5m, Loss Up 89% To $7.1m; Uscom H1 Revenue Up 232% To $2.3m, Loss Down 82% To $270k; IQ3 H1 Revenue Down 48% To $2.2m, Loss Up 130% To $2.2m; Allegra H1 Revenue Down 1.6% To $2.3m, Loss Down 86% To $188k; Rhinomed H1 Revenue Up 17% To $1.9m, Loss Up 3.5% To $5.5m; Universal Bio Revenue Down 54% To $3.2m, Loss Up 58% To $7.6m; Emyria H1 Revenue Up 165% To $1.15m, Loss Down 3% To $2.1m; Osprey Options Raise $14.5m; $1.4m US Government Loan; US ‘Forgives’ $1.44m Impedimed Covid-19 Loan; Founders Sue Bard1 For Performance Shares; Opthea: 1,980-Patient Phase III OPT-302 Wet AMD Trials; Resonance Adds CE Mark To Hepafat-AI Australian, US Approvals; Adalta: FDA IPF Orphan Status For AD-214; Malaysian Patent For Azure Tocotrienols; Recce To List On Frankfurt Exchange; Selector Funds Below 5% In Nanosonics; Director, CSO Dr Daniel Tillett Increases, Diluted To 7% Of Race; Cell Care Reduces To 17% Of Cryosite; Noxopharm Dr Graham Kelly Reduces To 11% For Options; Apeiron, Christian Angermayer Take Profit To 10% Of Bionomics
  
  
Editorial: Your R&D Tax Incentive Is Not Revenue; Genetic Sigs H1 Revenue Up 411% To $19m, Loss To $4m Profit; Impedimed H1 Revenue Up 26% To $3.6m, Loss Down 19% To $10.4m; Next Science Revenue Down 15% To $4.4m, Loss Down 17% To $15m; Cann Group H1 Revenue Up 36% To $1m, Loss Up 12% To $9.4m; Micro-X ‘Oversubscribed’ Share Plan Raises $3.5m; Total $34m; Azure Hopes For $3m NSX Listing; Noxopharm: Canaccord Underwrites $3.7m Options; Cynata Receives $1.4m Federal R&D Tax Incentive; Pharmaxis Enrols 1st PXS-5505 Myelofibrosis Patient; Japan Approves Telix TLX591-CDx Prostate Cancer Trial; Bionomics Reformulated BNC210 Pharmacokinetics; BTC To Distribute GPX Neola Lung Volume, Oxygen Monitor; Invion To Release 1.4b Voluntary Escrow Shares; CEO George Syrmalis Increases, Diluted To 20% Of IQ3; Emyria Appoints Dr Karen Smith Advisory Board Chair; Auscann: Charles Altshuler CFO, Maria Alexakis Med Director; Bod To Lose CFO Charles Altshuler; Medigard Faces ASX De-Listing On Fees
  
 
  
Pro Medicus H1 Revenue Up 8% To $32m, Profit Up 12% To $13.5m; BTC $19k H1 Revenue, Speciality Unit $3.6m, BTC Loss $179k; Visioneering Raises $22m, Share Plan For $1m More; Cyclopharm ‘Over-Subscribed’ Share Plan Raises $3m, Total $33m; Mesoblast: Remestemcel-L-Treated Children Recover From MIS-C; Amplia Begins AMP945 Multiple Ascending Dose Study; Bionomics, Empathbio MOU For BNC210-EMP-01 For PTSD; Proteomics Pleads Schultz, Good News To ASX 31% Price Query; Federal Court Grants Cann Group Cleansing Notice Extension; Resonance Requests ‘Regulatory Approval’ Trading Halt; Credit Suisse Takes 5% Of Bard1; Cell Care Reduces To 18.55% Of Cryosite; Jimmy Thomas, Ivy Ponniah Take 8.5% Of Living Cell; Burnet Opens Diagnostics Initiative, Jennifer Barnes Director; Stemcell Appoints David Plattner Sustainability Advisor
 
Dr Boreham’s Crucible: Chimeric Therapeutics; Glaxosmithkline: $6.9m For Australian Research; CSL: Astrazeneca Vaccine Manufacture ‘In Final Stage’; Imugene Begins 2nd Cohort PD1-Vaxx Dosing; Avita H1 Revenue Up 56% To $13m, Loss Up 11.5% To $20.5m; Starpharma, Merck Dep-Antibody Drug Conjugates Deal; Recce R327 ‘Reduces Sars-Cov-2 99.9%’ - In-Vitro; Botanix Receives $6.9m R&D Tax Incentive; Living Cell Pleads Schultz, Talks To ASX 39% Price Query; Tali Requests ‘Capital Raising’ Trading Halt; Incannex Requests ‘IHL-675A Results, Further Studies’ Trading Halt; Auscann Buys Back 8m Unmarketable Shares, 8k Parcels; Platinum Reduces To 6.8% Of Kazia; Orthocell CSO Ming Hao Zheng, Ying Fan Below 5%; BVF Partners Diluted To 15% Of Actinogen; Cochlear Appoints Stu Sayers CFO; Biointelect Appoints Four Executives
Optiscan Starts Breast Cancer Margin Microscope Study; Cann Group: $3.6m ‘Cyber Security Incident’; Proteomics Files FDA Promarkerd Pre-Submission; Telix Terminates Pi Medical Netherlands Distribution; Heramed: Sheba Herabeat Foetal Heart Monitor Trial; Anatara Ready For Garp IBS Diarrhoea Trial; Little Green: 1st German Commercial Marijuana Shipment; Creso Takes-Back Swiss Marijuana Distribution; Respiri: Pharmacy Catalyst To Sell Wheezo Asthma Monitor; Exopharm Pleads Schultz To ASX 30% Query; Stemcell Pleads Schultz To ASX 59% Query; Avecho Requests Capital Raising Halt; Medibio Requests Capital Raising Halt; Anglo Australian Christian Diluted To 14% In Cyclopharm; Perennial Holds 12% Of Micro-X; Regal Funds Takes 10% Of Elixinol; McRae Diluted To 27% In Neuroscientific; Actinogen Loses 6-Year CEO Dr Bill Ketelbey; Race Appoints Mary Harney Director; Neale Java To Replace Control Bionics CFO John Bell
January BDI-40 Down 1%, ASX200 Up 0.3%, Big Caps Down 4%, NBI Up 6%; Redhill: ‘DSMB Backs Opaganib For Covid-19 Trial’; Micro-X Raises $30.5m, Share Plan For $2.5m More; Althea H1 Receipts Up 204% To $4.7m; TBG Receipts Up 119% To $7.3m; THC Receipts Up 44% To $6.9m; Cardiex Suspended; H1 Receipts $2.3m; Polynovo Appoints Medival Novosorb BTM Italy Distributor; UK Approves Palla Norway Codeine Facility; Osteopore, Terumo Collaborate On Regenerative Medicine; Nyrada, Walter Reed, Uni NSW Brain Injury Collaboration; Anatara: Anr-Pf ‘Success’ For Poultry Necrotic Enteritis; Dorsavi Requests ‘Shortfall Placement’ Trading Halt; Botanix Requests ‘BTX1801 Trial Results’ Trading Halt; Suda EGM 36% Oppose Employee Option Plan; LBT To Lose Chair Kate Costello, Director Caroline Popper; Adherium Loses Director Bryan Mogridge; Chimeric Appoints Cindy Elkins Director; Emyria Appoints Dr Richard Magtengaard Advisor
 
Dr Boreham’s Crucible: Orthocell; Resmed H1 Revenue Up 9.5% To $2b, Profit Up 26% To $511m; Imex Receipts Up 25% To $8.7m; Regeneus H1 Receipts, Milestone $7.7m; Hydrix H1 Receipts Down 46% To $5m; Pharmaxis H1 Receipts Down 9.3% To $3.6m; Little Green H1 Receipts $3.3m; Mesoblast H1 Receipts Down 91% To $2.6m; Telix Receipts Up 8.5% To $3.9m; Creso Receipts Up 32% To $3.7m; Osteopore H1 Receipts Up 110% To $1.5m; Incannex H1 Receipts Up 192% To $1.4m; Rhinomed H1 Receipts Down 17% To $1.3m; Bioxyne H1 Receipts Down 37% To $1.3m; Cann Global H1 Receipts Up 85% To $1.1m; Correction: Next Science; Volpara Requests ‘Corporate Acquisition’ Trading Halt; Nyrada ‘Brain Injury Collaboration’ Trading Halt; Australian Ethical Takes 11.5% Of Cyclopharm; Karst Peak, Leitzes Increase, Diluted To 9.7% Cyclopharm; Peter And Helen Jones Below 5% Of BTC; Chimeric Appoints Prof Yvonne Chen Advisor
 
 
Cyclopharm $30m Placement, Share Plan For $1.5m; Genetic Signatures Easyscreen STI Wins CE-IVD; Telix Doses 1st US Zircon Renal Cancer Imaging Patients; Adventist Health Expands Mach7 Pacs Contract To $7.9m; Aroa Q3 Receipts $14.9m; Elixinol Receipts Down 57% To $14m; Atomo H1 Receipts $5.8m; Anteris Receipts Down 61% To $7.3m; Uscom H1 Receipts Up 146% To 2.7m; Medlab H1 Receipts Down 37% To $2.6m; IQ3 H1 Receipts Down 42.5% To $2.5m; Cellmid H1 Receipts Down 27% To $3.5m; $530k China Order; Pharmaust H1 Receipts Down 27% To $1.3m; 4D Starts XV LVAS US Pilot Program; Hapvida $58k, 2-Year Renewal Of Heramed Heracare Deal; Immutep Wins Safety Approval For IMP321 Covid-19 Trial; Universal Biosensors Appoints Enartis US Sentia Distributor; Emvision: FDA Advises De-Novo Path For Brain Scanner; Mitsubishi Singapore Ends Suda Zolpimist Licence; Little Green 2-Year French Government Marijuana Deal; Naos Takes 27% Of BTC; Mercer Street Takes 5% Of Anteris; Living Cell To Lose CEO Dr Ken Taylor; CSL Loses 4-Month Astrazeneca Director Dr Pascal Soriot; Factor Appoints Taylor Collison Advisor
  
  

Jan 17, 2021 

Special Summer Catch-Up Edition: 

Acrux Raises $7.8m, Share Plan For $2m More; Next Science: Blastx Wins CE Mark; Pharmaust: Epichem Extends Up-To $1m DNDI Contract; Nyrada NYX-PCSK9I ‘Reduces Cholesterol In Mice’; Vivazome, BIA Separations Work On Exosome Purification; Rainmaker, Marcus Liew Reduce In Osteopore; Perennial Takes 8.8% In Hydrix; Incannex Starts IHL-42X Marijuana Sleep Apnoea Trial; Elixinol Terminates Pet Releaf Agreement; Creso: Anibidiol Approved In Uruguay, $89k Purchase Order; Director Paul Benhaim, Raw With Life Diluted To 9% In Elixinol; Volpara 5-Year Queensland Breastscreen Contract; Starpharma Starts Viralese Covid-19 Nasal Spray Study; Universal Biosensors, J&J Lifescan Animal Diabetes Test; Alterity, Uniquest Licence For PBT2 Antimicrobial; M&G Reduces To 9% Of Starpharma; K1W1 Below 5% In Adherium; Bod: H&H Orders $871k Of Swisse Hemp Seed Oil For Italy; Director Michael Stork Diluted To 5.5% In Patrys; Stemcell Responds To ASX 172% Price Query; Palla Loses Founder, CEO Jarrod Ritchie; Pharmaust Ethics Approval For Dog Cancer Trial; MGC Wins $5m Malta Grant For Artemic For Covid-19; Cann Group: 1st UK Marijuana Oil Shipment; Genetic Signatures: Boston Medical Easyscreen Distributor; Palla Appoints Iain Ross Director; Avecho Begins ‘Observational’ CBD-TPM Study; Recce: R327, R529 Anti-Viral Effect In Hamsters; TGA Approves Orthocell Celgro; Resapp Ends Reckitt Benckiser Cough Diagnostic Deal; Noxopharm Approved For Overseas R&D Expenditure; Althea Appoints Lyphe UK, Jersey Distributor; Telix: ‘TLX101 Lengthens Glioblastoma Survival’; Invex To File Euro Application For Presendin For IIH; Pharmaust Begins Manufacturing Human-Grade Monepantel; Redhill Opaganib Covid-19 Trial Passes Safety Review; Simavita Extends $1.4m Convertible Notes; Resonance: Blackford Includes Hepafat-AI In Imaging Deal; Blackrock Takes 5% Of Immutep; Elixinol 17% ASX Price Drop Query; Phillip Thematic Below 5% In Adherium; Anteo Appoints Covid-19 Rapid Test Part Manufacturer; M&G Reduces To 8% Of Starpharma; Bruce Gordon Replaces Cellmid Chair David King; Nuheara $11.5m For Hewlett Packard Deal; End Lind Facility; Chiesi Pays Pharmaxis $9m Bronchitol Approval Milestone; Esense $812k Loan Agreements; Medibio: FDA Wants More Data For Medsleep Approval; Analytica Receives $649k R&D Tax Incentive; Phillip Asset Management Takes 15% Of Acrux; Samuel Terry Below 5% In Acrux; Phillip Asset Management Takes 10% Of Cynata; Blackrock Takes 6.6% Of Immutep; Mach7 Appoints Philippe Houssiau Director; Universal Biosensors, Bayer $1.3m Lab Service Deal; Anteris Placement Raises $1.1m; US Patent For Immutep IMP321 Combination For Cancer; Exopharm Pleads Schultz To ASX 68% Query; Regal Funds Reduce, Diluted To 10.5% Of Elixinol; Blackrock Takes 8% Of Immutep; Simon Harradence, DDH Graham, Lugarno Below 5% Of Acrux; Lifespot Rights Raise $1.6m, $793k Shortfall; Probiotec Completes $52.5m Multipack LJM Acquisition; Redhill: Topline Data Shows Opaganib Benefit For Covid-19; Federal Government: $10m For Covid-19 Related Trials; Federal $1.5m For Doherty Sars-Cov-2 Vaccine; Bionomics Starts BNC210 Dosing Study; Anteris Takes $1.2m Mitchell R&D Tax Loan; Genetic Tech: Simon Morriss CEO, Dr George Muchnicki CMO; Indira Naidu Replaces Immutep Joint Co-Sec Tom Bloomfield; Nova Taylor Replaces Lifespot Co-Sec Justyn Stedwell; Blackrock Below 5% In Immutep; Carl Charalambous Takes 6% Of Exopharm; Regal Funds Reduces To 9.5% Of Elixinol; Emyria To Take Marijuana EMD-003 To TGA; Imex Signs 41 Aquila Deals Worth $945k ARR; Cann, Iuvo Supply Deal, 19k Unit First Order; Rhythm Pleads Schultz, Fool, Tim Boreham To ASX 46% Query; FIL Takes 7% Of Somnomed; Elizabeth McGregor Replaces Exopharm Director David Parker; Eleanore Goodridge Reduces To 6.4% In Nyrada; Goodbye Tasmanian Alkaloids, Hello Extractas Bioscience; Anteris ‘Funding Package’: $1m Placement, $19m Loans; Nuheara Placement Raises $11.5m, Debt Repaid; Cardiex Share Plan Raises $3.2m; CMRI, Logicbio Extend Viral Vector Gene Therapy Program; Immutep: Patient Dosing Complete In Part C Of Tacti-002 Trial; Imugene Completes HER-Vaxx Patient Recruitment; Kazia Begins Glioblastoma Agile Trial Recruitment; Mayne Launches Generic Microgestin 24 FE In The US; Dr David Stamler Alterity CEO, Geoffrey Kempler Chair; Pharmaust, Leiden Uni Monepantel Water Solubility Research; Cann Group Receives $3.2m R&D Tax Incentive; Micro-X Receives $1.95m R&D Tax Incentive; Painchek Receives $980k R&D Tax Incentive; Viburnum Reduces To 15.5% In Universal Biosensors; Richmond Hill Takes 7% In Universal Biosensors; Australian Ethical Below 5% In Impedimed; Cannvalate Takes 19% In Lifespot; Auscann: Cannpal’s Layton Mills Replaces CEO Nick Woolf; Mesoblast: ‘Revascor Reduces Cardiac Events By 30%’; Impedimed Completes 1,100 Patient ‘Prevent’ Lymphoedema Trial; Neuren: EU NNZ-2591 Orphan Status For 3 Neuro Syndromes; Cogstate: $29m H1 Sales; Althea Hits $1m Marijuana Sales In Month Of December; Medibio Begins Mental Health Detection Testing; Paradice Takes 8% Of Impedimed; Allan Gray Reduces To 6% Of Impedimed; Loumea Reduces To 5.5% Of Rhythm; Chair Adam Blumenthal, Anglo, Atlantic Take 16% Of Creso; Platinum Below 5% In Antisense; Perennial Takes 8% Of Nuheara; Resapp Appoints Mike Connell Commercial Activities Head; Federal, MTP $38m For Diabetes, Heart Disease; Nuheara Launches HP Elite Wireless Earbuds; Acrux: FDA Approves Generic Testosterone; Creso: Pharma Dynamics $320k Purchase Order For Cannaqix; Optiscan: $350k Carl Zeiss Microscopes Order; Noxopharm: Safety Review Approves Veyonda Dose Increase; Jimmy Thomas, Ivy Ponniah Take 6% Of Living Cell; MGC Appoints Nicole Godresse Head Of Sales; Pro Medicus, Intermountain $40m Visage 7 Deal; Cyclopharm Targets FDA Technegas Approval For July; Orthocell FDA 510(K) Clearance For Celgro; Total Brain Receives $1.1m R&D Tax Incentive; C2, Cardiex Chair Cairns, CEO Cooper Increase, Diluted To 21%; Regal Funds Reduces To 12% Of Alterity; Respiri Begins Wheezo Sales Through Superchem; Aysha Hollingdale Replaces IQ3 Co Sec Gerado Incollingo; Bard1 Loses Director Dr Irmgard Irminger-Finger; Wasagi Corp, David Cannington Diluted Below 5% In Nuheara
 

 

 

 

 

 

Jan 1, 2021
2020: BDI-40 Up 24%, ASX200 Down 1.5%, Big Caps Up 6%, NBI Up 26%;
Amplia Up 550%, Alterity 271%, Telix 170%, Immutep 166%, Cyclopharm 119%
 
Dr Boreham’s Crucible: Micro-X; Mesoblast: DSMB Halts Remestemcel-L Covid-19 Ards Trial; 4D: XV LVAS Scans 1st Commercial Patient; Austco Receives $489k Legal Settlement; Impedimed Wins Hitrust Certification For Cyber Security; Paradigm Prepares FDA Ind For PPS For Osteoarthritis; Mayne Extends Debt Facility, Reduces Debt To $208m
 
Biotech Daily Editorial: 2020 - The Year In Review; Pro Medicus, Medstar $18m, 5-Year Deal For Visage 7; Micro-X, ADF $1.3m Deal For Rover Mobile X-Ray; Race Receives $387k Federal R&D Tax Incentive; Imugene Recruits 1st PD1-Vaxx Lung Cancer Cohort; Orthocell Celgro Passes TGA Conformity Assessment; Medadvisor $4m Shortfall, Total $42.2m; $6.5m New Contracts; THC Raises $2.75m For Medimar And Manufacturing; Neurotech $366k Placement, 38m Employee, Manager Options; Rhythm US Patent For Colostat Biomarkers; Immutep Expands IMP321 Manufacturing Capability; FIL (Fidelity) Increases, Diluted To 9% In Telix; Uniquest Below 5% In Emvision; Acrux Requests ‘Capital Raising’ Trading Halt; Visioneering To Release 6.6m Voluntary Escrow Shares; Anteris Loses Star Bright Director Dr Yanheng Wu; Emvision Appoints Prof Stuart Crozier CSO; Prescient Appoints Prof Henry Miles Prince Scientific Advisor
 
Ellume: FDA Sars-Cov-2 Test Emergency Use Approval; Mesoblast Requests ‘Corporate Update’ Trading Halt; Telix, Muana Kea Partner For Prostate, Kidney Cancer; Telix Files TLX591-CDx Prostate Imaging NDS To Health Canada; Aroa: 6-Patient Myriad ‘100% Healing’ For Bone, Tendon; Imagion Enrolment Opens In Magsense Breast Cancer Trial; Heramed, Mayo Herabeat, Heracare Study; Elixinol Plan Raises $12.3m Of Hoped-For $2m; Total $20.5m; Suda Raises $2.76m, Ordesa Terminates Co-Development Deal; Emyria Placement Raises $1.2m; Optiscan Appoints J&H Taiwan Microscope Distributor; Respiri: Pharmacy 4 Less To Sell Wheezo Asthma Monitor; Creso Marijuana Deal With Ontario Cannabis; Cronos Launches Hemp Soap In Japan, Hong Kong, Australia; THC Requests ‘Capital Raising’ Trading Halt; Credit Suisse Takes 7%, Ceases In Dorsavi; Perennial Below 5% In Immutep; Dr John McBain, Picton, 52nd Celebration Take 17% Of Rhinomed; Bod Appoints Medical Marijuana Advisory Board 
 
Mesoblast: ‘Revascor Misses Endpoint, Reduces Heart Events’; Clarity Placement Raises $25m; Althea Placement Raises $6m; Share Plan Hopes For $3m; Cochlear: US Supreme Court Denies Appeal; $472m Claim, Fees; Cardiex H1 Sales Up ‘More Than 30%’; TGA Drops Cannabidiol To O-T-C Schedule 3, But No Products; MGC: ‘Artemic Covid-19 Trial Meets Endpoints’; Incannex: IHL-216A Beats CBD For Brain Injury In Rats; Immuron, Monash Test Cow Colostrum Against Sars-Cov-2; Heramed: Teleperinatal To Distribute Foetal Monitors; Australian Ethical Takes 15% Of Nova Eye; Credit Suisse Takes 5% In Dorsavi; Regal Funds Reduces To 14% Of Elixinol; Regal Funds Below 5% In Medadvisor; Director Jim McDowell Rejoins Micro-X; Cochlear Appoints Stu Sayers Acting CFO
 
Medical Developments Raises $25m; Share Plan Capped At $5m; Telix, Kanazawa Start TLX591-CDx Japan Ethnicity Study; Alcidion $2m South Tees NHS Extension; Austco $1.3m Singapore Nurse Call Contract; Antisense Wins EU Orphan Status For ATL1102 For DMD; Safety Data Board Okays Adalta AD-214 Dose Escalation; Telix Completes Therapharm, Southampton Uni Deals; S&P Promotes 4D Medical, Demotes Avita, Resapp; Emvision Receives $1.3m Federal R&D Tax Incentive; Kazia Receives $1m Federal R&D Tax Incentive; Stemcell Raises $1.9m; Rhinomed Sars-Cov-2 Swab Equals Comparator; Botanix Completes Btx1801 MRSA Study Treatment; Zelira Appoints Hope Marijuana Washington Dc Distributor; Cellmid: Ourui To Distribute Hair, Skin Products In China; Emyria Requests Placement Trading Halt; Suda Requests Capital Raising Trading Halt; Exopharm Releases 35.7m Escrow Shares; Anatara Unmarketable Parcel Facility; Perennial Below 5% In 4D Medical; Jimmy Thomas, Ivy Ponniah Below 5% In Stemcell; Imex Loses Co-Co Sec Peter Webse; Reena Minhas Co Sec
 
Dr Boreham’s Crucible: Imex Health Services; CSL, UQ Close V451 Covid-19 Vaccine Trial; ANU, Janssen Work On Type 1 Diabetes Tests; Chimeric ‘Over-Subscribed’ $35m IPO Closes Early; Cynata Placement Raises $15m, Rights Offer For $5.5m More; Bod Placement Raises $8m; Patrys Rights Raise $2.4m, $2.4m Shortfall; Total $7.3m; L1, Obsidian Convert $3m Cann Global Notes For Shares; Zelira Receives $1.4m R&D Tax Incentive; Althea Requests Capital Raising Trading Halt; Regal Funds Increases, Diluted To 5% Of Medadvisor; Creso Marijuana For Martin & Pleasance
 
A Year In The Grass - Medical Marijuana Review; Immutep: Aipac Breast Cancer Sub-Group ‘Statistical Significance’; Ellume Sars-Cov-2 Home Test 96% Accurate; FDA Application; Starpharma: Viraleze For EU, Study Planned; Immutep, EOC China IMP321, Paclitaxel Breast Cancer Trial; Hydrix 1st Human Phyrari Heart Sensor Trial; Correction: Cynata Therapeutics; PNOC Includes Kazia Paxalisib In Brain Tumor Trial; Imugene Receives $4.8m R&D Tax Incentive; Medical Developments Requests Capital Raising Trading Halt; Bod Requests Capital Raising Trading Halt; Stemcell Requests Capital Raising Trading Halt; Noxopharm CEO Dr Graham Kelly Diluted To 14%; Telix To Release 2.8m Voluntary Escrow Shares; 4D To Release 10.9m ASX Escrow Shares; PYC: Sahm Nasseri US CEO, Director; Starts On $663k; Race CMO Prof Borje Andersson Steps Down From Board
 
Queensland Grant For Ellume Sars-Cov-2 Test Expansion; Resonance: FDA Clears Hepafat AI Liver Test; Uscom H1 5-Month Revenue Up 183% To $2.2m, Loss To $180k Profit; Anteo Options Raise $3.9m For Covid-19 Tests; Cann Global Raises $3.75m For Convertible Note Liabilities; India Approves Aroa Wound Treatments; MTP Connect $10m Fellowships Program Opens Next Week; Kazia: Results Confirm Cantrixil Ovarian Cancer Responses, Dose; Telix: TLX591-CDx NDA Ready For FDA Review; Dorsavi 12-Month Medtronic Evaluation; Cynata Requests $20.5m Capital Raising Trading Halt; Respiri Drops Wheezo Price 67% For Volume; Orders For 7k Units; Prescient: Covid-19 Screening ‘Inconclusive’; Japan Patent For Tali Detect, Train, Maintenance; Correction: Eleanore Goodridge, Nyrada; Creso Wins $288k In Recreational Marijuana Orders; MGC Sells $1.3m Unmarketable Parcel Shares; Stem Cell Pleads Schultz To ASX 128% Query; Simavita Postpones AGM To June 2021; Paradigm Appoints Amos Meltzer Director
 
Control Bionics $15m IPO Opens Up 87%; Anatara Develops 3FDC For Mood; Garp IBS Trial Delayed; Incannex Plans Psilocybin For Anxiety Trial; Redhill Increases Talicia For Helicobacter Pylori Coverage; Nuheara: ‘Record Monthly Direct-To-Customer Unit Sales’; Althea: ‘November Record Revenue Of $847k’; Tali $9.4m Deal With Times, Brand Capital For India; Antisense Receives $651k Federal R&D Tax Incentive; Recce: DIIS Approves Further $4.2m Offshore RDTI; Resonance Requests ‘Regulatory Clearance’ Trading Halt; Eleanore Goodridge Reduces To 8.3% In Nyrada; Geoff Hollis Replaces Imagion Co Sec Jovanka Naumoska
 
Doherty’s Dr Simone Park Wins $20k Victoria Premier’s Award; TGA Priority Review For Telix Prostate Cancer Imaging TLX591-CDx; CSIRO, Anatomics Collaborate On Smart Helmet For Seizures; Mesoblast: Biomarkers Back Remestemcel-L For GvHD; Lifespot 1-For-4 Rights Issue For $2.4m; Medadvisor: H2 Adheris Revenue Up 14.5% To $21m; Neuren: ‘EMA Positive Opinions For Orphan Status’; Noxopharm Finds Hard-To-Treat Cancer Candidates; Cann Global Requests ‘Capital Raising’ Trading Halt; Azure Applies For Tocotrienol Delivery Patent; Atomo: Prep Health Distributes HIV Self-Test; Ease Of Use Study; Universal Biosensors: Grapeworks Australia Sentia Distributor; Emvision Releases 16.8m Escrow Shares; Cogstate Appoints Darren Watson CFO, Ben Bloomfield CTO
 
Dr Boreham’s Crucible: Palla Pharma; Victoria $60m For Genomics Hub; Hexima Re-Opens On ASX With ‘Oversubscribed’ $3m IPO; Uscom Listed As China ‘High Technology Enterprise’; Medadvisor Retail Rights Raise $3.2m Of $20m, Total $38.2m; Cardiex Share Plan For $1m; Allegra Up 100% On Revised Spinal Cage Beating Previous Design; Medical Developments To Take Back EU Penthrox By March; Australia Backed UN Commission Marijuana Downgrade; Emyria Plans 200-Patient IBS Marijuana Observational Study; Althea, Africann $650k South Africa Marijuana Deal; Medibio: FDA Rejects Depression Test ‘Breakthrough Status’; Tali Requests ‘Partnership, Investment’ Trading Halt; Incannex Requests ‘Psychedelic Drug Trial’ Trading Halt; Unlimited Innovation (Cho Group) Distributes Invion Shares; Medibio To Release 15m Voluntary Escrow Shares; Yoav Elishoov Replaces E-Sense 9-Month CEO Itzik Mizrahi; Resapp Appoints Stephen Hewitt-Dutton Joint Co-Sec
 
Noxopharm Placement Raises $23m; FDA Wants More Data For Telix TLX591 Prostate Cancer Trial; UK Wants More Palla Data For Norwegian Codeine Plant; Imex: Aquila In-The-Cloud $675k Revenue In 6 Months; Telix Appoints Duchembio South Korea TLX591-CDx Distributor; Goodbye Avita Therapeutics, Hello Avita Medical; UN Narcotic Drugs Commission Downgrades Marijuana; Bod: H&H $200k Hemp Oil Order For Europe; Leon Serry, City Castle Below 5% In Antisense; Medical Developments Gordon Naylor Chair; David Williams
 
FDA Approves Academic Use Of Telix 68Ga-PSMA Prostate Imaging; TGA Okays Telix Prostate Cancer Therapy Trial; FDA Fast Track For Mesoblast Remestemcel-L For Covid Ards; 4D, Miami Uni ‘Breakthrough’ Lung Program; Rhythm: Biotem To Manufacture Colostat Colorectal Cancer Test; Bard1 Clarifies hTERT Test Texas Customer; China Patent; Simavita Loses Delisting Vote, Capital Reduction Passed; Zelira, Sprinjene US Marijuana CBD Toothpaste Launch; Creso $414k Animal Marijuana Orders Take 2020 Total To $975k; Genetic Technologies Revises Taliaz Predictix Deal; Amplia Receives $533k R&D Tax Incentive; Perennial Takes 12% Of Micro-X; Merchant Reduces To 9% Of Race; Kim Hogan, JK Below 5% Of Invex; Oncosil ‘Terminates’ CEO Daniel Kenny; Dr Chris Roberts Executive
 
November BDI-40 Up 15%, ASX200 Up 10%, Big Caps Up 2%, NBI 11%; Polynovo Details US Burns Trial; Polynovo Takes Back Breast Program; Correction: Telix; Imugene Starts Phase I PD1-Vaxx Lung Cancer Study; Spain CE Mark For Imex Hiruko Imaging; Noxopharm Requests Capital Raising Trading Halt; Bard1 Requests ‘ASX Information’ Trading Halt; Althea, Peak Deal For Canada Marijuana Drinks; Genetic Technologies To Sell Taliaz Anti-Depressant Predictix Test; Life Biosciences Diluted To 13% Of Alterity; Regal Funds Reduces To 15% Of Elixinol; Memphasys Chair Alison Coutts On $350k; Avita Appoints Kathy McGee COO
 
 
Dr Boreham’s Crucible: LBT Innovations; Control Bionics $15m IPO To Convert Thoughts To Speech; Federal $4m For Covid-19 Research; Anteo Receives $1.2m R&D Tax Incentive; Opyl Receives $249k R&D Tax Incentive; Resapp AGM 35% Oppose Director Options, 10% Capacity Fails; Somnomed AGM 12% Oppose Director Hilton Brett; Bard1 Withdraws Helen Fisher Re-Election Ahead Of AGM; Little Green AGM 9% Oppose 10% Placement Capacity; Nuheara AGM 96% Halt Warwick Sauer Board Bid; Tali Pleads Schultz, AGM To ASX 43% Price Query; Telix Requests ‘Commercial Acquisition’ Trading Halt; Australian Ethical Diluted To 6.75% Of Immutep; Regal Funds Takes 13% In Alterity; Peter And Helen Jones Reduce To 6% Of BTC; Jimmy Thomas, Ivy Ponniah Take 5% Of Living Cell; Neurotech Takes ‘Marijuana Cell Studies’ Halt To Suspension; Esense: ‘Marijuana Terpenes Kills Coronavirus, In-Vitro’
 
 
Volpara H1 Revenue Up 38.3% To $9.0m, Net Loss Up 10.7% To $8.4m; Nova Eye: 4-Month Glaucoma Sales Up 12.8% To $4.4m; Alcidion Expands Nextgate Deal For UK, Ireland; Telix: US FDA Reviews Phase III Plan For TLX-591; TGA Registers Rhinomed Nasal Swab; Emyria Launches Marijuana Mental Health Program; Cann Group Details $50m Debt Facility Terms; Licences; Prescient AGM 47% Oppose CEO, Directors Options; Pro Medicus AGM 10.45% Oppose Anthony Hall Re-Election; Nanosonics: AGM 8% Oppose CEO Michael Kavanagh Rights; IQ3 Corp Postpones AGM; Neurotech Requests ‘In-Vitro Marijuana Cell Studies’ Halt; Regal Funds Takes 16.15% Of Elixinol; Macquarie Group Takes 5% Of Nanosonics; Azure Becomes Austco; Bard1 Loses (Sienna) Director Helen Fisher 
 
Victoria Budget $13b For Health, Innovation; Telix: US FDA Accepts TLX591-Cdx Prostate Cancer NDA; Analytica: Pericoach Costs ‘Significantly Less’ Than Physio; Imugene Additional Data For HER-Vaxx Gastric Cancer Claim; Race: Bisantrene Combo Breast Cancer Efficacy, In-Vitro; Universal Biosensors: Wine Analyzer Accuracy Study; Bod Receives $1m H&H Hemp Seed Oil Order For Italy; Adherium Hailie Inhaler Sensor At 8 US Centres; MGC, Mercer $3.5m Draw Down Convertible Note; Suda Receives $662k R&D Tax Incentive; Immuron Receives $358k R&D Tax Incentive; Resapp Takes US FDA 510(K) Path For Sleepcheck; Azure: 36% Rem Report 1st Strike, 37% Placement Capacity Loss; Cann AGM 27% Defeat 10% Placement Capacity; Cynata: AGM 24% Oppose Director Options; Mayne: AGM 13.6% Oppose Election Of Chair Roger Corbett; Mesoblast: AGM 10.6% Oppose Donal O’Dwyer Election; Creso 198m Blumenthal, Everblu Shares, 109m Options EGM; Heramed Releases 40m ASX Escrow Shares, 20m Options; Australian Ethical Takes 8.4% Of Immutep; Sandon Capital Takes 10% Of IDT; Perennial Below 5% In Medadvisor; Oventus: Sue MacLeman Replaces Chair Dr Mel Bridges
 
Imagion ‘Heavily Oversubscribed’ Placement Raises $6m; Cann Group Takes NAB $50m Mildura Marijuana Loan; Imugene Claims HER-Vaxx Cancer ‘Statistical Significance’; Correction: Actinogen Medical; Azure $1.6m Tacera Nurse Call Sale To Canada Hospital; Redhill Begins Phase III RHB-204 Study For Lung Disease; Redhill: Safety Board Backs Opaganib Covid-19 Study; Osteopore Appoints MTG Germany, Austria Distributor; Next Science, 3m Drop Blastx Distribution Deal; Recce: Japan R327, R529 Patent For Viral Infections; Bard1: Texas hTERT Bladder Cancer Test Customer; Oventus: VGM To Promote O2vent; Visioneering Launches Shared Vision Education Platform; Incannex: ‘IHL-675A Outperforms CBD For Ards, In Mice’; Medibio: Compass Licence For Ilumen Mental Health Platform; Oventus: 10% Placement Facility Falls On 35% Opposition; Medadvisor 6m CEO, Director Options AGM; Antisense Dual Lists On Frankfurt Exchange; IQ Responds To Media Reports; MGC Completes $1.4m Medicinal Cannabis Clinics Acquisition; Elixinol Director Paul Benhaim, Raw With Life Diluted To 12.3%; Chimeric Appoints Jennifer Chow Coo, Dr Syed Rizvi CMO; Anteris Duravr Valve Wins ‘Best Innovation’ Gong
 
Dr Boreham’s Crucible: Actinogen Medical; Mesoblast, Novartis $1.9b Remestemcel-L For Ards Deal; I-Med Upgrades More Than 200 Nanosonics Trophon Systems; Analytica: Study Backs Pericoach For Stress Incontinence; Rhinomed Nasal Swab For URTI Registered With FDA; Orthocell Celgro: ‘Consistently Restores’ Upper Limb Use; Eye Co Phase Ib D-AMD Trial Cleared To Proceed; Neuroscientific Partners For Pre-Clinical Post-Covid Fibrosis; Genetic Signatures AGM: 14% Dissent To M-D Options; Starpharma AGM 18% Dissent, Director Richard Hazelton Goes; Bionomics AGM 18% Dissent, Director Peter Turner Goes; Platinum Increases, Diluted To 7.8% Of Kazia; Australian Ethical Below 5% In Prescient; Ebos Diluted To 7.8% In Medadvisor; Romida, Roxanne Da Gama Below 5% In Medadvisor; Elixinol To ASX: ‘Pet Releaf Paid $1.5m Of $27m; Benhaim Trade OK’
 
Immutep Raises $30m, Expands Tacti-002 Trial, HNSCC Trial; Queensland Uni: Prana’s PBT2 ‘Kills Resistant Bacteria’ In Mice; Pro Medicus, Zwanger Pesiri $8.5m Visage-7 Deal; Polynovo Novosorb In Benelux, Sweden; Telix $885k Belgium Grant For Prostate Cancer Imaging; Neuren Final NNZ-2591 Trial Approval; Canada Approves Painchek Pain Assessment; Micro-X, Carestream Nano Distribution ‘Non-Exclusive’; Starpharma SPL7013 Nasal Spray ‘Active Against RSV’ In-Vitro; Bionomics Licences BNC101 To Dr Deborah Rathjen’s Carina; Resapp, WMA 2-Year Respiratory Diagnostics Deal; Paradigm 35% Rem Report AGM Strike, Loses Chris Fullerton; Emyria, Mind Medicine Psychedelics For Mental Health; Little Green Exports $600k Of Marijuana Oil To Germany; Neurotech Readies Dolce Marijuana For Phase I Neuro Trials; Imagion Requests ‘Capital Raising’ Trading Halt; Incannex Requests ‘IHL-657A In-Vivo Results’ Trading Halt; Neuroscientific Requests ‘Covid-19 Fibrosis Results’ Halt; Platinum Investments Takes 6% Of Antisense; Medadvisor Director Jim Xenos, Kojent Diluted To 6%; Perennial Takes 5% Of Medadvisor; Medadvisor Director Josh Swinnerton, Wavey Below 5%; David Sietsma Reduces To 9% In PYC
 
Kazia: New Data Backs Paxalisib For Glioblastoma; CMRI, Alia Partner For Usher Syndrome; Redhill: FDA Clears Phase II/III RHB-107 For Covid-19 Trial; Dorsavi Rights Raise $300k Of Hoped-For $1.85m; Total $2.15m; Impedimed Sells 1st Heart Failure Sozo To Phoenix; Orthocell Requests ‘Celgro Nerve Results’ Trading Halt; Genetic Signatures Receives $2.6m R&D Tax Incentive; Anatara, Ridley, Murdoch Uni Study Bromelain For Piglet E Coli; Rhythm: AGM 24% Oppose Director Eduardo Vom Election; Micro-X 21% Oppose 10% Placement Capacity; Imugene Releases 106m ASX Escrow Shares; Althea Germany Marijuana Licence; Mid Wealth Takes 9.7% Of Lifespot; Pyxis Increases, Diluted To 6.6% Of Lifespot; Incannex Appoints Canary Capital Corporate Advisor; Federal Government Covid-19 Global Innovation Summit
 
Qbiotics: US FDA Approves Stelfonta For Dog Skin Cancer; Chimeric $30m IPO For Car-T Glioblastoma Therapies; Brandon MRCF $8.2m For UK’s Myricx Pharma; Redhill Completes Phase II Covid-19 Enrolment; Volpara Launches Breasted Breast Density Training Tool; Cardiex 160.5m Directors Performance Rights AGM; Credit Suisse Below 5% In Alterity; Cannvalate Diluted To 18% Of Lifespot; Niv Dagan, Freedom Trader, 10 Bolivianos At 7.1% Of Lifespot; Immutep Requests ‘Institutional Placement’ Trading Halt; MGC: ‘Marijuana Kills Glioblastoma, In-Vitro’
 
 
Dr Boreham’s Crucible: Telix Pharmaceuticals; Victoria $155m For $550m Infectious Disease Institute; Burnet; Mach7 $5.3m Trinity Deal For Eunity Platform; PYC Rights Raise $5.4m, $14.2m Shortfall; Total $40.6m; Polynovo Wins FDA IDE For 150-Patient Novosorb Trial; Medadvisor Extends US Messaging Pilot Program; Actinogen Rights Raise $1.4m Of Hoped-For $4.9m; Total $7.4m; Elixinol Requests ‘Capital Raising’ Trading Halt; Auscann Requests ‘Material Transaction’ Trading Halt; Pie Funds Takes 7.6% Of Probiotec; Allan Gray Reduces To 7.6% Of Impedimed; Credit Suisse Takes 5% In Alterity; Elixinol’s Paul Benhaim, Raw With Life Reduce, Transfer To 15%; D&G, David Newman, Gabriel Ettenson Below 5% In Elixinol; Respiri 65m Director Options, $2.3m Cash Bonuses AGM; Hydrix 500k Chair Gavin Coote Performance Rights AGM
 
 
Data Board Backs Mesoblast Remestemcel-L Covid-19 Trial; Antisense Raises $7.3m, EMA Committee Backs ATL1102 For DMD; Neuroscientific: Alphaswisse Placement Raises $2.4m; Avita Q1 Revenue Up 55.7% To $6.9m; Correction: Avita AGM; Cynata Starts Phase III Cyp-004 Osteoarthritis Trial; TBG: Sars-Cov-2 Rapid Antigen Test Wins CE Mark; Medlab: UK National Institute Accepts Nanabis Phase III Trial; Botanix: FDA Okays Cannabidiol BTX1801 Anti-Microbial Plan; Prescient Receives $1m R&D Tax Incentive; Regal Funds Takes 7.5% Of Hydrix; Exopharm CEO Dr Ian Dixon Diluted To 20%; Visioneering Appoints Thorney’s Andrew Silverberg Director
 
Probiotec $52.5m Multipack LJM Acquisition; Victoria $50k For Kynetyka DVT Diagnostic; TGA Approves Atomo HIV Professional Test; TGA Approves Optiscan Convivo Microscope; Immutep: 5 Complete Responses In Tacti-002 Cancer Study; Anteris: Duravr Aortic Valve Anti-Calcification; Recce: Recce-327 ‘Encouraging Inhibition’ Of Sars-Cov-2; Auscann To Sell Chile J-V Dayacann For $2.1m; Avita: AGM 47% Oppose Executive Compensation; Little Green, Health Insurance Fund Partner For Marijuana; Antisense Requests ‘Orphan Drug, Capital Raising’ Halt; Medadvisor Extends ‘Capital Raising, Acquisition’ Suspension; Elixinol Pleads Schultz To ASX 61% Price Query; Grand Decade (China Grand) Takes 7.6% Of Telix; Mayne To Lose Chair Roger Corbett, Pokies Bruce Mathieson; PYC Loses US Operations Head Douglas Huey
 
Prime Minister Appoints CSIRO’s Dr Cathy Foley Chief Scientist; Alcidion $9.5m South Tees Hospital Management System Deal; Astrazeneca Leases 200 Impedimed Sozos For 2nd Trial; ASX Approves Simavita Delisting; Patrys $2.5m Placement, Rights Issue For $4.8m More; Truscreen To Apply For ASX Dual Listing, Raise Up-To $1.9m; Antisense Applies To Dual List On Frankfurt Exchange; Avita, Houston Methodist Pre-Clinical Skin Collaboration; Immuron Vaccine Shows Infection Immune Response, In Cows; Noxopharm Veyonda, Nivolumab Cancer Study; Dimerix: Remap-Cap Covid-19 Trial Protocol Approved For DMX-200; Emyria, Zelira Hope Marijuana Autism Study; Resapp, Medgate Integrate Respiratory Diagnostic; Heramed, Ecare21 To Market Heracare; Immutep Granted IMP701 Australian Patent; Actinogen Files Xanamem Cognition, Manufacturing Patents; Neuroscientific Requests Placement Trading Halt; Recce Extends ‘Antiviral Results’ Suspension; Genetic Technologies 125m Directors Rights AGM; Regal Funds Reduces, Diluted To 7.8% Of Visioneering; Somnomed Appoints Karen Borg Director
 
Dr Boreham’s Crucible: Mach7 Technologies; Medadvisor Drops Price For $45m Raising; Suspension; Palla Files UK Application For Codeine Tablets, Caplets; Pharmaust AGM: 21% Oppose 10% Placement Capacity; Visioneering To Release 4.4m Voluntary Escrow Shares; Avita Loses CFO David McIntyre; All Change At GI Dynamics; Mark Lampert, BVF Reduce To 19.5% Of Pharmaxis
 
 
Micro-X Wins $5.6m US Airport Security Scanning Contracts; Nanosonics Covid Recovery, Unit Purchases Up 4%; Universal Biosensors Receives $2.8m R&D Tax Incentive; Lifespot: Mid Wealth Placement Raises $721k; Dr Ashray Gunjur Wins $210k Monash Foundation Scholarship; Actinogen: US FDA Requests Additional Xanamem Data; Avecho: ‘Improved TPM-Propofol Safe In Rats’; Adherium, HGE Evaluate Hailie Remote Monitoring; Pharmaxis: AGM 45% Oppose CEO Gary Phillips Rights; Cogstate Partner Eisai China J-V; Willoughby Capital Increases, Diluted To 16% Of Kazia; Richard Mann, Associates Take 5.7% Of Imugene; Starfish, Michael Panaccio, John Dyson, Trujon Have 35% Of Dorsavi; Esense Director Benjamin Karasik Resigns
 
Clarity Treats First 67Cu-Sartate Neuroblastoma Patient; Proteomics Receives $1.1m R&D Tax Incentive; Kazia Unmarketable Parcel Facility; Azure Rethinks ASX Listing Application; Micro-X Requests ‘US Funding Award’ Trading Halt; Recce Requests ‘Anti-Viral Results’ Trading Halt; Incannex Requests ‘Ards Animal Trial’ Trading Halt; THC Rebrands To Epsilon Healthcare; Arix Quits Pharmaxis; Proteomics CEO Dr Lipscombe Diluted To 18%, John Dunlop 5.5%; Osteopore: Dr Carl Runde CFO, Geoff Pocock Non-Executive; Regeneus CEO Karolis Rosickas Starts On $250k; Stemcell Appoints Paul Rosen Chair
 
October BDI-40 Down 5%, ASX200 Up 2%, Big Caps Up 3%, NBI Down 4%; US FDA Approves Pharmaxis Bronchitol For Cystic Fibrosis; Telix, China Grand Up-To $450m Radiotherapy Partnership; Imugene: US FDA IND Approval For Phase I PD1-Vaxx Cancer Trial; Emyria Receives $954k R&D Tax Incentive; Medadvisor $45m Capital Raise For Adheris Acquisition; Neurotech $2.5m Placement; Positive Pre-Clinical Results; Polynovo Appoints Biogenesys Greek Novosorb BTM Distributor; Painchek, Medi-Map Partner For NZ Aged Care Pain Management; Cellmid Lyramid Midkine Divestment AGM; Recce 7.65m Directors Options AGM; Neuroscientific 3m Directors Options AGM; Opyl 1.2m Directors ‘Incentive’ Options AGM; Thorney, Tiga Take 9.3% Of Anatara; Karolis Rosickas Replaces Regeneus CEO Leo Lee
 
Dr Boreham’s Crucible: Amplia Therapeutics; Resmed Q1 Revenue Up 10% To $1.1b, Profit Up 37% To $263m; Ausbiotech, J&J: Queensland Uni Wins 2020 Industry Gong; Hydrix Placement Raises $10m; Medical Developments, Mundipharm End Penthrox Deal; Osteopore Appoints LMT Surgical Distributor; Hydrix To Distribute Phyzhon’s Phyrari FFR-Wire; Immutep, Labcorp $177k For Immuno-Oncology Products; Simavita To Delist From ASX; ‘Covid-19 Impact’; Immuron AGM Faces 18% Dissent, Passes All Resolutions; Avita Adjourns AGM, 1% Short Of Quorum; Mach7 378k M-D Performance Rights, 63k Director Shares AGM; Exopharm 200,000 M-D Bonus Shares AGM; Telix Requests ‘Material Transaction, Investment’ Halt; Quest Takes 9% Of Kazia; Unisuper Takes 6%; Perennial Takes 11% Of Micro-X; Regal Funds Reduces To 6% Of Medadvisor; Jimmy Thomas, Ivy Ponniah Reduce 0.07% To 5% Of Stemcell
 
 
Biocurate, Abbvie Accelerate Drug Commercialization; Emvision Pilot Stroke Study Meets Primary Endpoint; Clinuvel Pilot Phase IIa Scenesse For Stroke Study; Telix, DKFZ Prostate Surgery Imaging Licence; Volpara H1 Receipts Up 33.2% To $9.1m ‘Despite Covid-19’; MTP Connect $300k For Ausbiotech Regenerative Medicine Body; Taiwan Approves Polynovo Novosorb BTM For Burns; Painchek Extends Alayacare Licence To Canada; Resapp Launches Resappdx On Samsung Devices; Perennial Takes 13.5% Of Genetic Signatures; Dr John McBain, Picton, 52nd Celebration Take 15% Of Rhinomed; Impedimed AGM 16% Oppose 10% Capacity; Race 5.6m Directors Options AGM; Auscann Hires Kidder Williams; Advisors; Suspends Facility; Hydrix Requests Capital Raising Trading Halt; Ausbiotech Appoints Linda Peterson Director; Race Loses Directors Dr Bill Garner, Chris Ntoumenopoulos
 
TGA Approves Clinuvel’s Scenesse For EPP; TGA Approves Atomo, Access Bio Sars-Cov-2 Rapid Antigen Test; Dimerix: ‘DMX-200 Reduces Kidney Disease Proteinuria’; Alterity Starts MSA Natural History Study; Telix Completes Phase I Renal Cancer Study Enrolment; Adalta: AD-214 Safe In 21 Phase I Volunteers; Zelira Launches Hope Marijuana For Autism In Australia; Rhythm Adds 7th Colostat Trial Site; Opthea Receives $8.5m R&D Tax Incentive; Actinogen Receives $2.9m R&D Tax Incentive; Acrux Receives $521k R&D Tax Incentive; Cogstate: 19% Oppose Remuneration Report; Bard1 30-To-1 Consolidation AGM; Suda 3m Director Dr Michael Baker Options AGM; Optiscan 35.7m Director, Investor Options AGM; Emvision 1.5m Director Options AGM; Nuheara 6m Directors Options AGM; Karst Peak, Adam Leitzes Take $21m Genetic Signatures Profit
 
Eisai $63m Global Cogstate Licence; FDA Orphan Status For Antisense ATL1102 For DMD; Clinuvel: ‘Scenesse Safe For 1st XP Patient’; Regulatory Halt; Mayne Suba-Itraconazole ‘Higher Uptake At Lower Dose’; Nova Eye - Alpharet Pty Ltd For 2RT Lasers, FDA IND; Prescient: US Patent For PTX-100 Breast Cancer Biomarker; Adherium Takes $3m Viburnum Convertible Note; Volpara, Veloz Explain Breast Scan Results; Noxopharm Enrols 1st Covid-19 Trial Cohorts; Cann Global Launches Marijuana Tablets In Australia; Avecho Pleads Schultz To ASX 100% Price Query; Cynata 4.5m Director ‘Incentive’ Options AGM; Mesoblast 1.2m CEO Prof Silviu Itescu Options AGM; Bod 500k Director Options, 462k CEO Rights AGM; Nanosonics CEO Michael Kavanagh 371k Rights AGM; Dorsavi 2.7m CEO Shares, Directors Options In Lieu AGM; Life Biosciences Diluted To 19.9% Of Alterity; BVF Partners Increases, Diluted To 17.3% Of Actinogen; Invion Appoints Alistair Bennallack Director; Bio-Melbourne ‘Covid-19 Progress Update’ Symposium
 
Dr Boreham’s Crucible: Rhythm Biosciences; Kazia $2.8m Retail Rights Applications, Raise $8.8m; Total $25.2m; Proteomics ‘Heavily Over-Subscribed’ Placement Raises $6m; Biosceptre, CMRI Work On Car-T For Multiple Cancers; Immutep, University Hospital Pilsen IMP321 Covid-19 Trial; Painchek, Nulsen Disability Pain Monitoring Study; FDA Wants More Data For PYC VP-001 Orphan Status; Patrys Pleads Schultz To ASX 26% Price Query; Neurotech Pleads ‘Marijuana Study’ To ASX 59% Query; Pro Medicus 100% Director Fee Pool Hike AGM; Althea: 5.5m M-D Joshua Fegan Performance Rights AGM; Baker Brothers Increases, Diluted To 10% Of Opthea; Arix Reduces To 9% Of Pharmaxis; Pokies Bruce Mathieson Reduces To 10% Of Respiri
 
Mesoblast Trials Endoscopic Stem Cells For Crohn’s Disease; Oncosil ‘First Commercial Sale In New Zealand’; Antisense Requests ‘ATL1102 DMD Orphan Status’ Halt; Movember Plans Global Prostate Cancer Database; PYC Rights Offer, Placement Raise $35.2m; $19.6m To Go; Dorsavi Raises $1.85m; Rights Offer For $1.85m More; Resapp: Astrazeneca Licences Cough Monitor Software; Exopharm Doses 1st Plexoval Patient; $2.1m R&D Tax Incentive; Hydrix Implants 5th Angel Guardian, 1st Woman Patient; Genetic Signatures Q1 Record $10.5m Revenue; Cellmid: ‘Australian Q1 Revenue Up 47%’, Receipts Down 20% To $2.1m; Rhinomed Q1 Revenue ‘Up 95%’ To $1.2m, Receipts Up To $641k; Auckland Trust, Lang Walker Diluted To 39.5% Of Next Science; Thorney, Tiga Take 5.7% Of Little Green Pharma; Azure Healthcare ‘Austco’ Name Change AGM; LBT 6m CEO Brent Barnes ‘Incentive’ Options AGM; Walter And Eliza Hall Institute ‘Brand’ Change To ‘WEHI’
 
US Law Firms Start Mesoblast Class Actions; Biotech Daily Editorial Comment; Correction: Amplia Therapeutics; Anatara Raises $1.7m, Share Plan For $750k More; Somnomed: ‘Q1 Improves Despite Covid-19’; Anteotech Sars-Cov-2 Antigen Test ‘Highly Sensitive’ In-Vitro; Emyria, Sapphire Partner For Marijuana Patient Data; Respiri, Cipla Launch Wheezo In Australian Pharmacies; Resapp Adds Health Engine To Sell Sleepcheck; Starpharma Receives $5.7m R&D Tax Incentive; Dimerix Receives $2.3m R&D Tax Incentive; Oncosil AGM: 38% 1st Strike Rem Report, 30% Oppose CEO Shares; Proteomics Requests Capital Raising Trading Halt; Regal Funds Takes 15.2% Of Opthea; Australian Ethical Below 5% In Antisense; Walker Reduces To 6.7% Of Atomo; Cellmid Loses Chair, Director, Lyramid CEO; Alternate Director; One Week To Ausbiotech Conference, Invest 2020
 
CSL R&D Briefing: Spend Up, Covid-19 Programs; Oncosil: Resected Pancreatic Cancer Survival 31 Months; Respiri ‘Over-Subscribed’ Placement Raises $12.5m; Impedimed Receives $2.6m R&D Tax Incentive; Bionomics Retail Rights Raise $1.2m; Total $2.2m; Cochlear Covid-19 Recovery; Stephen Mayne AGM Bid Lost; Amplia Pleads ‘1st Cancer Patient Dosing’ To ASX 22% Price Query; PYC Hopes To Raise $55m In Placement, 1-For10 Rights Offer; Ecofibre Profit Warning; Rhinomed 12.7m CEO Michael Johnson In-The-Money Options AGM; Micro-X $263k Peter Rowland Performance Rights AGM; Dorsavi Requests Capital Raising Trading Halt; Arix Reduces To 9.9% Of Pharmaxis; Ecofibre Appoints Kristi Woolrych Director; Auscann Loses CFO Quentin Megson; Stemcell To Buy 50.1% Of Shenzen Lentene For Sea Grapes 
 
Federal $30m For University, Business Covid-19 Collaborations; Avecho: ‘TPM Marijuana Increases CBD Bio-Availability In Rats’; Nuheara Iqbuds Boost On UK NHS; Q1 Defies Covid-19; Opthea US IPO Priced At $2.38, Expects To Raise $181m; Adalta Receives $806k R&D Tax Incentive; Anatara Requests Capital Raising Trading Halt; Patrys 14.6m Director Options AGM; Starpharma 973k CEO Performance Rights AGM; Alcidion 3.1m Executive Incentive Performance Rights AGM; Nyrada 1.8m Director Dr Ian Dixon Options AGM; Bionomics 500k Director Dr Jane Ryan Options AGM; Anatara Loses Director Dr Tracie Ramsdale; Neurotech Change: Brian Leedman, David Cantor, Peter Griffith; Geoff Hollis Replaces Imagion CFO Brian Conn
 
Dr Boreham’s Crucible: Impedimed; Kazia Pays GCAR $7.1m For Paxalisib Glioblastoma Trial; Recce Phase I/II Recce-327 Burns Trial Approved; Alterity Raises $35m; Cann Global Shortfall $859k; Total $2m Of Hoped-For $4.7m; Proteomics Appoints Italian Promarkerd Distributor; Rhythm Receives $1.1m R&D Tax Incentive; Anteris (Admedus) Extends $1.3m SIO Loan; Genetic Signatures 250k CEO Options, 80% Director Fee Hike AGM; Opthea Requests ‘US IPO Capital Raising’ Trading Halt; PYC Requests ‘Capital Raising’ Trading Halt
 
Pro Medicus, LMU Klinikum 7-Year, $10m Visage 7 Deal; Actinogen Up-To $11m Capital Raising For Xanamem Trials; FDA Orphan Status For Redhill RHB-204 For NTM; Acrux Receives $1.8m R&D Tax Incentive; Paradigm 1.1m Director Loan Shares AGM; Prescient 17m Director Options AGM; Cann Global Pleads Schultz, ‘Low Price’ To ASX 100% Query; Lazard Takes 5% In Mayne; Correction: Medical Developments; Cryosite: John Hogg CEO On $250k, Bryan Dulhunty Non-Exec
 
Next Science Share Plan Raises $5m; Total $15m; Pharmaxis Receives $5m R&D Tax Incentive; Tali Detect, Train On Sale In India; BTC Wins ISO 1345 Quality Certification; Recce Requests ‘Recce-327 Ethics Approval’ Trading Halt; Respiri Requests ‘Capital Raising' Trading Halt; Mayne $1.6m Shares, $3.1m Loan To CEO Scott Richards AGM; Noxopharm 3.25m Directors Options AGM; Allan Gray Reduces To 8.9% Of Impedimed; Quest Takes 6.3% Of Kazia; John McBain, Picton, 52nd Celebration Take 14% Of Rhinomed; Medical Developments: Brent Macgregor CEO, Gordon Naylor Ned; Little Green WA Facility Wins TGA Marijuana GMP Licence; L1 Below 5% In Creso; Amber Schwarz, Jamber Below 5% In Creso; MGC: Artemic ‘Not Toxic In Rats’ For Covid-19; Stemcell, Blue Aqua J-V For Singapore Sea Grapes
 
Mesoblast Phase III Remestemcel-L Covid-19 Trial Half-Way; Immuron Restarts Imm-124E Phase III Diarrhoea Program; Bionomics Receives $2.9m Federal R&D Tax Incentive; Actinogen Requests ‘Capital Raising’ Trading Halt; Invex 800k Director Dr Thomas Duthy Options AGM; Creso Cancels L1, Lind, Chifley Convertible Notes; W Whitney George Reduces To 40% Of Rhinomed; L1 Reduces To 10.5% Of Creso; Paradigm Appoints Three Executives
 
Biotech Daily Comment: ASX ‘Upgrade’; Opthea Hopes For $221m Nasdaq IPO; LBT Sells APAS Independence, MRSA To Limbach; Nuheara Earns Hewlett Packard $2m Ear Bud Milestone; Acrux: Dash To Sell Unnamed Generic In The US; Adalta Pleads Schultz, $8m Capital Raise To ASX 42% Query; Opthea 8% Oppose 4m Director Options; Polynovo 42% Directors Fees Pool Hike AGM; PYC Claims Compound For Autosomal Dominant Optic Atrophy; Noxopharm Treats Last Prostate Cancer Trial Patient; MGC Ships ‘High THC’ Marijuana To Brazil; Alterity Requests ‘Potential Capital Raising’ Trading Halt; Aurora Sells Cann Group 12%; PYC Loses 9-Month US CEO Doug Huey; Lifespot Appoints Matthew Golden CEO
 
Dr Boreham’s Crucible: Oventus Medical; Proteomics, QIMR Partner For Oesophageal Cancer Test; Anteris: ‘Duravr Aortic Value Exceeds Expectations’; Optiscan Invivage Oral Cancer Scope On-Track For FDA 510(K); Memphasys: Felix Sperm Separator Sales ‘On-Track’; Dorsavi Pleads Schultz To ASX 36% Price Query; Anteotech 6.9m Director Options AGM; Emyria 8.5m Director Options AGM; Medibio 14.15m Solitario Options AGM; Allan Gray Reduces To 11% Of Starpharma; FIL Takes 8% Of Starpharma; Creso: Nova Scotia Liquor Corp Orders $187k Marijuana
 
Federal $1.7b For CSL-UQ, Astra Zeneca Covid-19 Vaccines; Federal $17m For Doherty Research; Volpara H1 Revenue Up 27% To Record $18m; Amplia Doses 1st Phase I AMP945 Cancer Fibrosis Trial Subjects; Redhill Passes 2nd US Review Of Opaganib For Covid-19; Heramed Herabeat ‘Comparable To Hospital CTG Machines’; WEHI Slows Motor Neuron Disease, In-Vitro; Simavita Revenue Down 76% To $43k; ASX Suspension Lifted; Atomo To Release 19.8m Voluntary Escrow Shares; M&G Reduces To 10% Of Starpharma; Allianz SE Takes 7% Of Starpharma; Auckland Trust, Lang Walker Take 42% Of Next Science; Mark Lampert, BVF Take 17% Of Bionomics; Pyxis Increases, Diluted To 7% Of Lifespot
 
Budget Response: Swanson Reed, Ausbiotech, Australian Academy Of Science, Medicines Australia; US NIH $42m For Ellume Sars-Cov-2 At-Home Test; Creso Commitments For $9m; US FDA Rejects Mayne Nuvaring, Contraceptive Pill; Cellmid Disputes Call To Remove Chair Dr David King; Imagion: Phase I Magsense Breast Cancer Trial Approved; Dimerix: ‘DMX-700 Inhibits COPD Receptor Signals, In-Vitro’; PYC: ‘VP-001 Effective For Retinitis Pigmentosa In-Vitro’; Regeneus: Canada Patent For Sygenus Acne Treatment; Medibio, Medridge Depressive Burden Sleep Trial; MGC Launches Cannepil Application, ‘Library Of Cannabinoids’; Meurs Takes 7.3% Of Adalta; L1 Takes 12% Of Creso; Creso Appoints Bruce Linton Advisor
 
 
MTP Connect 2nd Covid-19 Impact Report; Telix 18f-Fet Wins FDA Orphan Status For Glioma Imaging; BARDA Pays Vaxxas $31m For ‘No-Needle’ Pandemic ’Flu Vaccine; Resonance Develops Alert-PE AI For Pulmonary Embolism; Universal Biosensors: Promedeus Xprecia Stride Distributor; Australian Patent For Patrys Deoxymab For Cancer; Rhythm 1.5m M-D Trevor Lockett Options AGM; Noxopharm Amends $4.2m Nora Goodridge Loan; Alterity Files $70m US SEC Registration Form
 
Bio’s Dr Jeremy Levin Replaces Opthea Chair Geoffrey Kempler; Bio-Melbourne, LSQ Governance, Directors Program; PYC Claims VEGF Inhibitor ‘2nd Potential Blockbuster’; Federal Research & Development Tax Incentive Survey; Recce Receives $640k R&D Tax Incentive; Former Optiscan Director Ian Mann Increases, Diluted To 7%; Shimano, M-D Peter Griffiths Take 6.2% Of Neurotech 
 
Dr Boreham’s Crucible: Osteopore; Mesoblast Falls 45% On FDA GvHD Trial Requirement; Antisense: New ATL1102 DMD Data ‘Statistically Significant’; Kazia Institutional Rights Raise $16.4m, $8.8m To Go; Incannex Options Raise $10m; Lifespot $960k Placement, Cannvalate Takes 19.7%; Painchek, Ramsay, Edith Cowan Pain Research Deal; Noxopharm Doses 1st Veyonda Covid-19 Patient; Medibio Files MEB-001 For FDA Breakthrough Status; US Patent For Imugene Immunotherapy Platform; Pharmaxis 942k CEO Performance Rights AGM; Australian Ethical Reduces To 5.5% Of Antisense; John McBain, Picton, 52nd Celebration Take 12.6% Of Rhinomed; Orchid Capital Takes 15% Of Optiscan; Julian Jarman, Troy Valentine Below 5% In Incannex; CSL Appoints Joy Linton CFO, Replacing David Lamont; Invex Appoints Dr Tom Duthy Executive Director, On $125k; Cogstate: Dr Chris Edgar CSO, Prof Paul Maruff To CIO; Race Appoints Prof Borje Andersson CMO, Executive Director
 
 
Antisense Wins FDA Rare Paediatric Disease Status; Starpharma Placement Raises $45m, Plan For $5m More; Micro-X: W.H.O. $1.4m Rover X-Ray Order For Pacific Islands; Astrazeneca $2m To Lease 175 Impedimed Sozos For Trial; TGA Approves 4D Lung Ventilation Analysis Software; Adalta: Study Backs AD-214 For Lung Fibrosis; Emyria, Zelira Deal For Zenivol (ZLT-101) Insomnia Study; Recce, Murdoch Children’s Test Recce-435 For Helicobacter; Kazia Requests ‘Entitlement Offer’ Trading Halt; FMR Below 5% In Somnomed; Little Green Releases 1.4m ASX Escrow Shares; Dr Rita Laeufle Replaces Imugene CMO Dr Mark Marino
 
Federal $9m For Paediatric Cancer Research; Paradigm: Bene Pharmachem 25-Year PPS Supply Deal; Atomo To Distribute Access Bio’s Sars-Cov-2 Antigen Test; Neuren Files NNZ-2591 EU Orphan Drug Applications; Rhythm Validates Final Colostat Biomarkers; Regeneus Receives $677k R&D Tax Incentive; Pharmaust: Monepantel Selective For Cancer Cells; 4D Requests ‘Regulatory Approval’ Trading Halt; Botanix Pleads Schultz To ASX 46% Price Query; Kazia 2m Directors Options, 25% Fees Hike AGM; Uscom 1.4m Chair Prof Rob Phillips Rights AGM; Osprey Wins Supplier Horizon Gong; Prof Phillip Dubois Replaces Emvision Director Ryan Laws; Mayne Appoints Interim CFO Peter Paltoglou CFO; Bio-Melbourne Corporate Governance Program
 
 
Dr Boreham’s Crucible: Suda Pharmaceuticals; Opthea Registers Up-To $212m Nasdaq IPO With US Sec; TGA Okays Starpharma OTC Vivagel For Bacterial Vaginosis; Allegra 3m Director Options AGM; Cogstate 1.25m CEO Options, 44% Director Fee Pool Hike AGM; Exopharm 340k M-D, Chair Rights, 75k COO Shares AGM; Immutep 1.3m Director Rights In Lieu AGM; Impedimed 7.4m CEO Rights, 6.2m Options AGM; Medical Developments 100% Directors’ Fee Pool Hike AGM; Probiotec 1.3m CEO Options AGM; Optiscan Receives $701k R&D Tax Incentive; Visioneering To Release 6.6m Voluntary Escrow Shares
 
Telix Files US NDA For TLX591-CDx; Chimeric $4.3m Baker Young Convertible Note; Incannex Ready For Phase IIb IHL-42X Marijuana Apnoea Trial; Osprey: Regional Health Care Australia, NZ Distributor; Cardiex, Mobvoi Partner For Heart Health Smartwatch; Cynata: Stem Cells Regenerate Cardiac Blood Vessels In Rats; Bionomics $2.2m 1-For-12.54 Rights Offer; Trading Halt; Azure: Canada Patent For Transmucosal Tocotrienols; Pharmaust, Leiden Uni Test Monepantel For Sars-Cov-2, Ex-Vivo; Invitrocue J-V Completes ACE-2 Lab Mice For Covid-19 Testing; Lifespot Requests ‘Placement’ Trading Halt; John McBain, Picton, 52nd Celebration Take 11% Of Rhinomed; Drs Washer Increase, Diluted To 23% In Emerald; Bionomics Loses Peter Turner; Gains Dr Srinivas Rao, Dr Jane Ryan
 
 
Roche Pays $617m For Queensland Uni, Dublin Inflazome; Chimeric, City Of Hope Chlorotoxin Car-T For Glioblastoma; Optiscan $9.8m Placement, $7.4m From Clermont Group; Kazia, Dana-Farber Trial Paxalisib For CNS Lymphoma; Neuren Manufactures NNZ-2591 For Phase II Trials; Suda: Dog Study Backs Lower Dose Anagrelide; Little Green: CBD Content Below TGA Minimum; Respiri Appoints Entech Wheezo Manufacturer; G Medical EGM Votes To Delist, Suspended From ASX; Cardiex Requests ‘Material Commercialization Deal’ Halt; Incannex Appoints Dr Paul Liknaitzky Scientific Advisor
 
Telix Doses 1st 89-Zr-Apomab Lung, Ovarian Cancer Patients; Azure Ready For IVB003 Tocotrienol Pancreatic Cancer Trial; Federal $3m For 2 Doherty-MIPS Covid-19 Vaccine Candidates; TBG: Medigen Distributes Sars-Cov-2 Test Kits; Adalta Progresses GE Healthcare I-Body Collaboration; Resapp Requests FDA Sleepcheck Pre-Submission Meeting; Pharmaust: $881k For Monepantel For Motor Neuron Disease; Creso: Nova Scotia Liquor Corp Orders $187k Marijuana; Invion Director Shares, Options In Lieu Of Cash AGM; Recce Requests ‘Capital Raising’ Trading Halt; THC Requests ‘Federal Court Orders’ Trading Halt; Optiscan Requests ‘Capital Raising’ Trading Halt; Allan Gray Reduces To 12% Of Starpharma; Constellation, Lishan Zhang Below 5% In Anteris; Opyl: Mark Ziirsen Director, Damon Rasheed Executive; Auscann Loses Director Dr Marcel Bonn-Miller
 
Dr Boreham’s Crucible: Proteomics International; Immutep: 3 Complete Responses To IMP321, Keytruda; Immutep: 5 Of 12 Solid Tumor Patients Have Partial Response; Cochlear Opposes Advocate Stephen Mayne Board Bid; Emerald Clinics EGM Backs Name Change To Emyria; Cardiex Sphygmocor Granted European Patent; Australian Ethical Takes 15% Of Nova Eye; Craig Darby Increases, Diluted With Washer Family In Emerald; M-D Dr Ian Dixon Diluted To 23% Of Exopharm; Race Appoints CSS Clinical, FDA Advisors; Noxopharm Appoints Destum Immuno-Oncology Advisor
 
Medadvisor Launches Electronic Prescriptions; Emerald, Mt Sinai Partner For Openly Remote Monitor; Avecho Receives $615k R&D Tax Incentive; FIL Takes 7% Of Starpharma; Eye Co Appoints Alison Coutts Director
 
Next Science $10m Underwritten Placement, $5m Share Plan; Rhythm Validates 2 Colostat Test Biomarkers; Zelira: Zenivol For Insomnia Through TGA Access Scheme; Heramed Herabeat Foetal Heart Monitor On Ecare21; Ausbiotech Invest 2020, Conference Go Online
 
Cyclopharm: Technegas US Trial Meets Endpoints Early; Clinuvel Doses 1st Scenesse XP Patient; IP Group: $650k For Augmented Bionics Non-Invasive Hearing Aid; Rhinomed Develops URTI Nasal Swab; Osteopore, Singapore Uni Study 3-D Jaw Implants; Emerald: TGA Registers ‘Openly’ For Remote Monitoring; Medlab Directors 12m Options, 100% Fees Pool Hike AGM; Yuuwa Capital Diluted To 22% Of Adalta; Avita Loses Director Damien McDonald; Cann Group Confirms Jenni Pilcher Director; Exopharm Hires Alison Mew, Canary Capital Corp Advisor
 
Dimerix Falls 76% On Dmx-200 Missing DKD Primary Endpoint; 3 Companies: ‘Covid-19 Recovery Ahead Of Expectations’; GI Dynamics Raises $13.7m In Crystal Amber Financing; Orthocell Treats 300 Access Patients With Celgro; Avita Enrols 1st Recell For Vitiligo Trial Patient; Starpharma: ‘SPL7013 Kills Sars-Cov-2, In-Vitro’; Auscann: Neuvis Marijuana Capsules Meet Endpoints; Orthocell 10m Director Options AGM; Althea Canada Marijuana Licence; Blum Manufacturing Deal; AGC Asahi Glass Takes 7.5% Of Regeneus; Althea To Release 81.6m Voluntary Escrow Shares
 
Dr Boreham’s Crucible: Kazia Therapeutics; Doherty Institute: ‘Covid-19 T-Cell Immune Response Low’; Federal $3.7m For 3D Meditech Covid-19 Nasal Swab Deal; Pro Medicus, NY Uni $25m Imaging Contract; Research Deal; Ellume Adds Qiagen Sars-Cov-2 Antigen To Antibody Test; FDA Suggests Improvements For Polynovo Novosorb Trial; Genetic Technologies Breast Cancer Risk Test On Sale In Us; Opthea 4m Director Options AGM; Regeneus 15.3m Director Options AGM
 
CMRI Challenges AAV2 As Liver Gene Therapy Vector; Morningside Funds Hudson Ovarian Cancer Therapy; Clinuvel Trials Scenesse For XP Skin DNA Regeneration; Rhythm Adds Newcastle Hospital To Colostat Trial; Resonance Licences Cystic Fibrosis Data For AI Analysis; Anteotech Wins ISO 13485 Quality Certification; Recce Appoints CMax For Recce-327 Trial; Cellmid Hires C14, Pharmaventures For Lyramid Midkine Sale; MGC: Up To $15m Mercer Equity-Drawdown Facility; Dimerix Requests ‘DMX-200 Kidney Trial Results’ Trading Halt; Australian Ethical Takes 14% Of Nova Eye; Sandon Capital Takes 9% Of IDT; Bonvoyolo Diluted Below 5% Of Neurotech; Opthea Appoints Daniel Spiegelman Director; Helen Wiseman Replaces Elixinol Chair Paul Benhaim; Ausbiotech, J&J Awards For Best Covid-19 Responses
 
Cyclopharm, McMasters Partner On Technegas For Covid-19; Clarity: 64-Cu-Sartate Wins FDA Rare Kids Disease Status; Pharmaust: Elanco Drops 2018 Monepantel Option; Covid-19; Imugene: Bell Potter Underwrites $5.7m Options; Memphasys Receives $1.3m R&D Tax Incentive; Anteotech Develops Covid-19, Influenza A, Influenza B Test; TGA Joint Session Drops Marijuana CBD To O-T-C Schedule 3; Memphasys, Hydrix Good Design Gong For Sperm Separator; Loumea Increases, Diluted To 6.9% Of Rhythm; Viburnum Takes 22% Of Universal Biosensors; Naos Takes 26% Of BTC; Kirman 2, Brian Sherman Take 5.7% Of Regeneus; Noxopharm Appoints Fred Bart As Non-Executive Chair
 
Opyl Picks Covid-19 Vaccine Winners; Amplia Phase I AMP945 Cancer Trial Approved; Emvision Pilot Stroke Imaging Study Enrolled; Recce: ‘327, 529 Reduce Sars-Cov-2, In-Vitro’; Botanix: BTX1801 ‘Eliminates MRSA Ex-Vivo, In-Vitro’; Noxopharm Hires Paraxel For Veyonda Prostate Cancer Trial; PYC Combines CPP, Lipid Nanoparticles For Drug Delivery; Zelira Subsidiary For Marijuana Toothpaste; Suda: Australian Patent For Anagrelide For Cancer; US Patent For Anteris (Admedus) Adapt Tissue Process; Optiscan Pleads Schultz To ASX 35% Price Query; MGC Requests ‘Financing Facility’ Trading Halt 
 
Federal $1.7b For CSL For UQ-CSL, Oxford-AZ Covid-19 Vaccines; Boehringer Ingelheim Hands Back Pharmaxis PXS4728A; Next Science: FDA Wants More Data For Xperience Surgical Rinse; Adalta Rights Raise $4.1m; Total $8.1m; Victoria $252k For Polynovo Hernia Cleanroom; Cynata: Cymerus Stem Cells Improve IPF In Mice; Cardiex, China’s Andon Partner For Remote B-P Monitor; Opyl Tells ASX: Covid-19 ‘1st Use’ For AI Trial Software; Biotron: ‘15 Compounds Show Activity For Sars-Cov-2’; Pharmaust Requests ‘Elanco Option’ Trading Halt; Recce Requests ‘Anti-Viral Testing Results’ Trading Halt; M&G Reduces To 8.8% Of Mesoblast; Elixxir Reduces To 21% Of Little Green Pharma; Neurotech Takes 80 Marijuana Samples To In-Vitro Testing; Bio-Melbourne Forum On Burnet Covid-19 ‘Optimise’ Study
 
Dr Boreham’s Crucible: Mayne Pharma; Safety Board Backs Mesoblast Restemcel-L Covid-19 Trial; Pennsylvania $412k For Redhill Opaganib For Covid-19; S&P Promotes Mach7 Into All Technology Index; CSL $9.5m CEO Performance Rights AGM; Allan Gray Reduces To 13% Of Starpharma; One Funds Takes 10% Of Bluechiip
 
Opyl: ‘A I Predicts Trial - Including Covid-19 - Results’; Telix, Varian Prostate Cancer Collaboration; Federal, MTP Connect $10.4m For 13 ‘Early Stage’ Projects; Imugene: US Approves PD1-Vaxx Lung Cancer Trial; Heramed Expands Completed Herabeat Foetal Monitor Study; Regeneus Pays CEO Leo Lee $325k Kyocera Bonus; Neurotech: Brain Therapeutics Greece Mente Autism Distributor; Biotron Requests ‘Compound Testing’ Trading Halt; Australian Ethical Diluted To 5.5% In Prescient; Chris Retzos Reduces, Diluted Below 5% In Prescient; Pie Funds Increases, Diluted To 5% Of Probiotec; Chair Otto Buttula Takes 13.6% Of Rhythm; Correction: Althea, SG Hiscock; SG Hiscock Takes 8.6% Of Bod
 
Rhythm Rights Raise $3.6m; Total $6m; Mesoblast Australian Approval For Phase III Covid-19 Trial; TBG Wins US FDA Covid-19 Rapid Antibody Test Emergency Use; G Medical: ASX Confirms Delisting; M&G Reduces To 9.1% Of Mesoblast; SG Hiscock Takes 5.1% Of Althea; Race: Phil Lynch CEO, Dr Daniel Tillett Back To CSO, On $200k PA; THC Loses CEO Ken Charteris, Jarrod White Interim; Executives; MGC Appoints Evan Hayes Director, 2 Executives
 
August BDI-40 Up 8.3%, ASX200 Up 2.2%, Big Caps Down 0.2%; THC H1 Revenue Up 63% To $3.5m, Loss Down 3.2% To $5.6m; G Medical H1 Revenue Down 31% To $2.7m, Loss Down 30% To $6.7m; Cardiex Revenue Up 13.7% To $4.6m, Loss Up 11.5% To $3.3m; MGC Revenue Up 210% To $2m, Loss Up 124.6% To $19.4m; Creso H1 Revenue Up 58.3% To $1.5m, Loss Up 177.3% To $17.4m; Immuron Revenue Up 5.5% To $2.5m, Loss Down 37.1% To $2.9m; TBG H1 Revenue Up 22.9% To $1.9m, Profit To Loss Of $1.2m; Cann Global Revenue Up 271% To $1.8m, Loss Down 12.8% To $8.1m; Emerald Revenue Up To $1m, Loss Up 95.2% To $5.2m; Telix: Ire Elit To Distribute TLX591-CDx In French Territories; Dorsavi: Study Links Improved Low Back Pain, Vimove Data; Medlab Signs CRO George Clinical For Phase III Nanabis Trials; Starpharma: Water-Soluble Dep-Remdesivir For Covid-19; Noxopharm Starts East Europe NOX66 Covid-19 Trial; Resapp Extends Morayfield Clinic Diagnostic Evaluation; Esense Israel Trial Of Terpenes For Sars-Cov-2 Sanitizers; Recce Wins Federal $37.5k Innovation Connections Grant; Respiri: Wheezo Detects 74% Of True Positive Wheezes; Pharmaust, Obsidian Partner For Waste To Fuels Tech; Bod: Lyphe Appointed Project Twenty21 Marijuana Dispenser; Genetic Technologies $22.1m Regains Nasdaq Compliance; Dimerix 100% Director Fee Pool Hike AGM To $500k; FIL Takes 6% Of Starpharma; Invion Appoints Rob Merriel Director
 
Compumedics Revenue Down 16% To $35m, Profit To Loss Of $6m; Palla H1 Revenue Down 55% To $12.3m, Loss Up 121% To $9.0m; Elixinol H1 Revenue Down 54% To $7.9m, Loss Up To $82m; Nova Eye Revenue Down 21% To $12.8m, Loss To Profit Of $35.7m; Atomo Revenue Up 10-Fold To $5.4m, Loss Up 82.4% To $9.2m; Pharmaust Revenue Down 5.5% To $3m, Loss Down 12.2% To $1.4m; Bioxyne Revenue Up 2.2% To $2.4m, Loss Down 53% To $593k; Nuheara Revenue Down 2.6% To $2.3m, Loss Up 16.6% To $11.7m; Little Green Pharma Revenue $2.2m, Loss Up 69% To $9.3m; Proteomics Revenue Down 3% To $1.4m, Loss Down 16% To $1.7m; Optiscan Revenue Up 14.3% To $1.2m, Loss Down 24.7% To $1.8m; Telix: FDA Orphan Status For TLX102 For Multiple Myeloma; Antisense Applies For EMA ATL1102 For DMD Orphan Status; Immutep, Monash Uni Win $671k ARC Linkage Grant; Clinuvel Opens Singapore Vallaurix Research Centre; Nova (Ellex) Reappoints Tom Spurling, Loses Mike Mangano; Recce Appoints Exec Dir James Graham CEO On $300k PA; Noxopharm, Nyrada Swap Dr Ian Dixon, Dr Graham Kelly; Amplia Appoints Dr Mark Devlin CSO; Anteris Appoints Prof Bernard Prendergast TAVR Advisor
 
Dr Boreham’s Crucible: Prescient Therapeutics; Cochlear: Consensus Paper Backs Implants; Avita Revenue Up 61% To $26m, Loss Up 68% To $58m; Genetic Signatures Revenue Up 132% To $11.3m, Loss Down 40% To $2m; IQ3 Revenue Up 12% To $6.9m, Loss Up 101% To $2.2m; Medlab Revenue Down 10% To $5.5m, Loss Up 65% To $13.5m; Micro-X Revenue Up 120% To $4.3m, Loss Up 2% To $10m; Total Brain Revenue Up 49% To $4m, Loss Down 11% To $7.6m; Adherium Revenue Down 20% To $2.2m, Loss Down 3% To $11.4m; Regeneus Revenue $1.7m, Loss Down 82% To $1.1m; Kyocera Pays Regeneus $1.3m Progenza Milestone; 4d Revenue Up 77% To $1.2m, Loss Up 239% To $22m; Emerald Raises $2.2m; Malaysia Approves Oncosil Radiation For Cancer; US Safety Committee Okays Redhill’s Opaganib For Covid-19; Optiscan: Advanced Microscopy North America Distributor; Anteris (Admedus) Ends Covid-19 Director, Executive 25% Pay Cut; Perennial Reduces To 6.35% Of Atomo; Cann Global: Marion Lesaffre COO, Franc Zvonar Sales
 
Probiotec Revenue Up 46% To $107m, Profit Up 72% To $6m; Mesoblast Revenue Up 92.3% To $44.5m, Loss Down 13% To $108m; Clinuvel Revenue Up 5% To $32m, Profit Down 8% To $17m; Mach7 Revenue Up 102% To $19m, Loss To Profit Of $170k; Alcidion Revenue Up 10% To $18.6m, Loss Up To $4m; Medadvisor Revenue Up 16.5% To $9.6m, Loss Up 21% To $9.8m; Cellmid Revenue Up 2.4% To $8.5m, Loss Up 17% To $5m; Starpharma Revenue Up 142% To $6.6m, Loss Up 3% To $15m; Althea Record Revenue Of $5.7m, Net Loss Up 66% To $8.6m; Dorsavi Revenue Down 27% To $3.2m, Loss Up 8% To $4.0m; Cann Revenue Down 72% To $911k, Loss Up 55% To $17m; Exopharm Raises $10m; WEHI Investigates Compounds For Covid-19; Ellume, Qiagen Partner For Covid-19 Diagnosis; C19 Licences AR-12 For Covid-19; Emerald Clinics Requests ‘Capital Raising’ Trading Halt; Hydrix: ‘Heart Warning Devices Programmed, Switched-On’; G Medical To Remote Monitor TAVR Patients; Nuheara, Hewlett Packard Develop ‘New Audio Experiences’; Respiri, Carlton Women’s Football Team Partner For Wheezo; Blackrock Reduces To 6% Of Cochlear; Australian Ethical Takes 7% Of Prescient; Bionomics Pleads Schultz To ASX 23% Query
 
Queensland Uni, CSL Covid-19 Vaccine ‘Positive Indications’, In-Vivo; Cogstate Revenue Up 8.5% To $32.9m, Loss Down 47% To $1.8m; Polynovo Revenue Up 54.6% To $22.2m, Loss Up 31.5% To $4.2m; Hydrix Revenue Up 12.2% To $16m, Loss Down 24% To $3.2m; Cyclopharm H1 Revenue Down 11% To $5.8m, Loss Up 87% To $5.6m; Immutep Revenue Of $7.5m, Loss Down 26.6% To $13.5m; Impedimed Revenue Up 38% To $5.7m, Loss Down 11.4% To $21.4m; Visioneering H1 Revenue Down 12% To $2.8m, Loss Down 23% To $7.2m; Cynata Revenue Of $4.5m, Loss Down 57% To $3.6m; Rhinomed Revenue Up 8.5% To $3.6m, Loss Up 22.3% To $7.3m; Next Science H1 Revenue Down 55% To $1.5m, Loss Down 22% To $9.3m; Prescient Placement Raises $7m, Total $13.5m; Neurotech $500k Placement For Dolce Marijuana; Platinum Takes 12.3% Of Adalta; Australian Ethical Below 5% In Prescient; Visioneering Pleads Schultz To ASX 87.5% Price Query; Incannex: ‘IHL-675A Ards Anti-Inflammatory Response, In-Vitro’
 
Nanosonics Revenue Up 19% To $100m, Profit Down 25.5% To $10m; IDT Revenue Up 17% To $14.2m, Loss Up 68.5% To $1.9m; Osprey H1 Revenue Down 56% To $1.1m, Loss Down 19% To $10.4m; Acrux Revenue Up 33% To $1.6m, Loss Up 14% To $9.5m; Biodiem Launches LAIV Influenza Vaccine In China; Emvision, Queensland Uni $180k Advance Fellowship; Bluechiip Pleads Schultz To ASX 52% Price Query; Platinum Reduces To 9% Of Kazia; Lazard Below 5% In Mayne; Aurora Cannabis Diluted To 12% Of Cann Group; Medadvisor Appoints Naomi Lawrie Co-Sec, General Counsel; Starpharma: ‘Spl7013 Inhibits Sars-Cov-2 Infection’; Pharmaust: ‘Monepantel Suppresses Sars-Cov-2 Up-To 95%’; MGC: ‘Russia J-V For Artemic For Sars-Cov-2’ 
 
Vale Living Cell’s Prof Bob Elliot (3.1.1934 - 21.8.2020); Correction: Adalta; Somnomed Revenue Down 2.7% To $57m, Loss Up 1013% To $438k; Kazia: US Orphan Status For Paxalisib For Glioma, DIPG; 61 Medical, 41 Medical, Queensland Accelerate Devices; Opthea Plans Nasdaq IPO; Cynata Begins Cymerus Covid-19 Trial; IDT Lists Vaccine Manufacture Info For Federal Government; Bosch Automatic Materials Line For CSL Behring; Azure Begins Food Additives Manufacture; Ecofibre Completes $59m Texinnovate Acquisition; Exopharm Requests Capital Raising Trading Halt; M&G Claims To Reduce To 9.9% Of Mesoblast; Australian Ethical Below 5% In Pharmaxis; Perennial Takes 7.6% Of Micro-X; Peter Meurs Takes 5% Of Adalta; Lazard Reduces To 5% Of Mayne; Immuron Exec Vice Chair Peter Anastasiou Reduces To 5.3%; G Medical ASX Delisting EGM 
 
 
 
CSL Revenue Up 7.2% To $12.6b, Profit Up 9.6% To $2.9b; BTC $295k Revenue, Speciality Unit $5.8m, BTC Loss $283k; Cann Group ‘Oversubscribed’ Plan Raises $25.9m, Total $40.2m; Imagion Raises $1.3m From 2018 Rights Options; Pharmaxis Plans US Pxs-5505 For Myelofibrosis Trial; Aroa: ‘Endoform Attracts Stem Cells For Tissue Repair’; US Patent For Regeneus Sygenus Platform For Skin Conditions; Medical Developments Buys-Back Penthrox From Mundipharma; Respiri, APA Wheezo Referral Agreement; Volpara: 30% Oppose 405k Director Karin Lindgren Options; Osteopore Requests ‘Capital Raise’ Trading Halt; Australian Ethical Reduces To 6% Of Pharmaxis; Yuuwa Capital Diluted To 26.5% Of Adalta; Trudell Diluted To 13.4% Of Adherium; Pyxis Takes 9% Of Lifespot; PYC Dr Rohan Hockings Back As CEO; Prof Sue Fletcher CSO; MGC Requests ‘More Artemic Covid-19 Results’ Trading Halt; Neurotech Requests ‘Price Query, Lab Results’ Trading Halt
 
Cochlear Revenue Down 6.5% To $1.4b, $238m Loss; Telix Doses 1st TLX250-CDx Renal Cancer Patient; Immutep Doses Stage 1, Part B IMP321, Keytruda Tacti-002 Study; Anteotech: Mahe Underwrites $3.76m Options; Medical Developments Requests ‘EU Distribution’ Trading Halt; KFT, GJK, Kepper Family Below 5% In Universal Biosensors; Regal Funds Takes 5.2% (Or 11%) Of G Medical; SG Hiscock Takes 7.2% Of Bod; Christine McLoughlin Replaces Cochlear’s Donal O’Dwyer; Dr Geoff Brooke Replaces Cynata Chair Dr Paul Wotton; Osprey Loses Director Andy Jane; Analytica Loses Director Dr Thomas Lönngren; Phillip Hains Replaces Suda Co-Sec Joseph Ohayon
 
Biotech Daily Editorial: R&D Tax Incentive Is Not Income; Uscom Revenue Up 18% To $4.3m, Loss Down 4.2% To $1.3m; Cochlear Settles Patent Case Interest, Fees For $104m; Starpharma, Chase Sun Partner For DEP Anti-Infective; Hydrix Up 260% On 1st Guardian Heart Warning Device Implants; Memphasys, Newcastle Uni Partner For Fertility; Painchek Expands CMS Partnerships In Australia, UK; Althea: 740 New Marijuana Patients In July For $692k; Bionomics Pleads Schultz To ASX 39% Query; Merchant Funds Takes 10.4% Of Race; Zelira Director Jason Peterson Diluted To 6.5%; Deputy Chair Harry Karelis, Gemelli Below 5% In Zelira; Phillip, Bioscience Managers Take 25% Of Adherium; Damon Crowe, K One W One (K1W1) Increase, Diluted To 5.1% Of Adherium; Emerald Change Name Change To Emyria GM; CFO Tom Howitt Replaces Cronos Co-Sec Lior Harel
 
 
Qbiotics, Merck EBC46, Keytruda Melanoma Trial; Pharmaxis Revenue Up 12% To $7.4m, Loss Down 31% To $14m; Osprey Wins CE Mark For Dyevert Power XT; Imagion Pleads Schultz To ASX 29% Query; Pharmaxis 942k CEO Performance Rights For AGM; Bio-Melbourne: ‘Manufacturing’s Covid-19 Rapid Response’
 
Victoria Keeps Regenerative Medicine Centre; LBT Share Plan Raises $367k Of Hoped-For $1m; Total $8.4m; Race: Williams, Emmanuel, Merchant Exercise $1.5m Options; US Patent For Immutep IMP321 Combination Therapy; Prescient Increases PTX-100 Cancer Trial Dose; Botanix Starts Phase IIa BTX1801 Surgical Infection Study; Respiri, APA Partner For ‘Real World’ Wheezo Asthma Study; Creso: DHS Portugal, Spain Marijuana Distributor; M&G Mostly Corrects Mesoblast Substantials; Emvision: Forough Khandan Program Management Head
 
Mesoblast Falls On FDA Remestemcel-L For GvHD Questions; Regeneus: Kyocera $26m Progenza Knee Osteoarthritis Deal; Painchek Raises $10m; Adalta Placement Raises $4m, Rights Offer For $4.1m More; Suda Places $533k; Total $3.56m; Acrux: Harris For US Generic Emla Anaesthetic Cream Sales; Telix Submits TLX101 Glioblastoma Drug Master File To FDA; Nuheara Wins ISO 9001:2015 Certification; Paradigm PPS Orphan Approvals, Regulatory Feedback; Perennial Takes 5.5% Of 4D Medical; Regal Funds Reduces, Diluted To 8.9% Of Visioneering; Impedimed Promotes Timothy Cruickshank To CFO 
 
Atomo: TGA Approves Rapid Sars-Cov-2 Antibody Test; Anatara Uni Of New England Work On Poultry Enteritis; Bard1 Euro Patent Validated In 6 Countries; Medibio Ilumen For Stress US Patent; Emerald, Canopy Deal For ‘Real-World Evidence’ System; M&G: Claims To Reduce To 11% Of Mesoblast; Allan Gray Reduces To 10.1% Of Impedimed
 
Dr Boreham’s Crucible: Exopharm; 4D Opens Up 98% In Oversubscribed $56m IPO For Imaging; Kazia: FDA Rare Kids Disease Status For Paxalisib For DIPG; G Medical $5m Placement; Allegra Improves Spinal Fusion Cage In Covid-19 Delays; South Korea Allows Cynata Cymerus Stem Cell Patent; M&G Reduces To 11% Of Mesoblast; Karst Peak, Adam Leitzes Reduce To 11% In Genetic Signatures; Director Michael Stork Diluted To 7% In Patrys; Painchek Requests ‘Capital Raising’ Trading Halt; Adalta Requests ‘Capital Raising’ Trading Halt; Regeneus Requests ‘Japanese Licencing Deal’ Trading Halt; Prescient Appoints Prof Phillip Darcy Advisor; MGC: ‘In-Vitro Study Backs Artemic For Covid-19’
 
Resmed Revenue Up 13% To $4.1b, Profit Up 32% To $963m; Alcidion: NHS To Use Smartpage For In-House Communication; Imugene Pre-Ind FDA Meeting On Vaxinia (CF33) Pathway; Neuren Plan Raises $200k Of Hoped-For $3m; Total $20.2m; Platinum Diluted To 16% In Amplia; Blueflag, Allan Moss Diluted To 7% Of Amplia; Total Brain Appoints Melissa Frieswick ‘Chief Revenue Officer’
 
Imagion Applies For Magsense Phase I Ethics Approval; Pharmaxis: $9.7m Bronchitol Milestone Payable On US Approval; Heramed Shortfall Raises $1.35m; Total $3.9m; Nova (Ellex) Claims Molteno ‘Utility’ For Glaucoma; Lifespot: ‘Apple Approves Fevertel Thermometer’; Imugene CEO Leslie Chong Exercises 27m Options; Credit Suisse Below 5% In Suda; Uniquest Diluted To 8.6% Of Emvision; G Medical Requests ‘Capital Raising’ Trading Halt; MGC Requests ‘Artemic Pre-Clinical Results’ Trading Halt; Auscann Appoints Nick Woolf CEO; Medlab Appoints Laurence McAllister Director; Adherium Appoints Geoff Feakes CTO 
 
Applications For $300k Gilead Grants Close August 14; Monash Uni, Janssen Oxytocin For Postpartum Haemorrhage; Patrys Underwritten Rights Raise $4.3m; Uscom Ventitest Calibrates Ventilators; Resapp Sleepcheck For Apnoea Available On-Line; Recce: ‘Recce-435 Reduces Helicobacter Pylori In Rats’; Alterity: ATH434 MSA Mouse Safety, Efficacy Presentations; Alterity 49m Director ‘Incentive’ Options EGM; Merchant Funds Takes 12.3% Of Bard1; Stephen Dobson Below 5% In Neurotech; Volpara: Katherine Singson US CEO, Mark Koeniguer Goes
 
July BDI-40 Down 2.4%: Big Caps Down 2.4%, ASX200 Up 0.5%; Hatchtech: FDA Okays Xeglyze For Head Lice (19 Years); Zelira ‘Oversubscribed’ Placement Raises $8.75m; Suda: ‘Oversubscribed’ Rights Raise $3.6m; $533k Placement; Redhill: FDA Allows Phase III RHB-204 For NTM Trial; Prescient Completes 1st PTX-200 For AML Cohort Dosing; Medlab: Nanabis 60% Reduction In Pain; Antisense Files ATL1102 For DMD FDA Orphan Application; Cogstate: Eisai To Link Nouknown With Easiit; THC H1 Receipts Up 123% To $3.2m; Creso H1 Receipts Up 314% To $2.9m; TBG H1 Receipts Of $2.8m; Adherium Receipts Down 22.5% To $2.7m; Regeneus Receipts Of $1.6m; Cann Global Receipts Up 54% To $1.3m; Perennial Takes 6% Of Micro-X; Credit Suisse Takes 9.6% Of Suda; Dr Paul Cozzie Increases, Diluted To 14.2% Of Cardiex; Bard1 Founder Dr Irmgard Irminger-Finger Diluted To 5.16%; Imagion To Release 2.5m Voluntary Escrow Shares; Esense Appoints Winton Willesee Director; Non-Compliance
 
Dr Boreham’s Crucible: Dimerix; Clinuvel Receipts Down 9% To $29m; Pharmaxis Receipts Up 13% To $7.8m; G Medical H1 Receipts Down 13% To $2.2m; Nuheara Receipts Up 44% To $3.4m; Bioxyne Receipts Up 61% To $2.8m; MGC Receipts Up 27% To $2.1m; Optiscan Receipts $1.3m; Correction: Dorsavi; Rhythm Rights For $3.6m To Take Total To $6m; BTC Sells Bio101 For $500k; Azure Completes Phase II NASH, NAFLD Protocol; Scott Kirkland Increases, Diluted To 5% In Emvision; Ryan Laws, Skaha Investments Below 5% In Emvision; Simavita: Tiga 17%, Fifty-Second 16%, Dussman 10%, Chevron 9%; McRae Diluted To 31% In Neuroscientific; Volpara 852k CEO, Director Options AGM; Anteris Pleads Schultz To 31% Fall, But No ASX Query
 
Mark Sullivan Wins Clunies Ross Entrepreneur Award; Cynata CYP-001 2-Year GvHD Follow-Up: 60% Survival Rate; Osprey: GE Healthcare To Distribute Dyevert; Paradigm 10 US Access PPS OA Patients Report Reduced Pain; Starpharma Starts DEP Docetaxel Combination Study; Antisense Plans Euro, US Trials Of ATL1102 For DMD; Aroa: Myriad CE Mark; Symphony FDA Approval; Orthocell Files Celgro Nerve Repair To TGA; Tali Supplies Detect To 1.6k Primary School Children; Mesoblast Receipts Down 18% To $35m; Hydrix Receipts Up 29% To $16m; Starpharma Receipts Up 158% To $7.2m; IQ3 Receipts Up 29% To $7.2m; Elixinol H1 Receipts Down 57% To $7m; Medlab Receipts Up 11% To $6.5m; Cardiex Receipts $5.1m; Bionomics Receipts Down 59% To $3.6m; Dorsavi Receipts Down 36% To $2.4m; Amplia Retail Rights Raise $1.83m; Total $4m; Zelira: 1 Quarter Cash; Capital Raising Trading Halt; Hemideina Wins Federal $660k For Hera Cochlear Implant; Elixinol AGM: 19% Oppose Duff, Ellery Rights; Neuren Appoints Lauren Frazer CFO, Co Sec; Neuroscientific Appoints Prof Dao-Yi Yu Advisor
 
Dimerix: DMX-200 Safe, Reduces FSGS Proteinuria 29%; Clarity Starts Cu-64 Sar-Bombesin Breast Cancer Trial; Ecofibre Revenue Up 42% To $51m, Profit Up 119% To $13m; Total Brain Receipts Up 81.5% To $5m; Proteomics Receipts Up 1.3% To $1.8m; Incannex Receipts Up 18% To $1.4m; Imagion ‘Oversubscribed’ Placement Raises $5m; Nova Eye (Ellex) Pays Investors $61m From Lumibird Sale; Nyrada Receives $1.1m R&D Tax Incentive; Ecofibre Pays $59m For Texinnovate; Cann Global Rights Raise $2.2m Of Hoped-For $4.7m; TBG Exprobe Sars-Cov-2 Test Wins Taiwan Emergency Use; Suda: TGA Approves Zolpimist For Insomnia; Invion Investigates Anti-Cancer Compounds; Bard1 Completes Sienna Acquisition; Cann Group Notes Convert To 17m Shares; Invion Loses CEO Craig Newton, Co-Sec Melanie Farris 
 
Genetic Signatures Receipts Up 85% To $8.8m; Impedimed Receipts Up 21% To $5.4m; Resonance Receipts Up 2% To $3.6m; Pharmaust Receipts Down 7.7% To $3.5m; Osprey: H1 Receipts Down 42% To $1.5m; Hydrix Rights Raise $2m, $1m Placement To Go; Atomo, Access Bio 2m North America Covid-19 Antibody Tests; Optiscan $350k For Microscopes To Unnamed China Customers; Visioneering: Oculus Naturalvue Asia Distributor; Oncosil FDA HDE Application For Bile Duct Cancer; Redhill: Envisionrx Takes Talicia For Helicobacter; Cellmid: Tru Beauty To Distribute Évolis Hair Care In The US; Elixinol Japan Marijuana Deal
 
CSIRO, Doherty Distance From ‘Tier 1’ Sars-Cov-2 Claims; Alcidion Receipts Down 3.2% To $20.8m; Mach7 Receipts Up 65.3% To $17.1m; Medadvisor Receipts Up 16.4% To $9.3m; Telix H1 Receipts Up 27.1% To $2.1m; Respiri: ‘Up To $8m Revenue In 2021’; Cardiex Raises $2.5m; Prescient Share Plan For $6.5m; Proteomics Patents, Trademarks, Secrets & Pricing; Opthea: ‘DME Subgroup Benefits From OPT-302’; Oventus Signs 2 Ontario O2vent Optima Deals; G Medical IDTF In 13 Unnamed US University Hospitals; Heramed Starts Herabeat Trial Recruitment; Respiri Completes Unmarketable Parcel Sale; Imagion Requests ‘Capital Raise’ Trading Halt; Dimerix Requests ‘DMX-200 FSGS Trial Results’ Trading Halt; Ecofibre Requests ‘Acquisition’ Trading Halt; Esense ‘Israeli Research Agreement’ Suspension; Noxopharm ASX Listing Rule 10.11 Breach; Anteris (Admedus) Pleads Schultz To Share Sales; Elixinol Appoints Pharmacann For Australia Marijuana Sales; Little Green Pharma Releases 22.4m Escrow Shares; Elixxir Reduces To 22.1% Of Little Green Pharma; Neurotech Pivots From Autism To Dolce Marijuana; MGC: Mice Survive Artemic For Sars-Cov-2 Toxicology Study; Pro Medicus Appoints Deena Shiff Director 
 
Dr Boreham’s Crucible: Aroa Biosurgery; Aroa IPO Opens Up 87% For Endoform Soft Tissue Regeneration; Immuron Raises $28.1m; Emvision To Raise $9m; Universal Bio H1 Revenue Down 73% To $1m, Loss Up 29% To $4.5m; Alcidion $1.5m Scotland NHS Patientrack Contract; Visioneering: 1st Canada Naturalvue Contact Lens Sale; Dimerix Doses Last DMX-200 Kidney Disease Patient; Factor To Acquire Longmile Vet Tech; David Brookes Chair; Adherium 20% Oppose 20m Chair, CEO Options; Bionomics: Aperion, Angermayer Acquisition AGM; Australian Ethical Reduces To 6.5% Of Prescient; Prescient Requests ‘Capital Raising’ Trading Halt; MGC Takes ‘Artemic Sars-Cov-2 Results’ Halt To Suspension; Mesoblast Appoints Dagmar Rosa-Bjorkeson New York COO; Opthea Appoints Lawrence Gozlan Director; Bard1 Appoints Dr Peter French CSO
 
Clarity Starts 67Cu-Sartate Neuroblastoma Trial; Pharmaxis Submits FDA INDA For PSX-5055 Myelofibrosis Trial; Amplia Appoints Nucleus Networks For Phase I AMP945 Trial; Adalta Begins Dosing AD-214 Lung Disease Trial; Invex: FDA, EMA Advice On Presendin For IIH; Incannex Starts Marijuana IHL-216a Rat Trail For Brain Injury; Cogstate Cognitive Assessments For ERT Trials; Rhythm $2.4m Placement, Rights For $3.6m; Cogstate Receipts Up 4.3% To $41m; Immutep Receipts $7.7m; Anteris (Admedus) H1 Receipts Down 62% To $3.8m; Next Science H1 Receipts Up 31% To 3.6m; Rhinomed Receipts Up 5% To $3.1m; Avecho Pleads Schultz To ASX 86% Price Query; Cardiex Requests ‘Capital Raising’ Trading Halt; Esense Requests ‘Israel Coronavirus Deal’ Trading Halt
 
Qbiotics Doses 1st Australian Head, Neck Cancer Patient; Immuron To Raise $28m; Somnomed Receipts Down 5.6% To $61.5m; Cellmid Receipts Up 29% To $8.2m; Atomo Receipts Up 456% To $2.7m; Micro-X Receipts Up 11% To $2.6m; Little Green Pharma Receipts Of $1.8m; Correction: Respiri; Impedimed Launches Sozo For Heart Failure; Emvision Imaging Algorithms Classify Strokes; Imagion: Iron Oxide Nanoparticles Enable Low-Field MRI; Osteopore, QUT Licence For 3-D Printed Bone Implant; Zelira, CVSCM Marijuana Deal For PAD, Diabetic Neuropathy; PYC Completes CPP Toxicity, Mouse Studies; Race Granted 4th US Bisantrene Patent; Botanix Tells ASX 22% Aware Query: FDA Info Held For 10 Days; Invex Requests ‘Regulatory Advice’ Trading Halt; MGC Requests ‘Artemic Pre-Clinical Results’ Trading Halt; Noxopharm Receives $130k From Lind, CST Facility; Adalta Appoints Dr David Fuller Director; Tali Appoints Expert Advisory Board
 
Mesoblast: US FDA Remestemcel-L Paediatric GvHD Review; Telix Receives $11.4m R&D Tax Incentive; Genetic Technologies Raises $7.3m; Bod Receipts Up 205.1% To $3.6m; Clarity, Imaginab Work On Antibodies For Cancer; Heramed Expands Mayo Pregnancy Platform Deal; G Medical, Homestay Deal For Remote Patient Monitoring; Invex: Exanatide US Patent For Intracranial Pressure; Immuron: ‘IMM-124E Antiviral Activity Against Sars-Cov-2’; Up 250%; Prescient: Doherty Tests 2 Unnamed Drugs For Sars-Cov-2; Respiri: Zip Co Wheezo Price $336 Over 6 Months; Zelira EGM: 22% Dissent To 150% Directors’ Fees Hike; Neuroscientific To Release 19.3m Escrow Shares; Everbest, Constellation Take Loss, Below 5% In Anteris (Admedus)
 
Uniquest, CSL Collaborate On Sjögren’s Syndrome; Micro-X: US FDA 510(K) Approval For Rover Mobile X-Ray; Ecofibre Receipts Up 27% To $43.0m; Optiscan: Federal $971k For Oral Cancer Screening Trial; Uscom: 1a Detects Early Pre-Eclampsia; Adalta: Data, Phase I Design ‘Sufficient For FDA Application’; Immuron: FDA Guidance To US Navy For Campylobacter, E Coli; Federal Court Okays Sienna, Bard1 Merger; Goodbye Sienna; Noxopharm: ‘NOX66 Increases Immune Cells In Tumors’; Patent; Correction Recce: 327 For CSIRO Sars-Cov-2 Program, Not 529; Genetic Technologies To ASX: ‘Covid-19 Details In Prospectus’; GI Dynamics: Crystal Amber $14m, 4 Directors To Go, Quit ASX; MGC: $1.4m For Cannvalate’s Medicinal Cannabis Clinic; Respiri: Buy-Now-Pay-Later Zip Co For Wheezo; Little Green Marijuana Permit; Prescient Requests ‘Collaboration’ Trading Halt; Zelira Requests US Licence Agreement Trading Halt; Heramed Takes ‘Material Collaboration’ Halt To Suspension; Peter Meurs Diluted To 12.6% Of Dimerix; Credit Suisse Below 5% In Kazia; Everbest, Constellation Take 5.5% Of Anteris
 
Dr Boreham’s Crucible: Hydrix; Federal $32.5b Takes MRFF To $20b Target; AAMRI Response; Russia, Israel Approve Redhill Opaganib Covid-19 Trial; Alcidion: ACT Health $1.3m 2-Year Contract Extension; Cann Group Raises $14.3m, Plan For $10m More; Receipts Up 17%; Genetic Technologies Placement For $7.3m; Palla: $8m UK Contract; Norway Facility Applies For Approval; THC Share Plan Raises $1.5m, Total To $8.1m; Respiri Appoints Cipla Australia, NZ Wheezo Distributor; Imugene: 2nd PD1-Vaxx Lung Cancer Trial Approval; Auscann Unmarketable Parcel Facility; Ecofibre: 2 US Trials Of CBD For Neuropathy, Agitation; Botanix, FDA Agree BTX1503 Acne Phase III Endpoints; Incannex IHL-675a Reduces Ards Sepsis, In Mice; Rhythm Requests ‘Capital Raising’ Trading Halt; Factor Takes ‘Potential Acquisition’ Halt To Suspension; G Medical AGM 57% Block 75m CEO Dr Yacov Geva Shares; HK’s Star Bright Takes Loss To 12% Of Anteris (Admedus); Cann Group Appoints Jenni Pilcher Director; Biotron Appoints Dr Stephen Becker CMO; Bio-Melbourne Hosts Regenerative Medicine Webinar
 
Bluechiip: ‘Labcon Unlawfully Terminates Supply Deal’; LBT Installs First UK APAS Independence; Biointelect: ‘Malaria Tafenoquine Kills Sars-Cov-2, In-Vitro’; Anteotech: Sars-Cov-2, Influenza A, B 3-In-1 Test; Recce, Path To Study Recce 327, 529 For Sars-Cov-2; Althea Full Year Marijuana Customer Receipts $4.6m; G Medical IDTF In 4 Unnamed US University Hospitals; Bod: 500-Patient ‘Observational’ Marijuana Medicabilis Study; Cronos Prepares Asia Marijuana Launch; Genetic Technologies Requests 200% Price Hike Trading Halt; Heramed Requests ‘Collaboration’ Trading Halt; Avita: ATO Class Ruling On US Move; Mason Stevens Takes 5% In Patrys; CSL Appoints Dr Pascal Soriot Director; Leanne Ralph Replaces Visioneering Co Sec Julian Rockett
 
Nyrada Delivers I-V NYX-242, NYX-1010 For Brain Injury, In Rats; Visioneering H1 Receipts Down 4.7% To $3.3m, Pandemic Effect; Osprey Halts $2.7m Rights Shortfall; Total Raised $12.8m; Sienna EGM Overwhelmingly Backs Bard1 Acquisition; Immutep Granted US Patent For IMP701 For Cancers; GI Dynamics: Crystal Amber Converts $7.7m Note; To Delist; Factor Requests ‘Potential Acquisition’ Trading Halt; Incannex Requests ‘IHL-675A Ards Animal Results’ Trading Halt; Cann Group Requests Capital Raising Trading Halt; Respiri Requests ‘Commercial Agreement’ Trading Halt; Merchant Funds Takes 9.3% Of Race; Naos Takes 24.8% Of BTC; W Whitney George Takes 41.5% Of Rhinomed; Bonvoyolo Reduces To 5.85% Of Neurotech; L1 Below 5% In Creso
 
Polynovo: Barda $21.6m For Novosorb BTM Trial; Pharmaxis: FDA Orphan Status For PXS-5505 For Myelofibrosis; Queensland Uni: 1st Covid-19 Volunteer Dosed; Vaccine Next Year; Alcidion $686k Murrumbidgee Miya Precision, Memre Contract; Mach7 Completes $41m Client Outlook Acquisition; Zelira Phase I ZTL-103 Marijuana Pain Trial ‘Safe, Tolerable’; Imugene Phase I PD1-Vaxx Trial For Lung Cancer Approved; Neuroscientific: Emtin B Increases Myelin Formation, In-Vitro; Heramed Share Plan Raises $233k, Total $2.55m; Nuheara Pleads Schultz To ASX 75% Price Query; ATO Sienna-Bard1 Merger Capital Gains Tax Relief; MGC Licence To Grow Marijuana For RMIT Research; Bluechiip Takes ‘Labcon Agreement’ Halt To Suspension; Anteotech Requests ‘Life Sciences Development’ Trading Halt; GI Dynamics Requests Crystal Amber Note Trading Halt; Regal Funds Below 5% In Medical Developments; Recce’s Dr Graham, Olga Melrose Take 25.3%; Platinum Takes 19.89% Of Amplia; Allan Moss, Blueflag Take 8.7% Of Amplia; Race Director Dr William Garner Diluted To 11.4%; Recce Appoints Dr Alan Dunton Director; Imagion Loses CFO Brian Conn; CFO Wanted
 
Avita: Barda Orders $13.2m Recell Systems; Uscom Customer Receipts Up 59% To $4m; Correction: Cynata Therapeutics; MTP To Run Federal $47m Diabetes, C-V Program; Federal $50k For Patrys, ONJCRI PAT-DX1 For Breast Cancer; Race: Williams, Emmanuel, Merchant Commit To $3m; Luina, Xing Work On Point-Of-Care Sars-Cov-2 Test; Imagion Joins Boston Uni’s Nanosystems Research Centre; Clinuvel: Prenumbra For Unnamed Acute, Systemic Diseases; Heramed: Ready For Joondalup Herabeat Trial; LBT Appoints Oneservice APAS Service Provider; Pharmaust: Monepantel Dog Cancer Trial Report With Elanco; Avecho: 31% Opposition To Equity Incentive Plan; Living Cell Tells ASX: ‘Not Material Info Sent Price 50%’; Cann Global Releases 706m Shares From ASX Escrow; Nuheara 6m Director Options AGM; Zelira Issues 12.5m Chairman, Director Performance Rights; Regal Funds Reduces To 5% Of Medical Developments; Jamber, James Schwarz Sells All 10m Esense Shares; Chifley Reduces To 8.7% Of Esense; Cochlear Loses CFO Brent Cubis; CFO Wanted; Invion Appoints Melanie Leydin CFO; Melanie Farris Director
 
Dr Boreham’s Crucible: Cynata Therapeutics; Compumedics ‘Covid-19 Hits Revenue’ Down 15% To $36m; Avita Unaudited Revenue Up 164% To $21m; Polynovo: FDA Requests More Novosorb Trial Information; Polynovo: ‘Record Novosorb US Sales’ In June, First UK Sale; Correction: Rage Biotech; Creso: Mernova $901k Israeli Marijuana Order; Memphasys: Canadian Felix Approval Vests 11.2m Options; Bluechiip Requests ‘Labcon Agreement Trading Halt; JM Financial, No Plan B Take 14% Of Universal Biosensors
 
Rage: IP Group, Monash, UWA Up To $10m For Lung Disease; LBT Placement For $8m, Share Plan For $1m More; Medibio Applications For $513k, $1m Shortfall; Total $2m; Orthocell Ortho-ATI Tendon Injury Survey: 87.5% Satisfied; Race Requests ‘Placement’ Trading Halt; Kinghorn Joins Starpharma Dep-Irinotecan Trial; Incannex Applies For Marijuana IHL-42X Sleep Apnoea Trial; Cellmid Tells ASX: ‘Wondfo Extension Not Material’, Up 30%; Cellmid To Distribute Immunodiagnostics Sars-Cov-2 Tests; Eleanore Goodridge Reduces To 9.6% In Nyrada
 
Greenlight: Trials Resilient Despite H1 18% Fall; Telix, Reflexion Combine Cancer Technologies; Telix: FDA Supports, Clarifies TLX591 Prostate Cancer Trial; 4D: $56m IPO For XV Respiratory Imaging; Recce 327, 529 In CSIRO, Doherty Sars-Cov-2 Program; Medlab Share Plan Raises $1.6m Of Hoped For $4m, Total $7m; Allegra Details Sr-Ht-Gahnite Patents; Visioneering Pleads Schultz To ASX 100% Price Query; Althea: Concierge For Online Marijuana Sales; MGC Granted Australian Marijuana Import Licence; CVC Sells All 24m Universal Biosensors Shares; Esense Issues Blue Science 10m CDIs
 
CSL Enrols 1st Patient In CSL312 Phase II Covid-19 Trial; LBT: Beckman Coulter Markets APAS In Europe; Trading Halt; Cyclopharm: H1 Sales Down 13.8% To $5.6m, Underlying Up; Esense: Blue Science US Terpenes Sanitizer Distributor; Total Brain: 3.8m Louis Gagnon, Dr Evian Gordon Options EGM; Cellmid Requests ‘Distribution Agreement’ Trading Halt; Life Biosciences Diluted To 25% Of Alterity; Lazard Takes 6% Of Mayne; Pyxis Takes 8% Of Lifespot
 
Mesoblast: US Allows Remestemcel-L For Covid-19 Children; Nyrada: ‘Oral NYX-PCSK9I Equals Injectables For LDL, In-Vitro’; Cogstate: $66m Clinical Trials Sales Contracts; Biotron: ‘BIT225 Enhances HIV-1 Immune Response’; Mayne: Novast Supply Agreement For 13 Contraceptives; Dimerix Advances DMX-700 Program For COPD; Allegra Acquires Sydney Uni Sr-Ht-Gahnite Patents; Cardiex Restructures Inhealth Collaboration; Creso Redeems 1.2m Kunna Non Performance Shares; Recce Requests ‘Research Agreement’ Trading Halt; Thorney, Tiga Increase, Diluted To 27% Of Visioneering; Eleanore Goodridge Below 5% In Noxopharm; Erlyn Dale, Winton Willesee Replace Esense Co-Sec James Bahen
 
Dr Boreham’s Crucible: Mesoblast; FDA Approves 4 Cochlear Nucleus, Custom Sound Products; Amplia Institutional Rights Raise $2m, $2m Retail To Go; Suda Rights Offer For $3.6m; Neurotech $500k Placement For Marijuana For Autism; Ecofibre: US Marijuana Neuropathy Trial Starts; Osprey Pleads Schultz To ASX 77% Price Query; GTG Tells ASX: ‘Early Media Release No Material Impact On Price’; Cann Receives $2m Victoria Regional Jobs Grant; Cann Global Rights Offer For $4.7m; MGC EGM: 23.5% Oppose Share Ratification; Oventus: 50% Directors Pool Hike, 6.9m Director Options EGM; Naos Takes 24% Of BTC Health; Anthony Grist, Oaktone, Denlin Below 5% Of Invex; David Hunnon, Chifley Take 12% Of Esense; Recce Founder Dr Graham Melrose Retires; Paradigm Appoints CMO Dr Donna Skerrett Director; Bionomics Appoints Apeiron’s Aaron Weaver Director; Peter Hatfull Replaces Esense Director Piers Lewis
 
Affinity Claims ‘Antibodies Block Sars-Cov-2’, In-Vitro; Alterity Placement Raises $1.6m; Ellex (Nova Eye) Pays $921k For Molteno-3 Glaucoma Device; Dorsavi: QBE $250k, 12-Month Visafe Deal; Actinogen Pleads Schultz, Alterity To ASX 59% Query; Resapp Raises $1.4m From M-D Dr Tony Keating Options; Osteopore Appoints Bioplate US Distributor; Oncosil Files For TGA Pancreatic Cancer Device Approval; Bod Q4 Marijuana Revenue Up 100% To $2.5m, YTD $6m; Incannex (Impression): $1.5m Maiden Marijuana Sales Revenue; THC: Medleaf Pays $260k; Expects Canada, European Orders; Neurotech Requests ‘Acquisition, Capital Raising’ Halt; Paul, Eleanor Stephens Below 5% In Rhinomed; Apeiron, Christian Angermayer Take 13% Of Bionomics; Mark Lampert, BVF Diluted To 17% Of Bionomics; Creso Chair Boaz Wachtel Below 5%; MGC Expands Artemic Covid-19 Trial To India; Cellmid Extends Wondfo Covid-19 Distribution
 
14-Year Data: Big Caps Up 963%, BDI-40 Up 450%, ASX200 Up 16%; Telix: FDA TLX250-CDx Renal Cancer ‘Breakthrough’ Status; LBT: Johns Hopkins - Apas Independence ‘No False Negatives’; TGA Approves Next Science Bactisure Surgical Lavage; Alterity Pleads Schultz To ASX 2,077% Query; ASX Misses 300%; Mach7 Retail Rights Raise $11.4m; Total $34.8m; Alcidion $560k Sydney Miya Precision Deal; Amplia Under-Written Rights For $4m; Resapp Partners With Coviu, Phenix; Medadvisor, Hms Integrate Health Platforms; Gi Dynamics Extends $6.6m Crystal Amber Note, Again; Cronos Launches 2 Medical Marijuana Oils In Australia; Creso CEO Miriam Halperin Wernli Below 5%; Suda Appoints Phillip Hains Joint Co-Sec; Alistair Warren Replaces Little Green Co-Sec Craig Basson
 
Race: Independent Mouse Study Backs Bisantrene For Cancer; Alterity, FDA Discuss Phase II ATH434 MSA Study Endpoints; Amplia: No Toxicities To Prevent AMP945 Phase I Trial; Redhill: UK Approves Opaganib Phase II/III Covid-19 Trial; Invion Receives 1st Guilin Pavay Cosmetics Order; Ellex Completes $97m Lumibird Laser, Ultrasound Sale; Orthocell Recruits Ortho-ATI Rotator Cuff Trial; Elixinol 1.36m Oliver Horn, Helen Wiseman Rights AGM; Factor Potential 2nd Strike Board Spill AGM; Resapp: Kenya’s Ilara Health Evaluates Resappdx; Australian Ethical Takes 12% Of Ellex; Pyxis Takes 6% Of Lifespot 
 
Neuren Raises $20m, Share Plan For $3m More; Immutep Doses Tacti-002 Study Part A; Avita US Move Completes July 1; Resapp US Defence Health Analytics Program Closes; Starpharma: DEP-Irinotecan Anti-Tumor Activity, In Mice; Amplia Requests ‘Tox Studies’ Trading Halt; Medlab: UK Orders 5k MG Optima Relax Marijuana Units; Resapp Launches Sleepcheck Apnoea Risk Application; Creso: 15m Shares To Mernova For Sales Licence Milestone; Thorney, Tiga Increases, Diluted To 13.9% Of Oventus; L1 Capital Takes 7.4% Of Creso; Little Green Pharma Ships Marijuana Oil To UK; Dr David Brookes Replaces Tali Director Mark Simari; Suda CEO Dr Michael Baker Appointed Director
 
Dr Boreham’s Crucible: Race Oncology; Zucero: ZU545 ‘Potent Activity’ Against Covid-19, In-Vitro; Respiri, Edinburgh Uni Partner For Data; Ellex $100m Lumibird Laser, Ultrasound Sale Finalized; Lifespot: 42% Remuneration Report 1st Strike; Cogstate Appoints John Glueck Co-Co Sec
 
CSL Pays $656m+ For Uniqure’s AMT-061 For Haemophilia-B; Visioneering Share Plan Raises $1.1m; Total $6.1m; Suda: ASX Halts Cancer Drug Acquisition, Back-Door Listing; Lifespot: TGA Registers Fevertel Thermometers; Neuren Requests ‘Capital Raising’ Trading Halt; Adherium 23m Director Options EGM; THC To Supply Marijuana To Medleaf NZ; Antanas Guoga Sells All 3.4m Opyl Shares
 
Pfizer $720m For Clinical-Stage Biotechs; Federal $36m For Rare Disease Projects; Rhinomed Underwritten Rights Raise $6.5m; Aroa 2-Day $45m IPO For Endoform Soft Tissue Regeneration; Mayne: US FDA Accepts E4/DRSP Contraceptive NDA; G Medical: 1st Italian Prizma Order; Botanix Resumes BTX1801 Recruitment; Althea: Drug Science Referral For UK Marijuana; Creso Ups Canada Medical, Party Marijuana Production; ‘Freeman Road’, Dr Ti Wan Ng Take 5% Of Heramed; Paradigm Loses Chair Graeme Kaufman; Simon Gray To Replace Ellex Co Sec Kimberley Menzies
 
Tali: Tali Detect Valid, Reliable Attention Diagnostic; Anatara: No Detach Partner By July; Invion: NZ Patent For Photodynamic Cancer Therapy; Clime Takes 9.1% Of Mach7; Australian Ethical Takes 5.5% Of Mach7; Eleanore Goodridge Reduces To 6.4% Of Noxopharm; MGC: 3-Year GMP Licence For Slovenian Facility
 
Victoria: Jaala Pulford Innovation, Medical Research Minister; Vic Aamri Welcomes 1st Dedicated Minister For Medical Research; THC Raises $6.6m, Share Plan For More; Dimerix Placement Raises $5.8m; Kazia: ‘Paxilisib Beats Temozolomide For Glioblastoma’; Tali Competes Monash Uni Research; Works With Duke; Imagion: 1st Magsense Breast Cancer Trial; Azure Prepares For IVB003 Pancreatic Cancer Trial; Emerald To Use Binah Tech For Covid-19 Vaccine Trial Monitoring; Patrys 1-For-3 Rights For $4.3m; Immutep Receives $1.4m R&D Tax Incentive; Federal Court Approves Avita US Move; GI Dynamics: EGM Backs ASX Delisting; Genetic Technologies: US Genetype Breast Cancer Test Patent; Althea, Collective To Manufacture Marijuana Beverages; MGC Unmarketable Parcel Facility; Medlab: Sean Hall 22%; Michael Hall 6%, Drew Townsend 6%; Star Bright Reduces To 21.6% Of Anteris (Admedus); Bionomics Chair Dr Errol De Souza Full-Time, Pro-Rata Pay Cut
 
Dr Boreham’s Crucible: Emvision Medical Devices; Redhill Expands Euro Opaganib Covid-19 Trial, US Trial Begins; Opyl Raises $739k; Nuheara Begins Shipping 5k Iqbuds Max; Noxopharm: East Europe Covid-19 Trial; Immuron, CSIRO Work On US Defense Bacterial Preventatives; Sienna Appoints Aenorasis For hTERT In Greece, Cyprus; GI Dynamics $1.1m Crystal Amber Convertible Bridge Note; Imagion: 10m CEO ‘Performance’ Rights, 6m Options AGM; Director Peter Anastasiou Reduces To 7% Of Immuron; Cronos Loses Director, COO Peter Righetti
 
Victoria, First State, Roc $250m Business Fund; Oventus ‘Over-Subscribed’ Share Plan Raises $2m, Total $6.65m; Cynata 440-Patient, Phase III Cymerus Osteoarthritis Trial Approved; Anteris (Admedus) Receives $735k R&D Tax Incentive; Lifespot Placement Raises $300k; Telix Resumes Phase III Zircon Trial In Europe; Acrux, Amring Unnamed Generic Drug Deal; Resapp, Reckitt Benckiser Cough Diagnostic MOU; Dimerix Requests Capital Raising Halt; Patrys Requests Capital Raising Trading Halt; Opyl Requests Capital Raising Trading Halt; Emerald Requests ‘Real World Evidence Platform’ Halt; Pie Funds Takes 5% Of Probiotec; Director Dennis Eck Takes 10% Of Cellmid; Noxopharm Chair Dr Graham Kelly Increases, Diluted To 17%; Eleanore Goodridge Takes 8% Of Noxopharm; Esense, Wise Wine J-V For Terpene-Infused Sanitizer; MGC Sells Nutraceuticals To Onassis For $9m In Shares; Pharmaust: ‘WEHI Confirms Monepantel For Sars-Cov-2 In-Vitro’; Respiri Pays Ex-CEO Mario Gattino ‘Immaterial’ Settlement
 
MTP Claims Sector ‘Hit Hard’ By Covid-19; Biocurate, Uniseed Join Forces For Commercialization; Speedx: Roche To Distribute Infectious Disease Tests; Dimerix Completes Phase IIa DMX-200 For FSGS Trial Dosing; Starpharma: DEP-Lutetium ‘Significant For Cancer’ In Mice; Anteris (Admedus) Heart Valve Feasibility Pig Study; Prescient: 2 US PTX-200 Patents For Leukaemia, Breast Cancer; Zelira, Levin Marijuana For Athletes With Chronic Pain; Zelira 150% Directors Fees Hike EGM; Rhinomed: FIRB Okays Whitney George To Underwrite $6.5m; Race Agrees To Buy-Back $800k Dr Peter Molloy Loan Shares; GI Dynamics Extends $6.6m Crystal Amber Note, Again; Kenneth Biddick, Authentics Australia Below 5% In Immuron; Regal Funds Increases, Diluted To 10% Of Visioneering; CSL To Lose CFO David Lamont; Bio-Melbourne Network Appoints Jeff Malone CEO; Bio-Melbourne Forum On Fast Coronavirus Vaccine Project
 
Race: Bisantrene For AML ‘40% Overall Response’; Neuren: Acadia Resumes Phase III Trofinetide Rett Trial; Starpharma: Vivagel BV In Central, Eastern Europe; Memphasys: Felix Sperm Separator Sales ‘On-Track’; Resapp: Phenix Licences Resappdx-EU For Telehealth; Cellmid: $1.2m From Japan TV Hair Loss Sales; Respiri, Pharmacy Guild Asthma Management Course; G Medical CEO Dr Yacov Geva 10m Shares, 65m Rights AGM; Lifespot Requests Capital Raising Trading Halt; THC Requests Capital Raising Trading Halt; Cynata CEO, Director Sell Shares; Australian Ethical Takes 11% Of Ellex; Investors Mutual Below 5% In Ellex; Australian Ethical Takes 17% Of Cogstate; FIL Takes 5% Of Starpharma; PYC: Chair Alan Tribe Aust Land 30%, Director Dr Hockings 9%; L1 ‘Below 5%’ In Creso; Holds 6.3%; Dr Darryl Maher Replaces Cynata Director Peter Webse, Co Sec; Ancila Desai Replaces IDT CFO, Co-Sec Joanna Johnson; Sinead Teague Replaces Exopharm Co Sec David Parker
 
Proteomics: ‘Promarkerd Significantly Predicts Renal Decline’; Avita Overwhelming Backs US Move; Noxopharm Underwritten Rights Raise $7.9m; Medlab Raises $5.4m, Share Plan For $4m More; Azure (Invictus) Prepares IVB001 Nafld, Nash Study; Cellmid: Wondfo Covid-19 Test 86% Sensitive; Doherty Says 69%; Perennial Takes 7.4% Of Atomo; One Funds Takes 8.4% Of Bluechiip; Cann Group Issues CSIRO 325k Shares For Marijuana R&D; Cann Global: ‘Marijuana Strain Stops MS In-Vitro’, Mice; MGC, IM Cannabis To Sell Marijuana Cannepil In Israel; THC: Cannatrek To Supply Dried Marijuana Flower; Esense, ANC J-V For Skin Care, Hair Care, Sanitizer; GI Dynamics Requests ‘Crystal Amber Note’ Trading Halt; Pharmaust Takes ‘Sars-Cov-2 Test Results’ To Suspension 
 
Dr Boreham’s Crucible: Alcidion Group; S&P Indices: 14 Biotechs, Australian Ethical Up; 4 Down; Scopus: City Of Hope Drug, Paul Hopper’s Bioscience Oncology; TBG: ‘FDA Approves Sars-Cov-2 Test Emergency Use’; Exopharm Licences NY State, Santa Clara Uni Exosome IP; Mach7 Placement, Insto Rights Raise $23.4m; $11.4m To Go; Ellex: Lumibird $100m Laser, Ultrasound Sale By June 30; Race Requests ‘Trial Results’ Trading Halt; Esense Requests ‘Joint-Venture’ Trading Halt
 
ACCC Allows Lumibird Ellex Lasers, Ultrasound Acquisition; Azure Acquires Invictus; Redhill Applies For Russia Opaganib Covid-19 Trial; Medlab 1st Nanocbd Patient; ‘Capital Raising’ Halt; Creso Welcomes Israel Marijuana Legalization Proposals; Sienna, Bard1: Federal Court Approves Merger; Lifespot Appoints Bodytel Software Distributor; Proteomics Requests ‘Results’ Trading Halt; Pharmaust Requests ‘Sars-Cov-2 Test Results’ Trading Halt; Cann Global: 3rd ‘Research Initiatives’ Suspension Extension; Fil Increases, Diluted To 7.4% Of Adherium; Jamber Increases, Diluted To 8.5% In Creso
 
Opthea Claims OPT-302 DME ‘Non-Significant’ Success; Bio-Melbourne: Dr Andrea Douglas Wins Leadership Award; Adalta Ready For AD-214 For Lung Disease Trial; Telix: New TLX591-CDx Data For US NDA; Immuron Pleads Schultz To ASX 442% Price Query; Mach7 Capital Raise To Buy Client Outlook For $41m; Micro-X Submits 510(K) To FDA For Rover Mobile X-Ray; Medibio Placement Raises $500k, Rights For $1.5m More; Rhinomed: Unnamed US Drug Store Orders Pronto Clear; Painchek Applies For Canada Pain Assessment Clearance; Avita Scheme Meeting To Move To The US; Osprey Option Exercise Dates; Creso Completes Due Diligence To Sell Marijuana In Canada; Adherium: Trudell 15%, One Funds 8%, Phillip Thematic 5.5%; Orthocell Appoints Dr Leslie Wise Executive Director
 
 
Dr Boreham’s Crucible: Volpara Health Technologies; CSL, UQ, CEPI Collaborate On Covid-19 Vaccine Candidate; Atomo: Rapid Covid-19 Test Australasia Distribution Rights; Heramed Raises $2.3m; Share Plan For $1.5m More; Painchek Receives 2nd $1.25m Federal Payment; LBT Cuts Costs, Reduces Work Week, Pay 20%; FIRB, Federal Approval For Avita US Move; Cyclopharm AGM Votes On 1m M-D Incentive, Loan Shares; Medibio Requests ‘Capital Raising’ Trading Halt; Suda Takes ‘Licencing, Capital Raising’ Halt To Suspension; Proteomics Requests ‘Clarification’ Trading Halt; JM Financial, No Plan B Increase, Diluted To 14% Of Mach7
 
Dimerix DMX-200 Joins Remap-Cap Global Covid-19 Ards Study; ASIC: Insider Trading - Ex-Sirtex CEO Gilman Wong 3 Year Bond; Azure Notes Raise $1.7m For Invictus; Correction: Paradigm; Clarification: Impedimed; LBT Apas Independence For MRSA 6-Month FDA Delay; Osprey Requests ‘Shortfall Placement’ Trading Halt; Pfizer Australia Hosts ‘Post-Covid-19’ Webinar; Lazard Takes 5% In Mayne; Regeneus Loses 5-Year Director Dr Glen Richards; Zelira US CEO Dr Oludare Odumosu Starts On $217k; Cellmid: ‘Emergence Deal For Covid-19 Tests’; Pharmaust: ‘Monepantel Suppresses Sars-Cov-2 50-95% In-Vitro’
 
Clarity: 67cu-Sartate FDA ‘Rare Disease’ For Neuroblastoma; Impedimed: BIS ‘Significant Lymphoedema Detection’; Nuheara: $2m In Iqbuds Max Pre-Orders; Medlab Receives 1st Nanabis From Tasmanian Alkaloids; Creso: DHS To Distribute Cannaqix Marijuana In Brazil; Impression Drops Mouthguards For Marijuana; Cann Global 2nd ‘Research Initiatives’ Extension Suspension; Regal Funds Reduce To 6% Of Medical Developments; Regal Funds Reduce To 10.7% Of Opthea; Perennial Takes 6.4% Of Atomo; Paradigm: Dr Jeannie Joughin COO, Dr Michael Imperiale Safety; Mayne Appoints Toni Nesci Head Of Contract Services
 
Federal $66m For Covid-19 Projects; Applications Open For $2.5m CSL Centenary Fellowships; Avita Submits Pivotal Recell For Vitiligo IDE To US FDA; Bionomics Apeiron, Rights To Raise $22m, 2 Directors, 50% Fee Hike; Resapp: German Hospital To Evaluate Resappdx-Eu; COPD Study; Sienna: Triolab Sweden hTERT Bladder Cancer Test Distributor; Respiri Unmarketable Parcel Facility; Lazard Below 5% In Mayne; Anthony Grist, Oaktone Reduce, Diluted To 5.3% Of Invex; Invex Chair Dr Jason Loveridge Below 5%; Regal Funds Reduces To 11.4% Of Visioneering; Elixinol Chair Paul Benhaim, Raw With Life Diluted To 28%; D&G, David Newman, Gabriel Ettenson Reduce To 6% Of Elixinol; Telix Appoints Dr Colin Hayward Chief Medical Officer; Clarity Appoints Dr Michael Ironside Director Of Operations; Dimerix Requests ‘Covid-19 Trial Opportunity’ Trading Halt; Pharmaust Takes ‘Sars-Cov-2 Results’ Halt To Suspension; Impression Marijuana, Hydroxychloroquine Ards Mouse Trial
 
Biotech Fully Recovered: May BDI-40 Up 14%, ASX200 4%; Big Caps Down 6%; Vaxxas: Merck $18m For No Needle Vaccine, Harro Höfliger; Protagonist Early Data Backs PTG-300 For Polycythemia Vera; Pro Medicus $22m Northwestern Memorial Visage 7 Deal; Mesoblast: 2010 Osiris Data Backs Stems Cells For COPD, Ards; Nuheara Share Plan Raises $4.5m; Oncosil: Singapore Approval For Pancreatic Cancer; Kazia: 1 Paxilisib Glioblastoma Patient Progression-Free; Immutep: Tacti-002 - IMP321 Improves Efficacy For Cancers; Immutep: 4 Of 12 Patients Partial Response To IMP321, Avelumab; Noxopharm: 10 Of 16 Reduce Pain In Veyonda Prostate Study; Creso Placement Raises $2.1m; Micro-X Completes Rover Mobile X-Ray Tests For Military Hospitals; Heramed Requests ‘Capital Raising’ Trading Halt; Suda Requests ‘Licencing Transaction’ Trading Halt; THC Completes Tetra Medical Marijuana Acquisition; Visioneering: 22% Oppose Placement Facility; Regal Funds Reduces To 7% Of Medadvisor; Prescient Appoints Dr Allen Ebens Director; Race Appoints Phillip Lynch Director; Cellmid Appoints Dr Dominic Burg COO
 
Dr Boreham’s Crucible: Nanosonics; Volpara Receipts Up 153% To $12m, Loss Up 73% To $19m; Immutep Receives $3.6m French R&D Tax Incentive; Acrux: Trupharma 6 Products US Distributor; Micro-X Ships $500k Nano Units In May; Mayne: Mithra To Supply E4/DRSP Contraceptive In Australia; THC Prescribes 1st Australian Marijuana; Niv Dagan, Freedom Trader, 10 Bolivianos Take 9.4% Of Lifespot; Micro-X Loses Co Sec Georgina Carpendale; Medadvisor Loses Simon Chamberlain, Victor Kovalev; Osprey 250% ‘Incentive’ Shares Hike In Lieu Of Fees AGM; Pharmaust Requests ‘Sars-Cov-2 Pre-Clinical Results’ Halt 
 
Federal $9.5m For Endometriosis; Mesoblast YTD Revenue Up 113% To $48m, Loss Down 34% To $68m; Imugene: Mimotope Vaccine Identifies PD1 Cancer Antibodies; CSL Leases Swiss Facility To Thermo Fisher; Osprey: Dyevert Reduces Contrast-Induced Kidney Injury; Cryosite Pleads Schultz To ASX 57% Query; ASX Misses 57%; Palla Tells AGM: $1.3b EU Codeine Market; G Medical Clarifies News Article: Not ASX Delisting; Stemcell, Temasek Seagrape Farming Deal; Esense, Sealaria J-V For Terpene, Red Algae Sanitizer; Invex: Forrest, Tattarang 11%; JK, Tisia 6%; McAuliffe Below 5%; Mark Licciardo Replaces Palla Co Sec Jaime Pinto; Situations Vacant: Medical Developments - International BDM
 
Cynata ‘Pleased’ By $11m Bids For $2m Plan; Total $8.4m; Genetic Technologies Raises $12m; CSL Rolls Out Additional Influenza Vaccine Supplies; Cyclopharm: FDA Approval To File NDA For Technegas; Neuren Loses Chair Dr Richard Treagus To BTC Health; Suda: ‘Spray Increases Anagrelide Bioavailability’; Recce Pleads Schultz To ASX 54% Price Query; Respiri: 65% Refuse Director Termination Benefits; Medibio, Partners For Health Settle Legal Action; GI Dynamics: ASX Consent To Delist; Acrux Requests ‘Licence’ Trading Halt; Creso Requests ‘Capital Raising’ Trading Halt; M&G Reduces To 12% Of Mesoblast 
 
Prescient Licences U-Penn, Oxford Uni Tech For Omnicar; Cyclopharm: 1st Technegas Sales In Russia; Imagion: ‘Magsense Manufacture On-Time Despite Covid-19’; Oncosil Rights, Shortfall Raise $5m; Total $19m; Elixinol Rights Raise $5.6m; Total $10.9m; Bioscience Managers Raise $5m For Adherium; LBT Draws Down Final South Australia Government $1.5m; Tasmanian Alkaloids Manufactures Zelira Marijuana Products; MGC: Israel Phase IIb Cannepil Epilepsy Trial; Palla Terminates UK Codeine Customer Acquisition; Owed $3.5m; Cann Group, IDT Supply Marijuana Products To Astral, Iuvo; Shunho Terminates Elixinol Hemp Foods Acquisition; Impression Name Change, 7.5m Shares, 205m Options, 32m Rights EGM; GI Dynamics ‘ASX Delisting’ Trading Halt; Allianz Takes 5% Of Starpharma; Lazard Takes 5% Of Mayne; Medical Developments Appoints Christine Emmanuel Director
 
Uniseed $3.5m For Ferronova Cancer Detection; Exopharm: ‘Plexaris Improves Anti-Cancer Drug In-Vitro’; Correction: Invex; Mesoblast: 3 Trials Support Ryoncil (Remstemcel-L) For GvHD; Medical Developments: Hungary Approves Penthrox For Pain; Resonance Files Provisional Patent For Liver Disease; Nyrada: ‘Compounds Reach Mouse Brain, Block Calcium Build-Up’; Goodbye Admedus, Hello Anteris; Proteomics Receives $200k For Covid-19 Research; Aeroflow Hires Regional Health For Oventus O2Vent; Blackcrane Reduces To 6% Of Avita; Carestream Below 5% In Micro-X; Anteotech Progresses Silicon Lithium Batteries; Prescient Takes ‘Material Licence’ Trading Halt To Suspension; Cann Global Extends ‘Research Initiatives’ Suspension
 
Dr Boreham’s Crucible: Invex Therapeutics; Antisense: ‘ATL1102 Duchenne Muscular Dystrophy Success’; Invex Placement Raises $26.2m; Applications Open For $316k Victoria Prizes, Fellowships; Botanix 39m Directors ‘Incentive’ Options EGM; Cellmid EGM Faces 13% Dissent Against Broker Options; Impedimed Pleads Schultz, ‘Broker Reports’ To ASX 37% Query; G Medical Receives $1.35m US Paycheck Protection Loan; Paul Cozzi Takes 14.5% Of Cardiex; Opyl Takes ‘Contracts’ Trading Halt To Suspension; Probiotec: Sandy Beard Chair, Jonathan Wenig Director; Cardiex Appoints CFO, Co Sec Jarrod White Director
 
4D: FDA Clears XV Lung Ventilation Analysis Software; Vivazome, Cytiva Deal For Exosome Purification Technology; TBG: CE Mark For Sars-Cov-2, Covid-19 Tests; Sienna Appoints Zotal For hTERT Bladder Cancer In Israel; Alterity: ‘ATH434 Potential MSA Efficacy In Humans’; Prescient Requests ‘Material Licence’ Trading Halt; Caledonia Reduces, Diluted To 6.6% Of Alcidion; THC: Canndeo Marijuana Available By Script In Australia
 
Federal $400m For 267 Medical Research Projects; Invex: ‘Exanatide Significant Reduction In ICP’; Clarity: 64Cu-Sartate For Neuroblastoma FDA Orphan Status; G Medical ECG Patch Wins FDA Covid-19 ‘Emergency Use Status’; Imagion, Siemens Work On Nanoparticle MRI Contrast; Mach7: Qatar’s Hamad Medical $4.2m Imaging Renewal; Suda: Japan Patent For Anagrelide For Cancer; Opyl: ‘Covid-19 Puts Focus On Digital Data’; Trading Halt; Heramed, Freeman Road, Phi Pilot Foetal Heart Monitor Studies; Antisense Requests ‘ATL1102 DMD Trial Results’ Trading Halt; Cann Global Takes ‘Research Initiatives’ Halt To Suspension; Regal Funds Below 5% Of Oncosil; Race Loses Founder, CEO Dr Peter Molloy
 
US Court Denies Cochlear Patent Appeal, To Pay $429m; Amplia: AMP945 Wins FDA Orphan Status For IPF; Imagion Nanoparticles For HIV Treatment; BTC Infusion Kit Orders Follow Elective Surgery Rules; Admedus Starts Adapt Anti-Calcification Rat Trial; M&G Reduces To 12.5% Of Mesoblast; Oneventures Appoints Dr John Westwater, Kelly Constable; Justyn Stedwell Replaces Lifespot Director Andreas Empl; Impression Appoints Rugby’s James Graham TBI Advisor; Noxopharm: ‘FDA Pre-IND NOX66 For Covid-19 Trial Submission’
 
MTP Connect: ‘Apply Now For Federal Covid-19 Funds’; Patrys: $2.85m US Grant For PAT-DX1 Inventor; Kyocera Pays Regeneus $1.5m For Progenza OA Due Diligence; Canada’s Careica Health To Refer Oventus O2Vent For Apnoea; Imugene Releases 22m Escrow Shares; GI Dynamics Extends $6.6m Crystal Amber Note To June; Perennial Takes 5% Of Micro-X; Race Requests ‘M-D Dr Peter Molloy Tenure’ Trading Halt; G Medical Requests ‘Product Registration’ Trading Halt; Cann Global Requests ‘Research Initiatives’ Trading Halt; Genetic Technologies Nasdaq Extension; Board Changes
 
Dr Boreham’s Crucible: Telix Pharmaceuticals; Cellmid Responds To Article, Extends Response Suspension; Telix: Pharmalogic To Distribute TLX591-CDx In The US; Thorney, TIGA Take 7% Of Micro-X; GI Dynamics Receives $302k US Covid-19 Paycheck Loan
 
Race, Newcastle Uni Work On Bisantrene Breast Cancer Combo; Anteotech, Axxin Develop Sepsis Multiplex Assay; Nuheara Surpasses 4k Iqbuds Max Pre-Orders; Mach7 $4.8m HAHK Software Order; Telix, FDA Meet For Phase III TLX591 Prostate Cancer Trial; Emvision Restarts Portable Brain Scanner Stroke Trial
 
 
Industry: ‘Federal Jobkeeper For Pre-Revenue Companies’; AAMRI: Research Losing Non-Government Funding; Orthocell Submits Celgro FDA 510(K) Application; Pharmaust: Monepantel ‘Success’ - 1 Dog Tumor Reduced; Suda Adds Drug Supplier To Zolpimist TGA Application; Memphasys Share Trading Increases In Germany; Simavita Extends $1.4m Notes Date To December; THC Acquires Tetra Health For $3m In Cash, Equity; Bod Receives UK Scripts From Project Twenty21 Patients; Paradigm Directors Sell 4.5m Shares To ‘Offshore Investors’; Clime Takes 7% Of Mach7; MGC Extends ‘Distribution Agreement’ Suspension
 
Micro-X ‘Underwritten’ Rights Raise $1.8m Of $6.25m; Rhinomed 1-For-2 Rights Offer For $6.5m; Mesoblast Requests ‘Financing’ Trading Halt; Cochlear: 60% April Sales Fall, Some Reopening, Kids First; Emerald Data Platform Earns $100k For Covid-19 Analyses; Admedus Implants 2nd SAVR Heart Valve Trial Patient; Queensland Clinic Evaluates Resappdx-EU Respiratory Test; Prescient Gains IP Rights To Carina Car-T Cell; Cellmid Takes ‘Media Article’ Trading Halt To Suspension; Bionomics: $10.4m Loan Repayments Deferred 6 Months; Avita: Court Approves Move To US EGM; Karst Peak, Adam Leitzes, Vermillion Below 5% In Avita; FIL Takes 8% Of Genetic Signatures; Walker Reduces To 8% Of Atomo; Allan Gray Reduces To 11% Of Impedimed; FIL Increases, Diluted To 9.5% Of Resapp; Creso Starts Canada Marijuana Sales; Trading Halt; Elixinol: Product Label Class-Action Dismissed; Little Green To Begin Marijuana Extract Production; MGC Takes ‘Distribution Agreement’ Halt To Suspension; Imagion Appoints Dianne Angus Director; Patrys Appoints Dr Peter Ordentlich Advisor
 
Dr Boreham’s Crucible: Cyclopharm; Federal $16.2m For Ovarian Cancer Research; Cynata Cymerus Stem Cell Covid-19 Trial Approved; South Australia Extends LBT $4m Loan Date; Australian Patent For Painchek Smartphone Pain Assessment; Heramed Appoints Medtech Edge Heracare Distributor; Elixinol Sells Nunyara Land For $2.6m; Pharmaust Requests ‘Trial Results’ Trading Halt; THC Requests ‘Acquisition’ Trading Halt; M-D Peter Rowland Below 5% In Micro-X; CM Capital, Australian Super Below 5% In Osprey; Noxopharm Appoints Fred Bart Director
 
CSL $1.2b Loan; Atomo: NG Biotech Orders 422k More Covid-19 Tests; Neuren Starts 1st NNZ-2591 Clinical Trial; Starpharma: DEP-Irinotecan ‘Safe’, Phase II Cancer Trial; Japan Patent For Immutep IMP321 Cancer Combination; Total Brain Receives $1.4m In US, Australian Covid-19 Relief; Cellmid Requests ‘Media Article’ Trading Halt; Noxopharm Requests Capital Raising Trading Halt; MGC Requests ‘Distribution Agreement’ Trading Halt; Australian Ethical Reduces To 10.3% Of Antisense; Australian Ethical Takes 6.6% Of Immutep; Jimmy Thomas, Ivy Ponniah Take 6.6% Of Stemcell United; Auscann To Lose 12-Month CEO Ido Kanyon; Stemcell United Appoints Alan Dronkers ‘Marijuana Advisor’ 
 
Tessara Raises $2.7m To Grow 3-D Brain Tissue; Kazia Share Plan Raises $1.8m; Total $9m; CSL Develops Covid-19 Immunoglobulin For Sars-Cov-2; Mesoblast Doses 1st Remestemcel-L Covid-19 Ards Patients; Cogstate $3.8m US Paycheck Protection Loan; Impedimed $1.8m US Paycheck Protection Loan; Respiri $1m Share Plan Raises $3.14m; Total $5.14m; Elixinol Institutional Rights Raise $5.3m; Retail For $5.6m More; Sienna Appoints Scientle NZ hTERT Bladder Cancer Test Distributor; Resapp Receives Handheld, Wearable Device Files; G Medical: Florida’s All County To Distribute Prizma; Bod: Health & Happiness Orders $1.4m Marijuana For UK; Emvision CEO Dr Ron Weinberger Promoted To M-D
 
Vivazome Licences Adelaide Uni Stem Cells For Exosomes; Pharmaxis Resubmits Cystic Fibrosis Bronchitol NDA To FDA; TBG: China Lifts Export Ban On Covid-19 Tests; Medical Developments Penthrox For Netherlands, Bosnia; Elixinol 1-For-2.51 Rights To Raise $11m At 48% Discount; Rhinomed Requests ‘Capital Raising’ Trading Halt; G Medical: TGA Approves Vital Sign Monitor Patch; Impedimed Appoints David Anderson Director; MGC Starts Artemic For Covid-19 Trial
 
Recce-327: ‘Significantly Reduces Gonorrhoeae In Mice’; IDMC Okays Imugene Phase II Her-Vaxx Cancer Study; Oncosil Placement, Rights Offer To Raise $19m; Oncosil Files For Approval In Singapore, Hong Kong, Malaysia; Nuheara 60% Underwritten Share Plan For $2.5m; Carl Zeiss Pays Optiscan Final $171k Convivo Milestone; Kazia Extends Share Plan For Late Applications; GI Dynamics Potential Delisting, Extends Crystal Amber Note; Neuroscienfitic: ‘Emtinb Not Toxic’; Bod: 1st UK Marijuana Medicabilis Prescriptions; Allan Gray Reduces, Diluted To 12% Of Impedimed; Paradice Investments Diluted To 6.5% Of Impedimed; Regal Funds Reduces To 12% Of Visioneering; Noxopharm Chair Dr Graham Kelly Increases, Diluted To 21%; Eleanore Goodridge Increases, Diluted To 7% In Noxopharm; Pharmaxis Appoints Dr Neil Graham Director; Oncosil Appoints Nigel Lange EMEA Head
 
Biotech Bounces Back: April BDI-40 Up 28%, ASX200 9%, Big Caps 3.5%; Correction: Atomo Diagnostics; Federal Government, Minderoo $67m For Childhood Cancer; Resmed Q3 Revenue Up 16% To $1,191m, Profit Up 47% To $291m; 4DX, Adelaide Uni, SAHMRI Develop Covid-19 ‘Field’ Ventilators; Telix Submits TLX591-CDX Prostate Cancer Euro File; Clinuvel Prepares US Scenesse For Vitiligo Application; Ellex: ‘ACCC To Review Lumibird Acquisition’; Oventus $4.65m Placement, Share Plan For $2m More; G Medical ‘Oversubscribed’ Placement Raises $6m; Neurotech Pleads ‘Covid-19 Tests’ To ASX 71% Query; Opyl Receives $201k R&D Tax Incentive; Medigard: ‘Lack Of Cash Threatens Kunovus KT009 Licence’; Althea: Nimbus To Sell Marijuana In Germany; Baillie Gifford Reduces To 6% Of Cochlear; Australian Ethical Diluted To 6% Of Impedimed; Perennial Reduces To 5% Of Atomo
 
Dr Boreham’s Crucible: Atomo Diagnostics; Mesoblast Starts Remestemcel-L Covid-19 Trial; Genetic Signatures: Sars-Cov-2 Test Record $1.8m Q3 Revenue; Paradigm Completes Zilosul US Program, MPS-1 Orphan Status; Cogstate Wins $1.3m For Memory Impairment Test; Uscom, A&D Partner For New Uscom BP+ Module; THC $4m Mitchell Loan; Nuheara Requests Capital Raising Trading Halt; Elixinol Requests Capital Raising Trading Halt; Australian Ethical Takes 7.8% Of Impedimed; Bellwether Takes 5% Of Bluechiip; Medibio Files FDA 510k Medsleep ‘Sleep Stage’ Application; Respiri Talks Wheezo With Practice Innovators; Noxopharm Claims: 4 Of 15 Patients ‘Abscopal Response’
 
Cochlear $50m Share Plan Raises $220m; Total $1.1b; Immutep Placement Raises $12m; Osprey Wins $2m US Covid-19 Paycheck Protection Loan; Osprey Rights Raise $10.2m Of Hoped-For $15.5m; Visioneering: $5m Placement; Share Plan For $1m More; Adherium, Monaghan US Sales Deal For Hailie Sensors; Oncosil Requests Capital Raising Trading Halt; G Medical Requests Capital Raising Trading Halt; Allan Gray Reduces To 17% Of Impedimed
 
Immutep: 9 Of 17 Tacti-002 Patients Respond To IMP321, Keytruda; Impedimed Retail Rights Raise $8.2m; Total $18.2m Of $24.9m; Pharmaxis Plans Phase II PXS-5505 Myelofibrosis Trial; Thailand Approves Medical Developments Penthrox; Qbiotics Euro Launch Of Stelfonta For Dog Cancer; Imagion Follow-On Placement Scaled-Back; Total Raised $2.5m; Azure, Invictus Fail Spread Rule For $10m Raising; Probiotec: Covid-19 Swings & Roundabouts; MGC $3.5m Placement; Auscann THC, CBD Marijuana Study Begins; Oventus Requests ‘Capital Raising’ Trading Halt; GI Dynamics Has One Quarter Cash; Neurotech 2nd Extension Of ‘ASX Price Query’ Suspension; Australian Ethical Reduces To 11% Of Antisense; Regal Takes 6% Of Micro-X; MGC Claims 2nd Israel Artemic ‘Covid-19’ Trial Site
 
Imugene To Start Phase I Vaxinia, PD1-Vaxx Trials This Year; Telix, Osaka Develop 2nd Generation TLX101 For Cancers; Immutep Requests Placement Trading Halt; Medadvisor Launches Telehealth, Home Delivery Service; Heramed: FDA Allows Herabeat Sales Amid Covid-19; Oventus Claims Covid-19 Benefits Sales; 6 New Sites; Australia, Japan Allow Cellmid Évolis Patent For Alopecia; Tasmanian Alkaloids Supplies Marijuana To Avecho; Australian Ethical Reduces To 12% Of Antisense; Elixinol CEO Oliver Horn Starts On $395k; Immuron Directors Cash Cut, Replaced With Shares; Avecho Appoints Dr Paul Gavin CEO, Dr Roksan Libinaki COO
 
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals; Mesoblast: MSCs Show Ventilator-Dependent Covid-19 Benefit; Correction Onko-Innate; Cardiex: 4 New Waveforms A ‘Major Milestone’; Botanix: Cannabinoid BTX1801 For Infections Wins FDA QIDP; Ellex EGM Backs Asset Sale, Name Change To Nova Eye Medical; Imagion Requests ‘Placement Correction’ Trading Halt; MGC Requests ‘Capital Raising’ Trading Halt; Adherium Appoints Mike Motion CEO, Anne Bell CFO; Global Health Takes 11% Of Atomo; Peter Rubinstein, Irwin, Rip Below 5% In Genetic Technologies
 
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies; Imagion ‘Oversubscribed’ Rights Raise $3m; Clinuvel, Winhealth Launch Scenesse For EPP In China; Canada Special Access Use Of Polynovo’s Novosorb BTM; SDI: Covid-19 50% Profit Warning, Cost Cutting; Admedus: More Than Two Quarters Cash; Recce: ‘Recce-327 Reduces MRSA Load, Heals Wounds In Rats’; Visioneering Requests Capital Raising Trading Halt; Cryosite Director Andrew Kroger Takes 40.3%; TDM Growth Partners Takes 23% Of Somnomed; G Medical Hires Fosun, Boustead For Nasdaq IPO; Polynovo Appoints CEO Paul Brennan Managing Director; Impression To Trial Marijuana IHL-216A For Brain Injury; Noxopharm Claims Isoflavonoid For Glioblastoma
 
 
Doherty Starts 2,500 Patient ‘Ascot’ Covid-19 Trial; Redhill Provides RHB-107 To US Agency For Sars-Cov-2; Emvision: ‘Preliminary Brain Images Correlate With CT, MRI’; Polynovo Novosorb BTM: ‘Up To 100% Wound Closure’; Volpara Placement Raises $28m; $7m Share Plan To Go; Genetic Technologies Raises $2.3m, Total $5.3m; Avita To Move To Us; Visioneering Receives $1.6m US Covid-19 Relief Loan; NSW Expands Impedimed Sozo Lymphoedema Prevention Program; Invitrocue Wins CE Mark For Onco-PDO Cancer Test; US Patent For Tali Attention Deficit Products; Adherium, Planet Innovation Develop Remote Sensors; Livecare To Distribute G Medical Prizma Device; Cardiex Requests ‘Sensor Development’ Trading Halt; Platinum Diluted To 10% Of Kazia; Cann Group 5-Year Marijuana Supply Agreement With Pure Cann; Neurotech Extends ‘ASX Price Query’ Suspension; Noxopharm Receives $409k From Cancelled Loan; Elixinol: Oliver Horn In, Stratos Karousos Out, Helen Wiseman; More Covid-19 Claims: Medlab, Noxopharm
 
Biotech Daily Editorial: Covid-19 Spruikers, Please Stop !
TGA Approves Osteopore Bone Void Fillers; Sienna Licences Sub-B2m For Cancer From Adelaide Uni; Recce-327 ‘Significant’ Anti-Influenza Activity In Mice; Neuroscientific: Mitsubishi To Manufacture Emtinb; Rhinomed Receives $337k R&D Tax Incentive; Bard1 Receives $464k R&D Tax Incentive; Re-Analysis Backs Impedimed BIS For Lymphoedema Prevention; Cynata Requests ‘Capital Raising’ Trading Halt; Avita Requests ‘Re-organization’ Trading Halt; Atomo: Kelly 13%, Walker 10%, Perennial 6%, Ellerston 6%; Craig Darby Takes 12% Of Emerald Clinics; Creso Pays Cohen $409k, Takes $1m Lind Facility; Abby Macnish Replaces Neuroscientific Co Sec Thomas Spencer
 
 
 
Atomo IPO Opens Up 95% With Covid-19 Antibody Test Orders; Starpharma: ‘SPL7013 Inhibits Sars-Cov-2 Infection Of Cells’; Recce Requests ‘Anti-Viral Results’ Trading Halt; Osteopore Requests ‘Regulatory Approval’ Trading Halt; Goodbye Benitec; Proteomics CE Mark For Promarkerd Immunoassay; Mayne US NDA For E4-DRSP Oral Contraceptive; Clinuvel Launches Scenesse In US; Botanix Drops Dermatology For Antimicrobial Targets; Acrux Corrects ‘Non-Material’ TGA Deficiencies; Batavia Develops Immutep Imp761 Cell Line; Adherium, HGE Work On Remote COPD Management; Anteotech Receives $967k R&D Tax Incentive; Regal Funds Takes 11% Of IDT
 
Volpara, Ambry Partner For On-Line Genetic Testing Orders; Impression: Marijuana, Hydroxychloroquine For Covid-19 Ards; Invion: ‘Photosoft Anti-Tumor Response In Mice’; Allegra Has Orders For 105k Face Shields; Nuheara: Malaysia Resumes Post-Covid-19 Iqbuds Production; Impedimed Launches Heart Failure, Kidney Disease Sozo Software; Bionomics Recruits 90-Patient BNC105 Colorectal Cancer Trial; MGC: Swiss Micelle Deal ‘Nothing To Do With Covid-19’; TBG Tells ASX: ‘Miscommunication’ On Now-Banned Covid-19 Test; Anteotech Pleads Schultz, RDTI To ASX 42% Query; Micro-X Requests Capital Raising Trading Halt; Little Green Exports ‘1st Australian Marijuana Oil’; Simavita: Dussman 21%, Thirty-Fifth 6%, Chevron Diluted To 13%; Stemcell Appoints Dr Kevin Yee Chang Chinese Medicine Advisor; Benitec Appoints Edward Smith Director
 
TGA Approves Genetic Signatures Sars-Cov-2 Test Kit; Cellmid Receives 12k Wondfo China Covid-19 Antibody Tests; FDA Waives Cyclopharm $4.5m Technegas NDA Fee; Avecho, Purisys Deal For TPM Marijuana; Painchek FDA Pre-De Novo Application; Bioxyne Directors 50% Pay Cut, Revenue Up 7%; Respiri, Phenix Partner For Wheezo Telehealth; Esense Everblu Loan Notes, Placement Raise $1.15m; Creso Issues 10.8m Collateral Shares To L1 Capital; Bod Launches 4 Marijuana CBD Capsules In UK; Admedus 2nd Name Change (To Anteris), Staff Incentives AGM; Telix 200k CEO Options AGM; Creso, Highnoon, Route 2 Pakistan Marijuana Distributors; G Medical Reconsidering Nasdaq Listing; Jencay Takes 8% Of Ellex; Neurotech Takes ‘ASX Price Query’ Trading Halt To Suspension; Adherium Appoints James Ward-Lilley Chair, Mike Motion COO
 
CSL, SAB Partner For Covid-19; Plasma, Finance Update; Mesoblast Trials Remestemcel-L For Covid-19 Ards; Bard1 To Acquire Sienna; Kazia Raises $7.2m, Share Plan For More; Platinum Takes 12.6% Of Kazia; Recce Phase I Safety Trial Of Recce-327 Antibiotic; Eye Co: Covid-19 Puts Fludrocortisone Study On Hold; Medibio Completes 4th Compass Ilumen Pilot Study; Neurotech Requests ‘ASX Price Query’ Trading Halt; Esense-Lab Extends Everblu $50k Notes Loan Suspension; Cryosite Director Andrew Kroger Takes 40.2%; Genetic Technologies Chair Dr Muchnicki, MJGD, JCM Below 5%; Probiotec Chair Geoff Pearce Retires
 
Adherium: ‘Untimely Death Of Chair Thomas Lynch’; US EPA Approves Next Science LMN8 Surface Disinfectant; FDA Expedites Cochlear Nucleus 7 Remote Check; Paradigm Raises $35m; Imagion Receives $2.2m R&D Tax Incentive; Telix: Cardinal For TLX591-CDx For Prostate Cancer US Sales; Polynovo: Australia Grants 4 Novosorb Patents; Immutep: EOC Advances IMP321 For Breast Cancer In China; Uscom, Uni Of Tasmania Partner For ‘Ideal’ BP Study; PYC: ‘CPP Safe, Less Toxic In Mice’; ASX Suspends MGC For Swiss Marijuana Covid-19 J-V Queries; G Medical Extends Magna Notes To April 30; US FDA Grants G Medical Prizma O-T-C Approval 
 
Micro-X Wins $1.2m Covid-19 Orders For Nano X-Ray Systems; CSL, Takeda Lead Covid-19 ‘Hyperimmune’ Alliance; Redhill: Italy Okay For Opaganib For Covid-19, Israeli Treated; Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’; Polynovo: ‘Novosorb BTM Beats Burns Benchmark’; Polynovo: ‘Despite Covid-19, Q3 Sales Up’; $9m Loan Facility; Proteomics Expands To Sars-Cov-2, Retinopathy, Cancer; Nuheara Iqbuds Max US, EU, Canada, Australasia Approvals; Volpara: 2020 ‘Annual Recurring Revenue’ Up 172%; Kazia: Paxalisib ‘Meaningful Extension Of Life’; Finance; Cellmid Pleads ‘Ignorance’ To ASX Query; $6m Placement; Cochlear: Up To 30% Covid-19 Director, Executive Pay Cuts; Optiscan Pleads Schultz To ASX 87% Query; Althea’s Peak Processing Canada Marijuana Application; Creso Delivers $215k Of Anibidiol To Virbac; Esense-Lab Takes $50k Everblu Loan Halt To Suspension; Amplia Releases 18.5m Voluntary Escrow Shares; Lumyna Below 5% In Oncosil
 
FDA Clears Mesoblast Remestemcel-L For Covid-19 Ards; FDA Clears Admedus Adapt Cardiac Expansion; Genetic Technologies Raises $3m; Resonance Files FDA 510(K) For Hepafat-AI; Avita: Treatments Continue Despite Covid-19; Q3 Revenue Up; Rhinomed Expands US Products, Distribution; Medlab, Randall Food Additives Deal; FDA Tells Paradigm: ‘2 Phase III Trials’, Capital Raising; China Bans TBG Unregistered Covid-19 Test Export; Rhythm Passes ISO13485 Audit; G Medical Prizma Italian Registration, Taiwan Permit; Cellmid Takes Capital Raising Trading Halt To Suspension; Perennial Takes 9% Of Genetic Signatures; Regal Funds Takes 8% Of Medadvisor; Elixinol: Benhaim Chair; Horn In; Duff, Ellery Out; Resapp Appoints Dr Michael Stein Director; MGC Reduces Salaries Up-To 50%
 
Dr Boreham’s Crucible: TBG Diagnostics; Atomo ‘Oversubscribed’ IPO Raises $30m, EU Covid-19 Test Sales; Impedimed: Pay Cuts, US SEC ‘No Action’, Opportunity Talks; Impedimed Institutional Rights Raise $10m; Osprey Part-Underwritten Rights Offer For $15.5m; Telix Completes Belgium Facility Purchase; Dimerix Takes $1m Radium R&D Tax Incentive Loan; Emvision: ‘Covid-19 Pauses Patient Enrolment’; Factor Rebuffs Ramcap J-V ‘Preliminary’ Proposal; Polynovo Requests Trial Result, Funding Trading Halt; Veritas Takes 5.6% Of Cochlear; Tribeca Below 5% In Bod Australia; Azure Extends Invictus Raising Closing Date, Delisting; Esense-Lab $50k Everblu Capital Loan For Working Capital; MGC 7th Marijuana Covid-19 J-V Suspension Extension
 
CSIRO Begins Testing Covid-19 Vaccines; Impedimed Rights For $25m; Genetic Technologies $3m US Placement; Orthocell: ‘Ortho-ATI Patient Symptom-Free At 12 Months’; Bard1, Griffith Uni Work On Cancer Diagnostics; Rhythm Colorectal Cancer Test ‘Key Biomarker’ Validated; Neuren: Israel Patent For Trofinetide; Avita: 9 Recell Burns Abstracts Published; IDT Completes Marijuana Oil Stability Testing; Cellmid Requests Capital Raising Trading Halt; Paradigm Requests ‘US FDA Update’ Trading Halt; Australian Ethical Reduces To 13.5% Of Antisense; Medadvisor Director Josh Swinnerton Reduces To 6%; TDM Takes 23% Of Somnomed; Visioneering: ‘Covid-19 Cuts Staff, Delays Launches’; MGC 6th Marijuana Covid-19 J-V Suspension Extension 
 
Covid-19 Hits All Indices: March BDI-40 Down 23%, ASX200 21%, Big Caps 5%; CE Mark For Genetic Signatures Sars-Cov-2 Detection Kit; Alcidion $1.5m, 5-Year Extension To NHS Fife Patientrack Deal; US FDA Accepts Mesoblast Ryoncil GvHD Application, Priority; Osprey Requests Capital Raising Trading Halt; Dorsavi, Theranow Deal For Physiotherapy Telehealth; Genetic Technologies: 100 Breast, Colorectal Cancer Kit Sales; Oncosil Pancreatic Cancer Device CE Mark, UK ‘Breakthrough’; PYC In-Vitro Models ‘Effectively Treat Retinitis Pigmentosa’; Medlab Completes Depression Trial, Results By July; Resapp Sleepcheck At-Home Sleep Apnoea Test; Exopharm: ‘Covid-19 Halts Plexoval Wound Healing Study’; Noxopharm Claims Idronoxil ‘Blocks Covid-19 Cytokine Storms’; Palla UK Business Option Expires, Talks Continue; China Trademark For Tali Train, Detect; Bod Receives $851k R&D Tax Incentive; Creso Wins $896k Univo Israel Order For Canadian Marijuana; GI Dynamics Extends Crystal Amber Note; Perennial Ceases In Rhinomed; Karl Pechmann Replaces Oncosil CFO, Co Sec Nicholas Falzon; Paul Stephenson Replaces Stemcell Director Ee Ting Ng
 
Proteomics, Janssen Expand Diabetic Kidney Study; Impedimed 1st US Cancer Centre Sozo Order; Medadvisor Launches Telehealth Service; Bye-Bye Benitec; Auscann Starts THC-CBD Dose Study; Nuheara: ‘Covid-19 Cuts Staff, Executive Salaries 50%’; Pharmaust: ‘Covid-19 Halts 3 Dog Trial Sites’; G Medical ‘Product Registration’ Halt, Report Suspension; Elixinol ‘Rebrands, Refreshes’ Products; MGC 5th Marijuana Covid-19 J-V Suspension Extension; Clarity Appoints Clinical Development Group 
 
Genetic Signatures Sars-Cov-2 Test ‘In Use, Pending Approval’; Cellmid Sells China Covid-19 Antibody Test; Sales Guidance; Cyclopharm Files FDA NDA For Technegas; LBT Files FDA 510(K) For APAS Independence MRSA Module; Mesoblast: 70-Patient Sub Study: Revascor Beats Saline; Opthea Completes OPT-302 Combo Trial For DME; Resapp, Coviu Integrate Tele-Health Respiratory Diagnostic; Suda: ‘Artimist On Hold Indefinitely’; Benitec: Court Approves US Move, FIRB Trading Halt; Pro Medicus Buys-Back 34k Shares, Renews 10% Buy-Back; Bod, Swisse Launch 9 Hemp Seed Oil Products; Lifespot Pleads Schultz, Fever Talks To ASX 306% Query; Impedimed Requests Capital Raising Trading Halt; PYC Requests ‘Material Results’ Trading Halt; Micro-X Appoints David Knox Director; GI Dynamics Loses Director Timothy Barberich; Resapp Loses Director Nathan Buzza; Esense Loses 5-Month Director Michael Edwards 
 
Dr Boreham’s Crucible: Zelira Therapeutics; Resmed Ramps Up Covid-19 Ventilator, Mask Production; Anteo Rights Raise ‘Excellent’ $2.15m Of Hoped-For $3.2m; Admedus Implants 1st SAVR Trial Aortic Stenosis Patient; Regal Funds Reduces To 6% Of Medadvisor; Morgan Stanley, Mitsubishi Cease In Opthea; Adalta Loses Dr Wilson, Dr Williams, $805k R&D Loan, Fees Cut; MGC 4th Daily Marijuana Covid-19 J-V Suspension Extension; G Medical Requests ‘Product Registration’ Trading Halt
 
Cochlear Placement Raises $880m Above Expected $800m; Somnomed Institutional Offer Raises $9.7m; Respiri Placement Raises $2m, Plan For $1m More; Alterity Placement Raises $123k; Immutep: IMP321, Paclitaxel Fails Breast Cancer Endpoints; MCRI 4k Health Worker Tb Vaccine Trial For Covid-19; Micro-X: Covid-19 Ramps Demand For DRX Nano, Production Up; Medadvisor Covid-19 Delivery Service For At-Risk Patients; Tali Digital: 13.9% Of Children Show Inattentive Performance; Cardiex Increases Bayer Contract $423k; Allegra: ‘Covid-19 Hits Revenue’; BTC Withdraws H1 Guidance Due To Covid-19 Restrictions; Actinogen: ‘Covid-19 Halts Occupancy Study Enrolment’; Exopharm: ‘Covid-19 Revises Development Programs’; Genetic Signatures Requests ‘Covid-19 Testing’ Trading Halt; Creso Delivers 1st Cannaqix Shipment To South Africa; Benitec Meeting Approves US Move; Avecho Defers AGM; ASIC Covid-19 Advice; Karst Peak ‘Takes’ Auckland Trust’s 14% Of Neuren; Lifespot Requests ASX Price Query Trading Halt; Little Green Pharma WA Facility Commissioned; MGC Daily Marijuana Covid-19 J-V Suspension Extension; Ferris, Knowles Replace MRCF Stockdale; Beattie Director; Noxopharm Appoints Boris Patkin Director
 
Prevatex, Barwon: ‘Mum’s P Copri Prevents Food Allergies’; Cochlear Placement, Share Plan For $850m; $150m Loan; Immutep: ‘IMP321 Improves Paclitaxel For Breast Cancer’; Amplia: FDA Orphan Status For AMP945 For Pancreatic Cancer; Botanix BTX1204 For Eczema Fails Endpoints; Zucero Investigates ZU545 Covid-19 Efficacy; Impression Plans Phase IIb IHL-42X For Sleep Apnoea Trial; Somnomed $15.5m Rights Offer For Covid-19 Impact, Working Capital; Imagion $2m Rights Issue, Director Bronwyn Le Grice Goes; Cardiex $1.5m Mitchell R&D Loan; Dorsavi: Covid-19 Cuts Staff Hours 30%, Expenses 20%; Medibio, DXC Partner For Ilumen Opportunities; Lifespot Adapts Bodytel For (Covid-19) Temperature; MGC Extends Marijuana Covid-19 J-V Suspension, Again; Vanguard Group Takes 5% Of Avita; Tali Appoints 3 Executives; Covid-19 Benefit; Jerry Kanellos Replaces Immuron CEO Gary Jacob - Covid-19
 
Doherty Institute Joins Covid-19 Trials; Pharmalex Trial List; Paradigm Doses 10 US Osteoarthritis Access Patients; Cyclopharm: ‘Covid-19 Boosts Technegas Use’; Compumedics Withdraws Guidance Due To Covid-19; Neuren: ‘Covid-19 Defers Trofinetide Rett, NNZ-2591 Trials’; Heramed: ‘Covid-19 Increases Herabeat, Heracare Demand’; Resapp, Phenix Tele-Health Deal; Ellex EGM For $100m Lumibird Sale; Cellmid ‘Potential Material Contract’ Voluntary Suspension; Creso To Launch Cannaqix Marijuana Instant Tea; Botanix Requests ‘BTX1204 Dermatitis Results’ Trading Halt; MGC Extends Marijuana Covid-19 J-V Suspension; Morgan Stanley, Mitsubishi Take 7% In Opthea
 
Impedimed: Unnamed 470 US Centre Sozo Lymphoedema Deal; Proteomics Identifies Biomarkers For Endometriosis; Regeneus: US Progenza Patent, ‘Covid-19 Link’; Suda: Up-To $870k Mitsubishi Tanabe Zolpimist Insomnia Deal; Clinuvel: April US Scenesse For EPP Launch; Cogstate, Eisai To Launch Nouknow For ‘Brain Health’ In Japan; Auscann Receives $1.2m Federal R&D Tax Incentive; GI Dynamics Proposed Funding EGM; Imagion Requests ‘Capital Raising’ Trading Halt; MGC Takes Marijuana Covid-19 J-V Halt To Suspension; Admedus Quotes $5m, 435k Director Options; Althea Extends Voluntary Escrow Of 10m Shares; Anthony Barton Takes 5% Of PYC, Again; IQ3: Dr Syrmalis, Ms Xu In; Mr Dimitriou, Mr Coolentianos Out; IDT Appoints Director Michael Kotsanis
 
Dr Boreham’s Crucible: Starpharma; Immutep: China’s EOC Recruits IMP321 Breast Cancer Trial; Kyocera Pays Regeneus $1.6m Progenza Milestone; Resonance ‘Controlled Placement Facility’ Raises $2.75m; Impedimed Expands Sozo Texas Lymphoedema Program; Vanguard Takes 5% Of Polynovo; Chair Ron Dewhurst, Kroy Wen Take 5% Of Rhinomed; Cellmid ‘Potential Material Contract’ Trading Halt; Neuren Requests ‘FDA Covid-19 Trial Guidance’ Trading Halt; Rhinomed CFO Sean Slattery Replaces Co Sec Phillip Hains; Total Brain Appoints Simon Poidevin Australasia CEO; Paltoglou, Loftus Replace Mayne CFO, Co Sec Nick Freeman; Timothy Cruickshank Replaces Impedimed CFO Morten Vigeland
 
Luina Bio, Griffith Uni ‘Collaborate On Covid-19 Vaccine’; Atomo: ‘To Develop Covid-19 Rapid Self-Tests’; Victoria Reopens 2 Hospitals For Covid-19; Painchek: 25k Bed Licences Triggers $1.25m Milestone; LBT Study To Validate APAS Independence VRE Module; Biotron Receives $753k R&D Tax Incentive; ASX Suspends TBG, Responds To ASX CE Mark Aware Query; Medibio Completes Sleep Stage Algorithm Test; Cann Global: Obsidian Refinances L1 Notes; Impression: Marijuana Inhalers For Lung Disease; Somnomed Takes Capital Raising Halt To Suspension; Respiri Takes Capital Raising Halt To Suspension; MGC Requests Swiss Covid-19 Marijuana J-V Trading Halt; Regal Funds Takes 13% Of Opthea; Clarity Appoints Prof Oliver Sartor Advisor 
 
TBG: CE Mark For Covid-19 Test, ‘Schultz’ To ASX 1,054% Query; Oncosil: Pancreatic Cancer Device ‘FDA Breakthrough Status’; Race Completes Phase II Bisantrene AML Trial Recruitment; Antisense Trial Database Lock, Results In April; Azure Wins ASX Listing Removal Extension; Neuroscientific: Emtinb Re-Myelinates Ms, In-Vitro; Lumyna Substantials In IDT, Oncosil; Cryosite Director Andrew Kroger Takes 40%; Pendal Group Below 5% In Althea; Next Science Launches On-Line Acne Cream 
 
Bio-Melbourne Covid-19 Breakfast Goes Virtual; US Appeal Court: Cochlear To Pay $437m On Patents; Neuren Defers Partnering For Trofinetide Rett Results; Next Science: Products ‘Kill Covid-19-Like Viruses’, Sales Hit; MGC Share Plan Raises $1m Of Hoped-For $3m; Total $2.1m; Recce: Recce-327 Antibiotic Trial ‘This Quarter’; Noxopharm Veyonda Australian Patent; Clime Takes 6% In Mach7; Investors Mutual Reduces To 8.7% Of Mayne Pharma; TBG Up 93%, Requests ‘Covid-19 Diagnostic Kit’ Trading Halt; Respiri Requests $2m Capital Raising Trading Halt; Somnomed Requests ‘Covid-19 Impact’ Trading Halt; Cann Global Takes ‘Investment’ Halt To Suspension 
 
Cochlear Withdraws Guidance, Freezes Hiring, Spending; Polynovo Files Novosorb BTM Burn Study Results To FDA; Patrys: PAT-DX1 Blood Brain Barrier Mechanism Confirmed; Telix: $500k R&D Grant For Radiation Cancer Drugs; Genetic Technologies Appeals Nasdaq Equity Non-Compliance; Neuroscientific Requests ‘Positive Results’ Trading Halt; Regal Funds Takes 7% Of Medical Developments; CEO Paul Rennie Increases, Diluted To 12% In Paradigm; Mason Stevens Below 5% Of Patrys; W Whitney George Takes 29% Of Rhinomed; Sienna Appoints Prof Geoff McCaughan Advisor
 
Dr Boreham’s Crucible: Qbiotics Group; Cardiex: Astrazeneca, Bayer Expand Xcel In Trials $984k; Visioneering: Canada Approves Naturalvue Myopia Lenses; Botanix: ‘BTX1801 Kills MRSA’; Surgical Infection Trial; Cann Global Requests ‘Institutional Investment’ Trading Halt; Harbour Takes 8% Of Volpara; Director Andrew Kroger Takes 39% Of Cryosite; Zoltan Varga Takes 19.99% Of Total Brain; Paul Wright Replaces Memphasys Director Marjan Mikel; Impedimed Loses Director Gary Goetzke 
 
Federal, Victoria, WEHI National Drug Discovery Centre; Painchek: ‘Business Model Minimizes Covid-19 Impact’; Biotech Daily Editorial: Covid-19 Coronavirus Claims; Biotron: BIT225 ‘Unmasks HIV-Infected Cells’; Little Green Pharma Expands Australian Marijuana Licences; L1 Capital Ceases Substantial In Creso; Auscann Appoints Dr Marc Russo Chief Medical Advisor; Bio-Melbourne Breakfasts On Covid-19 Coronavirus
 
Resapp: FDA Refuses Resappdx-US De Novo Approval; Orthocell: Celgro, Implant Regenerate Bone In Dogs; Admedus: Belgium Approves 1st Human Study Of …; Osteopore To Release 5m ASX Escrow Shares; Mach7 Completes Sentara PACS Installation; Neuroscientific: ‘Potential Emtinb Glaucoma Effect In Pigs’; China ‘Requests Respiri Wheezos For Covid-19’; Cynata Receives Extra $619k R&D Tax Payment; MSCs For Covid-19; Medlab: Marijuana Nanabis Cancer Pain Reduction ‘Significant’; G Medical Prizma Phone Case Blood Glucose Module; Race Director Dr William Garner Reduces To 13%; Merchant Funds Takes 7% Of Race; Medadvisor Appoints Steve Watt Chief Revenue Officer; Creso Appoints Jack Yu, Isaac Allen To Subsidiary Mernova
 
CMRI Collaboration Repurposes Stemetil For Cancer In Mice; Brandon Et Al $53m For George Institute For Chronic Diseases; Redhill Launches Talicia For Helicobacter Pylori; Japan Allows Cynata Cymerus Stem Cell Patent; Mesoblast To Evaluate Stem Cells For Covid-19 Coronavirus; Neuren: NNZ-2591 Phelan-Mcdermid Mouse Trial Significance; Adalta: ‘Targeting CXCRA Could Be Effective In Fibrosis’; Medadvisor: UK Pharmacy Association Backs Reminder Service; Creso Requests ‘Mernova Management’ Trading Halt; Medadvisor: Swinnerton, Wavey, Kojent, Romida Substantials; One Funds Management Takes 7% Of Bluechiip; Race Appoints Prof Didier Blaise Advisor
 
Medlab: ‘Marijuana Nanabis Safe, Efficacy For Cancer Pain’; FDA Grants Immutep IMP321 For Breast Cancer IND; Anteo, Merck KGaA Develop Antobind Europium P-O-C Tests; MGC Doses 1st Patient In Cognicann Marijuana Trial; L1 Capital Takes 5.5% Of Creso; Naos Takes 23% Of BTC; Resapp Requests ‘Regulatory Update’ Trading Halt; Neuroscientific Requests ‘Pig Glaucoma Study’ Trading Halt; Telix Appoints Prof Frederik Giesel Advisor; Medibio Appoints Kelly Trupovic, Dr Stephen Addis
 
Dr Boreham’s Crucible: Covid-19 Coronavirus Special; Neuren: NNZ-2591 Phelan-McDermid Dose Response In Mice; Kazia Completes II GDC-0084 Glioblastoma Trial Recruitment; Race Raises $1.8m; Gilead $300k Fellowship Grants For 7 Projects; Eyepoint Revenue Up 346% To $31m, Loss Down 34% To $86m; Redhill Revenue Down 25% To $9.5m, Loss Up 9% To $64m; Federal Government: 3rd Regional Health Innovation Centre; Azure EGM 99.91% Backs Invictus Acquisition; Director Andrew Kroger Takes 39% Of Cryosite; Universal Biosensors Appoints John Sharman CEO On $480k; Dr John Cullity Replaces Race Chair Dr Bill Garner; Dimerix Appoints Medical Advisory Board; Esense-Lab: Itzik Mizrahi CEO On $236k, James Bahen Co Sec
 
WEHI: WM382 Kills Drug Resistant Malaria Parasite In Mice; Avita Enrols 1st Recell Paediatric Scald Trial Patient; Atomo $30m IPO For HIV Professional, Self-Tests IPO; Micro-X $1m DRX Revolution Nano Orders, Covid-19; Cogstate Claims $9.1m Clinical Trial Contracts In 2 Months; Medadvisor: $825k From 2 US Patient Programs; Respiri Receives 1st 500 Wheezo Asthma Devices; Medlab Requests ‘Nanabis Cancer Results’ Trading Halt; Simavita: Dussman Diluted To 19.9%, Chevron 14%, Heggin 6%; Medical Developments To Lose 10-Year CEO John Sharman
 
Neuren, Acadia FDA Trofinetide Rett ‘Rare Paediatric’ Status; Starpharma Expands Okamoto Vivagel Condom Licence; Race Requests Placement Trading Halt; Botanix Data Analysis: ‘BTX1503 Beats Vehicle For Acne’; Servatus: Hugh Alsop Director, Dr Jessica Allegretti PI
 
Avita Starts Recell Soft Tissue Reconstruction Pivotal Trial; Next Science Bactisure Wins CE Mark; Dimerix DMX-200 Compassionate Use; Canada Patent For Cynata; Clinuvel, FDA Scenesse For Vitiligo Meeting; Bionomics Completes $3m French Subsidiaries Sale To Domain; Correction: Patrys; Noxopharm Doses Last Veyonda Cancer Trial Patient; Cohen Group Ends Creso Israel J-V; Potential Legal Action; Probiotec CEO Wes Stringer Sells 1.7m Shares; THC Expands Medical Marijuana Supply For 6k Patients; Pharmaust Opens 2 More Dog Cancer Trial Centres; Creso Appoints Farmagon Scandinavia Marijuana Distributor; MGC Extends, Amends Onix Brazil Distribution Agreement; Dr David Mazzo Replaces Visioneering Chair Fred Schwarzer; Chow Yee Hok Replaces Invitrocue Director Geoffrey Thomas
 
February BDI-40 Down 14%, ASX200 Down 8%, Big Caps Up 0.3%; Compumedics H1 Revenue Down 2% To $18m, Profit Down To $161k; Admedus Revenue Down 33% To $17m, Loss Down 75% To $6m; IQ3 H1 Revenue Up 46% To $4.3m, Profit To $950k Loss; G Medical Revenue Up 81% To $8m, Loss Down 8% To $23m; THC Revenue Up 80% To $4.8m, Loss Up 36% To $11.7m; Avecho Revenue Up 204% To $4.2m, Loss To $850k Profit; Creso Revenue Up 550% To $3.6m, Loss Down 9% To $15m; TBG Revenue Up 6% To $3.3m, Loss To $620k Profit; Rhinomed H1 Revenue Up 24% To $1.7m, Loss Up 85% To $5.3m; Uscom H1 Revenue Up 4% To $1.5m, Loss Up 97% To $1.5m; Anteotech Rights Offer For $3.2m; Regeneus, Kyocera $1.4m Progenza Deal, $4m Directors Loan; Patrys PAT-DX1-NP Across Blood-Brain-Barrier In Mice; Adalta: Dose Range Confirmed For Phase I AD-214 Study; Heramed: Heracare To Begin Pilot, Clinical Trials; Little Green Launches 4th Marijuana Oil Product CBD50; GI Dynamics Appoints Dr Praveen Tyle Director; Jonathan Hart Replaces Heramed Co-Sec Stephen Buckley
 
Dr Boreham’s Crucible: Immutep; Cryosite H1 Revenue Up 6% To $4.2m, Profit Of $1.2m; Next Science Revenue Up 43% To $6.2m, Loss Up 4% To $22m; Cardiex H1 Revenue Up 15% To $2.3m, Loss Up 44% To $2m; Pharmaust H1 Revenue Down 9% To $1.8m, Loss Up 439% To $485k; Bionomics H1 Revenue Down 40% To $1.8m, Loss Down 43% To $6.4m; Adherium H1 Revenue Up 44% To $1.4m, Loss Down 48% To $4.5m; Bioxyne H1 Revenue Down 4% To $1.4m, Loss Up 11% To $195k; Bod H1 Revenue Up 73% To $1m, Loss Down 50% To $1.4m; Nuheara ‘$1m Iqbuds Max Orders In 2 Months’; Clime Takes 5% Of Mach7; THC Requests ‘Marijuana Permit’ Trading Halt
 
Ex-CEO Mario Gattino, Respiri In Court On Pay; Zelira, Emerald Enrol Marijuana Opioid Reduction Trial; TBG: Zhang Ye Labs Approved Coronavirus Testing Lab; Palla Revenue Up 18% To $54.8m, Loss Up 32% To $7.6m; Mesoblast H1 Revenue Up 43% To $29.4m, Loss Down 32% To $46m; Elixinol Revenue Down 16% To $27.2m, Loss Up To $83.3m; Medadvisor H1 Revenue Up 14% To $4.4m, Loss Up 18% To $5.3m; Medibio Ilumen To Assess Stantec Mental Health; Little Green Appoints Demecan Distributor; Antisense Appoints Dr Gil Price US Consultant
 
Nanosonics H1 Revenue Up 19% To $49m, Profit Down 20% To $6m; Cogstate H1 Revenue Down 13% To $15m, Loss Up 5% To $3m; Polynovo H1 Revenue Up 80% To $10.2m, Loss Up 26% To $2.4m; Clinuvel H1 Revenue Up 11% To $10m, Profit Down 74% To $1.1m; Genetic Sigs H1 Revenue $3.7m, $2.3m Loss; Covid-19 Test; Cyclopharm Revenue Up 5% To $14m, Loss Up To $2.9m; Cellmid H1 Revenue Up 6% To $3.7m, Loss Down 60% To $1.4m; Universal Biosensors Revenue Down 90% To $6.9m, $4.8m Loss; Medlab H1 Revenue Down 18% To $2.5m, Loss Up 89% To $7.1m; Althea H1 Revenue $1.9m, Loss Up 253% To $8.4m; Immuron H1 Revenue Up 59% To $1.6m, Loss Down 6% To $1.5m; Redhill $174m Healthcare Royalty Loan For AZ’s Movantik; Simavita Raises $2.9m; Imagion Nanoparticles For HER2 Breast Cancer Trial; Admedus EGM: 78% Oppose SIO Shares; Admedus 2nd Consolidation – 100-To-1; MGC Supplies Marijuana For Polish Research; Elixxer Takes 23% Of Little Green Pharma
 
Osprey Revenue Up 46% To $5.5m, Loss Up 3% To $24.5m; Total Brain H1 Revenue Up 98% To $2.2m, Loss Down 14% To $3.9m; Invion H1 Revenue Up 58% To $1.9m, Loss Down 10% To $1.2m; Dorsavi H1 Revenue Down 25% To $1.4m, Loss Down 207% To $5.9m; FDA Gives Telix ‘Feedback’ For TLX591-CDx NDA; M-D Fleta Solomon Takes 15% Of Little Green Pharma; Michelle Burke Replaces Ausbiotech Chair Julie Phillips; Biointelect Expands To Melbourne, Hires Staff; Oventus Appoints Jake Nunn Director 
 
Mesoblast: 66% GvHD Patients Respond To Ryoncil At Day-28; Probiotec H1 Revenue Up 33.5% To $44m, Profit Up 65% To $1.8m; Alcidion H1 Revenue Up 12.5% To $8.2m, Loss Up 213% To $1.8m; Starpharma H1 Revenue Up To $5.7m, Loss Down 19% To $5.9m; Resonance H1 Revenue Up 3% To $1.9m, Profit To $1m Loss; Telix Revenue $3.5m, Loss Up 102% To $28m; Uscom: ‘Critical Care Guidelines Back Uscom 1A For Sepsis’; Stryker Leibinger Evaluates Dorsavi Sensors; Clinuvel Singapore Laboratory Expansion; Oventus Appoints Aeroflow Oventus Distributor; Little Green Pharma $10m More Marijuana IPO Opens Down 7%; Simavita Requests ‘Placement’ Trading Halt; Auscann: Clifford Hallam Replaces API As Distributor; Exopharm Clarifies Cevaris Statement; Neurotech Mente Discount Code Referral Program; Regal Funds Below 5% In Oncosil
 
Dr Boreham’s Crucible: Cochlear; Mayne H1 Revenue Down 17% To $227m, Profit To $18.6m Loss; Ellex H1 Receipts Down 6% To $42m, Loss Down 1% To $2.7m; Mach7 H1 Revenue Up 158% To $9.1m, $675k Profit; IDT H1 Revenue Up 10% To $7.2m, Loss Down 51% To $1.2m; Allegra H1 Revenue Up 26% To $2.3m, Loss Up 70% To $817k; Immutep H1 Revenue $7.5m, Loss Down 31% To $6m; Cynata H1 Revenue $4.5m, Loss Down 15% To $2.5m; Resapp Raises $5m; Sienna Rights Raise $2.1m Of $2.5m; Total $3.8m; Paradigm Meets US FDA For PPS Osteoarthritis Trial IND; Noxopharm: ‘FDA Approves Veyonda, Combo IND For Sarcomas’; Telix Loses Odile Jaume, Gains Christian Davis
 
Aroa Launches Myriad For Soft Tissue Repair In US; Impedimed H1 Revenue Up 58% To $2.8m, Loss Up 7% To $12.9m; Mesoblast: GvHD Study Takes Remestemcel-L To Pivotal Trial; Emvision, UQ Win $360k Fellowships; Life Sciences Queensland, India’s Able Collaborate; Resapp: TGA Approves Resappdx-EU Version 2; Exopharm: ‘Cevaris Works For Bladder Dysfunction, Ex-Vivo’; Race Appoints Prof Jaap-Jan Boelens Advisor; Bio-Melbourne Devices, Diagnostics Lab
 
Zelira: ‘Marijuana Reduces Insomnia Severity’; Immutep 8 Of 17 Cancer Patients Respond To IMP321, Keytruda; Medical Dev H1 Revenue Up 14% To $11m, Profit Up 82% To $240k; Avita H1 Revenue Up 95% To $13.5m, Loss Up 35% To $21m; Resapp Requests Capital Raising Trading Halt; G Medical Raises $350k; Opyl: Clinical Trial Predictor ‘Proof Of Concept’; Exopharm: ‘Cevaris Significant For Erectile Dysfunction Ex-Vivo’; Regal Funds Reduces To 5.5% Of Oncosil; Micro-X Appoints Kingsley Hall CFO, Co-Co Sec; Melbourne March Medical Marijuana Meeting
 
Cochlear H1 Revenue Up 9% To $778m, Profit Up 23% To $158m; Somnomed H1 Revenue Up 15% To $33m, Loss To $816k Profit; Paradigm Doses 1st US Zilosul Access Patient; Resapp Completes Handheld, Wearable Prototypes Tests; Bio-Melbourne Loses CEO Dr Julie-Ann White; OBJ Votes For ‘Welfully’ Back Door Listing; Noxopharm, Genesiscare Veyonda Compassionate Access; Auscann Tests Low-Dose Cannabinoid Capsules; Bod Fills 2k Medicabilis Marijuana Scripts In 12 Months; Blackcrane Reduces To 8% Of Avita; BV Healthcare, Ex-Chair Damien Lim Below 5% In Mach7; Amber Schwarz, Jamber Take 11% Of Creso; Ellex Interim CEO Maria Maieli Resigns; Chris Ridd Replaces Medadvisor Chair Peter Bennetto
 
FDA Approves Compumedics Orion Lifespan Meg; Memphasys: ‘Felix Validation On-Track For Clinical Trial’; Nuheara H1 Revenue Down 4% To $1.4m, Loss Up 43% To $5.7m; PYC, Murdoch Uni, Lions Eye $1.2m NHMRC Grant; Zelira Raises $54k, Total $4.6m; Results Trading Halt; Actinogen Receives Extra $650k R&D Tax Incentive; Total $5m; Creso Milestone: To Pay Mernova $900k, 8.3m Shares Vest; MGC Placement, Share Plan For $4m; Cann Global To Raise $419k In Placement; Heramed Details Mayo Monitor Study; Kemper Shaw Below 5% In Imagion; Race Appoints Dr Marinella Messina Clinical Program Head
 
Dr Boreham’s Crucible: CSL; SDI H1 Revenue Up 8% To $40m, Profit Up 12% To $3.5m; Uscom: China Backs Haemodynamic Monitor For Coronavirus; More Mouse Data Backs Invion Photosoft For Cancer; Recce: ‘Recce 327 Beats Kidney, UTI E Coli In Rats’; Noxopharm: Veyonda Prostate Cancer Benefit; Exopharm: ‘Exosomes Could Treat Erectile Dysfunction’; Oventus: US Approves O2vent Optima Reimbursements; Medibio Plans FDA De-Novo, 510(k), CE Mark For Depression, Again; Noxopharm $3m Placement, $5m Loan; MMJ Share Plan For $5m; Proteomics Pleads Schultz To ASX 9% Query; Up 18%; Benitec US Scheme Of Arrangement Meeting; Anthony Huntley Takes 5% Of IDT; Private Portfolio Managers Below 5% In Imugene; Respiri CEO Marijan Mikel Starts On $450k
 
Pro Medicus H1 Revenue Up 16% To $29m, Profit Up 33% To $12m; Micro-X $780k DRX Revolution Nano Orders For Covid-19; MTP Connect Translation Fund Closes March 6; Victoria Innovation Taskforce; Visioneering Revenue Up 74% To $8.5m, Loss Down 25% To $19m; Pharmaxis H1 Revenue Up 36% To $4m, Loss Down 18% To $10m; Cochlear Increases Nyxoah Investment By $13m; Starpharma Vivagel BV In Unnamed Asian Countries; Oventus Launches 3 More US O2Vent ‘Lab In Lab’ Sites; Paradigm PPS For MPS - 9 Months Behind Schedule; MGC Requests Capital Raising Trading Halt; Prof Paul Timpson Joins Amplia Scientific Advisory Board
 
CSL Record H1 Revenue Up 9% To $7.3b, Profit Up 7.5% To $1.85b; CSL Adjuvant For Queensland Uni Covid-19 Vaccine; Uscom Tells ASX: ‘Material Rise In China Orders Not Material’; North Star To Supply Clarity Copper-67; Invictus: US Patent For Tocotrienol Delivery; Exopharm: Plexaris, Cevaris Exosomes ‘Safe’ In-Vitro; Noxopharm Requests ‘Capital Structure’ Trading Halt; Allan Gray Reduces To 13% Of Impedimed; W Whitney George Takes 27% Of Rhinomed; One Funds Management Takes 6% Of Bluechiip; Starpharma Appoints David Mcintyre Director; Doug Huey Replaces PYC CEO Dr Rohan Hockings, On $892k; Respiri Re-Appoints Dr Thomas Duthy Director
 
Cochlear: ‘Up To 7% Coronavirus Profit Warning’; Federal $300k For Melbourne Innovation Summit; Uscom To ASX: ‘China Orders Up 124% From 17 To 38 Units’; Starpharma Receives $4.5m Astrazeneca Milestone; Nyrada: ‘3F Reduces Cholesterol In Mice’; G Medical Hopes To Raise $10m, Cancel $5m Magna Notes; Invitrocue Brazil Joint Venture; Creso To Launch Marijuana Horse Feed; Bod Licence To Import Additional Marijuana CBD Isolates; Opyl, Huumun Digital Products Deal; Unisuper Below 5% In Impedimed; LBT CFO Ray Ridge Replaces Co-Sec Dan Hill; Director Matt Callahan Returns To Botanix, Orthocell; Respiri Loses Director Prof Bruce Thompson
 
US Court: Innate Chris Collins 26 Months Jail; Takeovers Panel; Uscom: Coronavirus China Demand For Uscom 1A; ASX Halt; Clinuvel, FDA To Discuss Scenesse For Vitiligo; UK Nice Briefing Backs Osprey’s Dyevert; Impedimed: NCCN Guidelines Recognize Lymphoedema; Recce: Recce-327 ‘Well-Tolerated In Rats, Dogs’; Heramed, Mayo To Start Herabeat Study; Total Brain Receives $1.3m Federal R&D Tax Incentive; THC To Launch Canndeo Marijuana
 
Dr Boreham’s Crucible: Resmed; Cann Group Convertible Notes Raise $8m; Benitec US Scheme Meeting Court Order; Correction: Opyl; OBJ Extends Export Corp Takeover Date; Alterity Below Nasdaq $Us1 Bid Rule; Cronos COO Peter Righetti Resigns, Continues As Director 
 
Biotech Daily Editorial: 2019-nCoV Coronavirus; Biotron: ‘Evaluating Coronavirus Compounds’; Uscom Pleads ‘Coronavirus Speculation’ To ASX 59% Query; CMRI, GE Healthcare Optimize Gene Therapy Manufacturing; Antisense: ‘DMD Results Open ATL1102 Indications’; Invitrocue: Validation Study, Xylonix, New Cancer Platform; Israel Patent For Cynata Cymerus Mesenchymal Stem Cells; Sienna Appoints Immuno Diagnostic Oy For Finland; G Medical Appoints Meditel Italy Distributor; Creso Develops Oil-Free, Water-Based Marijuana Lozenges; Sienna Promotes CFO, Co Sec Tony Di Pietro To Director; Amplia Board: Lambert On; Behrenbruch, Cooke, Wilkinson Off; Brett Tucker Replaces G Medical Co Sec Steven Wood
 
Federal $32m For Research Innovation Partnerships; Azure Up-To $10m For Invictus Backdoor Listing; Zelira Placement Raises $4.6m; Probiotec: ‘H1 Revenue Up 34% To $44m, Ebitda Up 68% To $6m’; Creso Takes $17.5m L1 Capital Convertible Note; Visioneering 1st Naturalvue Singapore Sale; Memphasys: ‘Felix Sperm Separator Positive KOL Feedback’; Orthocell Canada, Japan Celgro Soft Tissue Patents; Pyxis, Mapletree Below 5% In Neurotech
 
Admedus Sells Adapt Technology To 4C Medical For $1.5m; Resonance Appoints 3DR For Ferrismart In The Us; Cellmid: China Patent For Évolis Hair Growth; Medlab Begins Pay-To-Play Nanabis ‘Observational Study’; Adherium: Trudell 18%, One Funds 10%, Fil 9%, Summatix 7%; Adherium Founder Garth Sutherland Diluted Below 5%; Dorsavi CEO Dr Andrew Ronchi Takes 5%
 
BDI-40: YTD - Up 125%, Big Caps 62%, ASX 20%, NBI 4% - January BDI-40 Up 13%, Big Caps 12% - All Records Broken; Adherium Completes $5.4m Raising; Painchek Receives $798k Federal R&D Tax Incentive; Invion To Supply Skin Care Product To China’s Pavay; Mesoblast Completes US FDA GvHD Application; TGA Reviews Clinuvel Scenesse For EPP; PYC Adds 6 Retinal Drug Delivery Programs; Cronos Takes 51% Of Cannadoc Health; Invictus Euro Patent For Tocotrienols Delivery; Zelira Requests Capital Raising Trading Halt; Elixinol Receipts Down 8% To $33m, Asset Sales; G Medical Receipts Up 106% To $8.1m; Cann H1 Receipts $1.6m; Less Than 2 Quarters Cash; Opyl H1 Receipts Down 3% To $464k; Neurotech H1 Receipts Down 58%; Less Than 2 Quarters Cash; Respiri Has Less Than Two Quarters Cash; Medigard Has Less Than One Quarter Cash; Phillip Thematic Takes 6.7% Of Adherium; James Middleweek Increases, Diluted Below 5% In Adherium; Correction: Crystal Amber Has 73% Of GI Dynamics; Heramed Appoints Alexander Radke US Executive; Respiri Appoints Ludekens, Van Hoof, Dr Shirazi Executives; Neuroscientific Appoints Abby Macnish As Co-Co Sec
 
Dr Boreham’s Crucible: Invion; Resmed H1 Revenue Up 14% To $2.1b, Profit Up 22% To $418m; Avita H1 Revenue Up 95.4% To $13.5m; Clinuvel H1 Revenue Up 2% To $13.5m; Admedus Receipts Down 35% To $18.4m; Medadvisor H1 Receipts Up 33% To $4.8m; IQ3 H1 Receipts Up 17% To $4.4m; Medlab H1 Receipts Up 63% To $4m; Pharmaxis H1 Receipts Up 27% To $4.0m; Osprey Receipts Up 52% To $5.5m; THC Receipts Up 83% To $4.7m; Bioxyne H1 Receipts Up 105% To $2m; Total Brain H1 Receipts Up 12% To $1.7m; Rhinomed H1 Receipts Up 59% To $1.6m; Nuheara H1 Receipts Down 2% To $1.4m; Dorsavi H1 Receipts Down 39% To $1.2m; Noxopharm Less Than 1 Quarter Cash; $26m Facility; Medibio Has 2 Quarters Cash; Esense-Lab Has Less Than Two Quarters Cash; Regeneus Has 1 Quarter Cash; MGC Has Less Than 1 Quarter Cash; Optiscan Meets US FDA For Invivage; Carl Zeiss Orders; EGP Capital Takes 5% Of Adherium; Paul Cozzi Takes 13% Of Cardiex; C2 Diluted To 21%
 
Federal $5m For Lung Cancer Genomics Research; Biotech Daily Appendix 4C Quarterly Reports Policy; Cellmid H1 Receipts Up 54% To $4.8m; Genetic Signatures H1 Receipts Up 25% To $2.9m; Pharmaust H1 Receipts Down 5.6% To $1.9m; Heramed Has Less Than Two Quarters Cash; US Patent For Adalta AD-214 For Fibrotic Disease; Sienna Appoints Dr Raoul Concepcion Advisor
 
Mesoblast H1 Receipts Down 26% To $31.2m; Cogstate H1 Receipts Down 25% To $18m; Next Science $6m Sales, $4.8m Customer Receipts; Telix Receipts Up 44% To $3.6m; Starpharma H1 Receipts Down 3% To $2.1m; Resonance H1 Receipts Up 9% To $1.7m; Adherium Rights Raise $526k Of $5.4m; Expects $2.5m; Botanix Receives $7.6m R&D Tax Incentive; Cann Group Cuts Staff 25%, Costs By $7m; Mildura Facility; Dorsavi, Heathrow Airport Renew Visafe Contract; Emvision Starts Brain Scanner Pilot Stroke Trial; Exopharm Begins Exosome For Wound Healing Study; Cardiex Hires Medl Mobile For Software; Medlab: Tasmanian Alkaloids To Manufacture Nanabis; Respiri Prepares Wheezo US FDA 510(K) Submission; Perennial Value Management Takes 8% Of Genetic Signatures; Platinum Investment Takes 9% Of Amplia; Amplia’s Dr Christian Behrenbruch, Elk River Below 5%; Esense Loses CEO Haim Cohen, Piers Lewis Interim CEO
 
TGA Cancels Neurotech Mente Autism; Imugene Readies For 2020 PD1-Vaxx Lung Cancer Trial; GI Dynamics Enrols 1st Patient In Endobarrier US Trial; Polynovo: 1st UK Novosorb Patients; Somnomed Revenue Up 15% To $33.3m; Alcidion Revenue $15.4m, Customer Receipts $9.2m; Immuron H1 Travelan Sales Up 55% To $1.7m; Lifespot Raises $330k; Admedus: 44m Director Options, 62m Loan Shares, 100-To-1 Consol EGM; Zelira, Parkinson’s Foundation Develop Marijuana Survey; MGC: 5-Year Deal With Anden For Bolivia, Peru Marijuana Sales; Creso Sells More Than 100,000 Cannaqix Packs; Jeremy Green, Redmile Reduce To 9.5% Of Avita; Crystal Amber Takes 76% Of GI Dynamics; Race Appoints Prof Borje Andersson Director; Imagion Appoints Dr Oliver Steinbach Clinical Head
 
Dr Boreham’s Crucible: Polynovo; Resmed Pays $60m To Resolve US ‘Kickback’ Allegation; Viralytics Back As Immvirx For Cancer Immunotherapies; Nuheara: $2.5m Lind Partners Draw-Down Equity Facility; Nuheara Sells Gold Mine Royalty For $292k, Cash, Scrip; Universal Biosensors H1 Receipts Up 149% To $60m; Jeffrey Emmanuel Takes 8% Of Sienna; Amber Schwarz, Jamber Reduce To 9% Of Creso; Neurotech Requests TGA Registration Trading Halt
 
Emerald Raises $6m Of $8m For Marijuana, Data IPO; US FDA Okays Telix Zircon Renal Cancer Trial; Mach7 H1 Receipts Up 89% To $8.3m; Uscom H1 Receipts Up 21.6% To $1.1m; Biotron Pleads Schultz, Directors, Meeting To ASX 40% Query; Australian Ethical Takes 5% Of Impedimed; Merchant Takes 16% Of Sienna; David Daglio Increases, Diluted To 6% Of Total Brain; G Medical Lists On OTCQB; Lifespot Requests Capital Raising Trading Halt; Cann Global Supplies T12 Hemp To Costco; Bard1 Appoints Prof Allan Cripps Director
 
Polynovo: 1st German Novosorb Patient; 1st Polymedics Order; Sienna: South Korea hTERT Cancer Test Validation Study; Impedimed H1 Receipts Up 17% To $2.7m; LBT Receives $1.1m R&D Tax Incentive; Redhill Ends Donnatal, Enteragam Deal For Talicia, Aemcolo; Admedus Starts 1st Human Adapt Aortic Valve Trial; Neuroscientific US Patent For Emtin Technology; Anatara: Garp Preclinical Studies; THC: TGA Grants Southport Facility GMP Licence; Creso Renews Everblu Corporate Advice Mandates
 
Sienna Rights Shortfall Raises $1.8m, Total $3.7m; Elixinol Pleads Schultz To ASX 20% Fall Query; Cogstate Chair Martyn Myer, Family Increase, Diluted To 14%; Alcidion M-D Kate Quirke 34% Pay Rise To $413k; Clarification: Auscann Board Changes
 
Vale Mesoblast’s Prof Peter Ghosh (4.8.1940 – 12.1.2020); Amplia Placement Raises $930k; Europe Okays Qbiotics Stelfonta For Dog Skin Cancer; Heramed Tells ASX: ‘News Followed 52% Share Jump’; Heramed: Mayo Data For Orion Monitor, Hires Uri Merhav; G Medical: Prizma Smartphone Case Approved In Taiwan; Robert Lederer, RTL Take 11% Of Anatara; Eleanore Goodridge Takes 11% Of Nyrada; THC To Sell MGC’s Canndeo Marijuana, 1st Purchase For $40k; THC Requests ‘Receipt Of TGA Licence’ Trading Halt; MTP Connect Appoints Alex Fowkes Director
 
Sienna Rights Raise $263k Of Hoped-For $2.5m, Total $2m; Cardiex $1.5m From C2 Ventures; Auscann: Max Johnston, Krista Bates In; Cheryl Edwardes Out; Australian Ethical Reduces To 15% Of Antisense; Orbis (Allan Gray) Ceases In Pharmaxis; Prescient Claims 91% PTX-200 Breast Cancer Response Rate; Novita Changes Name To Tali Digital; Telix Recruiting TLX101 Glioblastoma Trial; Clinuvel Files Scenesse TGA Registration Application; Allegra Receives Uni Of Sydney, NHMRC $786k Grant; Invion CFO Melanie Farris Replaces Director, Dr James Campbell; Platinum Reduces To 5% Of Antisense; Empery Below 5% In Benitec; Lifespot Starts Slim Line Marijuana Vaporizer Production; Ellex: Lumibird Pays $100m For Laser, Ultrasound Business; IDT Terminates US Temozolomide Mayne Distribution Deal; Imugene Completes Unmarketable Parcel Sale; Micro-X Raises $16.5m In ‘Oversubscribed’ Offer; Invion To Supply Dermatology Compound For China’s Pavay; Telix Files Phase III TLX250-CDx Kidney Cancer FDA IND Application; Kazia Receives $1.4m R&D Tax Incentive; Orthocell Share Plan Raises $1.4m; Total $14.4m; Alcidion $1.9m Deal With Dartford, Gravesham NHS Trust; Telix Submits TLX591-CDx Clinical Briefing Package To US FDA; David Hannon, DRH Super Below 5% In Noxopharm; Pro Medicus, Nines $6m Visage 7 Deal; Visioneering $3m Placement To Thorney; FDA Approves Avita Recell For Vitiligo Study; Dorsavi Raises $187k In Share Plan; Total Raised $1.9m; Starpharma Phase I AZD0466 Trial For Cancer; $4.3m Milestone; Invitrocue Tells ASX Query: Dr Lindner ‘Not Then A Director’; Creso Draws Down $518k Of Convertible Note Facility; Karst Peak, Vermillion, Adam Leitzes Take 12% Of Cyclopharm; Jencay Capital Takes 6% Of Ellex; Imagion Pleads Schultz To 21% ASX Price Query; Prescient Founder, Director Paul Hopper Steps Down; Nuheara Appoints Cheryl Edwardes Chair; Redhill Ends 2014 Salix Licence; Australian Ethical Takes 10% Of Cyclopharm; CVC Reduces To 9% Of Cyclopharm; Mesoblast Files FDA Remestemcel-L Data; Antisense Options Raise $5.5m; Robert Bazzani Replaces Mach7’s Damien Lim, Jennifer Pilcher; Adalta Loses Director Dr John Chiplin; Uscom 5-Year China NMPA Approval For Uscom 1a; Cellmid US, Euro Midkine Patents; Nuheara Launches Iqbuds Max, To Begin Shipping In March; Opthea Recruits OPT-302 Combo Trial For DME; Pharmaust Epichem Client Unity Biotechnology Ends Contract; Polynovo: ‘$2m Novosorb BTM December Sales’; MGC Australia, New Zealand Marijuana Mercury Pharma; Cynata Receives $1.9m R&D Tax Incentive; Dimerix ‘No Safety Concerns In DMX-200 Trials’; Cann Group, IDT Marijuana Resin Extraction Underway; Althea Beats 4k Marijuana Patient Target; Pharmaust Epichem Extends DNDI Contract To Dec 31, 2020; Elixinol Releases 78m Shares From ASX Escrow; Creso Pleads Schultz To ASX 24% Query; Creso Releases 500k Shares From Voluntary Escrow; Immutep Expands IMP321 Tacti-002 Cancer Study; Adherium Appoints Jane Lapon Market Access Head; MGC: 2k Marijuana Scripts; 1st Shipment In Brazil; Eli Lilly Pays $1.6b For Tom Wiggans’ Dermira; Thorney, Tiga Trading Take 15% Of Visioneering; Regal Funds Increases, Diluted To 14% Of Visioneering; Andreas Empl Replaces Lifespot Director Greg Plunkett; Avecho: Ex-Bioscience Managers Matt McNamara Director; Esense Appoints Dr James Ellingford Director; Total Brain Appoints David Daglio Director; Anteotech Pleads Schultz To ASX 72% Query; Anglo Charitable Increases, Diluted To 17% Of Cyclopharm; Race Dr Al-Behaisi Contract Ends - To Recruit Australian CRM; MMJ $2.2m Harvest One Cannabis Loan Agreement; UK Approves Cynata Cymerus Critical Limb Ischaemia Trial; CE Mark For Proteomics Promarkerd Hub; Adalta Phase I AD-214 Trial Delayed For More Data; Euro Orphan Status For Alterity PBT434 For MSA; Imugene: US Grants HER-Vaxx Cancer Immunotherapy Patent; Escrow End Takes Raw With Life, Elixinol’s Paul Benhaim To 40%; Investors Mutual Reduces To 6% Of Ellex; Karst Peak, Adam Leitzes, Vermillion Reduce To 6% Of Avita; Pharmaust Receives $713k R&D Tax Incentive; GI Dynamics Receives $6.7m From Crystal Amber Convertible Note; Reva Files US Ch 11 Bankruptcy; GI Dynamics: Endobarrier ‘Significantly’ Reduces C-V Risk; Karin Lindgren Replaces Volpara Director Prof Mike Brady; Barings Diluted To 15% Of Cyclopharm; Alterity Receives $4.8m R&D Tax Incentive; Orthocell Receives $2.9m R&D Tax Incentive; Japan Patent For Painchek Smart Phone Pain Test; Tali: Google For Education Partner Status; Naos Takes 22% Of BTC Health; Stemcell United Pleads Schultz To ASX 85% Query; ASX Queries Visioneering Cash Burn; Noxopharm’s Nyrada IPO Opens Up 52.5%; Lifespot Capital AG Reduces To 18% Of Lifespot; G Medical Completes China Trials For Prizma Approval; OBJ ‘Wellfully’ $50m Backdoor, 20-To-One Consolidation EGM; Merchant Funds Management Below 5% In Zelira 
 
2019: BDI-40 Up 118%; ASX200 Up 18%, Big Caps Up 46%, NBI Up 24%; Avita Up 919%, Orthocell 543%, Painchek 497%, Opthea 453%, Alcidion 408%

 

 

 
Dec 20, 2019
Dr Boreham’s Crucible: Avita Medical; FDA Approves UWA, Sarepta Vyondys-53 For DMD; Cartherics Raises $12m; Cyclopharm Raises $9.8m In Placement To Karst Peak; Telix, Victoria Cancer Centre Win $500k Grant; Cyclopharm, Cyclotek J-V For NSW Pet Opportunities; Cogstate: ‘Record H1 $19.1m Revenue’; Regeneus, AGC Terminate Japan Stem Cell J-V; Anatara Finalizes Garp Trial Protocol; Adalta, Radium Capital R&D Tax Incentive Loan; W Whitney George Takes 26% Of Rhinomed; Respiri Cancels Two Bulls Shares, Koswani Wall Options 
 
Dec 19, 2019
2019 – Biotech Daily’s Year In Review; Cardiex $1.9m Bayer Trial Contract; Resapp To Test Aboriginal COPD; Immutep Recruits 2nd Cohort For IMP321 Solid Tumor Trial; Alcidion $500k Taunton, Somerset NHS Patientrack Deal; Next Science Appoints Triad As Torrentx US Distributor; Emvision Brain Scanner Ready For Clinical Trials; Memphasys Ships First Batch Of Felix Devices; Anatara: ‘Garp Enhances Anti-Inflammatories In Mice’; Cann Group, IDT 1st Commercial Marijuana Product; Cann Global, Koegas South Africa Marijuana J-V; Palla Negotiates Better Loan Terms; Cyclopharm Requests Capital Raising Trading Halt; Jamber Takes 12% Of Creso; MGC Ships Marijuana Cognicann For Dementia, Alzheimer’s; THC Appoints Angela Macquire COO; Bod Alternative Director Stephen Thompson Resigns
 
 
Dec 17, 2019
Antisense Jumps 46% On ATL1102 For DMD ‘Safety, Efficacy’; Morgans Underwrites Antisense Options For $4m, Total $5.5m; Mesoblast Nears Cardiac Stem Cell Trial Completion; Noxopharm Raises $8.5m For Nyrada IPO; Zelira Completes Marijuana Insomnia Trial Dosing; Race Receives $159k Federal R&D Tax Incentive; Neurotech: Holy Stone Taiwan Mente Autism Distributor; Perennial Takes 7% Of Genetic Signatures; Jeffery Emmanuel Takes 7% Of Sienna; Gayle McGarry, Caperi Reduce To 6% Of Botanix
 
Dec 16, 2019
Telix Up-To $30m Atonco At-211 Bladder Cancer Licence; Polynovo Novosorb For White Island Burns Victims; Medlab ‘Oversubscribed’ Placement Raises $5m; Starpharma Receives $4.9m Federal R&D Tax Incentive; FDA Approves Orthocell Celgro Animal Study; Simavita Borrows $509k Against Federal R&D Tax Incentive; Antisense Takes ATL1102 DMD Results Halt To Suspension; Pharmaxis Requests Boehringer Ingelheim Trading Halt; Nuheara Walgreens Partnership; Bod, H&H Launch CBD In UK; Anteo Lithium Battery On Track For Commercialization; Asia Union Increases, Diluted To 27% Of Genetic Signatures; Karst Peak, Adam Leitzes Diluted To 13% In Genetic Signatures; Fidelity (FIL) Takes 6.7% Of Genetic Signatures; Director Donald Channer Takes 29% Of Medigard; Uscom Appoints Major Shareholder Xianhui Meng Director; Paul Molloy Replaces Oventus Director Neil Anderson; Cann Group Loses Director Neil Belot 
 
Dec 13, 2019
Dr Boreham’s Crucible: Medadvisor; Polynovo Jumps 27% On Novosorb BTM CE Mark Approval; Respiri: ‘Transforms To Software As A Service’; US Grants Next Science Xbio For Acne Patent; Medlab Requests Placement Trading Halt; Bank Of New York Mellon Pershing Reinstates Auscann; Creso Releases 2m Voluntary Escrow Shares; David Lilja Replaces Opyl Co Sec David Hwang
 
Dec 12, 2019
Federal $14.7m Horizon, Bridge Grants For 17 Projects; Prescient: 1 PTX-200 Ovarian Cancer Partial Response, Cost Cuts; WEHI, NIH Link Ripk1 To Cria Syndrome; Resapp Receives $1.8m R&D Tax Incentive; Antisense Requests ATL1102 DMD Trial Results Trading Halt; Ellex Extends Laser, Ultrasound Business Sale Suspension; Medlab, Cultech Expand Orsbiotic, Nanocbd In UK; Bod, Uni Of SA Research ‘Effect’ Of Marijuana Medicabillis; Holista Water Soluble CBD Marijuana Oil; Empery Tax Efficient Reduces To 6% Of Benitec, In 2018
 
Dec 11, 2019
Kazia GDC-0084 Joins ‘GBM Agile' Glioblastoma Multi-Drug Trial; Probiotec Buys Contract Pharma Services For $4.5m; Adherium Hopes To Raise $5.4m In Rights Offer; Bionomics Sells French Subsidiaries To Domain For $3m; Pharmaust Opens 2 More Dog Cancer Trial Centres; Baillie Gifford Reduces To 7% Of Cochlear; Regal Funds Takes 5% Of Medical Developments; Regal Funds Reduces To 12% Of Opthea; Executive Director Dr Ian Dixon Takes 9% Of Medigard; Alterity 587m Options Expire, Voluntary Escrow Release; Cogstate Appoints Keith Hawkins Co Sec 
 
Dec 10, 2019
4DX Pre-IPO Issue Raises $15m; Starpharma ‘Results Take DEP-Cabazitaxel Trial To Phase II’; Qbiotics: ‘EBC-46 Solid Tumor Safety, Efficacy’; Heramed Placement Raises $1.4m; Genetic Technologies: Breast Cancer Genetype Ready; Respiri’s Wheezo Wins CE Mark, TGA Registration; CSL Appoints Carolyn Hewson Director; Cochlear Appoints Michael Daniell Director; Palla $4m Euro Codeine Deal; Cann Global Olivia Newton-John Marijuana Formula Rights
 
Dec 9, 2019
Ausbiotech, Medicines Australia Hit Federal RDTI Change; Invitrocue, Chinalink: $15m Agreement, Hong-Kong J-V; Suda, Sanofi Oromist Feasibility Agreement; Admedus: Lemaitre 12.5k Unit Cardiocel, Vascucel Order; Botanix Readies For Cannabidiol BTX1702 Rosacea Trial; Creso Africa Marijuana Cannaqix Launch By April 2020; Claude Solitario Replaces Medibio’s David Kaysen, Relocation; Ms Farrell, Ms Dahiya Replace Cann Co Sec, CFO Mr Baker
 
Dec 6, 2019
Dr Boreham’s Crucible: Memphasys; Opthea Raises $50m; Sienna Raises $1.7m; Rights Issue For $2.5m More; Russia Accepts Medical Developments Penthrox Application; Elixinol Class Action: ‘Products Correctly Labelled’; Neuroscientific Emtin-B Not Significant For Alzheimer’s In Mice; Heramed Requests Capital Raising Trading Halt; Victoria, Medipharm Open Wonthaggi Marijuana Facility; Lifespot Marijuana Vaporizer, Software Evaluation; Australian Ethical Takes 6% Of Palla Pharma; Peters Takes 10% Of Painchek
 
Dec 5, 2019
Cynata Stem Cells Effective For Sepsis In Rats; Suda, Ordesa Co-Develop Unnamed Oromist Product; Optiscan Appoints Biotimes 2nd China Distributor; Neurotech, Neurofeedback Partner For Mente Autism; Smart Top, Xianhui Meng Take 21% Of Uscom; Capital Group Clients Cease Substantial In Mesoblast; Genetic Signatures 31% Oppose Tranche 1 Shares; Creso 1st Shipment Of Burleigh Heads Cannaqix 50; Pokies Bruce Mathieson Increases, Diluted To 13% Of Respiri; Race Appoints Prof Borje Andersson Advisory Chair; Imugene Appoints Prof Rebecca Auer Advisor 
 
Dec 4, 2019
CSL R&D Spend Up, New Asthma Drug Trial, Pipeline; Orthocell $13m Placement, Share Plan For $5m More; Painchek Confirms $5m Federal Grant; G Medical $30m Gem Global Draw Down Equity Facility; Avecho To Market 6 TPM Drugs; Zelira (Zelda) Takes Hope For Autism To Louisiana; THC Southport Facility 1st Medical Marijuana; Osteopore Appoints Jack O’Mahony Board Advisor
 
Dec 3, 2019
Mach7 Placement For $20m; Dimerix Placement Raises $2.5m; Uscom Commissions 28 US Sales Staff; Painchek 1,000 Bed Licence With PCS UK, 30 Bed Sale; Neuren NNZ-2591 Neurodevelopment EU Patent; Elixinol Sells Elixinol Japan For $346k After Non-Compliance; Ireland Approves MGC Marijuana Cannepil; Viburnum Takes 19% Of Universal Biosensors; Credit Suisse Takes 10% Of Prescient; Australian Land, Director Alan Tribe Take 27% Of PYC; PYC Director Dr Bernard Hockings Increases, Diluted To 13%; Kemper Shaw Diluted To 6% In Imagion; Merchant Funds Below 5% In Rhythm; Noxopharm Extends Lind, CST Equity-Draw-Down Facility
 
Dec 2, 2019
12-Month BDI-40 Up 114%, ASX200 21%, Big Caps 56%, NBI 9.5%; Opthea Placement For $50m; Imugene Placement For $24.6m; Phylogica Doubles Eye Drug Delivery In Mice; Medlab Nanabis ‘Observational’ Study: Pain Reduction; MGC 52% Blocks Founder Nativ Segev Rights, Strong Dissent; GI Dynamics 120k Director Option, $7m Notes EGM; Goodbye Zelda, Hello Zelira; Noxopharm Daart-1 Study: Partial Response In 1 Of 15 Patients; Orthocell Requests Capital Raising Trading Halt; THC Requests Marijuana Production Trading Halt; Blackrock Takes 6% Of CSL; Parker Family, Xylo Diluted Below 5%; Anthony Barton Diluted Below 5% In Phylogica; Sabby Reduces To 5.6% In Benitec
 
 
Nov 28, 2019
Ellex 80% Revenue Laser, Ultrasound Sale Suspension; Federal $20m For Ovarian Cancer Research; Pro Medicus Launches Visage AI Accelerator; Resonance, Siemens Partner For Ferrismart; Creso To Raise Up To $10m For Pharmacielo, Operations; Dorsavi Notes, Placement Raise $1.7m; Plan For $1m More; FDA Okays Impedimed Sozo For Protein Calorie Malnutrition; Resapp To Combine Diagnostic With Coviu Platform; Resapp 40% Oppose Director Options; Optiscan 19% Oppose 10 Percent Placement Facility; Painchek Directors Sell 45m Shares To Fund Tax Liability; Imugene Requests Capital Raising Trading Halt; Sienna Takes Capital Raising Trading Halt To Suspension; Noxopharm Requests NOX66 Cancer Trial Results Halt
 
Nov 27, 2019
Federal Police, ASIC Raid Regal Funds On Investments; Cyclopharm Vanda Gould ‘Guilty’; Disqualified As Director; Prescient: ‘3rd PTX-200 AML Complete Response, Trial Expands’; Invion: ‘Photosoft Reduces Tumor Size 50% In Mice’; Recce’s Recce-327 ‘Reduces MRSA In Rats’; New Phase Orders $300k Of Imagion Nanoparticles; Shareroot Name Change To Opyl, 100-To-1 Consolidation; Noxopharm’s Nyrada Hopes For $8.5m IPO; Cynata 32% Oppose Employee Option Plan; Mesoblast 17% Oppose Remuneration Report; Credit Suisse Takes 5% Of Opthea; Proteomics CEO Dr Richard Lipscombe Diluted To 20.7%; Former Proteomics Director John Dunlop Diluted To 6%; David Sietsma Increases, Diluted To 10% Of Phylogica; Actinogen CEO Dr Bill Ketelbey Repays $360k Share Loan; Benitec Quits Australia For The US; G Medical Requests ‘Funding Facility’ Trading Halt; Osteopore To Release 6.3m Escrow Shares; Suda Appoints Dr Michael Baker CEO, Starting On $250k; Simavita Appoints Dr John McBain Director 
 
 
Nov 25, 2019
Kazia: GCD-0084 Glioblastoma Early Data: ‘Clinical Benefit’; Novita Placement Raises $6.2m; Total $8m; Recce Requests ‘Test Results’ Trading Halt; Micro-X Installs 1st Mini X-Ray At Alfred Hospital; Avita, Gates Center: Spray-On G-M Skin For EB; Imugene Completes CF33 GMP Batches; Cynata Applies For UK CYP-002 Critical Limb Trial; Optiscan To Meet FDA For Oral Cavity Imaging; Dimerix: FDA Phase III DMX-200 FSGS Meeting ‘Provides Clarity’; Up To 13% Dissent At Adherium AGM, 2nd Spill Avoided; Correction: Pharmaxis; CE Mark Approval For Simavita’s Smartz Nappy; Up 480%; Heramed Herabeat For India’s Cloudnine Hospital Group; Auscann, Aspen 3-Year Packaging Agreement; US DEA ‘De-Schedules’ Botanix Synthetic Marijuana; Selector Takes 5% Of Nanosonics; Sienna CEO Carl Stubbings Starts On $327k; Respiri: Marjan Mikel CEO, Director; Mario Gattino Goes
 
Nov 22, 2019
Dr Boreham’s Crucible: Phylogica; Viertel Awards $425k Fellowships, Scholarships; Imagion Rights Raise $3.6m; Anatara Receives $847k R&D Tax Incentive; Prescient Pleads Schultz To ASX 23% Query; OBJ, P&G ‘Harmonize’ Agreements, Higher Royalties; Medibio 70% Oppose New Directors Ide, Wipperman-Heine, Ojala; Oventus 32% Oppose 10% Placement Facility; Pharmaxis AGM: 14% Oppose William Delaat Re-Election; Cann Group ‘Stages’ Mildura Marijuana Facility; MGC, Brasilinvest Expand Marijuana Sales In Latin America; Director Andrew Goodall Takes 23% In Memphasys; Chair Alison Coutts Diluted To 11% In Memphasys; Craig Cooper, Niall Cairns, C2 Convert Notes For Cardiex 20%; Director Dennis Eck Takes 8.5% Of Cellmid; Adherium CEO Dr Peter Stratford Starts On $571k
 
Nov 21, 2019
China Okay For Medical Developments Penthrox Trial; Starpharma EU Approval For Vivagel Condoms; Resonance Develops Automatic Liver Fat Assessment Tool; Phylogica Retail Rights Raise $5.3m, Total $26.8m; Immuron Phase III IMM-124E Trial For Travellers Diarrhoea; Kazia Requests GDC-0084 Glioblastoma Trial Trading Halt; Painchek: $1m Milestone, 30m Director Options Vest; Painchek Expects To Sign $5m Federal Government Contract; Memphasys Wins $549k ARC Grant For Cell Sorters; Memphasys Identifies 5 Countries For Initial Felix Sales; Heramed, Kinderheldin German Herabeat Midwife Service; Health House To Distribute Zelda, Ilera Hope Marijuana; Novita Requests Capital Raising Trading Halt; Anteotech To ASX: ‘IMRA Contract Lodged By Next Trading Day’; Jeremy Green, Redmile Reduce To 11% Of Avita
 
Nov 20, 2019
Volpara H1 Revenue Up 176% To $6.9m; Loss Up 56% To $7.5m; Bluechiip Plan Raises $4.5m; Total $9.1m; Prof Tim Scott Wins $150k Victoria Prize; Bio-Melbourne Women In Leadership Awards Nominations Open; Antisense Completes ATL1102 For DMD Dosing; Resonance Files Provisional Patent For Blood Markers; Visioneering: Cooper FDA Approval Clears Regulatory Path; Clinuvel 40% Oppose $44m CEO Dr Philippe Wolgen Rights; Cellmid: 19% Oppose Remuneration Report; Actinogen Pleads Schultz To ASX 27% Query; Medadvisor 7-To-1 Consolidation; Zelda, Ilera To Launch ‘Hope’ Marijuana For Autism; MGC Requests ‘Latin America Term Sheet’ Trading Halt; Peters Investments Takes 28% Of Memphasys; Bellwether Super Ceases In Bluechiip; Thorney, Tiga Increase, Diluted To 19% Of Palla; Imugene Appoints Prof Prasad Adusumilli Advisor; GI Dynamics Appoints Juan Morera Crystal Amber Observer
 
Nov 19, 2019
Micro-X Raises $16.5m In Placement; Amends Thales Loan; Hemideina Raises $4m For Wireless Hearing Implant; Genetic Signatures Share Plan Raises $2.5m, Total $37.5m; Regeneus Shortfall Raises $755k, Total $5.5m; Alcidion Launches Mobile Electronic Medical Records; Oncosil Submits Updated CE Mark Report; Medlab NRGbiotic Depression Trial On-Track; Mayne Licences Generic Dermatology Product For US; Osteopore, China’s Boao Yiling Nose Job Deal; Admedus Pleads Schultz To ASX 48% Query; Benitec 10-To-1 ADS Consolidation For Nasdaq Compliance; Washington Pattinson, Brickworks Diluted To 19.9% In Palla; Cogstate Appoints Ken Billard Chief Commercial Officer
 
FDA Okays Cochlear Osia 2 For Conductive Hearing Loss; Singapore Approves Visioneering Multi-Focal Lenses; Correction: Palla Pharma; Antisense: 7th Patient Data Backs ATL1102 For DMD; EMA Group Recommends Alterity’s PBT434 Orphan Status; Prescient To Work With Carina For Car-T Cells; Oventus Signs 2 More US O2vent ‘Lab-In-Lab’ Sites; Adherium, ‘Patients Know Best’ Collaboration; Imugene EGM Backs Vaxinia Acquisition; US Patent For Dorsavi Motion Analysis; Suda Receives $928k Federal R&D Tax Incentive; Anteotech, IMRA Deal For Lateral Flow Assays; Heramed Retracts Revenue Forecast, As Well As $13b Typo; FDA Clears Heramed’s Herabeat Foetal Heart Rate Monitor; Polynovo 25% Oppose Chair David Williams; IDT Survives 22.5% Remuneration 1st Strike Vote; Rhythm Releases 38.5m Escrow Shares; Founder Wayne Stringer Decreases To 13% In Probiotec; Avita: David Mcintyre CFO; Tim Rooney CAO; Nathan Jong Replaces Total Brain Joint Co Sec Harvey Bui
 
Nov 15, 2019
Dr Boreham’s Crucible: Uscom; Burnet Prof Brendan Crabb $80k GSK, Research Aust Gong; Palla Retail Rights Raises $10.1m; Total $30.7m; Proteomics ‘Heavily Oversubscribed’ Placement Raises $3m; Allegra Begins Sheep Sr-HT-Gahnite Cervical Fusion Study; Phylogica, Genentech Anti-Microbial Work Cancelled; Resapp, Sanofi Work On Respiratory Smartphone Diagnostic; Dorsavi Staff Cuts, Costs Down; Possible Capital Raise; Australian Patent For OBJ Bodyguard; Elixinol Pleads Schultz, Japan Issue To ASX 17% Fall Query; Novita Tells ASX: ‘NDIS News Published Quickly’; Heramed Requests 2nd ASX Price Query Trading Halt; CEO Dr Behrenbruch, Elk River Diluted To 10% Of Telix; Gnosis, Andreas Kluge Diluted To 10% Of Telix; CEO Paul Rennie Increases, Diluted To 12% Of Paradigm; Anteo Name Change To Anteotech; Respiri: Smedley Chair, Blair-Holt Out; Board Spill Withdrawn
 
Nov 14, 2019
Prescient Doses 1st PTX-100 Cancer Trial Patient; Race Trials Bisantrene For Residual AML Cancer; Combination; Immutep IMP701 Euro Patent For Cancer, Infectious Disease; Heramed Pleads Million-Billion-Schmillion Typo To ASX 52% Query; Sienna Loses 7-Year Director Dr David Earp; AGM Vote Withdrawn; Phylogica Takes 90% Of Vision Pharma With $15m; Simavita Receives $684k R&D Tax Incentive; Uscom Sells 346k Unmarketable Shares; Althea Wins UK Marijuana Licence; Zelda Marijuana For ‘Advanced Cancer Symptoms’ Trial; Australian Ethical Takes More Profit To 16% Of Antisense; Alcidion Director Prof Malcolm Pradhan Diluted To 14%; Former Alcidion Chair Ray Blight Diluted To 10%; Director Peter Anastasiou Reduces To 10.3% Of Immuron; Peter, Diana Diamond Below 5% In Novita 
 
Nov 13, 2019
Avita Raises $120m; Cogstate Retail Rights Raise $1.1m; Total $4m; Imagion: India Patent For Magnetic Nanoparticle Imaging; Proteomics Requests Capital Raising Trading Halt; Starpharma: Vivagel For Bacterial Vaginosis UK Launch; Althea Marijuana For ‘Advanced Cancer Symptoms’ Trial; Pokies Bruce Mathieson Increases, Diluted To 13% In Respiri; Ansila Energy Ceases Substantial In Factor; Alan Tribe, Australian Land Take 25% Of Phylogica
 
Nov 12, 2019
Proteomics: ‘Promarkerd CE Mark For Diabetic Kidney Disease’; US Patent For Orthocell Celgro Collagen Rope; Creso Terminates Sale To Pharmacielo; NDIS Extends Novita’s Tali Health Platform Registration; Impedimed AGM: 44% Back Spill Call; Rem Report Passes; Adherium Clarifies $1.2m Debt Note To $1.1m; Althea Appoints Nimbus German Marijuana Distributor; MGC $25k Federal Grant; London Listing; Uil, Utilico Take 5% Of Starpharma; Peter, Diana Diamond Reduce To 6% Of Novita; Dr Bernard Hockings Increases, Diluted To 13% In Phylogica; Ellume Appoints Joanne Moss Director
 
Nov 11, 2019
Adherium Tells ASX 4C Query: $1.2m Debt Note; Bionomics Receives $5.2m Federal R&D Tax Incentive; Zelda Receives $1m Federal R&D Tax Incentive; Anatara 46% Oppose Dr Ramsdale Rights; 10% Capacity Fails; Anteo AGM: 27% Oppose Placement Capacity; Bod 2.75m Director Options AGM Faces 27% Dissent; Avita Requests Capital Raising Trading Halt; Dorsavi Requests ‘Additional Capital Raising’ Suspension; Micro-X Extends Capital Raising Suspension; Medlab: Record Marijuana Sales In October; Antisense 45m Directors’ Options AGM; THC Southport Marijuana Manufacture Permit; Richard Cashin Diluted To 11% Of GI Dynamics; Creso, Pharmacielo Meetings Delay, Suspension Extended; Industry Holds Melbourne March Medical Marijuana Meeting
 
Nov 8, 2019
Dr Boreham’s Crucible: Genetic Signatures; S&P Promotes Avita To ASX200; Vivazome To Use Sienna Exo-Net For Ischaemia; Total Brain Raises $14m; Biotron: ‘Gleneagle Underwrites 103m Options To $5m’; Prescient Receives $1.6m R&D Tax Incentive; Azure Buys Invictus Food Additives For 35m Shares, $1.2m Debt; Cardiex Appoints Beijing Auden Atcor China Distributor; Bod Joins Project Twenty21 UK Marijuana Study; Crystal Amber Takes 73% Of Gi Dynamics; Suda Loses Andrew Curtis, Joseph Ohayon Part-Time; Michael Edwards Replaces Esense Director Galit Assaf
 
Nov 7, 2019
Export Corp $85m OBJ Backdoor To Be ‘Wellfully’; Zelda Marijuana Insomnia Trial Fully Enrolled; Cann, Symbion Marijuana Deal; Medadvisor, Sigma Prescription Deal - $1m Pa Revenue; Living Cell Board Spill AGM: Dr Kelly In, Laurie Hunter Out; Patrys Receives $672k R&D Tax Incentive; Heramed Software Tested On 750 Pregnancies In 15 Hospitals; Total Brain Takes Capital Raising Trading Halt To Suspension; Australian Ethical Takes Profit To 17% Of Antisense; Asia Union Decreases To 32% Of Genetic Signatures; Karst Peak, Adam Leitzes Diluted To 15% Of Genetic Signatures; Credit Suisse Takes 6.2% Of Kazia
 
Nov 6, 2019
Cellmid Share Plan Raises $1m; Total $2.5m; Acrux Receives Further $1.5m Federal R&D Tax Incentive; Oventus Receives $828k Federal R&D Tax Incentive; Cellmid, API To Sell Évolis At Priceline Pharmacies; Micro-X: ‘Capital Management, Raising’ Halt To Suspension; Eisai Takes 7.2% Of Cogstate; Sico Increased, Diluted To 7.7% In Palla, In 2017; Ellex To Lose Director Giuseppe Canala; Noxopharm Appoints Alexander Hunter CCO
 
Nov 5, 2019
FDA Okays Redhill’s Talicia (Sydney’s Heliconda) For H Pylori; Alcidion Raises $16.2m; Emvision Raises $4.5m; Eye-Co Fludrocortisone Acetate Early Trial Results; Cann Global Convertible Notes For $2.2m; Platinum Diluted To 9% Of Kazia; Peter, Diana Diamond Reduce To 7.7% Of Novita; Creso Takes ‘Pharmacielo Acquisition’ Halt To Suspension; OBJ Takes ‘Material Acquisition’ Halt To Suspension; Total Brain Requests ‘Capital Raising’ Halt 
 
Nov 4, 2019
Pro Medicus: Ohio State Uni $9m Visage 7 Deal; Phylogica Raises $14.3m, $12.5m To Go; Next Science Falls On Wrong Motley Fool 4c Report; Bionomics: FDA Fast Track Status For BNC210 For PTSD; Optiscan: FDA Confocal Microscope Oral Cancer Meeting; Rhythm: China Patent For Colostat; Imugene Receives $4m Federal R&D Tax Incentive; Nuheara Receives $1.7m Federal R&D Tax Incentive; Immuron Receives $532k Federal R&D Tax Incentive; Micro-X Requests ‘Capital Management, Raising’ Trading Halt; Invion Loses 6-Year Director Greg Collier; Elixinol Appoints Teresa Cleary Co Sec; Chris Mews Replaces Auscann Director Dr Paul MacLeman; Stemcell Loses Director Savio Ka Lung Cheung
 
Oct 31, 2019
Ausbiotech Invest, Partnering; Conference Gongs; Victoria AAMRI Wants $20m PA For Research ‘Indirect Costs’; Neuren: Acadia Starts Phase III Trofinetide Rett Trial; Starpharma: ‘DEP-Gemcitabine Best For Pancreatic Cancer In Mice’; Invion, Peter MacCallum Ano-Genital Cancer Studies; Phylogica ‘Underwritten’ Rights Offer To Raise $26.8m; Emvision Assembles 1st Portable Brain Scanner For Stroke Trial; Total Brain, Vault Partner For Mental Health Platform; MGC Prescribes 1,000 Marijuana Doses; Dr Muchnicki, MJGD, JGM Take 5% Of Genetic Technologies; Peter Rubinstein, Irwin, Rip Take 6% Of Genetic Technologies; Nanosonics Appoints Dr Lisa McIntyre Director; Cellmid Appoints Brian McGee US Advangen CEO
 
Oct 30, 2019
Ausbiotech National Conference Opens; Telix $30m To Aushealth For Apomab For Ovarian, Lung Cancer; Biocurate, Takeda Accelerate Therapeutics, Drugs Discovery; Clinuvel: TGA Scenesse Priority Registration; Genetic Technologies Raises $4.5m, Nasdaq Compliance; Sienna, Minomic Work On Pancreatic Cancer Blood Test; Suda $1.5m Cann Pharma Deal For Marijuana Spray; Somnomed, App-Nea Deal For Doctor Software; Medical Developments 18% Oppose Remuneration Report; Respiri Spill Call, Nick Smedley In, Alastair Beard Interim CEO; Mesoblast AGM For 2.4m Options; Neuroscientific 3m Director Options AGM; Althea AGM For 1.2m Joshua Fegan Rights; GI Dynamics: Less Than One Quarter Cash, $US10m Notes; Credit Suisse Below 5% In Opthea; Paradice Increases, Diluted To 7.8% Of Probiotec; Probiotec Chairman Geoffrey Pearce Diluted Below 5%; Merchant Takes 11% Of Sienna; Pendal Group Takes 5% Of Althea; Clarity Appoints Dr Colin Biggin CEO; Vivazome Appoints Dr David Haylock CEO; LBT 13-Year Director Stephen Mathwin Retires; Uscom: Dr Antonio Ferrario Euro Sales, Marketing Manager
 
Oct 29, 2019
Kira Raises $20m For KB312 For Immune Disorders; Imagion Rights Offer For $6.5m; IP Group Backs Uniquest’s Jetra Il-22 For Fatty Liver Disease; Adalta Monkey Study: ‘AD-214 Safe, Well-Tolerated’; Medical Developments, CSIRO Extend Drug Manufacture Deal; Oncosil Submits Updated CE Mark Report; Invion 4C: ‘Cho Group To Fund All Costs’; Proteomics Receives $1.1m Tax Incentive; Nuheara: ‘R&D Tax Incentive Makes Two Quarters Cash’; Telix To Release 67.6m Escrow Shares; Oncosil Withdraws 5m CEO Daniel Kenny Loan Shares; Shareroot: Opyl Name Change, 100-To-1 Consolidation AGM; Greg Plummer, Jetan Take 5% Of Uscom; Merchant Takes 11% Of Bard1; Thorney, Tiga Take 21% Of Palla Pharma
 
Oct 28, 2019
Genetic Signatures Raises $35m, Plan For $2m More; Kazia Raises $4m; Pharmaxis: ‘FDA Larger Clinician Study, 1 Month Delay’; Federal $50k Cynata Coronary Artery Disease Grant; Genetic Signatures Receives $2.1m Federal R&D Tax Incentive; Zelda Name Change To ‘Zelira’, 37.5m Director Options AGM; Resonance 12m Director Options AGM; Rhinomed 10m Directors Options AGM; Resapp 3m CEO, Director Incentive Options AGM; Bioxyne 36m M-D Performance Rights AGM; Benitec 5m Director Options AGM; Acrux 2.7m ‘50% In Lieu’ Directors Rights AGM; Althea Launches CBD100 In Australia; Cann Global Opens Laos Marijuana Subsidiary; David Daglio Takes 6.5% In Total Brain; Aphria Reduces To 5.25% In Althea; Polynovo Appoints CSL’s Dr Robyn Elliott Director; Auscann To Lose Dr Mal Washer, Cheryl Edwards; Noxopharm Appoints Chair Dr Graham Kelly Interim CEO; Exopharm Appoints Dr Christopher Baldwin CCO, On $330k; Genetic Signatures Loses 16-Year Director Phillip Isaacs
 
Oct 25, 2019
Dr Boreham’s Crucible: Elixinol Global; CSL Removes Pharming From Prof Joseph Dr Chiao Case; Resmed Q1 Revenue Up 16% To $999m, Profit Up 16% To $199m; Imagion Needs $1.6m For GMP Nanoparticle; Genetic Technologies Rights Raise $4.5m; Paradigm PPS Treats 10 US Footballers; Canada Allows Cynata Stem Cell Patent; Uscom Consolidates 346k Unmarketable Parcel Shares; Heramed Extends Consultus India Deal, 2nd Herabeat Order; Althea Expects 4k Medical Marijuana Scripts This Year; Respiri Has Less Than Two Quarters Cash; Respiri Opposes Ex-CEO Mario Gattino Re-Election AGM; Adherium 2nd Strike Board Spill AGM; Avita 40m CEO Dr Michael Perry Incentive Units AGM; Novita 14m M-D Options, ‘Tali Digital’ Name Change AGM; Genetic Technologies ‘Genetype’ Name Change AGM; Cynata AGM To Vote On Email Address Requests; Washington H Soul Pattinson Takes 23% Of Palla; Otto Buttula Replaces Rhythm Chairman Shane Tanner
 
Oct 24, 2019
Bluechiip Placement Raises $4.6m; Share Plan For More; Pharmaxis: LOX Inhibitor For Cancer ‘Dose Response, Safe’; Actinogen Receives $4.6m Federal R&D Tax Incentive; Acrux Receives ‘First’ $502k Federal R&D Tax Incentive; Medical Developments: ‘Penthrox 1st Line EU Pain Treatment’; Novita Tali Detect US Reimbursement Code; Up 145%; Genetic Signatures Requests Capital Raising Trading Halt; Kazia Requests Capital Raising Trading Halt; Medibio: PWC Australia To Use Ilumen For Mental Health; Adalta 5m CEO Dr Tim Oldham Options AGM; Credit Suisse Takes 5% Of Opthea; James Schwarz, Jamber Take 5% Of Esense; Nuheara Appoints David Buckingham Director; Invion CEO Craig Newton Starts On $280k
 
Oct 23, 2019
Botanix: Cannabinoid BTX1503 Misses Acne Primary Endpoint; Down 48%; Imugene: $825k US Defense Grant For CF33 Gastric Cancer Research; Medical Developments Launches Penthrox In Italy; Dimerix $50k Federal Dmx-700 COPD Grant; Impedimed Cancer-Related Lymphoedema Prevention Program; Elixinol Investigates ‘Non-Compliant’ Japan Cannabidiol; Oventus 570k CEO Options, 300k Directors Options; Althea Requests ‘Material Supply Agreement’ Trading Halt; Capital Group ‘Clients’ Reduce To 5% Of Mesoblast; M&G Takes Prudential’s 14% Of Mesoblast; M&G Takes Prudential’s 5% Of Medical Developments; M&G Takes Prudential’s 12% Of Starpharma; Wentworth Williamson Takes 8% Of Palla Pharma; Antanas Guoga Takes 13% Of Shareroot; Niv Dagan, Freedom Trader, 10 Bolivianos Take 8% Of Lifespot; Regal Funds Below 5% In Medibio; Clarity Appoints Dr Jennifer Rosenthal For Quality, Regulatory
 
Oct 22, 2019
Cochlear: Forecast OK, EPS Target Down, Going Greener; Cochlear 12.35% Oppose Director Donal O’Dwyer; Volpara H1 Receipts Up 171% To $6.8m; Medical Developments: Penthrox Superior For Pain; Bluechiip Requests ‘Capital Raising’ Trading Halt; Botanix Requests ‘BTX1503 Trial Results’ Trading Halt; Medibio 2nd Strike, 16.6m ‘In Lieu’ Directors Options AGM; LBT 1m Director Options AGM; Medadvisor 13m Director Options, 7-To-1 Consolidation AGM; Bluechiip 856k CEO Performance Rights AGM; Genetic Signatures 2nd Strike AGM; G Medical Responds To ASX Delay Query; Blackrock Takes 7.2% Of Cochlear; Mark Kerr Takes 12.7% Of Avecho; Jimmy Thomas, Ivy Ponniah ‘Below 5%’ In Genetic Technologies
 
Oct 21, 2019
LBT: Wisplinghoff Buys First Euro APAS Independence; Palla Pharma Raises $20.6m, $10.5m To Go; Cogstate ‘Underwritten’ $4m 1-For-10 Rights Issue; Imugene Plans 2 CF33 Trials For 2020; Cann Has One Quarter Cash, ‘Loan Coming’; WIPO Publishes Micro-X Carbon Nanotube Patent; Medibio Completes 1st Compass Ilumen Test; Correction: Cellmid; Orthocell 1m CFO, Director Options AGM; Phylogica Name Change To ‘PYC Therapeutics’ AGM; Purisys To Supply Botanix Synthetic Cannabidiol; Elixinol Requests ‘Japanese Subsidiary’ Trading Halt; Noxopharm Veyonda (NOX66): ‘80% No Cancer Progression’; 9 Days To Ausbiotech Biotech Invest, Conference; Mayne Loses 13-Year Director Ron Best; Matt McNamara Replaces Adherium Director Prof John Mills
 
Oct 18, 2019
Dr Boreham’s Crucible: Clinuvel Pharmaceuticals; CSL: Prof Joseph Chiao, Pharming Lawsuit On HA Data; Oncosil Receives $3.8m R&D Tax Incentive; Clinuvel 1.5m, $48m CEO Dr Phillipe Wolgen Rights AGM; Pharmaxis 927k CEO Gary Phillips Rights AGM; Starpharma 671k CEO Dr Jackie Fairley Rights AGM; Cellmid To Vote On 3m CEO Maria Halasz Options; Bionomics 2nd Strike AGM; Race 5.5m Directors Options AGM; Regeneus CEO Leo Lee 15m Options AGM; Althea Completes Canada Peak Acquisition; Noxopharm: ‘Glutamate-Inhibitor For Brain Cancer’; Merchant Funds Reduces To 5% Of Rhythm; Merchant Takes 12% Of Auscann
 
Oct 17, 2019
Alcidion: ‘Cash Flow Positive, Share Price Up 300% In 6 Months’; WEHI Team Wins $250k Prime Ministers Innovation Prize; Terumo Hands Back Avecho (Phosphagenics) TPM-Propofol; Palla ‘Underwritten’ $31m Placement, Rights Offer; Mesoblast: Lonza To Manufacture Remestemcel-L; Cynata, Sumitomo Quit Acquisition Talks; Pharmaxis Receives $6.2m R&D Tax Incentive; Painchek, Ward Pain Tests For Aged Care Facilities; CSL AGM Passes All Resolutions; 4.9% Dissent; Neurotech 6m Director Options AGM; Creso Delivers First Order Of 10% CBD Oil To Medleaf NZ; THC Receives S4, S8 Narcotics Licences For Marijuana; Recce’s Dr Graham Melrose, Olga Melrose Diluted To 23%; M-D Dr Ian Dixon Increases, Diluted To 29% Of Exopharm; CSL Loses Director Dr Tadataka Yamada; Imugene Appoints Prof Yuman Fong Advisor
 
Oct 16, 2019
Cronos: ‘Fully Underwritten’ $20m IPO For Medical Marijuana; Final Data Backs Immutep IMP321, Keytruda For Melanoma; Neuren NNZ-2591 Phelan-McDermid, Pitt Hopkins Orphan Status; Living Cell: Vertex Pays $1.1m For Semma Shares; Optiscan Appoints Guanzhou Yunxing China Distributor; Nuheara Pleads Schultz To 55% ASX Query; Regal Funds Takes 7% Of Medadvisor; Merchant Takes 5% Of Zelda; Invitrocue Loses Dissident Directors Prof Yu, Lui, Ng; Former IDT Chairman Graeme Kaufman Retires; Carl Stubbings Replaces Sienna CEO Matthew Hoskin; Noxopharm Loses 3 Month Director Dr Beata Edling/Niechoda
 
Oct 15, 2019
Federal, MTP Connect ‘Up To $1m’ Device Grants; Regeneus Receives $1.5m Federal R&D Tax Incentive; Admedus Amends Lemaitre Upfront Payment To $21.2m; Invex Exenatide Intracranial Hypertension Trial Recruited; Federal $50k For Botanix Synthetic CBD Analogs; Cynata Investors Request Email Addresses Resolution; Alcidion $400k Directors Fee Pool Limit AGM; Kazia AGM To Vote On 1.2m CEO James Garner Options; Clarification: Rhinomed, Odd Fellows, Perennial; Director, CSO Dr Daniel Tillett Diluted To 8% Of Race; Ebos Diluted To 10.8% In Medadvisor; Clinuvel To Lose 17-Year Chairman Stan McLiesh
 
Oct 14, 2019
Admedus: ‘Up-To $36m Adapt Lemaitre Distribution Deal’; Correction: Recce Pharmaceuticals; Victoria Boosts Epilepsy Marijuana; Ends IDT, Cann Deals; Cellmid Raises $1.5m; Share Plan For $500k More; Anatara Bromelain Garp Effective For IBD, IBS, In Mice; Cellmid, Australian Shopping Network Evolis Agreement; Telix Integrates GE Healthcare Gallium With TLX591-CDx; Medadvisor 3-Year Chemist Warehouse Deal; Polynovo 50% Director Fee Pool Hike To $600k AGM; Painchek $840k M-D, Directors Performance Rights AGM; Suda 40m Chair Paul Hopper Options, 25-To-1 Consolidation; Bard1 100% Director Fee Pool Hike To $400k AGM; Merchant Takes 11.5% Of Auscann; Canopy Ceases; ‘Odd Fellows’ Below 5% In Rhinomed; Pharmaust Appoints Colin La Galia Epichem CEO; Dr Keenan Director; Imagion Scientific Advisory Board
 
Oct 11, 2019
Dr Boreham’s Crucible: Recce Pharmaceuticals; Opthea OPT-302 Benefit For CNV, Wet AMD Lesions; Truscreen: W.H.O. Cervical Cancer Strategy Benefit; Neuren NNZ2591 Angelman Syndrome FDA Orphan Status; Oncosil: US FDA Humanitarian Use, CE Mark Progress; Oventus 5 O2vent ‘Lab-In-Lab’ Sites In US, Canada; Bluechiip: ‘More Than 2 Quarters Cash’; Invitrocue CEO Dr Steven Fang Survives Spill Meeting; Impedimed 2m CEO Shares, Options, 2nd Strike AGM; Platinum Reduces To 6% Of Antisense; HMS Takes 13% Of Medadvisor; Alcidion’s Ray Blight Increases, Diluted To 11%; Dimerix Loses Director David Franklyn
 
Oct 10, 2019
Recce ‘Strongly Supported’ Placement Raises $6.8m; Dimerix Receptor-Hit Discovers Dmx-700 For COPD; Immutep Receives $2.55m French R&D Tax Incentive; Dr Kamala Thriemer, Prof Daniel Thomas Win $1.25m CSL Grants; Cellmid Requests ‘Capital Raising’ Trading Halt; Emvision Pleads Schultz To ASX 13% Query; Medlab, ANC Expand Food Additive Business To US; Bod 67% Directors Fee Hike, 2.75m Directors Options AGM; M&G (Prudential) Diluted To 13% Of Mesoblast 
 
Oct 9, 2019
Vale Dr John Holaday
(1945 – 2019);
Clinuvel Up 63% On FDA Scenesse EPP Approval; Orthocell: ‘Celgro With Microsurgery Repairs Nerve Damage’; Phylogica: ‘CPP Takes Antisense Drug To Human Retina In-Dish’; Zelda, Ilera Marijuana Merger For Zelira; G Medical Tells ASX: ‘Revenue Awaiting Approvals’; Australian Ethical Takes Profit, Reduces To 18.5% In Antisense; CEO Kate Quirke Takes 6% Of Alcidion; Kennedy, Caledonia Increase, Diluted To 8% Of Alcidion; Mackinnon, Isle Of Wight Increase, Diluted To 8% Of Alcidion; Imugene Unmarketable Parcel Facility; Adalta Appoints Dr Tim Oldham CEO; Starts On $300k; Respiri Loses CEO Mario Gattino; Painchek CEO Philip Daffas 11% Pay Rise
 
Oct 8, 2019
Federal $35m For Macquarie Uni Synthetic Biology Research; Recce $4m Capital Raising Trading Halt; Visioneering Revenue Warning To $8.7m; Dimerix Receives $1.2m Federal R&D Tax Incentive; Neurotech Convertible Loans For Up To $600k; Bard1 Assay Validation Milestone; Sienna Clayton Move For Sien-Net Production; Mach7 810k Director Options AGM; Board Changes; Memphasys Pleads Schultz To ASX 23.5% Query; Zelda Requests ‘Material Control Transaction’ Trading Halt; BVF, Mark Lampert Below 5% In Opthea; M&G (Prudential) Takes 12.7% Of Mesoblast; ‘Odd Fellows’ Takes 5.4% Of Rhinomed
 
Oct 7, 2019
Medadvisor Raises $17m; Jeff Sherman Director; Antisense Pleads Schultz, Publicity To ASX 45% Query; Pharmaust Expects $1.5m Federal R&D Tax Incentive; Respiri Wheezo Passes CE Mark Safety; Feb 2020 Sales; Invex: Japan Patent For Elevated Intra-Cranial Pressure; Uscom Share Facility Price Change; Orthocell ‘Celgro Trial Results’ Trading Halt; Empery Takes 9% Of Benitec; Crystal Amber Takes 71% Of GI Dynamics; Telix Appoints Dr David Cade CBO, IR Head; Clinuvel Renews CEO Dr Wolgen; $1.4m Base Salary
 
Oct 4, 2019
Dr Boreham’s Crucible: Actinogen Medical; Genetic Technologies Rights Issue To Raise $4.5m; Suda: ‘Regulator Concern Over Artimist Use, Adherence’; Pharmaust’s Epichem Wins WA Export, Women’s Awards; Kolabtree: ‘Access To 10,000 Science Freelancers’; Imugene Unmarketable Parcels Facility; Resapp Joins Munich Start-Up Creasphere Program; Althea Prescribes 2,329 Marijuana Patients; Stemcell United, Yunnan Hongyi For Orchid Stem Cells; Living Cell Board Spill AGM; Imugene 100m Director Options AGM; Paradigm 100% Director Fee Hike, $1.1m Staff Shares AGM; Immuron CEO Dr Gary Jacob 5m Options AGM; GI Dynamics Exercises $2.9m Crystal Amber Warrants
 
Oct 3, 2019
Mesoblast Raises $75m; Telix Buys Belgian Radiopharmaceutical Production Site; Cynata Ready For Phase II Cymerus Osteoarthritis Trial; FDA Allows Clarity Sartate Neuroblastoma Trial; Federal $8m For Five Collaborative Trials; Federal Regional Queensland Stem Mentoring Launch; Pharmaust Raises $2.4m; Alchemia Raises $5.7m To Become Australian Primary Hemp; Suda Tells ASX: ‘Accounts In Order, Artimist Worth $5m’; Optiscan Receives $227k R&D Tax Incentive; Cardiex: Sphygmocor Xcell Q1 Sales Up 88% To $900k; MGC: 400 Cannepil, MXP100 Prescriptions; Court Approves Pharmacielo, Creso Acquisition Scheme Meeting; Medadvisor Requests Placement Trading Halt; Bard1 Grants CEO Dr Leanne Hinch 15m Incentive Options; Invex 2.2m Director ‘Incentive’ Options AGM; Sabby Takes 9% Of Benitec
 
Oct 2, 2019
Innate Chris Collins Pleads Guilty, Resigns US Congress; Ausbiotech Melbourne Biotech Invest, Conference; Immuron, US Defense $5.5m Collaboration; Medlab: 1st Export Order For Hemp/Marijuana Nanocbd; Heramed Intmed Brazil Heracare, Herabeat Collaboration; Mayne To Pay Mithra Up To $440m For US Contraceptive Deal; Resapp TGA Approval For Resappdx-EU Diagnostic; US FDA Changes Clinuvel PDUFA Date To October 8; Mach7 US Patent For Dynamic Media Management System; Anteo Buys Back 12.7m Unmarketable Shares; G Medical In Suspension: ‘Preparing ASX Query Response’; Ron Dewhurst, Kroy Wen Below 5% In Rhinomed; Federal Government Appoints Stem Cell Advisors
 
Oct 1, 2019
September BDI-40 Up 0.5%, ASX200 Up 1%, Big Caps Down 1.4%, NBI Down 3% - Paradigm Up 80%, Antisense 57%; Pro Medicus Down 25%, Amplia 20%; Actinogen: ‘Xanamem Improves Cognition In Healthy Volunteers’; Mesoblast ‘$75m’ Trading Halt; Benitec To Raise $3.3m, Warrants; Innate Director Chris Collins Insider Trading Charges; Opthea Receives $14.6m Federal R&D Tax Incentive; Paradigm: ‘PPS Inhibits Nerve Growth Factor Pain Mediators’; TGA Refuses Suda Artimist Appeal; Phylogica, Vision Join Lions Eye; Appoints Prof Sue Fletcher; Neuroscientific: ‘Emtin-B Hits Retina, Optic Nerve In Rabbits’; Visioneering Appoints Menicon Naturalvue Europe Distributor; Cellmid Germany, China Évolis Distribution Deals; Cryosite 1.3m Chairman Options AGM; Pharmaust Requests ‘Capital Raising’ Trading Halt; Resapp ‘Regulatory Approval’ Trading Halt; Race Appoints Director Dr Daniel Tillett CSO; Biotron Appoints Phase II HIV Trial Scientific Advisory Board; Patrys Appoints Dr Pamela Klein Director; Correction: Oncosil
 
Sep 30, 2019
Uscom To Raise Up To $1m In Private Placement; Kinoxis: Up To $7m US Grant For KNX100 For Opioid Withdrawal; Kazia: ‘Cantrixil Partial Response In 2 Of 9 Patients’; Resapp: ‘Algorithm Accurate For Obstructive Sleep Apnoea’; Invion Prepares For 2020 Basal Cell Carcinoma Light Trial; Noxopharm: ‘NOX66 Boosts 177Lu-PSMA For Prostate Cancer’; Invitrocue To Open Hong Kong R&D Laboratory; Immutep: 51m Performance Rights, 1-For-10 Consolidation AGM; Mesoblast To Release 14.5m Voluntary Escrow Shares; Phylogica ‘Partnership’ Trading Halt; Avita To List On Nasdaq; Morgan Stanley Below 5% In Avita; Osteopore: Mr Liew, Rain Maker, Mr Seng, Prof Teoh, Prof Yang; Admedus Requests 8th Funding Suspension Extension; Cyclopharm Appoints Sales, Regulatory, Service Staff; Oncosil CFO Nicholas Falzon In, Tom Milicevic, Dr Ash Soman Out
 
Sep 27, 2019
Dr Boreham’s Crucible: Suda Pharmaceuticals; Cellmid Receives $840k R&D Tax Incentive; Oncosil 4.85m CEO Loan Shares AGM; Actinogen Requests ‘Clinical Trial Results’ Trading Halt; Neuroscientific ‘Pre-Clinical Ophthalmology Results’ Halt; Alchemia Completes 1-For-20 Consolidation; Creso Resubmits Pharmacielo Scheme Booklet; Morgan Stanley Takes 7% Of Avita; Dissident Shareholders Take 5% Of Living Cell; Harry Karelis, Gemelli Below 5% In Auscann; Medibio Eliminates 4.65m Invalid Options/Partly Paid Shares; Truscreen Loses CEO Martin Dillon - Replacement Wanted
 
Sep 26, 2019
Brandon $14m For Denteric Porphyromonas Gingivalis Vaccine; Cynata Receives Fujifilm $4.4m Signing Fee; Immutep: ‘Positive Data, IMP321 Tacti-002 NSCLC Trial Go Ahead’; Adalta Invoices GE Healthcare $183k For Imaging; Visioneering Claims 1st Hong Kong Naturalvue Sale; CE Mark For Resapp Version 2 Respiratory Diagnostic; Dimerix Recruits DMX-200 Diabetic Kidney Disease Trial; FDA Approves Starpharma, Astrazeneca AZD0466 Trial; Bionomics Reformulated BNC210 Achieves Blood Levels; Elixinol Appoints Harmonia Life Finland Hemp Distributor; Probiotec Releases 1.95m Escrow Shares; Genetic Technologies EGM 14% Oppose Share Issue; Pac Partners Reduced To 6% Of Althea; Niv Dagan, Freedom Trader, 10 Bolivianos Take 7% Of Lifespot
 
Sep 25, 2019
Probiotec Raises $10.6m; JCR: Mesoblast Temcell For Epidermolysis Bullosa ‘On Hold’; Invitrocue Onco-PDO Validation Study; Victoria Call For Bio Europe Trade Mission; Phylogica CPP Delivers Antisense Drug In Mice Over 4 Weeks; LBT Finalizes Apas Independence CE Mark For MRSA; Invitrocue Directors Prof Yu, Mr Lui Reply To Spill Claims; Anteo, Axxin Work On Anteobind Assay Readers; Karst Peak Reduces To 8% Of Avita
 
Sep 24, 2019
Heramed Applies For Israel-Mayo Grant; Oventus Pleads Schultz To ASX 16% Query; Suda Loses 9-Year CEO Stephen Carter; Genetic Technologies Loses Chair Paul Kasian; Noxopharm Loses 5-Month CEO Dr Greg Van Wyk; Paradice Investments Takes 9% Of Probiotec
 
Sep 23, 2019
Osteopore IPO Up 263% To 72.5c For 3D Bone Replacement; Victoria: ‘$2b Drugs Top Value Manufactured Exports’; Immutep Earns $7m Glaxosmithkline LAG-3 Milestone; Rhinomed Placement Raises $6m; Optiscan: Confocal Microscope For 2nd Oral Cancer Trial; Sienna Receives $405k Federal R&D Tax Incentive; Genetic Technologies, Tgen Risk Tests Agreement; Universal Biosensors Finalizes Siemens Xprecia Deal; IQ3 Tells ASX Aware Query: ‘IT Glitch Stopped Announcement’; Probiotec AGM: CEO Wesley Stringer $4.9m Loan For Options; Acrux Resolution Calls To Appoint Norman Gray Director; ASX Suspends Oventus On Price Query; Merchant Group Reduces To 6.6% Of Rhythm; Jim Craig, Bellwether Reduce To 5.6% Of Bluechiip; Clinuvel Appoints Susan Smith Director; Mark Masterson Replaces Bod Chairman George Livery
 
Sep 20, 2019
Dr Boreham’s Crucible: Pharmaust; GI Dynamics: ‘Endobarrier Reduces HbA1c, Weight, BP’; Japan Patent For Recce Antibiotics; Respiri India Pre-Market Launch Of Wheezo For Asthma; CVC Below 5% In Probiotec; GI Dynamics CEO $663k Base Salary, 58m Options, 55m Shares
 
Sep 19, 2019
Avita: ‘Recell Improves Dermabrasian Acne Scar Healing’; Novita Rights, Shortfall Raise $2m; Rhythm ‘Colostat Differentiates Cancer, Healthy Tissue’; Bionomics Submits BNC210 PTSD US Fast Track Application; OBJ Establishes ‘Wellfully’ Subsidiaries; Living Cell $1.2m From Vertex Buying Semma; Rhinomed Requests Capital Raising Trading Halt; Anthony Eaton Replaces Invitrocue Director Dr Gary Pace
 
Sep 18, 2019
Cynata: ‘Fujifilm Up-To $67m CYP-001 GvHD Licence’; Antisense Up 100% On ATL1102 ‘Positive Drug Effect For DMD’; Eye Co: Hemp Seed Oil For Dry AMD Steroids In Mice; Adalta Receives $3.5m R&D Tax Incentive; Recce Receives $164k R&D Tax Incentive; Invitrocue EGM To Remove Dissident Directors; Cogstate 1m CEO Brad O’Connor Options AGM; Althea Peak Processing EGM; MGC Passes 200 Cannepil, MXP100 Prescriptions; Creso Takes Pharmacielo Trading Halt To Suspension; Peter, Diana Diamond Increase, Diluted To 9% Of Novita; NSW Uni Bio-Engineering Research Showcase Next Tuesday
 
Sep 17, 2019
Benitec: 3 Dog Studies For FDA BB-301 Phase I OPMD Trial; IQ Acquires Tex Core For Solid Tumors From University Of Texas; Antisense Requests ‘ATL1102 DMD Results’ Halt; Alcidion $895k, 3-Year Healthscope Partnership; Avita US Recell Trial For Skin Injuries; Living Cell Tells ASX 32% Fall Query: ‘Newsletter Not News’; ASX Suspends G Medical For Failure To Respond To Query; Novita: Tali Train Supply Agreement With UK’s Edtech Impact; Proteomics Promarkerd: ‘Validated’; Heramed, Mayo Collaboration For Pregnancy Monitor; Japanese Patent For Immutep LAG525 Antibody; US Patent For Dimerix DMX200 Combination Therapy; Pinnacle Reduces Below 5% In Cochlear; Macquarie Below 5% In Impedimed; Jimmy Thomas, Ivy Ponniah Take 6% Of Genetic Technologies; Invitrocue CEO Dr Steven Fang Replies To Spill Claims; Race Appoints Dr Daniel Tillett Director; Somnomed Appoints Matthew Conlon For North America Sales
 
Sep 16, 2019
LBT: APAS Wins CE Mark, Meets Golden Staph Standards; Adalta, GE Healthcare: Deal For I-Body Diagnostic Imaging; Botanix BTX1702 Papulo-Pustular Rosacea Trial; Novita Shortfall Raises $30k; Total $1.86m; Correction: Imagion, Telix; Cynata Requests ‘Fujifilm Option’ Trading Halt; Proteomics ‘Promarkerd Assay Development’ Trading Halt; Creso ‘Pharmacielo Acquisition’ Trading Halt; Creso Canada Marijuana Facility Licence; Alchemia To Be Australian Primary Hemp; Consolidation; Ed Graubart Replaces Polynovo US Sales Head Kevin Whiteley; Jeremy Green, Redmile Reduce To 12.4% Of Avita
 
Sep 13, 2019
Dr Boreham’s Crucible: Imagion Biosystems; Polynovo, FDA Novosorb Meeting For Burns; Proteomics Launches Promarkerd Kidney Test In Spain; Invitrocue Geoffrey Thomas Spill Call; Kifin Takes 7% Of Opthea; Viburnum Takes 19% Of Universal Biosensors; Phylogica Appoints Dr Fred Chen Advisor
 
 
 
 
Sep 9, 2019
Federal $15m For Reproductive Cancer Trials; Universal Biosensors, Siemens Xprecia Coagulation Deal; Pharmaust Starts Monepantel Dog Cancer Trial; Imagion Magsense ‘MRI Contrast Agent Potential’; Invitrocue Board Fight; Respiri Settles 14m Director Options Legal Action; Race Capital Raising EGM; Cardiex ‘Material Contract’ Trading Halt; Althea: Record Marijuana Scripts In August; Jencay Takes Profit To Below 5% In Bluechiip
 
Sep 6, 2019
Dr Boreham’s Crucible: Antisense Therapeutics; Botanix Synthetic Cannabidiol ‘Disrupts Bacterial Pathways’; CSL $12.4m CEO, CSO ‘Performance Rights’ AGM; S&P Promotes Polynovo To ASX200, Avita To ASX300; Pro Medicus Dr Sam Hupert, Anthony Hall Sell 2m Shares; Kinetic Below 5% Of Osprey; G Medical ‘ASX Query’ Trading Halt
 
Federal $32m For Translational Health Research; Novita Shortfall Raises $250k; Total $1.8m; Micro-X Wins $1.8m UK Defence Contract; Hyperion Below 5% In Cochlear; Crystal Amber Increases, Diluted To 68% Of GI Dynamics; WF Asian Below 5% In Simavita; Creso To Release 2.4m Voluntary Escrow Shares; Painchek Appoints Pete Shergill For UK Business Development; Cardiex Appoints Anthony Sloan, Rhonda Welch Executives; Auscann Appoints Dr Marcel Bonn-Miller Director 
 
Sep 4, 2019
Cynata: ‘MSCs Reduce Organ Transplant Rejection In Mice’; US FDA Lifts IDT Warning Letter; Orthocell: 8 Of 9 Rotator Cuff Patients Pain-Free; Immuron: ‘Travelan Binds To 71 Cholera Strains’; Clarity FDA Ind For Copper Sartate Neuroblastoma Trial; Adalta: I-Body Half-Life Can Be Customized; Respiri Launches Wheezo Asthma Diary; Mitsubishi Takes 5% Of Total Brain; BTC: Sharon Papworth CFO, Co Sec; Stuart Jones Corp Dev
 
Sep 3, 2019
Uniquest, Grünenthal Cone Snail Neuropathic Pain Drug; Phylogica: CPP Delivers Antisense Drug In Mice; Emvision Readies For Brain Scanner Stroke Pilot Trial; Starpharma: ‘One More SE Asian Vivagel BV Approval’; MGC 100-Patient Cannepil, MXP100 Marijuana Epilepsy Study; Bod: August Marijuana Pills Up 95% To 329 Scripts; Morgan Stanley Takes 5% Of Total Brain; Regal Funds Takes 10% Of Medibio; FIL Increases, Diluted To 9% Of Medibio
 
Sep 2, 2019
August BDI-40 Up 13%, Big Caps Up 3%, ASX200 Down 3% - Opthea Up 341%, Polynovo 31%; Osprey Down 32%, Clinuvel 21%; Compumedics Record Revenue $41.5m, Profit Up 43.2% To $4m; IQ3 Revenue Down 5% To $6.5m, Loss From $1k To $1m; Pharmaust Revenue Up 32.5% To $4.4m, Loss Down 36% To $1.6m; G Medical H1 Revenue Up 191% To $4.3m, Loss Down 20% To $10m; Cardiex Revenue Down 2.5% To $3.9m, Loss Up 1% To $3m; Immuron Revenue Up 30% To $2.4m, Loss Up 54% To $4.6m; THC H1 Revenue Up 67% To $2.1m, Loss Up 80% To $5.8m; Stemcell Revenue Up 437% To $1.6m, Loss Down 37% To $2.1m; US FDA Clears Oventus O2vent Optima; Antisense, Regulators Meet On ATL1102 For DMD; Amplia Receives 1kg AMP945 For Trial; Memphasys Receives $1.1m Federal R&D Tax Incentive; Neuroscientific Expects $2m Off-Shore R&DTI Over 3 Years; Director Andrew Kroger Takes 38% Of Cryosite; Allan Gray Reduces To 15% Of Impedimed; Medibio: Clarification; Admedus Requests 7th Funding Suspension Extension; Genetic Technologies Appoints Nick Burrow Director
 
Aug 30, 2019
Dr Boreham’s Crucible: Anatara Lifesciences; Mesoblast Revenue Down 3.6% To $25m, Loss Up 155% To $134m; Avita Revenue Up 50% To $17m, Loss Up 110% To $34.6m; Avecho H1 Revenue Up 409% To $4.2m, Loss To $2.3m Profit; Medlab Revenue Up 41% To $6.1m, Loss Up 72% To $8.2m; Allegra Revenue Down 15% To $4m, Loss Up 38% To $836k; Dorsavi Revenue Down 27% To $3.2m, Loss Up 8% To $4m; Adherium Revenue Down 53% To $2.8m, Loss Up 26% To $11.8m; Total Brain Revenue Even At $2.6m, Loss Down 63% To $8.6m; Nuheara Revenue Down 41% To $2.4m, Loss Up 35% To $10.0m; Micro-X Revenue Up 20% To $1.9m, Loss Down 41% To $9.8m; TBG H1 Revenue Up 21% To $1.6m, Loss To $10.5m Profit; Proteomics Revenue Up 25% To $1.5m, Loss Up 44% To $2.1m; Orthocell Revenue Up 26% To $1.2m, Loss Up 2% To $5.9m; Suda Revenue Up 186% To $1.2m, Loss Up 29% To $7.8m; Optiscan Revenue Down 52% To $1m, Loss Up 15% To $2.3m; Novita Shortfall Raises $1m; Total $1.6m; Regeneus Rights Raise $620k, $1.8m Underwritten; Telix Plans TLX250-CDx Japan Kidney Cancer Imaging Trial; CE Mark For Novita Tali Train; Elixinol: Appoints 25th Group Belgium, Luxembourg Distributor; Medibio, Compass 4th Deal For Ilumen Mental Health Study; Chelodina, Marble Bar Take 9% Of Medibio; Alcidion: Rebecca Wilson Chair, Ray Blight Director; Ingrid Player To Replace Cogstate Director Jane McAloon; Mach7 M-D Mike Lampron Starts On $410k A Year
 
Aug 29, 2019
Ellex Revenue Up 3% To $81.6m, Loss Up 14% To $5.8m; Probiotec Revenue Up 19% To $79m, Profit Up 33% To $4m; Palla H1 Revenue Up 20% To $27.4m, Loss Up 44% To $4m; Elixinol H1 Revenue Up 17% To $17.5m; Profit To $9m Loss; Alcidion Revenue Up 304% To $17m, Loss Down 96% To $84k; Benitec Revenue Up 4,175% To $16.2m, Loss To $4m Profit; IDT Revenue Down 9% To $12m, Loss Down 64% To $6m; Medadvisor Revenue Up 25% To $8.2m, Loss Up 83% To $8.2m; Invion Revenue Up 426% To $3.9m, Loss Up 175% To $2.55m; Rhinomed Revenue Up 51.5% To $3.3m, Loss Up 51.5% To $6m; OBJ Revenue Up 35% To $2.7m, Loss Up 1% To $1.7m; LBT Revenue Down 55% To $2.5m, Loss Up 62% To $4.4m; Starpharma: ‘HER-2 Dep-Drug Reduces Ovarian Cancer In Mice’; Janssen Exercises St Vincent’s Alzheimer’s Molecule Option; Paradigm: ‘PPS Reduces Cartilage Degradation 12%’; Alcidion Reports Chair’s Spouse’s Closed Period Share Sale; ASX Removes 3 Biotechs For Failure To Pay Fees; Total Brain, IBM Partner For Veteran Mental Health; THC Opens Gold Coast Marijuana Facility; BVF, Mark Lampert Take Profit To 5.25% Of Opthea; Bank Of America Reduces To 5.3% Of IDT; Richard Cashin Diluted To 12.7% In GI Dynamics; All Change At Medibio’s Board
 
Aug 28, 2019
Cogstate Revenue Down 25% To $32m, Loss Up 341% To $3.7m; Clinuvel Record Revenue Up 22% To $31m, Profit Up 37% To $18m; Cellmid Revenue Up 29% To $7.4m, Loss Up 58% To $6m; Genetic Signatures Revenue Up 71% To $5m, Loss Up 7% To $3.5m; Starpharma Revenue Down 45% To $2.7m, Loss Up 39% To $14.3m; Bioxyne Revenue Up 4% To $2.3m, Loss Up 4% To $1m; Bluechiip Revenue Up 83% To $1m, Loss Up 31% To $3.3m; Cogstate Raises $2.9m From Japan Distributor Eisai; Global Brands Buys Probiotec Celebrity Slim For $7m; Starpharma DEP-Cabazitaxel, DEP-Docetaxel ‘Early Efficacy’; Novita ‘Shortfall, CE Mark Application’ Trading Halt; FDA Guidance For Telix TLX591-CDx Prostate Cancer Imaging; US FDA Upgrades IDT; Australian Marijuana Licence; PBS Reimbursement For Mayne Pharma Kapanol Morphine; Heramed Herabeat, Heracare Hapvida Brazil Roll-Out; Medigard Cancels $615k Sol-Millennium Notes; Converts Loans; Noxopharm: ‘NOX66 Reduces Tumor Size; Pain, PSA Levels’; Regal Funds Takes 13% In Opthea
 
Aug 27, 2019
Nanosonics Revenue Up 39% To $84m, Profit Up 137% To $13.6m; Cann Revenue Up 174% To $4m, Loss Up 131% To $11m; Resonance Revenue Up 25% To $3.6m, Profit Up 466% To $1.3m; Cryosite $1m Legal Settlement; Novita Raises $485k Of Hoped For $2m; FDA Guidance For 2019 Mesoblast Cardiac Trial; BTC Chair Dr Richard Treagus $125k Bonus, $15k Pay Rise; Brian Leedman Exercises 5m Alcidion 8c Options; Cogstate Requests ‘Contract, Placement’ Trading Halt; Vivazome, Toolgen Collaborate On Crispr-Cas9 Research; Cann Lifts Mildura Marijuana Production By 40% To 70t; MGC Approval For Slovenian Medical Marijuana Research; Westmead Hospital 2019 Hospital Week; Bio-Melbourne ‘Formula For Success’ Conference
 
Aug 26, 2019
Admedus H1 Revenue Down 16% To $11m, Loss Up 3% To $12m; Mach7 Revenue Up 8% To $9.3m, Loss Up 43% To $7m; Acrux Revenue Down 64% To $1.2m, Loss Down 41% To $8.3m; Invitrocue Raises $966k; Exopharm Starts ‘Plexoval’ Exosome Wound Healing Trial; CE Mark Renewal For 3 Uscom Spirosonic Devices; Antisense: Acromegaly Europe Access Program On Hold; Nuheara To ASX: ‘NHS Recategorization Not Material’; Recce: 500% Production Increase; Cann Global, Pharmocann Marijuana Food, Cosmetics Deal; Pharmaust Receives Monepantel Dog Trial Tablets; G Medical Drops $25m Nasdaq IPO For OTCQB Listing; Noxopharm Receives $3.7m Federal R&D Tax Incentive; Crystal Amber Fund Takes 75% Of GI Dynamics; Matt Callahan, Stone Ridge, SRV Transfer Below 5% In Orthocell
 
Aug 23, 2019
Dr Boreham’s Crucible: Somnomed; Mayne Revenue Down 1% To $525.2m, Loss Up 111% To $283.8m; SDI Revenue Up 7% To $79.6m, Profit Up 30% To $7.3m; Next Science Revenue Up 222% To $3.5m, Loss Up 10% To $9.7m; Telix H1 Maiden Revenue Of $1.8m, Loss Up 100% To $10.4m; Oventus ‘Oversubscribed’ Rights Raise $2.3m; Total $9.3m; CE Mark For Resapp Smartphone Respiratory Diagnostic; W.H.O. Names Kazia GDC-0084 For Brain Cancer ‘Paxalisib’; MGC, Swinburne Test Marijuana Driving; Paul Cozzi Takes 10% Of Cardiex; Botanix, Orthocell Director Matthew Callahan Takes Leave
 
Aug 22, 2019
ASX Suspends Five Biotechs For Failure To Pay Fees; Pro Medicus Revenue Up 48% To $50m, Profit Up 92% To $19m; Polynovo Revenue Up 128% To $13.7m, Loss Down 47% To $3.2m; Cryosite Revenue Up 35% To $8m, Loss Up 39% To $1.7m; Cyclopharm H1 Revenue Up 2.5% To $6.5m, Loss Up 342% To $3m; PYC (Phylogica) CPP Delivers Antisense Drug In Mice; Mach7 $950k St Teresa’s Hospital Imaging Contract; GI Dynamics $10m Crystal Amber Notes; Adherium $1.8m One Funds, Summatix Convertible Notes; Immutep Granted European IMP321 Patent; Japan Accepts Orthocell Celgro Patent; European Patent Allowed For Cellmid Midkine Antibodies; Universal Biosensors: ‘Siemens Deal In September’; Resapp Requests ‘CE Mark Application’ Trading Halt; G Medical Requests Nasdaq Listing Trading Halt; Zelda: 103 Of 150 Marijuana Autism Trial Patients Recruited; Creso: Pharma Dynamics Africa Cannqix10 Distributor; Credit Suisse Below 5% In Adalta
 
Aug 21, 2019
Somnomed Revenue Up 12% To $59m, Loss Up 91% To $16.4m; Medical Developments Revenue Up 19% To $21m, Profit Up 327% To $1m; Impedimed Revenue Up 25% To $4.2m, Loss Down 12% To $24m; MGC Raises $4.75m, Plan For $1m More, To List On LSE; Cann Global (Qld Bauxite) Raises $5.95m, Return To ASX; Sloan Kettering Approves Optiscan Microscope For Trial; Noxopharm: NOX66 ‘Abscopal’ Response In Mice; Chair Dr Bill Garner Diluted To 17% Of Race
 
Aug 20, 2019
Visioneering H1 Revenue Up 99% To $3.4m, Loss Down 33% To $6.7m; Bionomics Revenue Down 5% To $4.5m, Loss Down 63.5% To $9m; Race Raises $1.45m At 10% Premium; Dr Daniel Tillett Takes 9%; Telix: 1st Australian Patient In Zircon Kidney Cancer Study; Adherium, Summatix Partner For Hailie Inhaler Sensors; Up To 28% Oppose Volpara Option Resolutions; Up To 17% Of Medibio EGM Oppose Share Issue; Creso: 1st Pharmacielo Columbian Marijuana To Switzerland; Jencay Capital Takes 5.5% Of Ellex; Escrow End Reduces Life Biosciences To 31% Of Alterity; Genera Loses Chair Dr Damian Pethica, Co Sec Melanie Leydin; Cardiex: Chris Dax Atcor Head, Doug Kurschinsky G-M 
 
Aug 19, 2019
Uscom Revenue Up 27% To $3.6m; Loss Down 29% To $1.4m; Telix: ‘$9.6m Applications For $5m Share Plan’; Acrux Files ANDA For Generic Emla Local Anaesthetic; Medibio Extends Share Plan To $1.2m; Ellume To Open Expanded Brisbane Offices; MGC Requests ‘Capital Raising’ Trading Halt; BVF, Mark Lampert Reduce To 9.5% Of Opthea; John Gleeson Below 5% Of Uscom
 
Aug 16, 2019
Dr Boreham’s Crucible: Opthea; Cochlear Revenue Up 7% To $1,446m, Profit Up 13% To $277m; Medlab Marijuana Extract Nanabidial ‘Safe, Fast-Acting’; Japan Patent For Neuren’s NNZ-2591 For Brain Disorders; Exopharm Share Plan Raises $1.1m Of Hoped-For $2.8m; Race Requests Capital Raising Trading Halt; Admedus Tells ASX 4C Funds Query: ‘Working On It’; Regal Funds Takes 12% Of Opthea; Cho, Unlimited Innovation Increase, Diluted To 68% Of Invion
 
Aug 15, 2019
Pharmaxis Revenue Down 74% To $13m, Profit To $20m Loss; Starpharma: 1st SE Asian Vivagel BV Approvals; Federal $3m For SDI Dental Amalgam Alternatives; Oventus: 2 More US Sleep Groups Adopt O2vent; Cynata Talks Take-Over, CYP-001 With Sumitomo, Fujifilm; Noxopharm’s Nyrada Hopes For $8m ASX IPO; Kifin Takes 5% Of Opthea; Walker Group Sells 14m BTC Shares To LHC; LHC Capital Takes 11% Of BTC; SG Hiscock Takes 6% Of Bod Australia; Pharmaxis Issues CEO Gary Phillips 927k Options
 
Aug 14, 2019
CSL Record Revenue Up 8% To $12.5b, Profit Up 11% To $2.8b; Osprey H1 Revenue Up 54% To $2.7m, Loss Up 5% To $12.6m; Mesoblast: Investigator Remstemcel-L For Chronic GvHD Trial; Nuheara NDIS Hearing Equipment Provider; Mach7 Wins 3 US Imaging Contracts Worth $500k; Bod: Human Proteins With Marijuana For Ageing; Baker Brothers Takes 11% Of Opthea; Australian Ethical Diluted To 4.99% Of Immutep; Suda Appoints Dr Richard Franklin Anagrelide Director; Vivazome Appoints Dr David Haylock CSO
 
Aug 13, 2019
MDGH: Novo Nordisk Buys Moxidectin River Blindness Voucher; Federal $1m For Emergency Stroke Treatment; Kazia Completes Phase I Part B Cantrixil Recruitment; Race Granted 3rd US Bisantrene Patent; Regeneus Reduces Staff, Pay, Costs By 50%; MGC: ‘100 Cannepil Marijuana Patients’; Tetra Deal 
 
Aug 12, 2019
Heramed Appoints Duttenhofer Germanic Distributor; ASX Suspends Invitrocue; Alchemia To Australian Primary Hemp AGM; Dr Fred Grossman Replaces Mesoblast’s Dr Donna Skerrett; Adalta Loses Founding CEO Samantha Cobb
 
Aug 9, 2019
Dr Boreham’s Crucible: Shareroot; MCRI Starts Paediatric Influenza Study; Botanix Completes $40m Placement; Suda Lodges TGA Marketing Knockback Appeal; Malta Approves MGC Marijuana Facility; Creso: Medleaf NZ ‘Targets Not Material’; Gayle Mcgarry, Caperi Reduce, Diluted To 7% Of Botanix; Callahan, Horgan, Shenasaby Diluted To 7% On Botanix; Phylogica ‘Re-Brands’ As PYC Therapeutics
 
Aug 8, 2019
Telix TLX591-CDx Tests Enzalutamide For Prostate Cancer; Nuheara Sells Peru Mining Interests For $369k; Invitrocue, Singapore Hospital Work On Onco-PDO; Bioscience Managers $5.5m For CSIRO, Pharmamark Intencap; Phylogica ASX 63% Query: ‘Results Published Next Morning’; Immuron: IMM-124E Fails Alcoholic Hepatitis Study; Singapore Approves Polynovo Novosorb Wound Treatment; Starpharma Begins Dep-Irinotecan Solid Tumor Trial; Recce European Antibiotic Patent; Admedus Loses Arcomed Distribution; Total Brain, Everyday Health Partner; Elixinol $27m Pet Releaf Marijuana Extract Deal 
 
Aug 7, 2019
Opthea Jumps 160% On OPT-302 Wet AMD Result; CSL To Move 3km To Haymarket; Victoria Government; Genetic Technologies Ends Blockshine J-V; Back On ASX; Correction: Cellmid; Novita Rights Offer For $2m; Paradigm Files Zilosul FDA IND, Expanded Access For OA; Althea Prescribes 1,523 Medical Marijuana Patients; Summit Medical Transfers BTC Distribution To Avanos; MGC Completes China Marijuana Food Additive Market Test; Total Brain, CNA Insurance Work On Mental Health; Zhang Lishan, Star Bright Took 23% Of Admedus Last Year
 
Aug 6, 2019
Immutep Rights Offer Raises $6m, Total $10m; Bod Director, Management Options Raise $1.2m; Suda: ‘Zolpimist Spray Beats Tablets For Insomnia’; Painchek: Singapore Approval; Allium Aged Care Licence; Phylogica: ‘Peptide Effective In Retina Tissue In-Vitro’; Imagion Files US FDA Pre-Submission; Cellmid: India’s K2B South Korea Évolis Distributor; Creso Appoints Medleaf NZ Marijuana Distributor; Volpara AGM: 900k Director Options; Bod CEO Joanne Patterson Increases, Diluted To 7.8%; Naos Takes 19.65% Of BTC; BTC Appoints Peter Mears Advisor
 
Aug 5, 2019
Telix, DKFZ Work On Fluoro Dye For Prostate Surgery; Anatara To Licence Detach Piglet Diarrhoea Treatment; Medlab To Expand US Food Additives; Reva Receives Further $1.8m Loan; Opthea Requests Phase IIb OPT-302 Results Trading Halt; Allan Gray Increases, Diluted To 16% Of Impedimed; Alterity (Prana) Releases 18.6m Escrow Shares, 10m Options; Admedus Requests 6th Funding Suspension Extension; BTC Appoints Bruce Hewett Director
 
Aug 2, 2019
Dr Boreham’s Crucible: Regeneus; Proteolytics: $6m For Opal-A, Pl-001 For Wound Therapy; Immutep Underwritten Rights Raise $6m; Total $10m; S&P Dow Jones Promotes Pro Medicus To ASX200; ASX Suspends Genetic Technologies On Chapter 10 Breach; Federal Government ‘Boosts Marijuana Industry’; Cann Global Appoints Austin, Cohen, Easterling Directors
 
Aug 1, 2019
July BDI-40 Up 6%, Big Caps Up 7%, ASX200 Up 3%, NBI Down 3% - CSL Breaks $100b, Pro Medicus Through $3b; Botanix Placement To Raise $40m; Regeneus Raises $2.3m, Rights Issue For $3.2m More; Polynovo Expects Revenue Of $9.4m; Admedus H1 Receipts $10m, Less Than 2 Quarters Cash; Telix: ‘TLX591-CDx Beats Axumin For Prostate Cancer’; Telix, Merck KGaA Combine Unnamed Molecules, Radiation; Probiotec Completes Abs Acquisition; Medadvisor Secures 1st UK Pharmacy Customer; Althea Launches Medical Marijuana In The UK; Creso: 1st Burleigh Heads Cannqix 50 Marijuana Order; Adalta Appoints Dr Rosalind Wilson Director; Botanix Appoints Richard Peterson CFO, Howie McKibbon, CCO; Ausbiotech, J&J Innovation Excellence Awards Open
 
Jul 31, 2019
Amplia Rights Raise $689k Of Hoped For $2.2m; Total $1.2m; Neuroscientific: Emtin-B ‘Statistically Significant’ In Rats; Clinuvel Receipts Up 36% To $32m; Mesoblast Milestones Take Receipts Up 203% To $45m; Avita Receipts Up 73% To $17m; Bionomics Receipts Up 22% To $9m; IQ3 Receipts Down 16% To $6m; Impedimed Receipts Down 3% To $4.5m; Pharmaust Receipts Up 27% To $3.8m; G Medical H1 Receipts Up 312% To $3.7m; Rhinomed Receipts Up 77% To $3.1m; Nuheara Receipts Down 42% To $2.35m; Micro-X Receipts Up 77% To $2.3m; Bioxyne Receipts Down 5% To $1.75m; Telix Posts $1.6m H1 Maiden Receipts; Suda 1st $1m Receipts, Without Westcoast; Invitrocue Less Than 2 Quarters Cash; Capital Raising; Regeneus Has Less Than Two Quarters Cash; Expects Funding; GI Dynamics: Surgical Specialists Of Louisiana Joins US Trial; Platinum Reduces To 7.6% Of Antisense; Tribeca Below 5% Of Cann; Investors Mutual Takes 9.7% Of Mayne Pharma; Memphasys Appoints Shane Hartwig Director
 
Jul 30, 2019
European Patent For Opthea OPT-302; Medibio, Compass Partner For Mental Health Trial; MGC: ‘Additional Information Cannabinoids And Brain Cancer’; Biotech Daily Appendix 4C Reports Policy; Elixinol Receipts Up 18% To $16.4m; Volpara Q1 Receipts Up 137% To $2.2m; Medadvisor Receipts Up 24% To $8m, 2 Quarters Cash, Just; Medlab Receipts Up 24% To $5.8m; Proteomics Receipts Up 111% To $1.7m, Almost 2 Quarters Cash; Cann Receipts Up 140% To $1.5m; Respiri Has 2 Quarters Cash, With $3.4m Placement; Recce Has Cash With Expected Capital Raising; Stemcell Has Two Quarters Cash; Imagion Has Less Than 2 Quarters Cash; ‘Will Raise Capital’; Botanix Requests Capital Raising Trading Halt; Neuroscientific Requests ‘R&D Program’ Trading Halt; Regeneus Requests Capital Raising Trading Halt; Hyperion Takes 5% Of Cochlear; Genetic Technologies To Appeal Nasdaq Notice; Clarity Appoints Ex-Viralytics Robert Vickery CFO
 
Jul 29, 2019
Applications Open For $250k Gilead 2020 Fellowships; Zucero Adds Bowel Cancer To Pixatimod, Opdivo Combo Trial; Alterity: ‘PBT434 Safe, Tolerated In Elderly Volunteers’; Neuren Files 3 NNZ-2591 FDA Orphan Applications; TGA Approves Proteomics Promarkerd; Indonesia Patent; Dorsavi Receipts Down 13% To $3.7m; Resonance Receipts Up 33% To $3.5m; Maiden Cash-Flow Positive; Medibio, Wellteq Partner For Employers, Insurers; Elixinol, Pharmacare Partner For Cannabidiol Capsules; Bod Appoints PCCA UK, Ireland Marijuana Distributor; Respiri Takes Capital Raising Halt To Suspension; Kinetic Increases, Diluted Below 5% In Impedimed; Macquarie Takes 5% Of Impedimed; Leon Serry, City Castle Below 5% In Adalta; Anteo CEO Derek Thompson Starts On $280k
 
Jul 26, 2019
Dr Boreham’s Crucible: Imugene; Resmed Revenue Up 11% To $3.8b, Profit Up 4% To $758m; Cellmid Receipts Up 19% To $6.4m; 6 Months Cash; Profit 2019-’20; Next Science Receipts $2.8m; Oncosil Pleads Schultz To ASX 31% Query; Oventus $7m Placement, $2.3m 1-For-20 Rights Issue; Proteomics $418k Linear Contract; Cann Wins Marijuana Manufacture Licences; Federal Court Grants Micro-X 2 Days For Cleansing Notices; Neuroscientific Releases 1.16m Shares From ASX Escrow; Kemper Shaw Reduces To 10% In Imagion; William Taylor Nominees Reduce To 7% In Imagion
 
Jul 25, 2019
Orthocell: ‘Celgro Repairs Rat Nerves Better Than Sutures’; Mesoblast: ‘Article Supports MPCs For Heart Failure’; Race Treats 1st Bisantrene AML Patient; Pharmaxis Revenue Up 29% To $12m; Genetic Signatures Receipts Up 49% To $4.8m; Redhill H1 Revenue Down 31% To $4.7m; Universal Bio H1 Revenue Down 71% To $4m; Creso: 1 Quarter Cash, Awaiting $122m Pharmacielo Sale; Imagion Receives $2m R&D Tax Incentive; Althea Raising $30m For Canada’s Peak Marijuana Processing; Bod: 220 Medical Marijuana Scripts In 2 Months; Airxpanders Files Liquidation With US Sec; Micro-X Requests Cleansing Notice Trading Halt; Respiri Requests Capital Raising Trading Halt; Benitec Below Nasdaq $US1 Bid Rule
 
Jul 24, 2019
Living Cell NTCell ‘Parkinson’s Benefit, Sans Other Drugs’; Exopharm Placement Raises $4.4m; Share Plan For $2.8m; US Patent For Painchek Facial Recognition Pain Assessment; Visioneering Myopia Contact Lenses Hong Kong Registration; Cynata Tells ASX: $204m Offer ‘Incomplete, Confidential’; Antisense Treats 5 Of 9 Duchenne ATL1102 Patients; Compumedics Pleads Schultz To ASX 9% Query; Althea Takes ‘Acquisition, Capital Raising’ Halt To Suspension; MGC Claims: ‘Cannabinoids Kill Glioblastoma’ - In Vitro; Australian Ethical Takes 10.5% Of Somnomed; FIL Diluted To 14% Of Medibio; Oventus Requests Capital Raising Trading Halt
 
Jul 23, 2019
Amplia: ‘AMP945 Reduces Tumor Sizes And FAK In Mice’; Phylogica: ‘Peptides Deliver 4 Times Antisense Drug In Mice’; Regeneus: ‘Progenza Reverses Allodynia In Rats’; ASX Queries Benitec Xmas Eve BB-401 Trial News; Palla (TPI) $36m Unnamed European Codeine Deal; Somnomed Receipts Up 8% To $65m; Cogstate Receipts Down 7% To $40m; Expanded Alcidion Receipts Up 416% To $21.5m; Mach7 Receipts Up 8% To $10m; Uscom Receipts Up 21.5% To $2.5m; Thomas Jefferson Joins GI Dynamics Endobarrier Trial; Pharmaust Pleads Schultz, Dog News To ASX 26% Query; Tribeca Takes 5% Of Cann; Hybrid Holdings Takes 7.5% Of Pharmaust; New H2 Takes 18% Of Bod, Tribeca 8%, SG Hiscock Below 5%; Sienna To Release 27m Escrow Shares; Medibio Capital Raising, 21.6m Management Options EGM; Simavita Appoints Alan Fisher Director, Michael Spooner Exec; New Elixinol Jobs For Ettenson, Smith, Harrison, Atcha; Bod Appoints Akash Bedi, Patrice Malard H&H Directors
 
Jul 22, 2019
Kazia, Sloan Kettering GDC-0084, Radiation For Brain Metastases; Patrys: ‘PAT-DX1, Radiation Reduces Tumors, No Tox, In Mice’; Corrections: Pharmaxis; Telix: Denmark For Europe TLX591-CDx Reference; Exopharm: Exosome Wound Trial, ‘Capital Raising’ Halt; Bionomics Further $1.3m Federal R&D Tax Incentive; Total $7.9m; Shareroot Shortfall, Placement Raise $780k; Total $1.3m; Regeneus: ‘Progenza For OA Pain Focus, Drop Animal Health’; Euro Patent For Suda’s Anagrelide; Althea Requests ‘Acquisition, Capital Raising’ Trading Halt; Elixinol Buys Microencapsulation IP For Hemp Products; Total Brain Joins American Heart Study; Invion COO Craig Newton To CEO, Dr Greg Collier Director; Anteo Loses CEO Harley Frankfurt, Christopher Parker Back; Simon Glover Replaces Medadvisor CFO Carlo Campiciano
 
Jul 19, 2019
Dr Boreham’s Crucible: Pharmaxis; Cynata Tells ASX: ‘Sumitomo Dainippon Offered $204m’; Impedimed Underwritten Rights Raise $14m; Noxopharm Takes Lind, CST $26m Equity-Draw-Down Facility; Resonance $1m Unnamed US Company Trial Contract; Medibio, Compass 2nd Deal For Ilumen Mental Health Study; FDA Tells Medical Developments: One More Animal Study; Telix Readies For Japan TLX250-CDx Kidney Cancer Trial; Zelda To Acquire Emerald Clinics Marijuana Data; Hong Kong’s Health & Happiness Takes 18% Of Bod; 2 Directors; Impedimed Pleads Schultz To ASX 27% Query; Simavita Lodges H1 Report, Reinstated To ASX; Australian Ethical Takes 5% Of Immutep; Avecho Loses Joint Co-Sec Michael Sapountzis; Maria Maieli Replaces Ellex 3-Month CEO Ged Wallace
 
Jul 18, 2019
Sienna: Building An In-Vitro Diagnostic Portfolio; Telix Receives $9.3m R&D Tax Incentive; Federal $21m For 13 Dementia Projects; Suda Appeals TGA Easter Artimist Regulatory Refusal; Imagion Up 155% On Magsense FDA Breakthrough Designation; Neurotech Pleads Schultz To ASX 32% Query; Visioneering H1 Receipts Up 103% To $3.5m, Two Quarters Cash; Anteo Unmarketable Parcel Facility; Shareroot Requests Shortfall Placement Trading Halt
 
Jul 17, 2019
Imugene - Prof Yuman Fong: ‘Industrial Process To Invent CF33’; Telix Placement Raises $40m; Share Plan For $5m More; Airxpanders Goes Under; Immuron To Raise $1.9m; Trading Halt; Shareroot Rights Raise $510k, $445k Shortfall; FDA Approves Livac Organ Retraction System; US, European Patents For Uscom 1A, BP+ Combo; Patrys European Patent For Doexymab 3E10; Memphasys Pleads Schultz To ASX 21% Query; Cynata Requests ASX Query Trading Halt; Bod Requests ‘Material Strategic Partnership’ Trading Halt; Elixinol’s Nunyara Wins Marijuana Manufacture Licence; Correction: Nuheara, Farjoy; Pinacle’s Hyperion Below 5% In Cochlear; CSL Appoints Anjana Narain Seqirus Head; Nanosonics Appoints Geoff Wilson Director
 
Jul 16, 2019
Biocurate, Servier To Accelerate Drug Discovery; Clarification: Victoria Government, Johnson & Johnson Innovation; Starpharma Receipts Up 1% To $2.8m, $51m Cash; Immuron Revenue Up 29% To $2.6m, 1st US $1m Travelan Sales; Universal Biosensors Siemens Strips Up 156% To $2.3m, $51m Cash; FDA Approves Airxpanders Aerofoam; Director Zeta Peach Resigns; Adalta Starts AD-214 For IPF Toxicology Study; Alcidion To Supply Script System For Dartford, Gravesham NHS; Oventus ‘Lab-In Lab’ Agreements With 3 US Companies; Stemcell United, Malaya Uni Research Agreement; Neuren Receives Final Payment From Lanstead; Total $12m; Nuheara’s Tim Robertson, Farjoy Increase, Diluted To 10%; M&G In And Out Of Medical Developments; Deutsche Bank Below 5% In Genetic Signatures; Bard1 Director Dr Irmgard Irminger-Finger Increases, Diluted To 8%; CEO Miriam Halperin Increases, Diluted To 8.5% Of Creso; Chair Boaz Wachtel Increases, Diluted To 5.5% Of Creso; Elixinol: Stratos Karousos CEO On $338k, Paul Benhaim CIO; Noxopharm: Dr Niechoda Director, Nyrada Board Changes
 
Jul 15, 2019
Victoria’s Innovation Minister Martin Pakula Talks Biotech; Telix: FDA Guidance For Zircon TLX250-CDx Kidney Cancer Trial; Telix ‘Capital Raising’ Trading Halt; Imugene Buys City Of Hope, Vaxinia CF33 Oncolytic Virus; Osprey: H1 Customer Receipts Up 67% To $1.8m; Rhinomed: ‘Pronto Vapor Dilators Win CE Mark’; Oventus: 1st ‘Material Contract’ With Unnamed US Group; Pharmaust Ethics Approval For Dog Cancer Trial; Botanix: ‘AB2367 Kills Clostridium Difficile In-Vitro’; Micro-X To Build Its Carbon Nanotube X-Ray Tubes; Adherium Wins FDA 510(K) Clearance For Hailie Sensors; Cogstate Chair Martyn Myer, Family Increase, Diluted To 15%; William Garner Takes 18.8% Of Race; Race CEO Peter Molloy Diluted Below 5%
 
Jul 12, 2019
Dr Boreham’s Crucible: Nuheara; Osprey Welcomes US Kidney Initiative; Nuheara ‘Kiosks’ In 10 Best Buy Canada Shops; M&G Prudential Takes 11.7% Of Mesoblast; Mason Stevens Takes 6% Of Patrys; Pura Vida Reduces To 10% Of Factor; Freshero, Canadian Nickel Cease Factor Substantial; Genetic Technol: CFO, Co Sec Viney Out; Hains, Stedwell In
 
Jul 11, 2019
Prescient Starts Phase Ib PTX-100 Multiple Cancers Trial; Dimerix Europe, Canada Patents; President Donald Trump; GI Dynamics: ‘Brigham And Women’s Lead Endobarrier Site’; MGC Revenue Up 569% To $1.7m; Two Quarters Cash; Rhinomed: ‘Mute Fastest Growing US Nasal Strip’; Zelda Pleads Schultz To 46% ASX Query; Micro-X Expands Adelaide Production Facility; Shareroot: ‘Opyl Platform Signs 1st Customers’; FIL Increases, Diluted To 8% Of Cogstate; Nebula Neuro, Howitt Diluted To 6% Of Cogstate; Jamber, Amber Schwartz Take 5% Of Creso; Genera Appoints CMO Dr Damian Pethica Chairman
 
Jul 10, 2019
Airxpanders: ‘TGA Lymphoma Fear May Suspend Aeroform’; Bard1 Rights Raise $2.5m; Total $7.5m; Medibio To Raise $4m In Placement, Share Plan; Cardiex: US Expands Blood Pressure Guidelines; Benefit; Dimerix Completes DMX-200 FSGS Recruitment; Total Brain, 3 Unnamed US Companies Partner For Monitoring; Factor Board Spill Group Withdraws Spill Request; Neuroscientific Releases 1.16m ASX Escrow Shares; Australian Ethical Takes 16% Of Cogstate; Dagmar Dolby Increased, Diluted To 15% Of Cogstate; Tom Granger, Anacacia, Wattle Below 5% In Cogstate; Regal Funds Takes 15% Of Visioneering; Willoughby, Hishenk, Abolakian Take 17.5% Of Kazia; Macquarie Below 5% In Patrys; Mason Stevens
 
Jul 9, 2019
Immutep Placement, 1-For-11.8 Rights To Raise $10m; Uscom: ‘Record Uscom1A, BP+, Spirosonic Sales’; Invex $12m IPO For Exenatide For Raised Intracranial Pressure; Mach7 Software Deal With Advocate Aurora Health; Memphasys $4.2m Placement For Felix Device Manufacture; Airxpanders: Q2 Revenue Up 14% To $2.6m; THC Wins Southport Marijuana Facility Licence; Medibio Takes ‘Capital Raising’ Trading Halt To Suspension; Unisuper Below 5% In Impedimed; Mason Stevens ‘Below 5% In Patrys’; Recce: Dr Prendergast Chair; Dr Melrose, Dr Ward Directors; Genetic Technologies Loses Director Sam Lee
 
Jul 8, 2019
Volpara Adds Screenpoint Transpara For Breast Screening; Imugene: ‘HER-Vaxx 80% Tumor Reduction’; Ellex: 4-Year Lead Trial Data Shows ‘2RT Slows AMD’; Cogstate Raises $4m From Australian Ethical; Cellmid Tells ASX 29% Query: ‘No Confidentiality Breach’; Somnomed: 500,000 Patients Treated With Somnodent; Anteo, Unnamed Brand Work On Battery Density; UBS Takes 5% Of Adalta; Crystal Amber Takes 65% Of GI Dynamics; Emvision Releases 300k Escrow Options
 
Jul 5, 2019
Dr Boreham’s Crucible: Orthocell; Nuheara Tells ASX: Samsung’s Harman Bid $82.5m; Nuheara Raises $4m; Shareroot Divests ‘Non-Core’ Ludomade; Cogstate Requests ‘Placement’ Trading Halt; Immutep Requests ‘Capital Raising’ Trading Halt; Memphasys Requests ‘Capital Raising’ Trading Halt; Macquarie Group Below 5% In Impedimed; Yuuwa Capital Diluted To 33% Of Adalta 
 
Jul 4, 2019
Medlab Q4 Revenue Up 135% To $3m; Cellmid Expects Q4 Record Revenue Of $2.45m; Elixinol Appoints Medvec German Distributor; Medibio Requests ‘Capital Raising’ Trading Halt; THC Requests Marijuana ‘Manufacture Licence’ Halt; Australian Ethical Below 5% Of Mach7; Platinum Increases, Diluted To 8.5% Of Adalta; Hishenk Takes 17% Of Kazia; Jimmy Thomas, Ivy Ponniah Take 5% Of Genetic Technologies; Jimmy Thomas, Ivy Ponniah Take 5% Of Stemcell United
 
Jul 3, 2019
Neuroscientific: ‘Emtin-B Grows Nerves, Synapses In Rats’; Sirtex CEO Gilman Wong Pleads ‘Guilty’ To Insider Trading; Unnamed Company Withdraws $83m Nuheara Bid Intent; Nuheara Requests Capital Raising Trading Halt; Uniquest Appoints Ex-WEHI Dr Julian Clark Director; Telix Appoints Grupo RPH For TLX591-CDx In Latin America; Creso Repays $5.15m Convertible Note Debt For Acquisition; BTC Director Peter Jones, Helen Jones Increase, Diluted To 7%; Emvision: Ruth Cremin Head Of Quality, Regulatory Affairs; Stemcell Appoints Theng Dar Teng Advisor
 
Jul 2, 2019
Painchek, MCRI Partner For Infant Study; Nuheara Iqbuds, Iqstream TV On Federal Hearing Program; Zelda Starts Marijuana Opioid Reduction Trial; Telix Signs PI Medical Netherlands TLX591-CDx Distributor; Correction: Probiotec; Micro-X, Thales Complete $10m Note Agreement; Pharmaust’s Epichem Repays $750k Federal Loan For Lab; Creso’s Mernova Sells 1st Marijuana Flower Harvest; E-Sense 300-Litre Vaporspec Marijuana E-Juice Order; CEO Paul Rennie Increases, Diluted To 12% Of Paradigm; Unisuper Reduces To 5.5% In Impedimed; Sigma Takes 10% Of BTC; Walker Group Diluted To 5.6% Of BTC; W Whitney George, Sprott Take 25% Of Rhinomed; Genera Loses 9-Year Chairman Lou Panaccio; Stemcell Loses Director Glenn Davies
 
Jul 1, 2019
13-Year BDI-40 Up 339%, Big Caps Up 681%, ASX200 Up 30%; 12-Month BDI-40 Up 40%, Big Caps Up 13%, ASX200 Up 7%, NBI Down 1%; 12-Month Stars: Avita 792%, Genetic Signatures 268%, Paradigm 236%; Probiotec $28m For Australian Blister Sealing; Profit Up; Avita: ‘Recell Reduces Diabetic Foot Ulcers 83%’; Volpara Retail Rights Raise $4.8m; Total $55m; Visioneering Rights Raise $5.8m, Total $11.1m; Emvision Prepares Stroke Brain Scanner Pilot Trial; Biointelect, Boston’s New Perspectives Partner For Support; US Patent For Sienna hTERT Cancer Test; Resapp Recruits 200 Of 250 Sleep Study Patients; Heramed Foetal Cardiac Monitor At Brazil’s Hapvida Hospitals; Auscann, Tasmanian Alkaloids Marijuana Resin Deal; Medibio Signs Compass For 1st UK Ilumen Test; Crystal Amber Extends Gi Dynamics Convertible Note Date; Admedus Requests 5th Funding Suspension Extension; Regal Reduces To 6.6% Of Oncosil; Director Dr William Garner Reduces To 14% In Race
 
Jun 28, 2019
Dr Boreham’s Crucible: Patrys; Victoria To Appoint Israel Liaison Officer; Rhinomed To Support Monash Uni Sleep-Suicide Study; Anatara Plans Australia Detach For Pig Diarrhoea Sales; Lifespot Requests ‘Product Development, Distribution’ Halt; Blackcrane Takes 9% Of Avita; Dr Errol De Souza Continues As Bionomics Interim Chairman
 
Jun 27, 2019
Impedimed Underwritten Rights To Raise $14m; Novita, Victoria Partner For Tali Attention Deficit Test; Starpharma Betadine Bacterial Vaginosis Europe Launch; LBT Receives Second $1.5m Of $4m SA Government Loan; Cryosite Write-Off; Mark Byrne COO, Bryan Dulhunty Exec; Phylogica ‘CPP Delivers More Drug To Mouse Retinas’; Imagion Loses Director Dr John Hazle, Continues As Advisor; Cardiex Appoints Chris Dax, Dr Sean Merritt Executives
 
Jun 26, 2019
Bionomics BMC210 Fails Agitation Trial; Suda ‘Oversubscribed Rights’ Raise $3.9m; Alcidion Renews $970k Western Sussex Patientrack Contract; Dimerix Opens WA Recruitment For DMX-200 Trials; Rhythm Adds Alfred Hospital To Colostat Trial; Bank Of America Sells, Transfers Shares, Takes 5% Of IDT; Jencay Capital Takes 12% Of Universal Biosensors; Macquarie Takes 5% Of Impedimed, Yet Again; Airxpanders 3rd ‘Debt Agreement’ Suspension Extension; Salesh Balak Replaces Universal Biosensors Rick Legleiter
 
Jun 25, 2019
Immutep Completes IMP321 Aipac Cancer Trial Enrolment; Althea Project Twenty21 For 20k UK Marijuana Patients; Anteo Works With Silicio Ferrosolar For Lithium Batteries; Factor Faces 2nd Board Spill Call; Impedimed Requests ‘Capital Raising’ Trading Halt; Unisuper Takes 7% Of Impedimed; Simon Chamberlain Replaces Alcidion’s Geoffrey Rohrsheim
 
Jun 24, 2019
FDA Orphan Status For Mesoblast’s Revascor; LBT Apas Independence ‘100% Accurate For UTIs In 13 Seconds’; Oventus Signs 2 Canadian Sleep Groups For $1m O2vent; Dimerix Licences Receptor-Hit To Excellerate Bioscience; Shareroot Rights Issue For $1m; 501-Implant Study Backs Admedus Cardiocel; Micro-X, Allora Settle $1.8m Invoice Dispute; Bionomics Requests ‘Trial Results’ Trading Halt; Credit Suisse Takes 5% Of Adalta; Dr John Lambert Replaces Amplia CEO Simon Wilkinson
 
Jun 21, 2019
Dr Boreham’s Crucible: Next Science; CSL Takes Over China Albumin Import; Nuheara: Puretone To Manage 3-Year Scotland NHS Contract; Australia Grants Immutep IMP321 Patent; Althea 1st UK Patient; Frankston Marijuana Plant Permit; Alchemia Quits Biotech To Be Australian Primary Hemp; Bod, Burleigh Heads Medicabilis (ECS315) Marijuana Deal; Morgan Stanley Below 5% In Total Brain
 
Jun 20, 2019
Pharmaxis: ‘FDA Wants Small Clinician Bronchitol Study’; Nuheara Iqbuds Boost On NHS Scotland Hearables Contract; Ashland $3.6m Avecho (Phosphagenics) Vital ET, TPM Licence; Medibio: ‘Heart Algorithm 80% Accurate For Depression’; TGA Registers Oventus Exvent For Sleep Apnoea; Botanix: ‘BTX1801 Kills Super Bugs In-Vitro, Mice’; Jeffrey Emmanuel Takes 8.5% Of Bard1; Merchant Funds Takes 7.7% Of Bard1; David Williams, Moggs Creek, Take 5.5% Of Bard1; Kinetic Takes 5.6% Of Osprey; Kinetic Takes 5.6% Of Impedimed; Immuron Vice-Chairman Peter Anastasiou Takes 11%; Mach7 David Chambers, Damien Lim Swap Chairs, Mike Lampron MD
 
Jun 19, 2019
Federal Frontiers $9.5m For 10 Projects; Painchek Placement Raises $4.15m; Orthocell: ‘Celgro Halves Dental Implant Time’; Botanix BTX1308 ‘Anti-Inflammatory, Immune Response’; OBJ Joins Little Green Pharma For Magnetic Marijuana; MGC Appoints Onix Brazil Marijuana Product Distributor; Next Science Pleads Schultz, Publicity To ASX 46% Query; Heramed Launches Herabeat Foetal Heart Monitor; Airxpanders Pays Oxford Finance $727k For Debt Breach; Invictus: FDA ‘Broadly Supports’ Fatty Liver, Cancer Plans
 
Jun 18, 2019
Editorial: BNYM & Substantial Shareholder Notices; Medlab 2,000 Patient Nanabis ‘Observational’ Study; Bard1 Places $5m, Rights Issue For $2.5m More; Rhythm Signs Monash For Colostat Trial; Cardiex ‘Material Contract’ Halt, Suspension ‘Not Material’; GI Dynamics: Withdraws AGM Delisting Proposal; Bank Of NY-Mellon Reduces To 58% Of Genetic Technologies; Botanix Requests ‘Psoriasis Phase Ib Results’ Trading Halt; Botanix 17m Directors Options, Termination Benefits EGM; Max Johnston, Philip Powel Replace Bard1 Brett Montgomery; GI Dynamics Appoints Prof Steven Opal Advisor
 
Jun 17, 2019
FDA Approves Cochlear Nucleus Profile Plus; Anteo, Lumos Collaborate On Assay Development; TPI, Tasmanian Alkaloids End Poppy Dispute; Medibio, Partnerships For Health Intelligence J-V Writ; Painchek Requests ‘Capital Raising’ Trading Halt; Cardiex Takes ‘Customer Contract’ Halt To Suspension; Thorney Technologies, Tiga Take 11% Of Visioneering; Regal Funds Reduce, Diluted To 9% Of Visioneering; Credit Suisse Below 5% In Prescient; Bank Of New York Mellon Clients Take 21% Of Immuron; Alcidion Releases 160m Escrow Shares
 
Jun 14, 2019
Dr Boreham’s Crucible: Heramed; Burnet, Oxford Find Antibodies To Stop Malaria; Clinuvel: ‘Upgraded To ASX200’; Zoetis Terminates Anatara Detach Licence; Adalta Rights Raise Hoped-For $2m; Optiscan Raises $1.7m; Volpara Completes $21m MRS Acquisition; Bard1 Requests ‘Equity Raising’ Trading Halt; GI Dynamics: ‘Endobarrier Reduces Sleep Apnoea’; Althea Prescribes 1,000 Medical Marijuana Patients; Harbour Takes 6% Of Volpara; Ausbil Below 5% In Bionomics; TPI Changes Name To Palla Pharma; ASX Code To ‘PAL’
 
Jun 13, 2019
Academy Awards Clunies Ross Gongs; Telix Appoints Eczacibasi-Monrol Distributor; Osprey, Premier Quest Kidney Injury Data; Immutep Recruits 1st IMP321 Tacti-002 Cohort Patients; Oventus O2Vent Splint With Valves ‘Reduces Sleep Apnoea’; GI Dynamics Contracts First US Pivotal Trial Sites; THC Wins Marijuana Manufacture Licence; Cardiex Requests ‘Material Customer Contract’ Trading Halt; Phillip, Bioscience Managers Below 5% In Avita; Kinetic Ceases In Osprey; Kinetic Ceases In Impedimed; Crystal Amber Takes 49% Of GI Dynamics; Bank Of New York-Mellon Clients Reduce To 19% Of Immuron; BNY-Mellon Clients Reduce To 59% Of Genetic Technologies
 
Jun 12, 2019
Bod 300-Patient Pay-For Marijuana PTSD Observational Study; BTC Share Plan Raises $1.2m, Total $9.2m; Amplia Placements, Rights For $2.73m; US Patent For Starpharma, Astrazeneca DEP-Bcl2/Xl Inhibitors; Immuron: ‘Travelan Reduces Dysentery Inflammation In Monkeys’; Resapp Receives $1.8m R&D Tax Incentive; Telix, Osaka Uni Extend TLX101 For Cancer Collaboration; Avita: 3 Vitiligo, Acne Posters At Dermatology Meeting; Optiscan Requests Capital Raising Trading Halt; THC Requests ‘Manufacture Licence’ Trading Halt; Credit Suisse Reduces To 6% Of Prescient; Karst Peak, Adam Leitzes Reduce To 9.5% Of Avita; Paul Cozzi Takes 8% Of Visioneering; Paul Benhaim, Raw With Life; D&G Health Diluted In Elixinol; Canopy Growth Takes 13% Of Auscann; Eye Co Appoints Prof William Sponsel Advisor
 
Jun 11, 2019
Mesoblast, JCR Expand Temcell To HIE In Japan; Elixinol, RFI Partner For US Marijuana Expansion; Genetic Technologies Tells ASX: ‘Director Lee Training’; Next Science To Release 711k Escrow Shares; Zelda’s Mara Gordon Reduces To 5.8%; Merchant Takes 3.6%; Ming Hao Zheng, Ying Fan Increase, Diluted To 5% Of Orthocell; Credit Suisse Takes Loss, Reduces To 7.8% In Prescient; Respiri To Issue 10m Management Options
 
Jun 7, 2019
Dr Boreham’s Crucible: Medical Developments; Axovant Terminates Benitec $954m BB-301 OPMD Deal; Bio-Melbourne Women’s Lunch ‘Sold Out’; Nuheara Trades On US OTCQB Exchange; Canada’s Pharmacielo To Buy Creso For $122m In Shares; Imagion To Release 78m Escrow Shares, 9.6m Rights; MMJ 10m Share Buy-Back; Embark Investment Manager; MGC, RMIT Digital Cannabinoids Library; Noxopharm’s Nyrada Receives $486k R&D Tax Incentive; Paul Anderson, Matt Callahan, SRV Diluted In Orthocell; Chairman Dr Michael Monsour Takes 25% Of Analytica; Levenson Takes 7% Of Anteo; James Middleweek Takes 5% Of Adherium; Deborah Ambrosini Replaces Acrux CFO, Co Sec Tim Bateman
 
Jun 6, 2019
Visioneering Placement, Rights, Notes For $11m; Immutep Doses First Patient In Merck, Pfizer Cancer Trial; Benitec Requests ‘Existing Material Contracts’ Trading Halt; GI Dynamics 4 Endobarrier Meeting Presentations
 
Jun 5, 2019
Volpara Placement, Rights Raise $50m; Retail Rights For $5m; Elixinol Placement Raises $50m; LBT Raises $5m In ‘Oversubscribed’ Placement; Anteo ‘Oversubscribed’ Placement, Rights Raise $3.65m; Analytica Rights Raise $913k Of Hoped-For $2.7m; Suda, Cann Pharma $1.5m Plan For Cannabinoid Oral Spray; Global Kinetics Kinetigraph For Parkinson’s Brain Stimulation; Althea Wins Victoria Hemp Licence; Tissue Culture; Neurotech Pleads Schultz, Board Renewal To ASX 208% Query; Neurotech Launches Mente Autism Clinic Website; Regal Funds Takes 10% Of Opthea; Jencay Capital Takes 5% Of Bluechiip; OBJ Appoints Paul Peros Beauty CEO, Starts On $580k; Resapp Appoints Dr Naomi Fried, Dr Joseph Kvedar Advisors
 
Jun 4, 2019
Applications Open For $316k Victoria Prizes, Fellowships; Paradigm PPS Beats Saline For Ross River Virus Joint Pain; Starpharma: ‘Okamoto Launches 003 Vivagel Condom In Japan’; Imugene: ‘High Dose HER-Vaxx Shrinks Tumors’; Visioneering Requests ‘Transaction, Capital Raising’ Halt; Elixinol Requests Capital Raising Trading Halt; GI Dynamics ‘Considers Delisting From The ASX’; Suda Signs US, Hong Kong Companies For Expansion; Pharmaust: Catalent Makes Dog Cancer Trial Monepantel; MGC Receives Bulk Marijuana, Revenue; Admedus Requests 4th Funding Suspension Extension; Adrian Trevisan Sells All 19m Neurotech Shares
 
Jun 3, 2019
May BDI-40 Up 7%, Big Caps Up 4% ASX200 Up 1%, NBI Down 6%; Federal Opposition: Clare O’Neil, Brendan O’Connor Innovation; Volpara To Raise $55m, To Pay $21m For MRS Systems; Suda 3-For-1 Rights Issue For $3.4m; Uniquest, Pfizer Partner For Cancer; Starpharma, Astrazeneca 2nd Oncology Agreement; Clinuvel: FDA Extends Scenesse PDUFA Date; Medical Developments: Mundipharma For Penthrox Australia; OBJ Appoints Parafix Manufacturing Partner; Bard1 Euro Patent Validated In 6 Countries; Smart Top, Xianhui Meng Take 19% Of Uscom; LBT Requests Capital Raising Trading Halt; MGC Requests ‘Customer Contract’ Trading Halt; Alchemia Further Extends ‘Change In Activities’ Suspension; David Torrible Replaces Total Brain Director Stephen Koslow; Recce Appoints Dr David Bowers Advisory Chair
 
May 31, 2019
Dr Boreham’s Crucible: Invitrocue; Ausbiotech: ‘Sector Worried By Threat To R&D Incentive’; Althea Launches UK Concierge Marijuana Platform; Telix, Emory Trial TLX591-CDx For Cancer Imaging, ASX Query; BTC Completes $6.3m Admedus Infusion Acquisition; Up To 22% Oppose Imagion Placement Facility; TPI Backs Palla Name Change, 22% Support Withdrawn Spill; Yuuwa Diluted To 39% Of Adalta; Nanosonics Loses 9-Year Director Richard England; Admedus Loses 5-Month Director Lishan Zhang
 
May 30, 2019
Minister Karen Andrews Talks Biotech; Orthocell Raises $10.6m; Immuron Raises $2.9m; Patrys ‘PAT-DX1 Kills Breast Cancer Brain Metastases In Mice’; Mesoblast Begins FDA GvHD Submission; Noxopharm Enrols Darrt-1 NOX66 Prostate Cancer Trial; Resapp Names UK Consultancy Avanti Med; Universal Biosensors, Siemens Extend Term Sheet; BVF Reduces To 21% Of Pharmaxis; Immuron Chair Peter Anastasiou Increases, Diluted To 10.6%; Alcidion Pleads Schultz To ASX 13.6% Query; Airxpanders Loses CFO, COO Scott Murcray
 
May 29, 2019
Resapp Hires Unnamed UK Group For New Products; Actinogen Higher Dose Xanahes Trial Passes Safety Review; Bionomics Completes Strategic Review; Neurotech Pleads Schultz To ASX 55% Query; MGC, RMIT Win Australian Marijuana Research Licence; Empery, Ryan Lane Below 5% In Immuron; Cardiex Appoints Rhonda Welch Head Of Marketing; Redhill Appoints Prof June Almenoff CSO
 
May 28, 2019
Invion IVX-P02 Hits Cancer, No Cell Toxicity In Mice; Telix, FDA Prostate Cancer Imaging Meeting; Distributors; Paradigm: ‘Osteo-Arthritis Knee Pain Down 51%’; Federal Court Extends Micro-X Cleansing Notice; Orthocell Requests Capital Raising Trading Halt; Medlab Appoints Mega Lifesciences Nanabis Distributor; Sigma Takes 5% Of BTC; Walker Group Increases, Diluted To 8.5% Of BTC; Cellmid Appoints Bart Wuurman Lyramid Midkine CEO; TBG Loses Director, COO Eugene Cheng
 
May 27, 2019
Victoria $267m For Research, Jobs, Investment Funds; Federal Biotech Ministers: Karen Andrews, Greg Hunt; Biotech Daily Comment; Next Science: Grace Medical Distributes Sinus Lavage; TGA Registration For Genetic Signatures Easyscreen; Painchek: UK Contract 1st Offshore Deal; Bard1 Receives $521k R&D Tax Incentive; Cardiex: Presentation Backs Blumio BP Sensor; Chair Dr Richard, Karen Treagus, Diluted To 13.7% Of BTC; Director Peter, Helen Jones Increase, Diluted To 9.8% Of BTC; Micro-X Takes ‘Cleansing Notice’ Halt To Suspension; Eye Co Appoints Prof Jan Provis Advisory Chair; Stemcell Appoints Yanhua Huang, Qi Lu Directors
 
May 24, 2019
Dr Boreham’s Crucible: Oncosil Medical; Immuron To Raise $2.9m; Antisense ATL1102 DMD Trial Enrolled; Starpharma: DEP-Irinotecan, Cetuximab Kill Cancer In Mice; MGC Claims ‘Marijuana Toxic To Glioblastoma’, In-Vitro; Naos Takes 18.5% Of BTC Health; Goodbye Phosphagenics, Welcome Avecho
 
May 23, 2019
Starpharma: ‘Bacterial Vaginosis Trial Possible, FDA Talks’; Adalta Raises $5m, Rights Offer For $2m More; Genetic Technologies ADSs Raise $1.75m; Imagion Toxicology Study: ‘Magsense Safe For Breast Cancer’; Immutep IMP321, Chemotherapy Patent For Europe; Noxopharm Expands NOX66 Prostate Cancer Trial; FMR Takes 5% Of Somnomed; G Medical 2m Director Shares, 14.5m CEO Loan Shares AGM; Micro-X ‘Late Cleansing Notice’ Trading Halt; Creso Harvests First Canadian Marijuana Crop
 
May 22, 2019
Phosphagenics To Be Avecho Biotech; Dr Ross Murdoch; Oventus: Lane Dental, Sleepcues For O2Vent In Nth Carolina; Bio-Melbourne Moves To Collins Street; Rhythm Wins ISO Quality Certification; 2nd Chinese Patent For Sienna Sien-Net Blood Test; Total Brain Test ‘80% Accurate For Depression Drugs’; Investors Mutual Takes 8.5% Of Mayne Pharma; Redhill Hires 3 Staff For Talicia (RHB-105) Sales; Auscann: Ido Kanyon Starts As CEO
 
May 21, 2019
Cardiex Business, Marketing Operations In China; Adalta Requests Capital Raising Trading Halt; Cellmid Buys Back 499k Unmarketable Parcel Shares; Admedus Requests 3rd Funding Suspension Extension; ‘Bank Of New York Mellon’ Takes 26% Of Avita; Macquarie Takes 5% Of Impedimed, Again; Morgan Stanley Takes 7% Of Total Brain
 
May 20, 2019
Longas Morphoseq For DNA Sequencing; Nick McCooke CEO; FDA Approves LBT Apas Independence; Kazia, Alliance Partner On GDC-0084 For Brain Metastases; Noxopharm Claims NOX66 Efficacy For Prostate Cancer; Alcidion $700k NSW Child Health Contract; IDT Medical Marijuana Manufacturing Licence; Medadvisor, Zeullig Pharma Signs 1st Customer; Cardiex Partners With Health160 For China Tele-Health; G Medical Hopes For $24m Nasdaq IPO; Stemcell Takes 51% Of Yunnan Hemp Co For $794k; Alterity (Prana) To Release 270m Escrow Shares, 540m Options; Jason Colquhoun, 0971224 BC Below 5% In THC; Och Ziff Exits Total Brain; Cynata: Dr Brooke Replaces Dr Chiplin; Hires Dr Lipe; Imugene Appoints Dr Jens Eckstein Director; Botanix Appoints Vince Ippolito Executive Chairman On $400k PA
 
May 17, 2019
Dr Boreham’s Crucible: Pro Medicus; WEHI GSK126 For Cancer Targets Cause Of Asthma In Mice; Neuren NNZ-2591 Efficacy For Angelman, Pitt Hopkins In Mice; Immutep IMP321 Reduces Tumor Size At 9 Months; Rhinomed FDA, TGA Pronto Vapor Release Registration; Australian Super 6% Orthocell Notice; Matt Callahan; LBT US FDA Submission Trading Halt; Airxpanders Extends Debt Suspension, Postpones AGM; Suda: David Phillips Director; Joseph Ohayon CFO, Co Sec
 
May 16, 2019
Federal Election 2019: Policies & Comment; Vittail $6m For Peter Mac, CSIRO E6AP Cancer Target; Bionomics BNC210 PTSD Data ‘Justifies Further Evaluation’; Nuheara Iqstream TV On Sale; Canadian Patent For Prescient PTX-200 For Cancer; G Medical US Phone Sensor Deals; News Correction; Botanix ASX Query Retracts ‘Bacterial-Resistant’ Claim; Cann Global: ASX In-Principle Relisting Approval; CSL Appoints Dr Paul McKenzie COO
Opthea Completes OPT-302 Wet-AMD Trial Visits; BTC Raises $8m For Admedus Infusion Business; Share Plan; Cann Australian Marijuana Resin For Victoria; THC Wins Australian Marijuana Export Licence; Elixinol Wins New York Marijuana Authorization; Medibio Faces 23% Opposition To 14.5m ‘In Lieu’ Options; Avita Loses CFO Dale Sander; Tim Rooney Interim CFO; Suda: Paul Hopper Chairman; Steven Carter CEO; Mach7 Appoints Travis Nuzzi Sales, Marketing Head Race Ready For 1st Bisantrene Leukaemia Trial In 25 Years; Mayne Falls On Expected H2 Downturn; Admedus AGM Clears Rem Report, 46% Star Bright Dissent; Blackcrane Takes 8% Of Avita Volpara Density ‘Effective In Breast Cancer Risk Model’; Living Cell: NTCell Shows ‘Benefit’ For Parkinson’s; BTC Health Pays $6m For Admedus Infusion Business; Airxpanders Dumps Revenue Forecast; 2nd Loan Breach; FDA Clears Somnomed Somnodent Avant; DIIS Approves Imagion Overseas R&D; Expects $1.7m; Correction: Next Science; John Gleeson Takes 5% Of Uscom; Regal Funds Again Reduce To 11% Of Visioneering
 
May 10, 2019
Dr Boreham’s Crucible: Rhythm Biosciences; Genetic Technologies: ‘New Colorectal, Breast Cancer Tests’; Analytica $2.7m 1-For-6 Rights Issue; Simavita $3m Convertible Notes; Next Science To Release 2.3m ASX Escrow Shares; FIL Below 5% In Actinogen, Takes Loss
 
May 9, 2019
FDA Committee Backs Pharmaxis Bronchitol For Cystic Fibrosis; Paradigm Completes $78m Capital Raising; Zelda Receives $769k R&D Tax Incentive; Admedus Takes $1m SIO Loan At 12%, $125k Fee; GI Dynamics $4.3m Crystal Amber Note; Osprey Director Options Face 13% Dissent; Airxpanders Hires Cowen For Financial Advice; LBT Receives First $1m Of $4m SA Government Loan; Australian Ethical Takes Loss On Actinogen; Australian Ethical Takes 8.4% Of Ellex; Robert Lederer, RTL Group Take 10% Of Anatara; Och-Ziff Reduces To 6% Of Total Brain; Factor Loses Director Tim Hughes, Directors Fees Back; Genera Loses Director Jim Kalokerinos
 
May 8, 2019
Redhill NDA For Talicia (RHB-105) For Helicobacter Pylori; Clarity Raises $10m; Orthocell: ‘Celgro Regains Muscle Function’; Compumedics Barrow Orion Lifespan Meg ‘Largest Contract’; Osprey Launches ‘Dyeminish’ Patient Registry; Anteo 1-For-5 Rights Issue For $2.6m; Pharmaust Receives 25kg Monepantel For Cancer Trials; Bank Of New York Mellon Files 8 Substantial Biotech Notices; Credit Suisse Takes 10% Of Prescient; Regal Funds Diluted Below 5% In Prescient
 
May 7, 2019
Actinogen: ‘Xanamem Fails Alzheimer’s Endpoints’; THC Share Plan Raises $3m; CSIRO, Genesiscare $5m For Cancer ‘Theranostics’; Medadvisor, Zuellig JV For Asia Script Reminders; Zucero Completes $6m TBG (Progen) PG500 Deal; Admedus Extends Funding Suspension; Adherium Tells ASX: ‘Revenue Coming, Possible Capital Raising’; Australian Ethical Diluted To 11% Of Prescient; Living Cell Appoints Prof Carolyn Sue Director; Shareroot Appoints Dr Julian Chick Chairman
 
May 6, 2019
Alterity: ‘PBT434 Passes Blood-Brain-Barrier, Well-Tolerated’; Kazia ‘60mg GDC-0084 For Glioblastoma Tolerated’; Ellex Launches Eye Prime Diagnostic; Pharmaust Monepantel Dog Cancer Study ‘Flexible Dosing’; TBG Completes Zhangsha Zhangye Acquisition; MGC Appoints Grow Biotech, IPS Specials UK Distributors; W Whitney George, Sprott Take 24% Of Rhinomed; Anteo Requests Capital Raising Trading Halt; Hamish George Replaces Dimerix CFO, Co Sec Ian Hobson; Polynovo Appoints Ashok Srinivasan COO; Invitrocue Appoints Dr Wahab Insurance Advisor; Oneventures Appoints Jim Scopa, Dr Dan Baker
 
May 3, 2019
Dr Boreham’s Crucible: Cynata Therapeutics; Resmed Q3 Revenue Up 12% To $947m, Profit Down 4% To $151m; Actinogen Requests Xanadu Alzheimer’s Results Halt; Impedimed: ‘Study Backs BIS For Lymphoedema’; Respiri, Medachievers J-V For Wheezo India; Genetic Technologies Nasdaq Market Cap Warning; Airxpanders Extends ‘Debt Agreement’ Suspension
 
May 2, 2019
Polynovo: ‘April Revenue $1m, Close To Break-Even’; Airxpanders Cuts 45% Of Workforce, 33% Of Cash Expenditure; Adalta Confirms AD-214 Manufacture; MGC Signs Health House, Cannvalate Australia Distributors; Noxopharm Claims 8 Of 14 Prostate Cancer ‘Progression Free’; Australian Ethical Takes 15% Of Prescient; Regal Funds Take 6% In Prescient; Spill Call Investors Take 14% Of Factor
 
May 1, 2019
April BDI-40 Up 18%, ASX200 Up 2%, Big Caps Up 3%, NBI Down 5%; Brandon $210m For MRCF5; ‘Australia’s Biggest VC Firm’; Novita Tali Attention For Oregon School; 4DX: Lung Health Initiative $960k Federal Grant; Polynovo US Defence Novosorb Contracts; Orthocell Takes Celgro For Ligament Repair To TGA; US Patent For Bard1 Cancer Diagnostics; Recce Receives $204k Radium R&D Tax Incentive Loan; Genera Has $50k Cash; ‘Loans, Placement’; Adherium Has Less Than One Quarter Cash; Invitrocue Has Less Than One Quarter Cash; Placement; Nuheara Has Less Than Two Quarters Cash; ‘More Coming’; Micro-X Has Less Than One Quarter Cash; Thales $10m Note; FIL Below 5% In Starpharma
 
 
Apr 29, 2019
MCRI Trials Marijuana For Behavior Problems; Federal $5m For Painchek Roll-Out; Polynovo Appoints Polymed Novosorb Distributor; Respiri To Start Wheezo Clinical Study; Somnomed ‘Has Two Quarters Cash’; Admedus Has Less Than One Quarter Cash; Dr Chiplin, Dr Dunton Replace Regeneus Dr Aston, John Martin
 
Apr 26, 2019
Dr Boreham’s Crucible: Sienna Diagnostics; Telix: ‘Study Backs TLX591 For Prostate Cancer’; Neuren NNZ-2591 Phelan-McDermid FDA Submissions; Antisense To Issue 45m Director Loan Shares, Options; Prescient Rights Raise $890k; Total $9.1m; EGM 14% Dissent; Cann $6m For 20% Of Pure Cann NZ For Medical Marijuana; Eye Co Files Marijuana For Amd Patent; Imagion Less Than Two Quarters Cash, ‘Possible Capital Raise’; TPI 2nd Strike Board Spill, Name Change AGM; Painchek Requests ‘Government Funded Trial’ Trading Halt; Polynovo Appoints Kevin Whiteley As US Vice President 
 
Apr 24, 2019
Pro Medicus $14m, 7-Year Duke Health Contract; FDA ‘Clinical Hold’ On Race Bisantrene For AML IND; Elixinol Buys 25% Of Altmed Pets For $9m Cash, Scrip; Creso ‘Brazil Cannaqix50 Pain Licence’ Conditions; Airxpanders Postpones AGM To June; Mach7 Q3 Receipts Up 231% To $3.6m; Neurotech Pleads Schultz, Board Renewal To ASX 457% Query; Sebastian Andre Replaces Esense Co Sec Ian Pamensky
 
Apr 23, 2019
Admedus Coridon Sale Fail; ASX Query; Funding Suspension; Resapp Claims 86% Adult Respiratory Diagnostic Accuracy; Alcidion Q3 Receipts Up 50% To $6.2m; Cogstate: ‘Alzheimer’s Trials Hit Q3 Revenue’, Down 28% To $8.5m; Elixinol Q1 Receipts Up 37% To $8m; China Approves Cardiex Oscar 2 With Sphygmocor; Airxpanders Files $21m US Sec Registration Form; Polynovo: ‘Poster Backs Novosorb BTM For Leg Ulcers’; Total Brain Offers Free Trial To Mental Health America; FIL Takes 6% Of Actinogen; Blackcrane, Daniel Kim Take 6% Of Avita; Founder Dr Matthew Myntti Takes 11.5% Of Next Science; G Medical To Release 234m Shares, 20m Options From Escrow; Imugene: Dr Lesley Russell Director; 75m Director Options; Ellume Appoints David Green CFO, Co Sec; Mark Boyle CBO; Noxopharm Dr Graham Kelly Chair, Dr Greg Van Wyk CEO; Ausbiotech Medical Technologies May Melbourne Conference
 
Apr 18, 2019
Dr Boreham’s Crucible: Compumedics; Next Science Opens 40% Above $1 IPO Price; Victoria Supports Trajan Expansion; CE Mark For Analytica Pericoach For Pelvic Prolapse; Total Brain Places $1m Shortfall Shares; Visioneering AGM Faces 12% Dissent; Telix 895k Director Options, 25% Pay Pool Hike AGM; Phosphagenics Name Change AGM, Again; Elixinol: Stratos Karousos CCO; Rights, 46% Pool Hike AGM; Novita Tali Attention Train 1st US School District Sale; Creso: Brazil Licences Cannaqix50 For Chronic Pain; Suda Requests ‘TGA Artimist Malaria Submission’ Trading Halt; Oncosil To Release 6.5m Escrow Loan Shares; THC Releases 37.5m Escrow Shares
 
Apr 17, 2019
Next Science ‘Oversubscribed’ IPO Raises $35m, Lists Tomorrow; Paradigm Places $61.4m, $16.5m To Go; Medibio, Humanitas Uni Collaborate On Mental Illness; MGC Signs Yushop For Marijuana In China; Admedus Takes Coridon Sale Trading Halt To Suspension; Cann To Release 33m Escrow Shares; Renaissance Below 5% In Visioneering; Neurotech Rolls Board, Co Sec; Jumps 237.5%; Immuron Appoints CEO Dr Gary Jacob Director
 
Apr 16, 2019
Cochlear Launches MRI-Friendly Nucleus Profile Plus Implant; Starpharma, Aspen Launch Vivagel BV For Bacterial Vaginosis; FDA Allows Mesoblast Rolling GvHD Application; Rhinomed Pronto Vapor For Sleep, Decongestion; Medlab, Chronic Pain Australia Medical Marijuana Education; Osprey: Q1 Revenue Up 56% To $1.2m; Resonance Pleads Schultz To ASX 37.5% Query; Genetic Technologies Chair Dr Paul Kasian Full-Time, Pay Rise; CFO Robert Meissner Replaces Althea Co Sec Peter Gillis
 
Apr 15, 2019
Paradigm Raising $78m On PPS Osteoarthritis Pain Results; Study Backs LBT APAS For MRSA (Golden Staph); Resapp Files FDA Application For Resappdx-US; Immuron Claims 9-Month Sales Up 23% To $1.7m; Admedus Vaccines Sale, 3m CEO Options, 2nd Rem Strike AGM; Admedus Requests Coridon ‘Immunotherapies Sale’ Halt; Prana ASX Code PBT Changes To Alterity ATH; Karst Peak, Adam Leitzes Take Profit, Reduce To 10.5% In Avita; MMJ Hands Embark Marijuana Investments, Drops Share Plan; Micro-X Loses Richard Hannebery; Harley Frankfurt Replaces Anteo CEO Christopher Parker
 
Apr 12, 2019
Dr Boreham’s Crucible: Osprey Medical; Bio-Melbourne Appoints Dr Julie-Ann White CEO; Nuheara Launches Self-Assessment Hearing Website; Medibio 14.5m Directors Options In Lieu Of Pay EGM; Volpara To Release 51m Voluntary Escrow Shares; MGC: UK Marijuana Import Permit; Australia, UK Sales; Empery Reduces To 6% In Immuron; Renaissance Increases, Diluted To 5% In Visioneering; Elixinol Appoints Greg Ellery Director; Genera Appoints Dr Guillermo Elias For North America
 
Apr 11, 2019
Creso To Raise $5.35m Via Secured Loans; Imagion Supplies Nano-Particles To Israel’s New Phase; Starpharma, FDA Discuss Vivagel For Bacterial Vaginosis; Immuron Takes Travelan For Travellers’ Diarrhoea To FDA; Pharmaust ‘Oversubscribed’ Shortfall Raises $700k; Total $2m; Osprey 13.5m Directors Options AGM; Paradigm Requests ‘Secondary Endpoints’ Trading Halt; JM Financial Group Takes 16% Of Mach7; RACI Dines On ‘Innovation To Impact’ With J&J’s Kathy Connell; Total Brain For Emory Goizueta Coaching Diploma
 
Apr 10, 2019
Admedus Pleads Schultz, Vaccine Sale To ASX 109% Query; Actinogen Investigates Xanamem For Mood Disorders; Noxopharm Plans NOX66, Doxorubicin Sarcoma Trial; Total Brain Rights Raise $897k Of Hoped-For $1.9m; $963k To Go; Chris Retzos Increases, Diluted To 6% Of Prescient; Clarity Appoints Advisor Dr Gillies O’Bryan-Tear Director; Factor Appoints Dr David Brookes Director
 
Apr 9, 2019
Ellume In Pre-IPO Mode For Respiratory Diagnostics; Goodbye Prana, Hello Life’s Alterity; $11.4m Raised; Bio-Melbourne Gongs: Anna Lavelle, Clara Gaff, Evelyn Chan; Painchek Signs Churches Of Christ Queensland Aged Care; Visioneering Q1 Sales Up 104% To $1.6m; Memphasys: 5 More Centres Assess Felix IVF Sperm Separation; Airxpanders Backs Radformation Radiation Software; Oceania, HCI Quit Mach7; Australian Ethical Takes 5% Of Mach 7; SG Hiscock Below 5% Of Neurotech; Creso Requests ‘Capital Raising’ Trading Halt; GI Dynamics Appoints Prof Judith Korner Advisor; G Medical Loses Director Sam Skontos
 
Apr 8, 2019
Volpara: 2019 ‘Annual Recurring Revenue’ Up 85%; Genetic Technologies, Tgen Develop Risk Tests; Dorsavi Wins $540k UK Myvisafe Contract; Novita, Tali, Carestarter Partner For Autism, ADHD; Reva $5.35m Goldman Sachs Loan, $1.1m Fees; THC Share Plan Ahead Of Final Marijuana Licence; Noxopharm To Release 31m Voluntary Escrow Shares; Karst Peak, Adam Leitzes Reduce To 14.5% In Avita; Ged Wallace Replaces Ellex CEO Tom Spurling, On $320k; Somnomed Appoints Hervé Fiévet CFO
 
Apr 5, 2019
Dr Boreham’s Crucible: Starpharma; Avita: ‘Recell To Save Burn Centre $39m PA’; Prana Okays Life Takeover, Alterity Name Change; Atomo HIV Self-Test On Sale In Australia; Creso Tells ASX ‘Sensitive’ News Not New; Ellex Requests ‘Leadership Change’ Trading Halt; THC, Heleogenics Partner For Malaysia Medical Marijuana; Memphasys Pays Monash IVF 4m ‘Consulting’ Shares; Peters Investments Takes 21% Of Memphasys
 
Apr 4, 2019
Airxpanders: Aeroform Breast Expander ‘Superior’; Suda Submits TGA Zolpimist Insomnia Application; Euro Patent For Cynata Cymerus Stem Cells; GI Dynamics Endobarrier Data At NY Diabetes Meeting; Antisense On-Track For ATL1102 For DMD Results This Year; Althea: ‘511 Medical Marijuana Patients; Q3 Sales $183k’; Australian Ethical Takes 11% Of Prescient; Regal Funds Below 5% In Prescient; Kinetic Below 5% In Visioneering; Actinogen Appoints Malcom McComas Director
 
Apr 3, 2019
Budget Comment And Analysis - Biotech Daily, CSIRO, AMRAB, AAMRI, Medicines Australia, Ausbiotech; Nanosonics Welcomes French Disinfection Guidance; Acrux Settles Valeant Jublia Generic Patent Litigation; Correction: Anatara; Allan Gray Takes 17% Of Osprey; Clarity COO Colin Biggin Replaces Matt Harris As Acting CEO
 
 
Apr 2, 2019
Anatara Re-Focusses On O-T-C Bromelain For Human Health; Immuron Lodges Form F-3 To Raise Up To $US100m; Sienna Buys Sevident Exosome Cancer Test For $4m; Airxpanders Debt Suspension For Revenue Shortfall; Imugene Key-Vaxx And B-Vaxx ‘Reduce Tumor Growth In Mice’; Imugene: High Dose HER-Vaxx Tumor ‘Responses, Antibodies’; LBT APAS Independence Golden Staph Control Study; Cardiex To Begin Sphygmocor Cardiovascular Trial; Impedimed Launches Gen 3 Sozo, Improves Security; European Patent For Cellmid Monoterpenoids For Alopecia; Jencay Takes 9.5% Of Universal Biosensors; Oceania, HCI Reduce To 6% Of Mach7; Pro Medicus $150m, 10m-Share Buy Back; GI Dynamics Appoints Dr Allon Friedman Advisor
 
Apr 1, 2019
March BDI-40 Up 6%, ASX200 Up 0.2%, Big Caps Flat; Micro-X $10m Thales Deal For X-Ray Technology; Kazia: Cantrixil For Ovarian Cancer ‘Safe, 1 Response’; Euro Patent For Amplia AMP945 For Fibrotic Diseases; Exopharm Plans Plexaris Platelets For Wound Healing Trial; GI Dynamics Extends Crystal Amber Note; Invion Pleads ‘Research, Social Media’ To ASX 39% Query; Bard1 Tells ASX: ‘Assay Development’ Led To 25% Jump; Memphasys Chair Alison Coutts Increases, Diluted To 14.6%; Director Andrew Goodall Takes 24.6% Of Memphasys
 
March 29, 2019
Dr Boreham’s Crucible: Immutep; GI Dynamics: ‘Endobarrier Reduces Weight, HbA1c, Apnoea’; Micro-X Begins $13.7m Allora Federal Court Proceedings; Resapp Recruits Breathe Easy Study, FDA Submission; Clinuvel To Host EPP Expert Meetings In Europe; Oncosil Meets BSI, Committee On CE Mark; Alchemia Requests Suspension For ‘Change In Activities’; Airxpanders Requests Loan Breach Trading Halt; Spill Call Shareholders Reduce To 12% Of Factor; Total Brain 2m Director Ajay Arora Options EGM
 
March 28, 2019
Mach7 Wins Sentara Picture Archive Contract; Volpara Welcomes FDA Breast Density Changes; Genetic Technologies Opens Hong Kong, China Operations; Pharmaust Monepantel For Cancer ‘Safe In Dogs’; Analytica Receives $745k Tax Incentive; Paradigm Pleads Schultz To ASX 18% Query; John McBain, Picton, 52nd Celebration Take 8% Of Rhinomed; Blue Sky Ceases In Alcidion; Bio-Melbourne Loses 5-Year CEO Dr Krystal Evans; Invictus Appoints Dr Jordan Moon Advisor
 
Mar 27, 2019
Neurotech, Founder Dr Attard Trevisan And His Ph D; Mesoblast, Mt Sinai Revascor New Heart Failure Trial; Dorsavi Tells ASX ‘We Are A Going Concern’, Funding; Memphasys Raises $1.9m, $1.7m To Go; Factor Survives Board Spill AGM; 43% Rem Report 1st Strike; Prescient 5m Director Options EGM; G Medical $35m Nasdaq Shares, 14m Dr Yacov Geva Shares EGM; Genetic Technologies Requests ‘Expansion’ Trading Halt; Phosphagenics Dr Murdoch Steps Down, Dr Collier Steps Up; Suda Appoints David Simmonds Director
 
Mar 26, 2019
Federal $80m For Peter Mac Cancer Centre Car T-Cell; Federal: $66m For Genomics Research Grants; Women Win 4 Of 5 Victoria Premier’s Research Awards; CEO David Kaysen Resets Medibio Heart-Mental Health Test; Final Review Backs Actinogen Xanadu Alzheimer’s Trial; FDA Meets Pharmaxis For Bronchitol Recommendations; Genera: $243k Applications Of Hoped-For $11.4m; E-Sense Lab Cuts Expenditure By $840k; THC’s Vertical Canna Buys 1,858m2 Canada Marijuana Plant; Altium Growth Below 5% In Immutep; Bank Of America Below 5% In IDT; Och-Ziff Reduces, Diluted To 7% Of Total Brain; Clarity Appoints Dr Thomas Ramdahl Director
 
Mar 25, 2019
Oncosil Falls 87% On Pancreatic Cancer Radiotherapy Doubts; Prescient To Raise $9.1m In Placement, Rights Issue; FDA Issues WEHI-Discovered Abbvie Venetoclax Warning; Reva $4.2m Loan; Jeff Anderson Replaces CEO Reggie Groves; Uscom Wins Chinese Medical Device Certificate; Mesoblast, JCR Stem Cell Licence For Epidermolysis Bullosa; Race Files Bisantrene For AML IND With US FDA; Factor Receives $2.5m R&D Tax Incentive; Simple Sleep Services Closes Owing Somnomed $1.1m; UK NHS Moves Nuheara Iqbuds Boost To ‘Hearable’; Thorney, Tiga Take 17% Of TPI; THC Requests Canada Acquisition Trading Halt
 
Mar 22, 2019
Dr Boreham’s Crucible: Rhinomed; Prof Alan Trounson: ‘Australia Handicapped On Cell Therapies’; Federal $25m For Regional Cancer Trials; GE Healthcare To Sell Volpara Density Worldwide; Adheris To Sell, Promote Medadvisor Adherence Program; Pharmaust Rights Raise $1.3m Of $2m; $700k To Go; US Patent For Immutep IMP321, Chemo For Cancer; Smart Top, Xianhui Meng Take 18% Of Uscom; BVF Increases, Diluted To 19% Of Actinogen; Goodridge Takes 8% Of Noxopharm; Mesoblast Appoints Joseph Swedish Chairman; Phylogica Appoints Dr Rakesh Veedu Advisor
 
Mar 21, 2019
Cynata Falls 43% On Fujifilm Option Extension; J&J, Monash Work On Inhaled Oxytocin; Compumedics $1.4m US Adventist Monitor Deal; Alcidion $1m Patientrack Deal With UK Hospitals; Biocelect, 60 Degrees Kodatef For Malaria In Australia; Telix, Cyclotek Complete Visact Manufacture; Prescient Requests Capital Raising Trading Halt; Medibio Reviews Heart-Mental Illness FDA Submission; Spill Call Shareholders Take 19.97% Of Factor; FMR Below 5% Of Resmed; Invictus Appoints Prof Ed Gane Advisor
 
Mar 20, 2019
Next Science Raises $35m For Xbio Antibacterial; GSK Awards $150k, Collaborations To 2 Research Projects; Telix Manufactures TLX250 For Kidney Cancer Trials; FDA Provides Guidance For Imugene Key-Vaxx IND; Factor Responds To Dissident Investor Letter; Eye Co Files Patent For Dry AMD; FIL Below 5% In Impedimed; JM Financial Group Takes 11% Of Mach7; Medadvisor Requests ‘Commercial Agreement’ Trading Halt
 
Mar 19, 2019
Truscreen Back For Cervical Cancer Screening; Cynata Requests Fujifilm Licence Trading Halt; Immuron IMM-529 Clostridium Difficile Trial ‘Slow’; Patent; Kazia Sells Noxopharm Holding For $2.1m; Cann, Aurora Marijuana Deal; $11m Mildura Greenhouse; Cellmid Unmarketable Parcel Buyback; Visioneering To Release 8m Escrow Shares; Regal Funds Below 5% In Medibio; FIL Takes 16% Of Medibio
 
Mar 18, 2019
Resapp Diagnostic ‘Better Than Clinicians For Croup’; Telix Welcomes EAU Prostate Cancer Guidelines; Alcidion $2.1m Miya, Patientrack, Smartpage UK NHS Deal; Rhythm Recruits 1st Colostat Colorectal Cancer Patient; Inside Diagnósticos To Distribute Sienna’s hTER Test In Brazil; Prana Receives $3.3m R&D Tax Incentive; Total Brain Hopes To Raise $7m; GI Dynamics $1.4m Crystal Amber Convertible Note; Medigard Tells ASX ‘Working To Comply With Rules’; KT009; Australian Ethical Takes 19.96% Of Antisense; Platinum Takes 8.6% Of Antisense; Leon Serry, City Castle, Sked Take 6% Of Antisense; Capital Group Reduces To 6% Of Mesoblast
 
Mar 15, 2019
Dr Boreham’s Crucible: Mesoblast; GI Dynamics Endobarrier Study: ‘Significant Weight, HbA1c Drop’; Eyepoint H1 Revenue Up 122% To $4m, Loss Up 280% To $63m; Next Science $35m IPO For Xbio For Biofilm-Protected Bacteria; Suda’s Anagrelide Potential Role For Cancer; Praxis Picks Victoria For Asia-Pacific HQ; Wintermute Moves US Operations To Latrobe Uni; Clinuvel, UK Nice Talk Scenesse Appeal, Managed Access; Dr Errol De Souza Continues As Bionomics Exec Chair; Dorsavi Cuts Costs 40%, CEO Dr Andrew Ronchi Pay Cut; Shareroot Appoints Michelle Gallaher CEO
 
Mar 14, 2019
NHMRC Awards 23 Research Excellence Awards; Hemideina Wins Federal $800k For Hera Wireless Implant; Medlab: ‘Marijuana Nanabis Reduces Pain In 5 Patients’; Imugene Doses 1st HER-Vaxx Gastric Cancer Patient; US Patent For Recce Antibiotics, Recce-327; Pharmaust Monepantel ‘Dog Tumor Suppression, Regression’; Phylogica, Tel Aviv Uni Collab For siRNA Therapies; Medibio Outsources Ilumen To Ex-Staff-Owned Alta; FIL Takes 5% Of Actinogen; Investors Mutual Takes 7% Of Mayne Pharma; Total Brain Requests Capital Raising Trading Halt; Alastair Beard Replaces Respiri Co Sec Julian Rockett 
 
Mar 13, 2019
Antisense Raises $1.6m To Accelerate ATL1102 For DMD; Reva Further Extends Capital Raising Suspension; Genera Further Extends Rights Offer Closing Date; Resapp Expects $1.7m R&D Tax Incentive; Offshore Finding; Spill Call Shareholders Take 19% Of Factor; CEO Dr Philippe Wolgen Takes 7% Of Clinuvel; Clinuvel Takes 9% Of Itself; E-Quits Orders $7k Esense Marijuana Terpenes; MGC Appoints Dr Stephen Parker Director; Respiri Appoints Gerry Bullon Investor Relations Consultant
 
Mar 12, 2019
Ellex Lasers Beat Drops For Ocular Hypertension, Glaucoma; MHRA Backs Cynata Critical Limb Ischemia Trial; Starpharma Receives $4m Federal R&D Tax Incentive; Medibio Rights Raise $923k Of Hoped-For $4m; Cogstate Tests In J&J’s US Spravato CIII Depression Trials; Springboard Program For 6 Australian Biotech Women; US Patent For Imagion Magnetic Nanoparticles For Cancer; Zelda, Ilera Partner To Co-Develop Medical Marijuana; Phylogica ‘Peptides Deliver Antisense Drugs In Mice’; Kit Wei Lui Replaces Invitrocue Director Jamie Gee Choo Khoo
 
Mar 11, 2019
CE Mark For Admedus Cardiocel 3D, Vascucel; Federal $50m For Alfred Traumatic Brain Injury Mission; Victoria Funds Melbourne Uni, Cynata Stem Cell Project; Antisense Requests Duchenne Muscular Dystrophy Funds Halt; Avita: 10 Presentations At American Burns Meeting; Mach7 Restructure: Mike Lampron Replaces CEO Mike Jackman; Sandon Capital Takes 8% Of IDT; Jamore, Danshe Take 5% Of Nuheara; Australian Ethical Takes 8.65% Of Somnomed; Amplia Appoints Prof Lara Lipton, Prof Phil Hansbro Advisors
 
Mar 8, 2019
Dr Boreham’s Crucible: Volpara Health Technologies; S&P ASX All Ordinaries: 6 Biotechs, Aust Ethical In; 7 Out; Immutep: ‘IMP761 Reduces Primate T-Cells’, Clinical Trials; Federal $500k For Griffith Uni Plasprotect Malaria Vaccine; Federal Health Boards ‘50% Women’; Prof Dorothy Keefe; Universal Biosensors Loses 33% Staff, CEO Rick Legleiter; Cochlear: UK Nice Expands Hearing Implant Suitability; Immutep Receives $872k Federal R&D Tax Incentive; Wentworth Williamson Takes 7% Of Tasmanian Poppy; ASX Suspends Medigard On Accounts
 
Mar 7, 2019
DSMB Backs Opthea Phase IIb OPT302 Wet AMD Trial; Immutep Doses 1st IMP321, Keytruda Cancer Patient; Medibio: Ilumen Shows 26% Of Staff Depressed, Anxious; Correction: Orthocell; Employee Sues Neurotech Founder, Subsidiaries; Kinetic Investment Reduces To 5.3% Of Visioneering; Creso To Release 2m Voluntary Escrow Shares; Althea: Aphria’s Jakob Ripshtein Replaces Gregg Battersby
 
Mar 6, 2019
Osprey: ‘Breakeven By 2022’; Prana: Boston Life Biosciences Control, Name Change EGM; Immutep: ‘9 Of 24 Respond To IMP321, Keytruda’; Orthocell To Complete Ortho-ATI Recruitment By July; Reva Further Extends Capital Raising Suspension; Zelda Cannabidiol Breast Cancer Biomarker Patent; Cardiex Bayer Sphygmocor Contract Up $494k; Telix To Release 814k Voluntary Escrow Shares; Pinnacle (Hyperion) Takes 5% Of Cochlear; CVC Takes 13.5% Of Universal Biosensors
 
Mar 5, 2019
Medlab, Pharmascience Nanabis Deal; Total Brain, Blackthorn Partner For Neuro-Behavior; Pinacle’s Hyperion Takes 5% Of Cochlear, Again; Jersey’s D&A Income Takes 7% Of Pharmaxis; Leydin, Polonsky Replace Alchemia’s Gennari, Book; G Medical Appoints Prof Zeev Rotstein Director
 
Mar 4, 2019
Volpara Dense Breast Study: ‘Interval Cancer Drops Dramatically’; Cynata, NSW Uni: ‘Cymerus Heart Disease Efficacy, In-Vitro’; Avita EU Recell ‘Sales Interruption’; M3 To Market, Distribute Avita’s Recell In Japan; Factor Tells ASX: $1.2m R&D Incentive A ‘Forecast Figure’; G Medical Revenue Up 2709% To $4.3m, Loss Down 40% To $23m; Montoya Ceases In Pharmaxis; Jim Surek Replaces Osprey Head Of Sales Hank Butcher; Genetic Signatures Appoints CFO Peter Manley Co Sec; Alcidion: Melanie Leydin, Michael Sapountzis Joint Co Secs; G Medical Loses Director Louis Antoniou
 
Mar 1, 2019
February BDI-40 Up 11%, ASX200 Up 5%, Big Caps Up 0.4%; Dr Boreham’s Crucible: Cochlear; Federal $608m For NSW Children’s Cancer Centre; Admedus Revenue Up 127% To $25.6m, Loss Up 180% To $24.7m; TBG Revenue Down 9% To $3.2m, Loss Up 33% To $4.4m; THC Revenue Up 45% To $2.7m, Loss Up 237% To $8.6m; Cardiex H1 Revenue Up 2% To $2m, Loss Up 26% To $1.4m; Pharmaust H1 Revenue Up 44% To $1.9m, Loss Down 94% To $90k; Dorsavi H1 Revenue Down 18% To $1.8m, Loss Down 3% To $1.9m; OBJ H1 Revenue Down 29% To $1.1m, Loss Up 92% To $788k; W Whitney George Takes 23% Of Rhinomed; Oceania, HCI Reduce To 7.6% Of Mach7; G Medical Requests Final Preliminary Report Suspension; Damian Lismore Replaces LBT Director Dr Glenn Haifer; Clarity Appoints Dr Robert Miller CMO; MGC Loses Joint Co Sec Kate Sainty
 
Feb 28, 2019
Zelda: ‘Endo-Cannabinoid HER2 Breast Cancer Path’; TPI Revenue Up 109% To $47m, Loss Down 65% To $6m; Neuren Revenue Up 49% To $15.2m, Profit Down 7% To $3.1m; Airxpanders Revenue Up 100% To $11m, Loss Down 8% To $37m; Avita H1 Revenue Up 53% To $6.8m, Loss Up 115% To $15.6m; IQ3 H1 Revenue Down 15% To $2.9m, Profit Up 333% To $320k; Uscom H1 Revenue Up 4% To $1.5m, Loss Down 30% To $758k; Phosphagenics Revenue Up 21% To $1.4m, Loss Down 53% To $4m; Adherium H1 Revenue Down 63% To $986k, Loss Up 74% To $8.6m; Total Brain H1 Revenue Up 4% To $1.1m, Loss Down 62% To $4.6m; Micro-X Quits Xinray; Adalta, Excellerate Collaborate On I-Body; Regeneus $2.5m Directors Loans; Harbour Takes 5% Of Volpara, Again; Simon Harradence, DDH Graham, Lugarno Take 6% Of Acrux; Spill Call Shareholders Take 18% Of Factor; Pyxis Takes 6% Of Neurotech; Duncan Cornish Replaces Anteo CFO, Co Sec Julien McInally
 
Feb 27, 2019
Compumedics H1 Revenue Up 16% To $18.7m, Profit Up 27% To $811k; Cogstate H1 Revenue Down 17% To $15.5m, Loss Up 436% To $3.9m; Cyclopharm Revenue Up 2% To $13.4m, Loss Down 98% To $35k; Cryosite H1 Revenue Up 36% To $4m, Profit To Loss Of $1.3m; Redhill Revenue Up 109% To $11m, Loss Down 15% To $54m; Invion H1 Revenue Up 394,450% To $1.2m, Loss Up 14% To $1.3m; Memphasys To Raise $3.64m, Lists On Frankfurt Exchange; Dimerix Two DMX-200 Phase II Trial ‘On-Track’; Regal Funds Reduces To 12.4% Of Visioneering; SG Hiscock Diluted To 7% Of Neurotech; Niall Cairns Replaces Cardiex Chairman Donal O’Dwyer
 
Feb 26, 2019
Aravax PVX108 ‘Safe’ For Peanut Allergy; Imugene B-Cell Vaccine ‘Anti-Tumor Activity’; Optiscan Microscope At Sloan Kettering; Optiscan, Summit Work On Microscopes, Imaging; Elixinol First H1 Revenue $37.1m, Loss $860k; Probiotec H1 Revenue Up 35% To $37m, Profit Up 258% To $1.1m; Benitec H1 Revenue Up 3392% To $14.6m, Loss To Profit Of $9.1m; Clinuvel H1 Revenue Up 27% To $9m, Profit Up 189% To $4.1m; Osprey Revenue Up 54% To $3.5m, Loss Up 22% To $24.5m; LBT H1 Revenue Down 49% To $1.8m, Loss Up 59% To $1.7m; Botanix BTX1503 ‘5 Times Others CBD’; MGC Marijuana ‘More Than 35% THC’; Cardiex Appoints Harry Kim Advisor
 
Feb 25, 2019
Nanosonics H1 Revenue Up 36% To $41m, Profit Up 221% To $7m; Alcidion H1 Revenue Up 479% To $7.3m, Loss Down 47% To $563k; Medadvisor H1 Revenue Up 19% To $3.8m, Loss Up 99% To $4.5m; Genetic Signatures H1 Revenue Up 41% To $3.5m, Loss Up 3% To $1.7m; Mach7 H1 Revenue Down 9% To $3.5m, Loss Up 31% To $4.4m; Resonance H1 Revenue Up 40% To $1.8m, Profit Up 693% To $935k; Alcidion Extends $711k ACT Health Contract; Neurotech Rights Raise $783k Of Hoped-For $3.3m; Pharmaxis: Boehringer Completes PXS‐4728A Nash Enrolment; Reva Extends Capital Raising Suspension; TPI, Tasmanian Alkaloids Codeine Poppy Patent Fight; Total Brain, Onedigital Partner For Brain Health; Memphasys Requests Capital Raising Trading Halt; Auscann Appoints Ido Kanyon CEO; Race Appoints Prof Roland Walter Bisantrene Trial PI
 
Feb 22, 2019
Dr Boreham’s Crucible: Cellmid; Pharmaxis Starts LOX Inhibitor For Pancreatic Cancer Trial; Mayne H1 Revenue Up 13% To $274m, Loss To Profit Of $1m; Universal Bio Revenue Up 176% To $70m, Loss To $38m Profit; Ellex H1 Revenue Up 9% To $41.6m, Loss Down 0.4% To $2.7m; Medlab H1 Revenue Up 17% To $2.3m, Loss Up 60% To $3.7m; OBJ P&G Licence Deal For Olay Magnetic Infuser; Factor Board Spill AGM; Redhill Appoints Director Rick Scruggs COO; Melanie Leyden Replaces Medibio Director Andrew Maxwell; Stephen Denaro Replaces Novita Co Sec John Osborne
 
Feb 21, 2019
Mesoblast H1 Revenue Down 7% To $19m, Profit To $62m Loss; Editorial: Your R&D Tax Incentive Is Not Revenue; Somnomed H1 Revenue Up 15% To $28.8m, Loss Up 90% To $12.4m; Pro Medicus H1 Revenue Up 60% To $25.4m, Profit Up 184% To $9m; Polynovo H1 Revenue Up 109% To $5.7m, Loss Down 41% To $1.9m; Cellmid H1 Revenue Up 12% To $3.6m, Loss Up 221% To $3.5m; Allegra H1 Revenue Down 22% To $1.8m, Loss Up 142% To $481k; Impedimed H1 Revenue Up 19% To $1.8m, Loss Down 16% To $12.1m; Bioxyne H1 Revenue Up 83% To $1.4m, Loss Down 72% To $203k; Proteomics US Biomarker Patent For Kidney Disease Target; Resmed, Fisher & Paykel Settle Patent Dispute; Suda Improving Anagrelide Solubility; Althea: Cannvalate Australia Marijuana Distributor; Auscann To Buy Marijuana Resin From Medipharm; Anteo, Geneodx To Launch Anteobind In China; Noxopharm Review: Prioritize Prostate Cancer, US Listing; Botanix Appoints Dr Stewart Washer Interim Chairman; Julian Rockett Replaces Visioneering Co Sec Leanna Ralph
 
 
Feb 19, 2019
Cochlear H1 Revenue Up 11% To $712m, Profit Up 16% To $129m; Visioneering Revenue Up 214% To $4.6m, Loss Down 1.5% To $23.5m; Hemideina Raises $1m For Hera Wireless Hearing Aid Implant; Takeovers Panel Dismisses Pura Vida Factor Complaint; Victoria $1.5m For ‘Teletrials’ Program; Alcidion Launches Miya Precision At NZ Mid-Central Health; Last Patient Dosed In Phase III Mesoblast Heart Trial; TGA Okays Mayne Kapanol (Morphine) For Breathlessness; Admedus: ‘TAVR Safe, Potential Benefits, In Sheep’
 
Feb 18, 2019
Federal $22m For Early Stage Research; Clarity Raises $9m, Open For $1m More; Emerald Clinics Raises $2.5m For IPO; Pharmaust Rights Issue To Raise $2m; Neuren NNZ-2591 ‘Effective For Phelan-McDermid In Mice’; Bionomics Up 54% On ‘Significant’ BNC210 PTSD Blood Response; J&J Lifescan Pays Universal Biosensors Test Strips $44m; Pharmaust, Epichem Extend DNDI Contract; Suda European, Chinese Patents For SUD-003, SUD-004; Proteomics To Release 3.9m Escrow Shares; Reva Requests Capital Raising Trading Halt; Canada Marijuana Cultivation Licence For Creso; Telix Appoints Gabriel Liberatore Group COO; Invitrocue Appoints Prof Arial Zeng Yi Consultant
 
Feb 15, 2019
Dr Boreham’s Crucible: CSL; Federal $39m For 23 Rare Cancers, Diseases; Victoria Backs Master Of Cancer Sciences; Pharmaxis H1 Revenue Down 91% To $3m, Profit To $13m Loss; Bionomics H1 Revenue Up 3% To $2.4m, Loss Up 19% To $10.6m; Bard1 5-Peptide Good For Mesothelioma, Not Others, In Mice; Neurotech, Anchovy Partner To Deliver Mente Autism
 
Feb 14, 2019
Minomic Appoints Cirrus Dx For Micheck Prostate Cancer Test; Nominations Open For Victoria Manufacturing Hall Of Fame; Federal $26m For Heartkids, Childhood Heart Disease; Paradigm Plans Phase II/III MPS Trial; GI Dynamics Ready For US Pivotal Endobarrier Trial; Colleges Back Althea Medical Marijuana Education; Medlab Expands Nrgbiotic Depression Trial Recruitment; Creso, Hempmate Collaborate On Marijuana For Europe
 
Feb 13, 2019
CSL Record H1 Revenue Up 9% To $6.3b, Profit Up 7% To $1.6b; Orthocell: ‘Ortho-ATI 82% Success’; Invictus Requests FDA Liver, Pancreas Drugs Meeting; Mayne To Sell Lexette For Psoriasis In US; Cross-Party Launch Of Medicinal Cannabis Industry Australia; Creso: Burleigh Heads To Distribute Medical Marijuana; Esense 80% Dump CEO Haim Cohen As Director; Painchek Pleads Schultz, ‘Publicity’ To ASX 71% Query; Race Chair Dr William Garner Reduces To 15.8%; FIL Reduces To 7.1% Of Adherium
 
Feb 12, 2019
Federal $32m For Researcher Entrepreneur Training; Nanosonics: ‘90% Of Japan Vaginal Probes Contaminated’; Invion Completes Chronic Airway Therapeutics Spin-Out; Creso Deals Could Trigger ASX Chapter 11; Volpara Appoints Paul Reid Chair; Botanix Appoints Dr Michael Thurn Executive Director; Zelda Hires ICCI For Marijuana Trials; Victor Kovalev Replaces Medadvisor CTO Dr David Chatterton
 
Feb 11, 2019
Actinogen Begins Xanamem Dose Escalation Trial; Invitrocue, Dr Chen J-V For Immune Mice, Cells; Universal Biosensors, Siemens ‘Modify Relationship’; Beagles Back Pharmaust New Monepantel Taste; Total Brain, Mapmygenome Partner For ‘Brain Optimization’; Capital Group Reduces To 8% Of Mesoblast; Starfish Below 5% In Impedimed; FIL Reduces To 8.5% Of Adherium; Phylogica Loses Sahm Nasseri
 
Feb 8, 2019
Dr Boreham’s Crucible: Adalta; Vale Botanix Chair Graham Griffiths (19.8.1955 – 6.2.2019); Recce Raises $1.8m; Rhythm: Ethics Ok For Colostat Colorectal Cancer Trial; Cryosite, ACCC Agree $1.1m Cartel Penalty; Nucleus Buys Q-Pharm For Early Clinical Trials; Correction: Anatara; Phylogica Peptide ‘Outperforms Zebra Competitor’ In Mice; Goodbye ITL
 
Feb 7, 2019
Cellmid: ‘Midkine Antibodies For Heart Inflammation’; Koligo $7m IPO For Kyslecel For Pancreatitis, Pipeline; Anatara ‘Garp’ For Irritable Gut Proof-Of-Concept; Uscom Appoints Koneska Spirosonic US Distributor; Elixinol Buys $2.6m, 60-Acre NSW Property For Marijuana; E-Sense To Supply Marijuana E-Juice To Vaporspec; Spill Call Pura Vida, Freshero Take 15% Of Factor; FIL Reduces To 5% Of Impedimed; Respiri Appoints Michael Clarke Wheezo Ambassador
 
Feb 6, 2019
Federal Government $20m For Phenomics Research; Recce Requests ‘Capital Raising’ Trading Halt; Noxopharm: Veyonda (NOX66) ‘Well-Tolerated’; Total Brain Launches 40 New ‘Trainings’, Videos
 
Feb 5, 2019
Eyepoint (Psivida) US Launch Of Yutiq (Durasert); Factor Raises $417k; Abu Dhabi, Perth Board Spill Call; Correction: Neuren, Acadia; Respiri ‘Oversubscribed’ Placement Raises $1.6m; Unisuper, BNP Paribas Take 5% Of Impedimed; Creso Takes ‘Share Issue, Transactions’ Halt To Suspension; Nanosonics Hires Renee Salaberry, David Morris, Rod Lopez; Reva Cuts HQ Staff By 44% To 22; Elixinol To Appoint 12-Staff European Team
 
Feb 4, 2019
Federal $55m For Type 1 Diabetes; Neuren, Acadia: ‘Phase III Trofinetide Rett Trial This Year’; Sienna Signs Mediwell As Singapore Distributor; Oventus Launches O2vent Optima In Canada; China Study ‘Validates’ Cardiex Sphygmocor; Niall Cairns Replaces Cardiex Chairman Donal O’Dwyer; Dr Willy Hsu Replaces TBG COO Eugene Cheng; MMJ Loses CEO Jason Conroy
 
Feb 1, 2019
January BDI-40 Up 10%, ASX200 Up 4%, Big Caps Up 1%, NBI Up 13%; Dr Boreham’s Crucible: Resmed; Neuren: Acadia RoW Offer ‘Not In Shareholders Interests’; Genetic Technologies, MSK, Cambridge Uni Breast Cancer Test; Genera Rights Offer For $11.4m; Mesoblast H1 Receipts Up 296% To $28.5m; THC Receipts Up 61% To $2.6m; Nuheara H1 Receipts Down 19% To $1.4m; Invitrocue Has One Quarter Cash; MGC Grows 700kg Marijuana Crop, More Than 35% THC; Cardiex Takes 41% Of Inhealth; E-Sense Lab To Release 44m Escrow CDIs; Creso Requests ‘Share Issue, Transactions’ Trading Halt; Regeneus CEO Leo Lee Starts On $325k; Auscann Appoints CFO, COO Quentin Megson Joint Co Sec; Creso Appoints Colombia’s Dr Ricardo Salazar Advisor
 
Jan 31, 2019
Brandon, Okogen Trial OKG-0301 For Viral Conjunctivitis; FDA Orphan Status For Prana PBT434 For MSA; Cogstate H1 Receipts Up 30% To $23m; Elixinol Posts Receipts Of $36m; Clinuvel H1 Receipts Up 35% To $13m; Bionomics H1 Receipts Up 33% To $4.8m; Mach7 H1 Receipts Down 28.1% To $4.4m; 2 Quarters Cash; IQ3 H1 Receipts Up 64% To $3.7m; Medadvisor H1 Receipts Up 18% To $3.6m; Pharmaust H1 Receipts Up 62% To $1.9m; Adherium H1 Receipts Up 51% To $1.8m; Less Than 2 Quarters Cash; Total Brain H1 Receipts Up 72% To $1.6m; Less Than 2 Quarters Cash; Avita H1 Receipts Up 25.4% To $1.2m; Micro-X Has Less Than Two Quarters Cash; Reva Receipts Up 360% To $886k; One Quarter Cash; Race Receives $229k Federal R&D Tax Incentive; Kemper Shaw, William Taylor Each Take 11% Of Imagion
 
Jan 30, 2019
Federal $37m For Parkinson’s Disease; Airxpanders 2018 Sales Up 211% To $12m; G Medical Less Than 2 Quarters Cash; $30m Hygea Contract; Invion Backs Demerger, 209m Director Options; Mayne Anti-Fungal Tolsura (Suba-Itraconazole) US Launch; API To Sell Medlab Food Additives; LBT Appoints Simon Arkell US Director; Creso Marijuana Beer Licenced To Switzerland’s Einhor Bräu
 
Jan 29, 2019
Visioneering: ‘Naturalvue Reduce Myopic Progression 90%’; Correction: Neuren; Universal Biosensors Sales Down 7% To $24m; J&J To Pay $45m; Osprey 2018 Sales Up 62% To $3.4m; Volpara Q3 Record Receipts Up 192% To $1.8m; Invion 4C: ‘Cho Group To Fund All Costs’; Invion Hires Guilin Xingda For Cancer Equipment Manufacture; Neurotech Rights Issue For $3m; Japan Patent For Opthea’s OPT-302; Adalta AD-214 Manufacturing ‘On-Track’; Pharmaust, Elanco Monepantel Data Sharing Deal; ITL Delists February 8; Nasdaq 3rd Genetic Technologies Non-Compliance Letter; Avita: 9 Abstracts At US Burns Meeting; Impedimed To Present ‘Detailed Prevent Trial Results’; Cynata Presents CYP-001 GvHD Results; G Medical Requests ‘Purchase Orders’ Trading Halt; MGC Completes Derma Sale To Cannaglobal
 
Jan 25, 2019
Dr Boreham’s Crucible: Neuren Pharmaceuticals; Resmed H1 Revenue Up 10% To $1.75b, Profit Up 9.6% To $336m; Botanix BTX-1204 Eczema Trial On-Track; Auscann Buys Perth Marijuana Drug R&D Facility; Cardiex 20m CEO Performance Shares, 3m Director Options EGM; Colin Mackinnon Replaces Alcidion CFO Duncan Craig
 
Jan 24, 2019
Proteomics Axes Prism US Licence; Visioneering 2018 Receipts Up 311% To $4.8m; Creso Placement Raises $3m; Cyclopharm $2.4m R&D Tax Incentive, Recruits 100th US Patient; Telix Licences 99m-Technetium-Ipsma For Prostate Cancer; ITL Unmarketable Parcel Facility Buys Back 166k Shares
 
Jan 23, 2019
Cartherics, Toolgen Gene-Edit Stem Cells For Cancer; Cellmid: ‘December Profit; Cash Flow Positive In 2020’; Invitrocue, Shanghai Inst Develop Breast Cancer Onco-PDO; NZ Allows Elixinol Medical Marijuana; ‘Australia Lags’; MMJ Share Plan For $10m, EGM; Leo Lee Replaces Regeneus CEO John Martin; Anatara Appoints Dr David Brookes Director
 
Jan 21, 2019
Living Cell: ‘4-Year NTCell Parkinson’s Safety Data Positive’; Clarification: Immuron Warrants Over 701.5k US Shares; Pharmaust: ‘Diet, Excipients Improve Monepantel For Cancer’; Biotech Daily Appendix 4C Quarterly Reports Policy; Admedus Has Less Than Two Quarters Cash; New York’s Sio Takes 22% Of Admedus; Acrux Receives $2m Federal R&D Tax Incentive; Creso To Sell Terrascend 100kg/Month Marijuana Flowers; Jeremy Green, Redmile Take 13.4% Of Avita; One Funds Diluted Below 5% In Avita
Benitec Late BB-401 Head, Neck Cancer Trial Closure; Rhinomed Share Plan Raises $95k Of Hoped-For $1m; Phosphagenics: Anna Legg Out; Melanie Leydin, Michael Sapountzis In; Phylogica Loses CSO Dr Robert Hayes; ASX ‘Verbal Confirmation’ Queensland Bauxite Relisting; Race CEO Peter Molloy Increases, Diluted To 5%; FIL Below 5% In Starpharma, Again; Telix Completes $8.3m AMNI SA Acquisition; MGC Exports Cannepil From Slovenia; Micro X Raises $2m; Altium Takes 7.5% Of Immutep; Medibio Loses Christopher Indermaur, Appoints Claude Solitario; Cann Gives Pays CSIRO 91k Shares; Dorsavi CEO Dr Andrew Ronchi Diluted Below 5%; Prudential (M&G) Takes 5% Of Medical Developments; Elixinol Releases 52k ASX Escrow Shares; MMJ Medipharm Receives Canada Approval Marijuana Production; Race Chair Dr Bill Garner Takes 17.5%; Race CEO Peter Molloy Increases, Diluted To 5.2%; FDA Requests ‘Clinical Data’ To Approve Starpharma Vivagel BV; Prana Raises $44.6m From Life Biosciences, Investors; Lanstead Reduces Below 5% In Neuren; GI Dynamics Extends $6.6m Crystal Amber Loan; Resapp Submits CE Mark Tech File For Smartphone Diagnostic; Japan Approves Starpharma Vivagel Condom; Total Brain Releases 474k Shares From Escrow; Creso ‘Takes Advantage’ Of Israeli Marijuana Export Rules; Immuron Receives $1.19m Federal R&D Tax Incentive; Resonance Licences Wisconsin Fat-Diseases Patents; Bionomics Phase II BNC105 Combination Cancer Trial Underway; Leigh Elkolli Replaces Reva CFO, Co Sec Brandi Roberts; GI Dynamics Appoints Stephen Linhares Clinical, Regulatory Head; Australia Accepts Cynata Stem Cell Patent Application; Mesoblast Phase III Trial Completes Recruitment; Starpharma Tells ASX: FDA Data Material, Japan Approval Not; Nuheara Launches Iqbuds Max; Imugene Appoints Prof Michael Caligiuri Scientific Advisor; Immutep $6m Collaboration With Cytlimic; Reva Expands Into Seven European Countries; Creso To Distribute Medical Marijuana In Sri Lanka; FIL Reduces To 6.5% In Impedimed; Polynovo: H1 Novosorb BTM Sales Up 320%; Patrys Receives $556k R&D Tax Incentive; Telix: Huj591 Data Supports Phase III Prostate Cancer Trial; Avita US Launch Of Recell System; Elixinol CFO Ron Dufficy To US, Kim Bradley-Ware Co Sec; Oventus Launches Nylon O2Vent Optima For Sleep Apnoea; ITL Health Votes To Quit ASX; MMJ Appoints Michael Curtis Director; Zelda Pleads Schultz To ASX 20% Query; Medlab: ‘Nanostat Improves Atorvastatin’; Nuheara Launches Hearing Services App, Iqstore; Jencay Capital Takes 8% Of Universal Biosensors; Creso, Medleaf Partner For NZ Medical Marijuana; Cancer Trials Joins Shareroot’s Media Consent; FDA: July 8 PDUFA Date For Clinuvel’s Scenesse For EPP; Niv Dagan, Freedom Trader Take 5.5% Of Lifespot; Invitrocue Appoints Dr Steven Fang Chairman; Nuheara Launches Iqconnect; Invitrocue Appoints Prof Masakazu Toi Clinical Advisor; Memphasys: Uni Of Florence, Isfahan Clinic Test Felix; Federal $25m For WEHI Drug Discovery Centre; Mesoblast Takes $21m From Hercules Credit Facility; FIL Takes 5% Of Starpharma; Zelda Director Jason Peterson Transfers, Reduces To 9.6%; Anatara Receives $1.25m R&D Tax Incentive; CEO Richard Hannebery Takes 13.4% Of Genera; Memphasys: Boston IVF, University Of Munster Test Felix; Pharmaust: ‘Monepantel Shows Anti-Cancer Activity’; Cardiex, Anthem To Co-Market Inhealth; Immuron Offers Warrants Over 701.5k US Shares; Resonance: Envoyai To Distribute Ferrismart In US; Kazia Receives $2.2m R&D Tax Incentive; Prescient Receives $939k R&D Tax Incentive; Mark Fortugno Replaces THC CFO Jarrod White; Invion: Lynda Spelman, Louis Irving, Nathan Lawrenstchuk Advisors; Painchek Works With Allity Aged Care, Ward Medication; Invitrocue Appoints Prof Jesús García-Foncillas Clinical Advisor; Impedimed Signs Ascension For Sozo; Pharmaxis Ready For Phase II LOXL2 Trials; Phosphagenics, FDA Discuss TPM-Oxymorphone Path; EMA Approves Medlab SME Qualification; Genera Receives $438k R&D Tax Incentive; Anteo Works With Sona Nanotech, Ellume; Esense-Lab Ships 2l Cannabidiol Vape Product To E-Quits; Malaysia Approves Polynovo BTM; Buys Production Facility; Cardiex Tells ASX: ‘Jan 5 Anthem News Published Jan 15’; Invitrocue Rolls-Out Onco-PDO Screening Germany; Antisense: ATL1102 For DMD Trial Recruitment Half-Way; Bioxyne Loses Director Maxwell Parkin; Auscann To Release 133m ASX Escrow Shares

 

 

 
 
Dec 21, 2018
Dr Boreham’s Crucible: More Medical Marijuana; Invion Demerger, 209m Director Options EGM, ATO Ruling; Genetic Technologies Pays $250k For Blockshine J-V; LBT Files FDA 510(K) For APAS Independence; LBT Receives $1.85m Federal R&D Tax Incentive; Bionomics Earns $654k From Cancer CRC, Pfizer Deal; Ellex Trades On US OTCQX; THC Wins 2 Australian Medical Marijuana Licences; Creso Completes Kunna Canada Acquisition For 9.4m Shares; Elixinol Welcomes US Hemp Approval; Neurotech: ‘New Strategy For US Mente Autism Sales’; Telix Appoints Nannette Rich Head Of US Sales, Marketing
 
Dec 20, 2018
2018 - Biotech Daily’s Year In Review; Starpharma $142m US Vivagel Bacterial Vaginosis Deal; Patrys: ‘PAT-DX1 Kills Breast Cancer Brain Metastases In Mice’; Qbiotics Raises $15.5m Of Hoped For $26m; Dimerix Receives $1.1m Federal R&D Tax Incentive; Pharmaxis Resubmits US FDA Application For Bronchitol; Universal Biosensors $6.3m US Tax Liability; Cuts, Staff Go; Memphasys: Colorado Centre Tests Felix Sperm Device; Micro-X Requests Capital Raising Trading Halt; Noxopharm Receives $3.3m R&D Tax Incentive; Creso Hails US Hemp Law Change; Neurotech Founder Dr Attard Trevisan Back As Advisor; Esense Loses Director Kobi Zecharia
 
Dec 19, 2018
Cyclopharm: Canada Guidelines Back Technegas For Imaging; Telix Applies For Japan TLX250-CDX Kidney Cancer Imaging Trial; Immutep Raises $7.2m; Suda $1.4m Mitsubishi Tanabe Zolpimist Insomnia Licence; Akaal, Boston Pharma Deal For AKP-11 For Psoriasis, Arthritis; Clinuvel: ‘Scenesse Good For Vitiligo, Dark Skin Rejected’; Alcidion Extends ACT Health Contract; Phosphagenics, Mylan, Strides Settle For $176k, New Deals; Lifespot’s Vaporizer For CBDS US Marijuana Trials; Bard1 Dr Irmgard Irminger-Finger Increases, Diluted To 11%; MGC Trades On US OTCQB; THC Requests ‘Marijuana Permits’ Trading Halt; Mesoblast Promotes Dr Eric Strati To Commercial Head
 
Dec 18, 2018
Paradigm: ‘PPS Reduces Osteoarthritis Pain’; Respiri Places $3.2m; Plan For $1m More; Workplace Wheezo; Merchant Places Bard1 $1.1m Shortfall; Total Raised $3.3m; Dorsavi Raises $2.1m Of Hoped-For $3.2m; Avita Receives $1.4m Federal R&D Tax Incentive; Botanix Ready For Phase II BTX1204 Eczema Trial; Analytica Resumes US Pericoach Sales; OBJ: Procter & Gamble Licence For 1st Integrated Product; Cynata Sends GvHD Results To Fujifilm For Option Decision; Mayne Re-Acquires Suba-Itraconazole Rights From Hedgepath; Cardiex, Unnamed Company Partner For Sleep Disorders; Recce Chair Dr Graham Melrose Lends $200k; Lifespot To Release 28m ASX Escrow Shares; Medical Developments Loses Allan McCallum; ‘Help Wanted’
 
Dec 17, 2018
Imugene: HER-Vaxx For Gastric Cancer ‘Safety, Responses’; Genetic Signatures Easyscreen Respiratory Kit CE Mark; Federal Government $3m For Paediatric Leukodystrophies; Imagion, Planet Innovation To Develop Magsense; Nuheara, UK Specsavers Partner For Iqbuds Sales; Race: Truemed Sells AML Named Patient Bisantrene In Israel; Dorsavi Requests ‘Rights Issue Results’ Halt; TBG Buys Zhangye Medical Lab For China Testing Services; Virbac Orders $350k Creso Animal Marijuana Products; Genera AGM Passes All Resolutions; Vinva Below 5% In Mayne; Grey Innovation, Two Bulls To Take Respiri Stake; China; Neuren CSO Dr Larry Glass Retires As Director; Oventus Appoints Sharad Joshi Director
 
Dec 14, 2018
Dr Boreham’s Crucible: Medadvisor; Admedus Rights Raise $5.4m Of $20m; $13.6m Underwritten; Australian Super Takes 8% Of Osprey; Paradigm ‘OA, Bone Bruising Trial Results’ Trading Halt; Respiri Requests Capital Raising Trading Halt
 
Dec 13, 2018
Cynata: ‘NHMRC $2m For Osteoarthritis Stem Cell Study’; Bard1 Raises $1.2m; $3.3m Expected; Pharmaxis Resumes US Sales Of Aridol, $2m Potential; Geneodx To Distribute Anteo Molecular Glue In China; Perth’s Oncores Wins British Royal ‘Entrepreneur’ Gong; Mesoblast, FDA Agree GvHD Regulatory Pathway; Adherium Loses US CEO Arik Anderson, CFO David Allinson; Paradigm CEO Paul Rennie Increases, Diluted To 16.7%; Regal Reduces To 6.5% In Prescient; Race Chair Dr Bill Garner Reduces To 15%
 
Dec 12, 2018
Federal Government: NHMRC $526m For 682 Projects; Federal $25m Grants For Mental Illness Open; Redhill Raises $28m; FDA Approves Mayne (Halcygen) Suba-Itraconazole; US Patent For Starpharma SPL7013 Conjunctivitis Eye Drops; Cellmid: ‘Record $2.2m Q2 Revenue’; From Glass To Plastic; Cardiex Expands Blumio Wearable BP Monitor Deal; Resonance Pleads Schultz, News, Deals To ASX 29% Query; ASX Suspends MMJ; Phosphagenics Takes ‘Mylan Talks’ Halt To Suspension; Jeremy Green, Redmile Take 9.4% Of Avita; One Funds Increases, Diluted To 5% Of Avita; Robert Lederer, Rtl Group Take 9% Of Anatara; Benjamin Karasik Diluted Below 5% Of Esense; Admedus: Star Bright Lishan Zhang, Dr Yanheng Wu Directors; Factor Loses Director Dr Robert Ryan
 
Dec 11, 2018
Orthocell Raises $1.8m; Birmingham Dental Approves Celgro; Bionomics Share Plan Raises $250k Of $2m; Total $10m; FIL Returns To 5% In Starpharma; Bionomics Receives $6.5m Federal R&D Tax Incentive; Rhythm Receives $284k Federal R&D Tax Incentive; Polynovo Appoints Jan-Marcel Gielen CFO, Co Sec; Gi Dynamics: Charles Carter CFO, Co Sec; Dave Bruce Goes; Genetic Technologies Appoints Paul Viney COO, CFO, Co Sec
 
Dec 10, 2018
Prescient: ‘Breast Cancer Responders Progression-Free’; Pro Medicus Extends Unnamed German Hospital Contract; CE Mark Approval For Speedx Gonorrhoea Test; Impedimed: ‘Study Backs L-Dex For Breast Cancer Lymphoedema’; Medibio Notes Raise $2.5m; Rights Offer For $4m More; Phosphagenics Requests ‘Mylan Negotiations’ Trading Halt; Allan Gray Diluted To 15% Of Osprey; Oncosil Appoints Michael Bassett Director; Painchek, Blamey Saunders Win UK ‘Rocketship’ Travel Grants
 
Dec 7, 2018
Dr Boreham’s Crucible: Mach7 Technologies; Phylogica Claims HSV-1 Vaccine Efficacy In 9 Of 12 Mice; Paradigm New Data Backs Osteoarthritis Pain Reduction; Genetic Signatures Receives $2.6m Federal R&D Tax Incentive; Orthocell Requests Capital Raising Trading Halt; Brandon, MRCF, Australian Super Hold 27% Of Osprey; Adam Leitzes, Karst Peak Increase, Diluted To 17.3% Of Avita; Deutsche Bank (Karst Peake) Quits Genetic Signatures, Again
 
Dec 6, 2018
Federal $240m For ‘Innovative, Transformational Research’; Cardiex Raises $5.5m For Inhealth; Gilead $250k For 6 Research Projects; Mesoblast To ASX: ‘We Did Not Tell Media Of Chair Retiring’; Zelda, Suda Work On Marijuana Oral Spray, $200k Options; Medadvisor, Thrivor Partner For Patient Care; E-Quit Orders Esense Marijuana Terpenes; Deutsche Bank AG Takes 14% Of Genetic Signatures, Again; Vinva Takes 5% Of Mayne Pharma; Medibio Requests ‘Material Capital Raising’ Trading Halt; LSQ Loses CEO Mario Pennisi; Claire Blain Acting; Dr Gopisetty
 
Dec 5, 2018
CSL R&D Spend Up, Approvals, ’Flu Vaccines, Pipeline; Biotron Options Raise $4.7m; Rhythm Completes Colorectal Cancer Test Reagents; Chair Allan Tribe, Australian Land Take 23% Of Phylogica; Prana Registers 1m ADRs; Stemcell: ‘ASX OK Marijuana Cosmetics; Dragon’s Blood’
 
Dec 4, 2018
Redhill Phase III Confirms RHB-105 For Helicobacter Pylori; Avita Raises $40m For US Sales; Atomo: ‘TGA Approves HIV Self-Test’; Federal $10m For MTP Connect; Nuheara ‘Oversubscribed’ Placement Raises $5m; Reva Fantom Encore 1st Italy Implant; Antisense Receives $285k Federal R&D Tax Incentive; Phylogica Peptides Deliver CAS9 To Laboratory Cells; Medlab Europe Subsidiary For EMA Registration; Jencay, Brett Rock Increase To 7% Of Universal Biosensors; Bori Liberman, Jagen Take 7% Of Opthea; Cardiex Requests ‘Capital Raising Activity’ Trading Halt; Admedus Appoints Dr Kiran Bhirangi CMO; Correction: BDI-40 With Market Capitalization
 
Dec 3, 2018
November BDI-40 Down 5%, ASX200 3%, Big Caps 4%, NBI Up 5% - Paradigm Up 42%; Factor Down 95%, Admedus 65%; Resonance Up 139% On FDA Ferrismart Clearance; Osprey Signs Premier For Dyevert; TPI Buys Melbourne Property; China Patent For Regeneus Stem Cell Biomarkers; Pharmaust Scalable Monepantel Kills Cancer In-Vitro; ITL Opens Unmarketable Parcel Facility; Medadvisor, Zuellig J-V For Prescription Reminders In Asia; Neurotech Facility Fail, 23% Oppose Remuneration Report; Phosphagenics Ends US OTCQX Listing; Creso To List On Toronto’s TSX-V
 
Nov 30, 2018
Dr Boreham’s Crucible: Oventus Medical; Mach7 ‘Oversubscribed’ Placement Raises $3m; Mesoblast ‘Renewal’ Starts With Chair Brian Jamieson; Mesoblast 23% Oppose Remuneration Report; Options; Genetic Signatures 31% Remuneration 1st Strike; Optiscan 33% Oppose Director ‘Performance Rights’, Options; Avita Requests Capital Raising Trading Halt; Nuheara Requests Capital Raising Trading Halt; BVF, Mark Lampert Diluted To 15% Of Opthea; Thorney Takes 14% Of TPI; Rhinomed Appoints Sean Slattery CFO, Loses Shane Duncan; Phylogica Board: Dr Rohan Hockings In, Dr Robert Hayes Out; Genera Loses 10-Year Director David Symons; Esense Appoints Piers Lewis Chair, Amit Edri Director
 
Nov 29, 2018
Victoria Appoints Martin Pakula Minister For Biotech; Osprey Rights Raise $4.3m Of Hoped For $10.5m, Total $14.3m; Telix, Nihon Work On Actinium-225 For Kidney Cancer; Noxopharm NOX66 Tolerated, ‘Suspends Tumor Growth’; European Patent For Immutep IMP321; ITL Delisting, Buy-Back EGM; Ellex’s 35% Oppose Director Alex Sundich; Adalta 17% Oppose Dr John Chiplin’s Share Purchase; MMJ Votes 22% Against Remuneration Report; Genetic Technologies Faces Up To 23% Dissent At AGM; 10.5% Dissent For Mayne Pharma Remuneration Report; Correction: GI Dynamics; ATO Delays Invion, Chronic Airway Demerger; Empery Reduces To 7% In Immuron; Richard Cashin Increases, Diluted To 21% In GI Dynamics; Wentworth Williamson Takes 6% Of TPI
 
Nov 28, 2018
Opthea 2014 Options Raise $13.3m; Dimerix To Expand Use, Licence Receptor-Hit Platform; Mach7 Requests ‘Capital Raising’ Trading Halt; Admedus Ends 4-Month Suspension To Raise $20m; Falls 57%; UK NHS Adds Nuheara Iqbuds Boost For Hearing Loss; Immutep 3 Of 6 Patients Respond To IMP321, Keytruda; Patent; Polynovo 5-Month Novosorb Sales $2.8m; Orthocell Treats Last Celgro Dental Implant Patient; Cardiex, Inhealth, Kaiser 7-Year Diabetes Lifestyle Study; GI Dynamics, India’s Apollo Sugar Trial Endobarrier; LBT 24% Avoids Remuneration Report 1st Strike; THC To Market Dutch Medical Marijuana In New Zealand; Cooper Below 5% Of TPI; TPI Appoints Sue Macleman Director; Glenn Gilbert Replaces Rhythm CEO Dr Trevor Lockett, On $260k
 
Nov 27, 2018
Medibio, AIAA Ilumen Mental Health Contract; Phosphagenics $228k Takes R&D Tax Incentive To $833k; Race 21% Oppose Remuneration Report; All Change At Respiri (Isonea, Karmelsonix) - Again; BVF Partners, Mark Lampert Reduce To 22% Of Pharmaxis; Grandlodge, Peter Anastasiou Have 12% Of Immuron
 
Nov 26, 2018
Telix Buys Partner ANMI For $9.3m Cash, Scrip; BTC Licences Episil Oral Pain Relief From Camurus; LBT 1st APAS Independence In The US; Local Sales Delayed; Proteomics, Janssen Work On Diabetic Kidney, Heart Function; Alcidion: MKM $12m Queensland Referral Contract; Opthea Enrols Last Of 366 Patients In OPT-302 Wet AMD Trial; Actinogen Enrols Last Patient In Xanamem Alzheimer’s Trial; Zelda, St Vincent’s Trial Marijuana For Pain; Mesoblast, Tasly Meet For Stem Cell Heart Drug Pathway; Dimerix Wins $100k Federal Grant To Identify Targets; Bluechiip Loses Director Blair Healy; Simavita To Lose Director Warren Bingham, Damien Haakman In; Peter Griffiths Replaces Neurotech CEO, M-D Wolfgang Storf; Admedus Appoints Matthew McDonnell Interim CFO
 
Nov 23, 2018
Dr Boreham’s Crucible: Memphasys; ITL To Delist In February: ‘Low Share Price, Liquidity’; Botanix Receives $4.6m Federal R&D Tax Incentive; Recce Takes Radium $256k R&D Tax Incentive Advance; Mark Kerr Takes 11% Of Phosphagenics
 
Nov 22, 2018
Biotech Daily Victoria Election 2018 Editorial; Dimerix Starts DMX-200 FSGS Trial; Dorsavi $106k Workright NW Workplace Safety Agreement; Paradigm Icahn PPS Licence For Muco-Poly-Saccharidoses; Hidden Hearing Distributes Nuheara Iqbuds Boost In Ireland; Memphasys, Gred To Validate Felix Sperm Separator; MGC 54% Remuneration 1st Strike; Pharmaxis 15% Oppose Malcolm McComas; Resolution Dropped; Vanguard Below 5% In Cochlear; Deutsche Bank Sells Genetic Signatures 14%; Karst Peak 18%; Hydroponics Changes Name To THC Global
 
Nov 21, 2018
Allegra: ‘FDA Okays Sr-HT-Gahnite Spinal Cage Path’; Simavita Raises Further $100k, Total $3.075m; Dorsavi Rights Offer For $3.2m; EU Orphan Status For Dimerix DMX-200 For FSGS; Up To 17% Dissent Against Clinuvel Chair Stan McLiesh; Micro-X AGM Placement Facility Faces 12% Dissent; Vanguard Takes 5% Of Cochlear; Genetic Technologies To Lose CFO, Co Sec Kevin Fischer; Noxopharm Appoints John Moore Director
 
Nov 20, 2018
Pro Medicus Signs $27m Partners Imaging Deal; Eye Co Fludrocortisone Acetate For Dry AMD Trial; Pharmaxis Readies For LOX Inhibitor Pancreatic Cancer Trial; Kazia Plan Raises $800k, Total $4.2m; Resonance Receives $326k Federal R&D Tax Incentive; Nuheara Unveils Iqstream TV For Independent Volume Control; Biotron 43% Remuneration 1st Strike; Options; Adherium 33% Remuneration 1st Strike; Share Plan; Universal Biosensors Repays $21m Athyrium Loan; MMJ Completes Phytotech Sale To Harvest One; Name Change; Adam Leitzes, Karst Peak Take 19.8% Of Avita; Fil Sells, Takes Loss On All 83.3m Factor Shares; Cochlear Appoints CSL’s Abbas Hussain Director
 
Nov 19, 2018
Volpara H1 Revenue Up 53% To $2.5m; Loss Up 22% To $4.8m; Imagion Rights Offer Raises Full $4.3m; Cynata Receives $1.3m Federal R&D Tax Incentive; Allan Gray Sells, Takes Loss On All 123m Factor Shares; Dimerix Starts DMX-200 Diabetic Kidney Disease Trial; Genetic Technologies Files $15m Kentgrove Prospectus; Cellmid Appoints Pharmaceutical Services NZ Distributor; China Copyrights, Trademarks For Uscom 1A, BP+, Spirosonic; Invion To Release 2.75b Escrow Shares; MGC, RMIT, Hebrew University Of Jerusalem To Launch Cannahub; Immuron: Dr Gary Jacob CEO Starts On $479k; Dr Kanellos COO; Invitrocue Appoints Dr Lindner Europe CEO, Prof Waugh Advisor; Somnomed Neil Verdal-Austin Replaces CEO Derek Smith On $480k; Admedus Loses CFO Catherine Costello; Medibio Appoints Mathew Watkins Joint Co Sec
 
Nov 16, 2018
Dr Boreham’s Crucible: Regeneus; CMRI, Logicbio Partner For Viral Vectors; Avita Hires 20 US Sales Staff; Starpharma Dep-Chemo Stops Pancreatic Cancer In Mice; Optiscan To Lose Founding Director, Inventor Peter Delaney; Medibio AGM Repels Elias Leo ‘The Gun’ Khouri Board Spill; Hydroponics 30% Oppose In-The-Money Options; Canada Co; Painchek Receives $751k Federal R&D Tax Incentive
 
Nov 15, 2018
Pharmaxis: LOXL2 Drug ‘Safe, 85% Enzyme Inhibition’; Federal $4m For Autism Research; Prof Georgina Long, Prof Richard Scolyer Win GSK $80k; Paradigm Receives $2.3m Federal R&D Tax Incentive; Suda Receives $745k Federal R&D Tax Incentive; US Patent For Dorsavi Body Orientation Technology; Cynata Survives 24.55% Remuneration Dissent; Suda Survives 22% Remuneration Dissent; Resapp 18% Placement Facility Dissent At AGM; MGC Starts UK Legal Proceedings Against Varm Cosmo; BVF, Mark Lampert Take Profit To 16% Of Opthea; Dimerix Loses Kathy Harrison
 
Nov 14, 2018
Factor Falls 97% On VF001 Venous Leg Ulcer Fail; Victoria $100k For Compumedics, Deakin Sleep Diabetes Study; Exopharm $7m IPO For Exosome Regenerative Medicine; Bionomics 2nd Placement Raises $2m Of $4m; Total $9.8m; Bionomics 37% Remuneration 1st Strike; Opthea Recruits Phase IIb OPT-302 AMD Trial; Painchek Launches On-Line Training Course; Resapp ‘ISO Compliant’ For CE Mark, TGA; Rhinomed AGM For 9m Director Options; Kinetic, Aust Super Increase; Brandon, CM Diluted In Osprey; Proteomics: Adelaide Equity, Scintilla Corporate Advisors; Anatara Appoints Steven Lydeamore CEO On $395k
 
Nov 13, 2018
Qbiotics 1st EBC-46 Solid Tumor Trial: ‘2 Complete Responses’; Cochlear $20m For Nyxoah OSA Hypoglossal Nerve Stimulation; Imugene: ‘HER-Vaxx Safe, Antibodies For Gastric Cancer’; Sienna Receives $443k Federal R&D Tax Incentive; IDT Buys-Back, Cancels 659k Shares; Factor Requests ‘Trial Results’ Trading Halt; Pharmaust: Catalent GMP Monepantel For Dog Cancer Trials; Imugene 18% Oppose 25m Chair Paul Hopper Options; Auscann Hires PCI Pharma For Marijuana Capsules For Pain; MGC Sells Derma To Cannaglobal Canada
 
Nov 12, 2018
Mesoblast Stem Cells Miss Heart Endpoint, Reduce GI Bleeding; Bionomics To Lose CEO Dr Deborah Rathjen; Raise $12m; Immutep IMP321, Keytruda ‘Some Melanoma Efficacy, Safety’; Uscom Establishes Beijing Office; Phosphagenics Loses $416m Mylan Case; Race Chair Dr William Garner Transfers, Reduces To 16%
 
Nov 9, 2018
Dr Boreham’s Crucible: Allegra Orthopaedics; Cochlear, Denmark’s GN Group Expand Collaboration; Proteomics Ships 1st Commercial Promarkerd Kidney Test; Imugene Receives $1.85m Federal R&D Tax Incentive; BVF, Mark Lampert Take 18% Of Opthea; NZ Harbour Asset Management Below 5% Of Volpara
 
Nov 8, 2018
Imagion Readies For 1st Human Magsense Breast Cancer Trial; Federal Government Sets 12 Research, Innovation Priorities; Bard1 To Raise $3.3m In Entitlement Offer; Euro Guidelines ‘Challenge’ Reva; Richard Kimes Goes; Strides Pays Suda $1.4m For SUD-001H For Migraine In US; Visioneering: ‘Lenses Slow Children’s Myopia By 81%’; Optiscan Receives $776k R&D Tax Incentive; Phosphagenics Receives $604k R&D Tax Incentive, $200k More; Cellmid 16% Oppose 33% Director Fees Pool Hike; Genetic Technologies CEO Dr Paul Kasian $47k Pay Rise
 
Nov 7, 2018
Resmed Pays $1b For Matrixcare Software; FDA Okay For Optiscan, Carl Zeiss Convivo Microscope; Biotech Daily 13th Birthday Editorial; South Korea Approves Nuheara Iqbuds, Iqbuds Boost; Europe Allows Cynata MSC Patent; US, EU Patents For Cellmid’s Midkine N-Domain; Botanix Treats 1st BTX1308 Psoriasis Patient.; Invion IVX-P02 Anti-Cancer Gel, Pre-Clinical Studies Partners; Paradigm New 20-Patient Data Backs Osteoarthritis Pain Reduction; Zelda To Release 224m Shares, 40m Options From ASX Escrow; Suda Requests ‘Licence Agreement Negotiations’ Trading Halt; Bard1 Requests ‘Capital Raising’ Trading Halt; MGC Extends ‘Cannaglobal, MGC Derma Sale’ Suspension; Polynovo To Lose Co Sec Greg Lewis; CFO, Co Sec Wanted
 
Nov 6, 2018
Qbiotics $26m IPO For Rainforest Cancer, Wound Drugs; Global Kinetics PKG Improves Parkinson’s; Savings; Investors Mutual Takes 7% Of Ellex; Elixinol Takes 50.5% Of Elixinol Japan; Elixinol CEO Paul Benhaim, Associates Diluted To 63%; David Newman, Gabriel Ettenson, D&G Diluted To 10% In Elixinol
 
Nov 5, 2018
Cochlear Ordered To Pay $372m Over Patent; Appeal; Mach7 Works On Sentara Radiology Upgrade; Japan Patent For Resapp Respiratory Diagnostic; Vanguard Takes 5% Of CSL; MGC Takes ‘Cannaglobal, MGC Derma Sale’ Halt To Suspension
 
Nov 2, 2018
Dr Boreham’s Crucible: Cryosite; Living Cell: ‘18-Month 80-NTCell Benefit For Parkinson’s’; Rhinomed Raises $5m, Share Plan For $1m More; Biocurate, Novartis To Accelerate Drug Discovery; Court Orders Cellmid To Pay Ikon $939k; Mexican, Hong Kong Patents For Orthocell Celgro Scaffold; Optiscan Takes ‘Regulatory Approval’ Halt To Suspension; G Medical To Buy Telerhythmics For $2.7m; Hydroponics Supplies 1st Marijuana Patients; Genera AGM Extended, Rights Issue For $11.2m; Medibio Appoints David Kaysen CEO On $500k, Sacks US Staff
 
Nov 1, 2018
October BDI-40 Down 16%, ASX200 6%, Big Caps 7%, NBI 15% - Volpara Up 52%; Bionomics Down 86%, Airxpanders 39%; Reva Launches Fantom Encore; Post-Market Trial; MTP Connect, Federal Government: ‘$6b Regenerative Medicine’; India Approves Polynovo Novosorb; Myovatec Distributor; Cardiex, Blumio Wearable BP Sensor Trial; Oventus Receives $1m Federal R&D Tax Incentive; Cellmid Repays R&D Loan, Expands US Évolis Availability; Race Appoints Biosynergy For Bisantrene Deals; Credit Suisse Below 5% In Bard1; Creso Launches Cannaqix50 For Chronic Pain In Brazil; MGC Requests ‘Cannaglobal, MGC Derma Sale’ Trading Halt; Micro-X Has Less Than Two Quarters Cash; Avita AGM To Vote On 15m CEO Dr Mike Perry Options; Neurotech AGM For 609k Director Shares; Fisher & Paykel Appoints Neville Mitchell Director; Admedus Appoints Stephen Denaro Director, Co Sec; Dr Dean Moss Replaces Ausbiotech Director Lawrence Gozlan; Ausbiotech J&J Gongs: Dr Anna Lavelle, MDGH, Telix, Microba
 
Oct 31, 2018
Resapp ‘Very Pleased’ With Results; ‘Beats Stethoscope’; Resonance: ‘Unnamed US Pharma $1m Trial Contract’; Opthea Receives $12m Federal R&D Tax Incentive; Biotech Daily AGM Reporting Policy; Mesoblast AGM For 990k Director Options; Stemcell AGM For 18.6m Director Options; Correction: Recce; Optiscan Requests ‘Regulatory Approval’ Trading Halt; Rhinomed Requests ‘Capital Raising’ Trading Halt; Founder Yacov Geva Lends G Medical $9.9m More; Raises $4.5m; Invitrocue Has Less Than Two Quarters Cash; Fund Raising; Stemcell Has Less Than One Quarter Cash; Medical Developments To Lose 12-Year Director Dr Harry Oxer; Bioscience Managers Appoints Dr Kate Rowley
 
Oct 30, 2018
Resapp Misses 1st Primary Endpoint, Mixed US Trial Results; Allan Gray Invests $10m In Osprey; $10.5m Rights Issue; Medlab: From Phase I Nanabis Cancer Pain Trial To Phase II; Cellmid Receives $808k Federal R&D Tax Incentive; Imagion Has One Quarter Cash, ‘More Coming’; Medigard Licences Kunovus KT009 For Disc Degeneration; Biotron Tells ASX: HIV Trial Data ‘Currently Confidential’; Optiscan AGM For 1.94m Director ‘Rights’, 12.8m Options; Recce 250k Director Dr John Prendergast Shares AGM; Invitrocue AGM For 6m Director Options; Zelda AGM For 25m CEO Dr Richard Hopkins Options; Tim Robertson, Farjoy Take 11.5% Of Medlab; MGC Epilepsy Action Online Information, Access Portal; Creso Edible Marijuana R&D Centre Of Excellence
 
Oct 29, 2018
Clinuvel’s Vallaurix Expands Laboratory To Analytics; Anatara Detach For Piglets Approved; Pork CRC Options; Cann Wins Victoria Marijuana Resin Supply Contract; Pharmaust Develops Monepantel GMP Method; Resapp Extends ‘Smartcough-C-2 Trial’ Suspension; Osprey Requests Capital Raising Trading Halt; G Medical Requests ‘China Facility Audit’ Trading Halt; Mayne $6m CEO Loan Shares, 50% Pay Pool Rise AGM; Phil Hodges; Clarification: Opthea AGM; Paradigm AGM For 300k CEO Paul Rennie Loan Shares; Genetic Signatures 200k CEO Dr John Melki Options AGM; Brain Resource Name Change To Total Brain AGM; Mach7 Has One Quarter Cash, ‘Seasonal Costs Down’; Platinum Takes 11.5% Of Kazia; Credit Suisse Takes 6% Of Bard1; Admedus Loses Director, Co Sec Catherine Costello; Prescient Appoints Dr James Winkler For Business Development
 
Oct 26, 2018
Dr Boreham’s Crucible: Biotron; Opthea 12-Week Opt-302 Combination For DME ‘Positive Data’; Cancer Therapeutics CRC $668m Pfizer Collaboration; Neuren, Acadia Negotiate Trofinetide For Rest-Of-World; Mayne $45m For US, Australia Halobetasol For Psoriasis Rights; Cardiex $300k Astrazeneca Sphygmocor Contract; Somnomed One Quarter Cash; Better Quarter Coming; Compumedics AGM Rolls Director Dr Alan Anderson; Uscom AGM For 1.2m Chairman Prof Robert Phillips Rights; Bioxyne AGM For 7.5m Director Rights, 1m Options; Opthea AGM For 7m Director Options; Nuheara AGM For 3m Director Kathryn Foster Options; Auscann AGM For 67% Directors Fee Pool Hike To $500k; Starpharma To Vote On 675k More CEO Performance Rights; Phosphagenics Pleads Schultz To ASX 27% Query
 
Oct 25, 2018
Victoria $1.5m For CSIRO Biologics Manufacturing Facility; Australia-Texas Medical Center Collaboration; Paradigm Raises $9m; PPS Deal To Treat Retired US Athletes; Patrys Receives $3m Pat-Sm6 Settlement; Redhill Assesses Final Phase III RHB-105 Heliobacter Patient; Oncosil: ‘Analysis Backs Brachysil For Pancreatic Cancer’; Avita Begins Recell Trial For Paediatric Burns; Compumedics China JV Talks ‘Stalled’; $1.1m China Order; Cann Collaborates With CSIRO On Medicinal Marijuana; Credit Suisse Takes 5% Of Bard1, Again; Airxpanders EGM 22% Oppose Chair Barry Cheskin Shares; Bluechiip AGM For 2.3m CEO ‘Performance’ Rights; Adalta 375k CEO Replacement Options AGM
 
Oct 24, 2018
Mesoblast Expands JCR Deal To Epidermolysis Bullosa; Proteomics Licences Promarkerd For Spain; Wins WA Gong; Adalta Receives $2m Federal R&D Tax Incentive; Resapp Takes ‘Smartcough-C-2 Trial’ Halt To Suspension; Euro Patent For Invictus Transmucosal Tocotrienols; Bard1 Granted Additional China Patent For Cancer; Memphasys Tells ASX: Anova News ‘Not Material’; Queensland Bauxite, Bonify 3t Import-Export Marijuana Deal; Medibio $30k Unnamed Company Contract; Actinogen 18m Directors Options AGM; Proteomics 800k Director Options, 316k Shares ‘In Lieu’ AGM; Proteomics Founder Director Dr John Dunlop To Retire; Respiri Appoints Dr Tom Duthy Director
 
Oct 23, 2018
Bard 1: ‘Breast Cancer Blood Test 86% Accurate’; Telix Starts Zircon TLX250 Renal Cancer Imaging Trial; Phosphagenics $425m Mylan Case ‘Progress’; Nuheara Receives $1.9m Federal R&D Tax Incentive; Hong Kong Approves Medical Developments Penthrox; Japan Patent For Orthocell Celgro Collagen Device; Fisher & Paykel ‘Court Finds Infringed Resmed Patent’; Resonance Pleads Schultz To ASX 86% Query; Correction: Resapp; IDT Loses 2nd Strike Vote, Wins Spill Vote, Again; Patrys 24m Director Options, 60% Director Fee Pool Hike AGM; Paradigm Requests ‘Capital Raising’ Trading Halt; Esense To Supply E-Quits Marijuana Terpenes; Biotron Appoints Prof Stephen Locarnini Director; Invitrocue Appoints Dr Gary Pace Director; Anatara Appoints Product Development Advisory Board; Neurotech: Prof Emanuela Russo CSO, Advisory Board; Stemcell Glenn Davies, Ee Ting Ng In; Chair Jamie Khoo Out 
 
Oct 22, 2018
One Week To Ausbiotech Melbourne, Brisbane Conferences; Memphasys, Anova To Validate Felix Sperm Separator; Imagion Rights Offer Raises $411k Of Hoped-For $4.3m; Kazia, Dana-Farber Trial GDC-0084 For Breast Cancer To Brain; Antisense Inventor Dr Frank Bennett Shares $4m Prize; Resapp Requests ‘Smartcough-C-2 Trial’ Trading Halt; Invictus: Capstone Supplement Manufacture For US Launch; Actinogen To Close Xanamem Alzheimer’s Trial Recruitment; Peter Manley Replaces Genetic Signatures CFO Mark Langan; Invitrocue: Prof Iyer Advisor Chair, CSO Dr Dasgupta Goes; LBT Loses 12-Month Director Matthew Michalewicz; Erlyn Dale, Winton Willesee Replace Creso Co Sec Sarah Smith; Noxopharm Appoints Dr Greg Van Wyk CMO
 
Oct 19, 2018
Dr Boreham’s Crucible: Redhill Biopharma; MGC Derma Sale To Cannaglobal Delayed; Queensland Bauxite To Distribute Pharmocann Products; Factor Has Less Than 2 Quarters Cash, ‘Pivotal Trial Ending’; Brain Less Than 2 Quarters Cash, ‘Significant Revenue Rise’; Pharmaxis AGM For 690k More CEO Performance Rights; Prescient AGM For 2m CEO Steven Yatomi-Clarke Options; Race 4m Director Options AGM; Living Cell Pleads Schultz To ASX 177% Query; Stemcell Pleads Schultz To ASX 28% Query; Respiri Hires M&C Saatchi To Launch Wheezo Asthma Detector
 
Oct 18, 2018
Telix Starts TLX101, Radiotherapy Glioblastoma Trial; Cynata Stem Cells Impact Brain, Skin Cancers In-Vitro, Mice; Kazia Raises $3.4m, Share Plan; Elixinol To Add Medical Marijuana To OTC Hemp Foods ‘Soon’; Avita 1st US Recell Sales; Oventus Trials Show Significant O2vent Benefit; European Patent For Regeneus Progenza Fat Stem Cells; Esense Tells ASX Aware Query $25k Sales ‘Not Material’; CSL 16% Oppose $8.5m CEO Paul Perreault Shares, Again; Charter Life Sciences Diluted To 20% Of Visioneering; Novita Completes Sale Of Newly To Healthcarelink; Memphasys Pleads Schultz To ASX 65% Query; ASX Misses 148%; Ellex Appoints Dr David Lubeck CMO
 
Oct 17, 2018
Acrux New Generic Testosterone FDA Application; Airxpanders: ‘Radiation OK With Aeroform Breast Expander’; CPS Underwrites $4.7m Expiring Biotron Options; Proteomics Receives $834k Federal R&D Tax Incentive; Telix, Radboud TLX250 Renal Cancer Manufacturing Deal; Prescient, Unnamed US Company New Formulations Work; Nuheara Welcomes US FDA De Novo Device Path; Impedimed 44% Remuneration 1st Strike; Alchemia Pleads Schultz To ASX 187.5% Query; Suda Pleads Schultz, ‘Tweets’ To ASX 100% Query; Resapp Pleads Schultz To ASX 24% Query, Media After; MGC Pleads Schultz, Canada Marijuana Law To ASX 25% Query; Kazia Takes ‘Capital Raising’ Halt To Suspension; Clinical Genomics Mary Padbury, Katherine Kalin To Board
 
Oct 16, 2018
FDA Approves Eyepoint (Psivida) Yutiq (Durasert); Telix: Seibersdorf To Manufacture TLX101 For Glioblastoma; Cardiex To Pay More Than $4.6m For 50.5% Of Inhealth; Factor Hires Taylor Collison For VF001 Leg Ulcer Deals; Medibio Back To Bioprospect Future Board Spill AGM; Phylogica 10m CEO Dr Rohan Hockings Options AGM; Antisense Pleads Schultz To ASX 59% Query; ASX Misses 159%; MGC Requests ‘ASX Price Query’ Trading Halt; Prudential (M&G) Reduces To 14% Of Mesoblast; Australian Ethical Takes 7.4% Of Actinogen; Peter, Diana Diamond Take 12.2% Of Novita; Hydroponics Welcomes Canada Recreational Marijuana; Esense Requests ‘Commercial Supply Agreement’ Trading Halt
 
Oct 15, 2018
Telix: Study Backs Cancer Imaging Trial; ANMI, Cyclotek Deals; Optiscan Starts Breast Cancer Margin Trial; Adalta Ad-214 ‘Major Manufacturing Milestone’; Esense-Lab Raises $3.15m; Medibio Receives $3m Federal R&D Tax Incentive; Biotron Receives $1m Federal R&D Tax Incentive; Pharmaust Monepantel ‘Palatable To Beagles’, Activity; Kazia Requests ‘Capital Raising’ Trading Halt; W Whitney George Takes 22% Of Rhinomed; Tiga Takes 12% Of Simavita; Living Cell AGM For 3.4m CEO, Director Options
 
Oct 12, 2018
Dr Boreham’s Crucible: Novita Healthcare; WEHI: New Mouse Model Mimics Complex Human Cancers; University Of Melbourne, Beijing No 1 Biochemical Partner; Tasly Pays, Invests $57m In Mesoblast For China Heart Deal; Cyclopharm FDA 505 (B) 2 Technegas Path ‘Lower Cost, Risk’; Alcidion Q1 Receipts Up 229% To $5m; Cash Flow Positive; Volpara Sells 1st Public Sector Breast Screen Enterprize; Impedimed Completes Xitron Technologies Sale; Sienna AGM For 1.8m Director Options; Hydroponics 6m Options, 380k Shares, Name Change AGM; Zelda CEO Dr Hopkins Pay Up To $300k, Option Prices Down; Jianfang Wang Below 5% In Stemcell United; Cardiex Requests ‘Material Transaction’ Trading Halt
 
Oct 11, 2018
Pharmaxis: LOXL2 Drug ‘Highly Meaningful Enzyme Inhibition’; Saudi Arabia Approves Medical Developments Penthrox; Resapp Claims Sleep Apnoea Algorithms ‘90% Accurate’; Orthocell Receives $2.5m Federal R&D Tax Incentive; Cardiex: CEO Craig Cooper, Director Niall Cairn $1.5m; Zelda Ends Chile Marijuana Research Program; TGA Approves MGC Marijuana Cannepil For Epilepsy; CVC Takes 12% Of Universal Biosensors; Simavita: Post-Placement Substantial Holders In, Out, Diluted; Suda Appoints Andrew Curtis For US Business Development; Clarity Appoints Prof Jason Lewis To Advisory Board 
 
Oct 10, 2018
Cochlear Investigates ‘Fully Implantable’ Hearing Aid; Clinuvel UK Nice Scenesse EPP Decision ‘Remitted’; Telix, Genesiscare TLX101 Glioblastoma Compassionate Use; Childrens Hospital Foundation $10m For Brain Cancer; MTP Connect $690k For Three Projects; Actinogen Receives $3.2m Federal R&D Tax Incentive; Kazia Completes Cantrixil Ovarian Cancer Dose Escalation; Impedimed Starts US Sozo Heart Failure Trial; Zelda Begins US Marijuana Autism Trial; Queensland Bauxite’s Medcan Wins Marijuana Licences; Immuron 437k Director Shares, 2m Options, 43% Fee Pool AGM; Correction: MGC; LGCc Diluted Below 5% In Bluechiip; Medadvisor Appoints James Rotsart, Lucas Merrow Advisors
 
Oct 9, 2018
Visioneering: Medilens Nordic 1st Naturalvue Euro Distributor; Probiotec Completes $13.5m Branded Products Sale To Inova; Phylogica Receives $2.9m Federal R&D Tax Incentive; Resapp Requests ‘Sleep Apnoea Trial’ Trading Halt; MGC Requests ‘TGA Application Deal’ Trading Halt; NZ Harbour Asset Management Takes 5% Of Volpara; Investors Mutual Reduces To 6% Of Mayne Pharma; Creso To Release 23m Escrow Shares; Marijuana Beer Launch; Nanosonics 54k CEO Michael Kavanagh Rights, 287k Options AGM; Cellmid AGM For 630k Director Shares, 33% Pool Hike; Esense Placement, Share Capital EGM; Nuheara: Ex Microsoft, Doppler Exec Brian Hall Advisor
 
Oct 8, 2018
Victoria Government $300k For Ballarat R&D Collaboration; Medical Developments, Daiichi Sankyo For Penthrox In China; Patrys $50k Federal Grant For Yale Breast Cancer Studies; Volpara Pleads Schultz, Analyst Report To ASX 27% Query; Analytica Appoints Unnamed Pericoach Manufacturer For US; Creso Applies For Canada Marijuana Licence; $2.7m Loan; Ausbil Reduces To 6.4% Of Bionomics; FIL Below 5% In Starpharma; Resonance AGM For 21.5m ‘Employee’ Options; Imugene Leslie Chong Pay Rise, Options, Paul Hopper Options
 
Oct 5, 2018
Dr Boreham’s Crucible: Simavita; Prana: ‘PBT434 Targets Key MSA Pathology’ In Mice; GI Dynamics: Intertek ‘Notified Body’ For Endobarrier CE Mark; Benitec AGM For 10m Executive Chair Dr Jerel Banks Options; MMJ EGM Backs Change, 25% Oppose Director Options; Memphasys: Alison Coutts 16%, Andrew Goodall 24.5%; Clinuvel Stan McLiesh: ‘I’ll Retire On FDA Scenesse Approval’
 
Oct 4, 2018
Simavita Placement, Convertible Notes Raise $3m; Patrys Targets Breast And Brain Cancer For PAT-DX1; Orthocell: ‘Celgro Improves Outer Bone Repair’ In Rats; Factor Last Leg Ulcer Patient Treated; Results Next Month; Airxpanders Aeroform Study Satisfaction, No CO2 Leaks; Adherium Hailie In Smartairla Asthma Program; Neurotech Mente Autism In Netherlands, Yemen; Study Plans; Fatima Dickey, Richard Bayles, Lagoda Below 5% In Clinuvel; Imugene Appoints Dr Josep Tabernero Advisor; Pharmaxis Loses Director Dr Simon Buckingham; Dr Wenyi Gu Replaces Admedus Director Dr Simon Buckingham; Neurotech Appoints Prof Neil Fong Director
 
Oct 3, 2018
Kazia Starts US GDC-0084 Paediatric Brain Cancer Trial; Telix: Cardinal To Prepare, Distribute Prostate Cancer Kit; Bluechiip Share Plan Raises $1.95m, Total $7.45m; Recce Receives $680k R&D Tax Incentive; Painchek, Leecare Aged Care Collaboration; Rhythm Colostat Test On-Track; Pauline Moffatt Co Sec; Medibio Launches Ilumen Corporate Health Platform; Hishenk Takes 14% Of Kazia; Sue MacLeman Starts As MTP Connect Chair
 
Oct 2, 2018
Bionomics Falls 69% As ‘BNC210 Fails PTSD Primary Endpoints’; Que Q-122 Phase II Post-Breast Cancer Hot Flush Trial; Resapp Sleep Apnoea Study Results ‘Within A Week’; Visioneering Appoints Australia, New Zealand Distributors; Neurotech Submits US FDA Mente Autism Application; Auscann Online Medical Marijuana Courses; Lifespot Acquires Seng Vital Cannabis Vaporizer; G Medical Hires Unnamed Underwriter For Nasdaq Offer; Richard Cashin Takes 23% Of GI Dynamics; Australian Ethical Below 5% Of Immutep; Neville Bassett Replaces Pharmaust Director Dr Wayne Best
 
Oct 1, 2018
September BDI-40 Up 11%, ASX200 Down 2%, Big Caps Down 9% - Bionomics Up 106%, Clinuvel 49%; Prescient Down 15%; Rhinomed, Columbia Care Sign 12-Year Nasal Marijuana Deal; Micro-X Notes Raise $3m; Leo ‘The Gun’ Khouri Takes Medibio Back To Bioprospect Future; Clinuvel To Trial Scenesse For Variegate Porphyria; Probiotec Completes $24.5m Facility Sale, Leaseback; Auscann, Dayacann, Khiron To Promote Medical Marijuana; Imugene: Pravin Kaumaya Advisor, Ex-CSO Urusla Wiedermann; Race Appoints Tom Lee For Partnering, Funding
 
Sep 28, 2018
Dr Boreham’s Crucible: Footy Finals Bio-Sports Special; Biotron Up 105% On BIT225 HIV Combo ‘Significant Benefit’; Elixinol Raises $40m; Bionomics Requests ‘BNC210 PTSD Trial’ Halt; Oncosil AGM To Votes On 3.3m CEO Daniel Kenny Loan Shares; CVC Takes 9.4% Of Universal Biosensors; ‘Freeman Road’ Reduces To 6% Of Resapp; MMJ Postpones Phytotech Sale EGM One Week; Anatara Loses Director Iain Ross
 
Sep 27, 2018
Atomo Signs Mylan For Developing World Rapid HIV Test; Clinical Genomics ‘Can’t Confirm, Deny’ AFR $40m IPO; Orthocell: ‘Silver-Coated Celgro Prevents Infection’ In-Vitro; Invion, Chronic Airway Hire R&G For China Nadolol For COPD; Australian Ethical Reduces To 5% Of Immutep; Botanix BTX1308 Psoriasis Trial Approved; MGC To Sell Marijuana Derma Division To Cannaglobal; Micro-X Requests ‘Capital Raising’ Halt; Elixinol Requests ‘Capital Raising’ Halt; Simavita Takes ‘Placement’ Halt To Suspension; Sienna Loses Director Dr John Chiplin; Auscann To Lose M-D Elaine Darby, Gains Dr Paul MacLeman
 
Sep 26, 2018
J&J Lifescan $44m For Universal Biosensors Strip Fee Rights; ASIC: Ex-Sirtex CEO Gilman Wong Insider Trading Charge; Zelda Doses 1st Marijuana Insomnia Patient; Avita Receives $1m Federal R&D Tax Incentive; IDT 10% Share Buy-Back, Unmarketable Parcel Facility; BVF Partners, Mark Lampert Take 23% Of Pharmaxis; BVF, Mark Lampert Reduce To 15.7% Of Opthea; Painchek To Release 254m Escrow Shares
 
Mesoblast MPC-150-IM ‘Safe’ For HLHS In Children; Invion ‘Photosoft Oral, IVX-P02 Kill Cancer Better, In-Vitro’; Paradigm Claims PPS 52% Reduction For OA Knee Pain; MGC: Varm Cosmo $1m Default; Canada Deal Suspension; Probiotec Releases 2m Escrow Shares; Bioxyne Pays $121k For Indonesia PT Gamat Utama For Sales; Simavita Requests ‘Placement’ Trading Halt; Arix Takes 11% Of Pharmaxis; JCP Below 5% Of Nanosonics; JCP Below 5% Of Osprey 
 
Sep 24, 2018
Immutep, Merck KGaA, Pfizer Cancer Trial; FDA Clearance For Volpara Enterprise, Density, Live; Valeant Fights Acrux, 13 Others On Generic Jublia; Oncosil Receives $4.3m Federal R&D Tax Incentive; Dimerix AGM Votes On 6.35m CEO Dr Nina Webster Options; Airxpanders Votes On 29m CEO Frank Grillo Shares; Elixinol Takes 50.5% Of Japan Hemp Company; Elixinol Japan; Noxopharm’s Nyrada Discovers IRAK4 Inhibitor
 
Sep 21, 2018
Dr Boreham’s Crucible: Paradigm Biopharma; US FDA Approves Avita Recell For Severe Burns; Ellex Trial Misses Endpoint, AMD Progress Slowed Trend; Imugene Hires Ambiopharm For Key-Vaxx; Patent Application; Acrux Director ‘Rights’, Potential Spill AGM; IDT AGM To Vote On Directors, Potential 2nd Strike Spill; OBJ 60% Directors Fees Hike, Potential Spill AGM; Cogstate AGM To Vote On 1m CEO Brad O’Connor Options; FIL Takes 10.5% Of Resapp; MGC Requests ‘Canada Marijuana Deal’ Trading Halt; Medibio Director Jack Cosentino Out, Jennifer Solitario In
 
Sep 20, 2018
Biocelect, 60 Degrees Tafenoquine For Malaria FDA, TGA Ok; Mesoblast: ‘69% Day-100 Paediatric GvHD Survival’; GI Dynamics Raises $7m; Crystal Amber Note; Consolidation; Imagion $4.3m Rights Offer; Osprey, GE US Kidney Health Education Program
 
Sep 19, 2018
Medical Developments Plan Raises $7.5m Of Hoped-For $5m; Resapp Raises $7.5m; Cynata ‘MSCs Relieve Cytokine Release Syndrome’ In Mice; Proteomics, Dublin’s Atturos Join Forces For Diagnostics; Brain Expands, Renames Technology ‘Total Brain’; Medical Dev Chair David Williams Increases, Diluted To 14.5%; Benitec Appoints Dr Gregory Reyes Senior Scientific Advisor
 
Sep 18, 2018
CSL: TGA Approves Hizentra For CIDP; Memphasys Works With Monash On Felix Sperm Separation; Pharmaxis: 30% Oppose Placement; Edward Rayner Elected; Italy’s Vision Group Trials Nuheara Iqbuds Boost; Lifespot Buys Seng Vital For Marijuana Vaporizer; HK Julian Biotech, Wu Yanheng 19% Of Admedus; Zhang Overlap; Race Chairman Dr William Garner Transfers, Reduces To 18.5%; Elixinol To Trade On US OTCQX; Imugene Appoints Mayo’s Prof Tanios Bekaii-Saab Advisor
 
Sep 17, 2018
Race Hires NSF For Bisantrene FDA Pathway; Genetic Technologies ‘Invited’ To Market Cancer Test In China; Mesoblast: Tasly Wins China Approvals; Micro-X Receives $4m Federal R&D Tax Incentive; Loan Repaid; Impedimed Votes On 2.5m CEO Options, 3m ‘Performance’ Rights; Resapp Requests ‘Capital Raising’ Trading Halt; Imagion Takes Capital Raising Halt To Suspension; Acorn Below 5% In Telix; Zhang Lishan, Star Bright, Associates Take 19.99% Of Admedus
 
Sep 14, 2018
Dr Boreham’s Crucible: Elixinol Global; Opthea Presents More Phase I/II OPT-302 Wet AMD Data; Qld Bauxite To Be Cann Global, Buy Marijuana Companies; Kazia $1.25m Shares For Paul Hopper, Leslie Chong; CSL $8.5m More CEO ‘Performance Rights’ AGM; Lifespot Requests ‘Acquisition’ Trading Halt; FIL Reduces To 6% Of Starpharma; Jim Craig, Bellwether Take 6.6% Of Bluechiip; Director Dennis Eck Takes 6.4% Of Cellmid
 
Sep 13, 2018
Biotech Revenue Up 17% To $17b; Non-Big Cap Up 6% To $1.6b; Biotech Daily Top 40: Sirtex Out, Starpharma Up, Paradigm In; Genesiscare Invests $5m In Clarity For Cancer Collaboration; Eyepoint Revenue Down 61% To $4.1m, Loss Up 188% To $74m; Redhill Meets FDA For 2 Phase III RHB-102 IBS Trials; Recce Takes Radium R&D Tax Incentive Loan; Imagion Requests Capital Raising Halt; Goodbye 1-Page
 
Sep 12, 2018
CSIRO Fund Raises $232m; 3 Of 9 Investments Biotech; Federal Court OK, Sirtex Departs Tomorrow; Phylogica Raises $9.1m; Mouse Kidney Data Takes Cellmid CAB102 To FDA, EMEA; Proteomics To Receive $928k From Sale Of CPR Shares; Visioneering Plan Raises $334k Of Hoped-For $3m; Total $9.2m; Suda: Priorities; Hunts Business Development Head; Licences; Cochlear $1.7m CEO Dig Howitt Options, Rights AGM; Up To 22% Of Cynata Oppose $1.8m Director Options Loans; 1-Page (European Cannabis Corp) To Delist From ASX; Auscann Trades On US OTCQX; FIL Below 5% In Clinuvel
 
Sep 11, 2018
Telix $14m Cash, Scrip For Atlab, BZL Prostate Cancer IP; Federal Government: $10m For Six Rare Disease Trials; Imugene Phase Ib HER-Vaxx Cancer Trial Recruited; Goodbye Innate, Welcome Amplia; Sirtex Departs ASX On Thursday; Fisher & Paykel Seeks Resmed US Exclusion Order; Medlab Wins Marijuana Product Export Licence; Suda Requests Unspecified Trading Halt; Phylogica Takes 3¢ Capital Raising Halt To Suspension; Inbridge Below 5% Of Invitrocue; Credit Suisse Below 5% Of Bard1; Dr Göran Ando Replaces Eyepoint Chair Dr David Mazzo; Nuheara Appoints Philip Newton ‘Chief Sales Officer’
 
Sep 10, 2018
Bluechiip Raises $5.5m, Share Plan; Sirtex Voters 99.7% Back $1.9b CDH Bid; 92.6% Don’t Vote; Phosphagenics Questions Mylan Generic Daptomycin Sales; Correction: Botanix Pharmaceuticals; Painchek Licences Application To Allity Aged Care; US Okays Novita Tali Train For ADHD; Pharmaust: Cancers Sensitive To Monepantel In-Vitro; Imagion Optimizes HER2 Breast Cancer Test Nanoparticles; Australian Patent For Invion Photosoft Cancer Therapy; Medadvisor To Use Patient Database For Trial Recruitment; Suda Wins Federal Home Affairs ‘Trusted Trader’ Status; Telix Requests ‘Acquisition’ Trading Halt; Anteo’s ‘Short Term’ CEO Christopher Parker Continues
 
Sep 7, 2018
Dr Boreham’s Crucible: Botanix Pharmaceuticals; S&P ASX300: Clinuvel, Polynovo In; Impedimed Out; Osprey, Device Access, Cardiologic Take Dyevert To UK; Sirtex Receives $1.7b From CDH Genetech & China Grand; Micro-X Wins $2.4m Government Funding; Respiri Hires SRX To Manufacture New Wheeze Test; Phylogica Requests ‘Capital Raising’ Trading Halt; Director Simon Panton, Southam Increase To 18% In Resonance; Oventus CEO Chris Hart Starts On $400k, CTO Neil Anderson $225k; Ausbiotech Invest In Melbourne, Brisbane Conference
 
Sep 6, 2018
Federal Government, Movember $12m For Prostate Cancer; Bard1 Ovarian Cancer Test ‘97% Accurate’; Medibio Claims Heart Rhythm Depression Test ‘70% Accurate’; Eyepoint (Psivida) C-Code Reimbursement For Dexycu; Regeneus Receives $2.4m Federal R&D Tax Incentive; Nuheara Receives $145k Export Grants; Factor: Leg Ulcer Trial Results In November; MGC: AM Mangion Europe, Mid East, Nth Africa Distributor; Bluechiip Requests Capital Raising Trading Halt; Vivo Takes 19.9% Of Airxpanders; Novita Appoints Sue MacLeman Chair; Automic’s Lee Tamplin Replaces Cellmid Co Sec Raymond Ting; Suda Appoints Prof Stephen Watson Anagrelide Advisor
 
Sep 5, 2018
Invion Spins-Out INV102, INV104, Dr Mitch Glass To Chronic Airway; Starpharma DEP-Irinotecan Beats Irinotecan In Mice, Again; Immuron: Travelan Protects 6 Of 8 Primates From Dysentry; Opthea: DSMB Backs OPT-302 Wet AMD Trial; Redhill: 2nd Phase III Talicia (RHB-105) Helicobacter Trial Enroled; Goodbye Innate, Hello Amplia; Clinuvel: FDA Requests Scenesse Manufacturing Information; Noxopharm Doubles Prostate Cancer Trial Cohort To 32; Nuheara US Distribution Deal With Adco Medical; Sydney Optometrist 1st Visioneering Non-US Sale; FIL Decreases To 5.45% In Clinuvel; CVC Below 5% In IDT; Dr Chris Hart Oventus CEO, Neil Anderson CTO; Advisors
 
Sep 4, 2018
Telix Ready For TLX101 Glioblastoma Trial; Brandon, MRCF, Yuuwa $16m For Polyactiva Glaucoma Trial; Uni NSW: Switchable Car-T For Pancreatic Cancer, In Mice; Medlab: Sydney Uni Study Backs Nanocelle; Phosphagenics Up-To $416m Mylan Decision ‘Shortly + 3 Weeks’; Pharmaust: Monepantel Tablet For Dog, Human Trials; Zelda Appoints Hapa For German Manufacture, Distribution; Australian Ethical Reduces To 6% Of Immutep; Macquarie Group Takes 6% Of Patrys
 
Sep 3, 2018
August BDI-40 Up 4%, ASX200 1%, Big Caps 14%, NBI 5%; Resapp Claims ‘Outstanding’ Paediatric Diagnostic Results; Star Bright Lends Admedus $5m, Invests $7.7m; 4 Directors; Cellmid ‘Oversubscribed’ Share Plan Raises $1m; ITL Revenue Down 30% To $24m, Profit Down 12% To $3m; Admedus H1 Revenue Up 13% To $13m, Loss Up 31% To $11.5m; IQ3 Revenue Up 10% To $6.5m, Loss Down 98% To $1.1k; Cardiex Revenue Down 7% To $4m, Loss Down 9% To $4.4m; Pharmaust Revenue Down 1% To $3.3m, Loss Up 88% To $2.5m; Optiscan Revenue Up 63% To $2.2m, Loss Down 31% To $2m; Prescient Finds Improved Manufacturing Route For PTX-100; Immutep To Begin Cell Line Development For IMP761; Cynata Meets With Japan Regulators For Cymerus Stem Cells; Fisher & Paykel To Contest Resmed US Patent Case; Investors Mutual Reduces To 7.3% Of Mayne Pharma; Viburnum Funds Takes 7% Of Airxpanders; Peter, Diana Diamond Take 11.7% Of Novita
 
Aug 31, 2018
Dr Boreham’s Crucible: Cann Group; Starpharma: Astrazeneca Applies For DEP-BCL2/XL Patent; Ellex Revenue Up 10% To $79m, Loss Up 463% To $5m; TPI H1 Revenue Up 281% To $23m, Loss Down 58% To $3.7m; Avita Revenue Up 40% To $11.4m, Loss Up 29.4% To $16.5m; Medadvisor Revenue Up 56% To $6.6m, Loss Up 29.9% To $4.5m; Airxpanders H1 Revenue Up 291% To $5m, Loss Down 8% To $19m; Dorsavi Revenue Up 13% To $4.4m, Loss Down 4% To $3.7m; Medlab Revenue Down 3% To $4.3m, Loss Up 24% To $4.8m; Alcidion Revenue Up 21% To $4.2m, Loss Up 1% To $2.1m; Brain Resource Revenue Up 9% To $2.6m, Loss Up 134% To $23m; Rhinomed Revenue Up 26% To $2.2m, Loss Down 9.9% To $4m; Bioxyne Revenue Up 16% To $2.1m, Loss Up 71% To $1.3m; TBG H1 Revenue Down 5% To $1.7m, Loss Up 131% To $2.3m; Hydroponics H1 Revenue Up 295% To $1.3m, Loss Up 339% To $3.2m; Ellex: Novartis Competitor Withdrawal ‘Implications’; CVC Takes 8% Of Universal Biosensors; Merchant Funds Takes 9% Of Sienna; David Williams Takes 7.7% Of Sienna; Mason Stevens Takes 6.5% Of Patrys; John McBain Takes 7% Of Rhinomed; Resapp Requests ‘Trial Update’ Trading Halt; Living Cell Loses Roy Austin; Elizabeth McGregor Co Sec; Genera Appoints Dr Damian Pethica, Seong Chen; $11.2m Rights; Hydroponics CFO Jarrod White Ceases As Joint Co Sec
 
Aug 30, 2018
Cynata CYP-001 Stem Cells Phase I Safety, Efficacy For GvHD; Prescient: 2 PTX-200 AML Complete Responses; Extension Study; Sienna, RMH Study hTERT For Indeterminate Thyroid Cancer; DSMB Okays Medical Developments Youth Penthrox Trial; Compumedics Revenue Up 7.5% To $37m, Profit Up 113% To $2.8m; Clinuvel Revenue Up 52% To $26m, Profit Up 86% To $13m; Mesoblast Revenue Up 619% To $17m, Loss Down 54% To $48m; LBT ‘Rebate Revenue’ Up 0.6% To $6m, Loss Down 47.7% To $2.7m; Cryosite Revenue $5.9m, Loss $1.2m; Impedimed Revenue Down 15% To $5.2m, Loss Down 1.4% To $27m; Resonance Revenue Up 15% To $2.9m, Loss To $225k Profit; Immuron Revenue Up 32% To $1.8m, Loss Down 55.5% To $3m; Micro-X Revenue Up 144% To $1.6m, Loss Up 28% To $16.6m; G Medical H1 Revenue $1.4m, Loss Up 61% To $11.7m; MMJ ‘Loss Of Control’ Revenue Up 40,034% To $49m, Profit $34m; Botanix: FDA ‘Confirms’ Cannabidiol BTX1204 Eczema Trial; Medadvisor, Ebos, HPS Work On Hospital Drug Management; Oncosil Appoints Iqvia Market Advisor For The EU; Cellmid Neiman Marcus, Soft Surroundings Évolis Launch; Innate To Rename As Amplia; Director Niall Cairns, C2, Carnethy Take 15% Of Cardiex
 
Aug 29, 2018
ANU Clot Diagnostic Identifies Cardiac, Stroke Risk; Bluechiip Wins 3-Year, $16m Labcon Supply Deal; Antisense Doses 1st Patient In ATL1102 Duchenne Phase II Trial; China Okays Mesoblast, Tasly $55m Cardiac Stem Cell Deal; Medibio Loses M-D, CEO Jack Cosentino; Sirtex Revenue Down 7% To $221m, Profit Down 2% To $41.5m; Elixinol H1 Revenue Up 111% To $15m, Maiden H1 Profit $120k; Genetic Signatures Revenue Up 39% To $3m, Loss Up 22% To $3m; Proteomics Revenue Up 27% To $1.2m, Loss Up 57% To $1.4m; Medical Developments To Answer FDA Penthrox Questions; Neuren, Lanstead Pause Settlements For 120 Days; MMJ Phytotech Sale, Name Change, 1m Director Options AGM; Deutsche Bank Below 5% In Avita; G Medical Pleads Schultz To ASX 49% Query; Anatara: Sue MacLeman, Jane Ryan In; Jay Hetzel, Paul Grujic Go
 
Aug 28, 2018
Patrys, WEHI Win Victoria $100k For 7D10-PAT-DX1 For Cancer; Probiotec To Sell Impromy To Blackmores For $9m; Nuheara Revenue Up 61% To $4m, Loss Up 53% To $7.4m; Adherium Revenue Up 150% To $6m, Loss Down 27% To $9m; South Australia $4m ‘Low Cost’ LBT Loan Approved; Paradigm: Ross River Virus Phase IIa Recruitment Complete; Inbridge Reduces To 6.3% Of Invitrocue; Medibio Requests ‘Staff Changes’ Trading Halt; Anatara Loses Co-Founder, CSO Dr Tracey Mynott
 
Aug 27, 2018
Atmo, RMIT, Spect Win $300k J&J, Victoria Quickfire Challenge; Airxpanders Placement, Rights Raise $20.3m; Cellmid Revenue Up 23% To $7m, Loss Down 17% To $3.7m; Osprey H1 Revenue Up 69% To $1.6m, Loss Up 31% To $12m; Simavita Signs 1st Major Deal With Belgium’s Drylock; Noxopharm Claims Nyrada NYX-330 ‘Cholesterol Progress’; Medlab Multibiotic Safety, Tolerability Chemotherapy Trial; MGC Marijuana Cognicann For Dementia, Alzheimer’s Trial; Probiotec Sells Property For $24.5m, Leases Back; CSL $8m More CEO ‘Rights’ AGM; Resonance Details Trial Contracts; Dimerix Appoints Dr Nina Webster CEO, M-D; Starts On $300k
 
Aug 24, 2018
Dr Boreham’s Crucible: Visioneering Technologies; Resonance Claims 2 New Trial Contracts Worth $721k; Telix, Melbourne Uni, Peter Mac Work On Colorectal Cancer; Sienna Rights Offer Raises $3.6m, Total $5.2m; Mayne Revenue Down 7% To $530m, Profit To $134m Loss; Mach7 Revenue Down 16% To $9m, Loss Down 7% To $5m; Allegra Revenue Down 5% To $4.7m, Profit To $604k Loss; Probiotec Sells Branded Products To Inova For $13.5m; ITL Extends Blood Bank Contract; ASX Impedimed Aware Question, Ignores Share Jump; Seminars; Adherium Claims To Expand Vitalus Deal; Mitsubishi, Morgan Stanley Take 5% Of Medadvisor; MMJ Loses Joint Co Sec Eryln Dale
 
Aug 23, 2018
Biotech Daily Liberal Leadership Editorial; Telix Applies For European TLX250 Renal Cancer Trial; Publication Backs Impedimed L-Dex For Lymphoedema; Genetic Signatures Expects $417k More R&D Tax Incentive; Biotech Daily Editorial: Reporting, Maths And Tax Incentives; Probiotec Revenue Up 25% To $76m, Profit Up 54% To $4m; Cyclopharm H1 Revenue Up 5% To $6.3m, Loss Down 52% To $685k; Cann Posts Maiden $616k Marijuana Revenue; Burnet, Eliminate Hepatitis C To Eliminate Hepatitis C By 2030; Qatar’s Hamad Medical Corp Upgrades Mach 7 Platform; Proteomics Pipeline Progress, Mesothelioma Discontinued; Avita Begins Manufacturing Recell In US; Brett Crowley Replaces Uscom Director Sheena Jack; Imugene Appoints Dr Mark Marino Chief Medical Officer; Race Loses CSO Dr John Rothman, Gordon Beck; Clarity Appoints Dr Gillies O’Bryan-Tear Advisor; Goodbye Scigen
 
Aug 22, 2018
‘Expert Panels’ Back Global Kinetics PKG For Parkinson’s; St Vincent’s Buys 1st LBT Apas Independence; Victoria $3m For 30 Research Projects; IDT Revenue Up 39% To $13m, Loss Up 2097% To $17m, Impairment; Uscom Revenue Down 18% To $2.8m, Loss Up 9% To $2m; Immutep Posts $2.6m Revenue, Loss Up 36% To $12.8m; Somnomed Revenue Up 29% To $64m, Loss Up 158% To $8.6m; Acadia Pays Neuren $13.6m For Trofinetide Licence; Immutep Receives $1.9m French Tax Rebate; Actinogen: DSMB Backs Xanadu Phase II Trial, Again; Suda Wins SUD-003, SUD-004 South Africa Patent; Regal Takes 13.4% Of Visioneering; Kinetic Takes 6.7% Of Visioneering; Adalta Releases 24m Shares From ASX Escrow; Micro-X Loses Directors Jim McDowell, David Symons; Zelda: Prof David Casarett, Dr Dustin Sulak Advisors
 
Aug 21, 2018
Starpharma Revenue Up 34% To $5m, Loss Down 32% To $10m; Analytica Claims Pericoach Incontinence ‘Significance’; TGA Grants Suda GMP Facility Status; Genetic Technologies ‘Invited To Discuss China Entry’; Creso: Pharmacare UK Marijuana Cannaqix Distributor
 
Aug 20, 2018
Nanosonics Revenue Down 10% To $61m, Profit Down 78% To $6m; Correction: Anatara Lifesciences; Sirtex: China Grand Shareholders Approve Purchase; Admedus Further Extends Capital Raising Suspension; Creso Options Raise $1.2m Of Hoped-For $2.8m; Shortfall; Nuheara: Quantum To Sell Iqbuds Boost On Amazon; Arix Bioscience Takes 5.6% Of Pharmaxis; Adrian Trevisan, Paloma Reduce To 19.9% (18%) Of Neurotech; Australian Trademark For Noxopharm Veyonda (NOX66)
 
Aug 17, 2018
Dr Boreham’s Crucible: Anatara Lifesciences; Pharmaxis Revenue Up 182% To $51m, Loss To $18m Profit; Medical Dev Revenue Down 5% To $18m, Profit Down 87% To $243k; Bionomics Revenue Down 56% To $12.5m, Loss Up 258% To $25m; Acrux Revenue Down 86% To $3.4m, Loss Up 5,736% To $14.1m; Visioneering H1 Revenue Up 289% To $1.6m, Loss $10m; JCP Reduces To 6.2% Of Nanosonics; Tim Robertson, Farjoy Take 10.5% Of Medlab; Robert Lederer, RTL Group Take 8% Of Anatara
 
Aug 16, 2018
Resapp, US DARPA, Lockheed-Martin Partner For Combat Health; Telix, Nihon Partner For TLX250 For Renal Cancer In Japan; Memphasys Receives $593k Federal R&D Tax Incentive; Pro Medicus Revenue Up 14% To $36m, Profit Up 37% To $13m; Polynovo Revenue Up 59% To $6m, Loss Up 20% To $6m; Genetic Technologies, Zishan Health China J-V; Auscann Produces Final Dose Cannabinoid Hard Capsule; Micro-X Clarifies: Carrying Value A Non-Cash Impairment; 1-Page To Buy Back $5m Shares, Toronto IPO; QLD Bauxite Votes On 3 Marijuana Entities, To Be Cann Global; Allan Gray Reduces To 6% Of Pharmaxis
 
Aug 15, 2018
CSL Record Revenue Up 15% To $10.5b, Profit Up 29% To $2.4b; Redhill Raises $35m, Most For Australian Technologies; Visioneering $9m Placement, Share Plan For $3m More; Paradigm Claims ‘60% Reduction In Osteo-Arthritis Pain’; FDA Okays Pharmaxis Aridol Plant; $2m US Sales A Year; Actinogen: Xanamem Alzheimer’s Trial 75% Enrolled, Mindmate; Cann Supplies 1st Patients Aurora Medical Marijuana; Australian Patent For Resapp Respiratory Diagnostic; Regal Funds Reduce To 8% Of Prescient; Regal Reduces Below 5% Of Avita; Robert Peters Takes 18% Of Memphasys
 
Aug 14, 2018
Cochlear Revenue Up 9% To $1,351m, Profit Up 10% To $246m; TGA Approves Polynovo Novosorb For Australian Register; Federal, VC $6m For Paragen Hookworm Auto-Immune Drugs; CVC Reduces To 10.4% Of Cyclopharm; Innate Tells ASX: ‘Trading Halt Followed Trial Bad News’; Adherium Hailie Monitor Direct-To-Customer O-T-C Launch; Creso: Schmidgall For Austria, Northern, Eastern Europe; CSIRO Appoints Dr Cathy Foley Chief Scientist; Cochlear Director Prof Edward Byrne To Retire; Memphasys 15-To-1 Consolidation Record Date
 
Aug 13, 2018
Vale Bard1’s Prof Geoff Laurent: 23.2.1948 – 12.8.2018; FDA Clears GI Dynamics US Endobarrier Re-Start; NHMRC, MRFF, Federal $200m For 337 Research Projects; Sloan Kettering Starts Telix Kit Prostate Imaging Trial; Compumedics, Health 100 JV ‘Unexpected Complexities’ Delay; Cogstate Revenue Up 10% To $40m, Loss Down 12% To $778k; Universal Bio H1 Revenue Up 6% To $13.5m, Profit To Loss; Micro-X Expects Unquantified Xinray Impairment Charge; Cynata Lends Dr Ross Macdonald, Dr Stewart Washer $1.8m; Admedus Further Extends Capital Raising Suspension; Visioneering Technologies Requests ‘Capital Raising’ Halt; Merchant Group Takes 8.1% Of Rhythm; Macquarie Group Takes 6.2% Of Impedimed; Thorney Takes 12% Of TPI; Medicines Australia Appoints Dr Anna Lavelle Chair; MMJ: Medipharm Appoints Sybil Taylor, Michael Perron
 
Aug 10, 2018
Dr Boreham’s Crucible: Dimerix; Telix Kyzeo JV Extends Endocyte Agreement; Neurotech Ships Improved Mente Autism Devices; GI Dynamics Requests ‘Endobarrier FDA IDE’ Trading Halt; Australian Ethical Takes 11.5% Of Cyclopharm
 
Aug 9, 2018
Innate Ex-Director Chris Collins, Family ‘Insider Trading’; Federal $1.3m For 2 Men’s Health Grants; FDA Expands Avita Recell Compassionate Use To 108 Patients; Auscann Raises $1.9m Of Hoped-For $8m; Total $35.3m; Admedus, Summit Extend Distribution To 2026; Qbiotics: Virbac For EBC-46 Dog Cancer Sales In US, EU; Naos Takes 17% Of BTC Health
 
Aug 8, 2018
Federal $18m For 29 Women’s Health Grants; Medical Developments Raises $17m, Share Plan For $5m More; Genetic Technologies, Kentgrove $20m Draw Down Facility; Nanosonics Trophon2 North America, Europe Launch; Cyclopharm H1 Revenue Up 5% To $6m, Loss Up 15% To $1m; Admedus Extends Capital Raising Suspension; Mach7 Distribution Deal With Envoyai; Harvey Nichols Adds MGC Marijuana Derma To 2 More Shops; G Medical To List Chinese Subsidiary On Hong Kong Exchange
 
Aug 7, 2018
Acadia $630m For Neuren Trofinetide North America Rights; Immutep Doses Imp321 Tactimel Trial 4th Cohort; Alcidion: MKM Software For Alfred Health; Sienna Appoints Shaanxi Gaoyuan China Distributor; Canada Patent For Immutep LAG3, IMP731; IDT, Cann Marijuana Manufacturing Deal; JCP Reduces To 7.2% Of Nanosonics; Rhythm Releases 9.75m Escrow Shares; Scigen To Delist From ASX August 28; G Medical Requests Hong Kong Listing Trading Halt
 
Aug 6, 2018
Oneventures $100m Credit Fund; Pharmaxis Raises $24m, 3% Premium; Edward Rayner Director; Invictus, MIPS Tocotrienol Pro-Drug Proof-Of-Concept; Medical Dev Revenue Down 5%, Profit Down 87%; Trading Halt; Reva Amends Rutgers Licence; Paradigm: Phase IIb For Bone Bruising Recruited; Cann, Agriculture Victoria ‘More Marijuana R&D’; Admedus Takes Capital Raising Trading Halt To Suspension; Anteo Battery Material Transfer Agreement
 
Aug 3, 2018
Dr Boreham’s Crucible: IDT Australia; Resmed Revenue Up 13% To $3b, Profit Down 8% To $429m; Telix Eligible For $55m Off-Shore Spending Tax Rebates; Airxpanders Placement, Rights Offer For $20.3m; TPI: $9m Codeine Deal; Allegra Wins $2.4m For Kangaroo Ligaments; Pharmaxis Requests Placement Trading Halt; Genetic Signatures Names Australian Clinical Labs; Volpara: 900k In-The-Money Directors Options AGM; Mach7: Prof Siegel, David Chambers In; Dr Finch, Nobuhiko Ito Go
 
Aug 2, 2018
Medicines Australia Addresses Gender Inequality; La Trobe University $27m Medicinal Marijuana, Opium Hub; Sirtex CDH Genetech, China Grand Scheme Meeting; Acrux First-To-File For Generic Jublia For Nail Infection; Genetic Signatures Gen 2 Easyscreen Sales Contract; Uscom Launches BP+ Reporter Blood Pressure Interface; Polynovo Enrols US Novosorb Feasibility Trial; Resapp Completes Paediatric Respiratory Trial Enrolment; Genetic Technologies Signs Blockchain Agreement; Admedus Requests ‘Capital Raising’ Trading Halt; Adalta Releases 24.6m Escrow Shares; Cryosite Profit Warning; Queensland Bauxite Claims Marijuana Inhibits T-Cells; Israel’s Supermedic To Sell Creso Cannaqix To Middle East
 
Aug 1, 2018
July BDI-40 Up 4%, ASX200 1%, Big Caps 2%, NBI 6%; Federal $3m For Stem Cell Research; Suda Raises $6.8m; Airxpanders Revenue Up 649% To $5.7m; Capital Raising Halt; Pharmaust Receipts Up 0.3% To $3m; Stemcell United Has Less Than 2 Quarters Cash; Resapp Completes Smartcough-C-2 Enrolment; Patrys: PAT-LM1 European Patent; Queensland Bauxite Compliance, Capital Raising Suspension; ASX Approves 1-Page Delisting; Paradigm Wealth, Investment Admin Below 5% In Sienna; Prof Trevor Perrior Dines On Drug Discovery With RACI
 
Cellmid Raises $9m, Share Plan For $1m More; Biocurate Initial $1.5m For 6 Biomedical Research Projects; Redhill RHB-104 (Myoconda) Effective For Crohn’s Disease; Cynata: Cymerus Improves Cardiac Recovery In Rats; Immutep IMP321 Cancer Trial FDA IND Approved; Australian Patent For Recce Antibiotics; Biotech Daily Appendix 4C Quarterly Reports Policy; Admedus Q4 Receipts Up 68% To $7.6m; H1 $14m; Avita Receipts From Customers Up 22% To $9.6m; Mach7 Receipts Up 14% To $9.5m; Mesoblast Receipts Up 207% To $7.6m; Cellmid Revenue Up 21% To $6.7m; Adherium Receipts Up 127% To $5.4m; IQ3 Receipts Up 36% To $4.9m; Medlab Receipts Up 48% To $4.7m; Nuheara Receipts Up 114% To $4.1m; Immutep Receipts Up 313% To $3.5m; Rhinomed Revenue Up 24% To $2m; Uscom Receipts Down 26% To $2.1m; Hydroponics Receipts Up 316% To $1.4m; Micro-X Receipts Up 114% To $1.3m; One Quarter Cash; OBJ Receipts Up 339% To $1.2m; G Medical Has Less Than Two Quarters Cash; Hydroponics: ‘Endoca Medical Marijuana In Australia’; MGC Appoints Prof Wendyl D’souza Medical Marijuana Adviser
 
Jul 30, 2018
Clinuvel Receipts Up 32% To $23.7m, Q4 Cash-Flow Positive; Actinogen Expands Xanamem Indications, 3 New Studies; Regeneus: ‘RGSH4K Safe, Tolerable, Immune Response’; Opthea Doses First Patient In OPT-302 Phase IIa DME Trial; Phylogica Peptide With Cre Outperforms Cre In Mice; Elixinol Marijuana Revenue Up 103% To $14.6m; Brain Resource Receipts Down 3% To $2.4m; Genetic Technologies Appoints Swisstec Asia Distributor; Hydroponics Scraps Biofloral Canada Deal; Merchant Funds Takes 8% Of Sienna; David Williams Takes 5.6% Of Sienna; Empery Reduces To 8.2% In Immuron; Mitsubishi Below 5% In Impedimed; Queensland Bauxite Requests Marijuana Deal Trading Halt; Imagion Appoints Prof John Hazle Director; Bio-Melbourne: Molecules, Medicines & Markets
 
Jul 27, 2018
Dr Boreham’s Crucible: Resonance Health; Saudi Arabia Okays Polynovo Novosorb, Al Mofadaly Distributor; Ellex Sales Up 10.5% To $79m; Genetic Signatures Revenue Up 39% To $2.8m; Visioneering H1 Revenue Up 265% To $1.6m; Phylogica Peptides ‘Stronger’ For Cancer In Mice; Aphria’s ‘Biggest Marijuana Oil Export’ For Medlab Pain Trial; Federal Government Renews Nuheara Contract; FDA 510 (K) Clearance For Adherium Hailie Sensor; Cellmid Requests Capital Raising Trading Halt; Mitsubishi, Morgan Stanley Take 5% Of Impedimed; Deutsche Bank Reduces To 5.7% In Avita; Peter, Diana Diamond Take 11% Of Novita; Botanix Appoints Dr Stephane Levy, Jillian Chapas-Reed
 
Jul 26, 2018
Polynovo: Prof Greenwood, Novosorb For Greek Fire Victims; Orthocell Celgro 1st Sales, Use In Ireland; Opthea OPT-302 For DME ‘Safe, Well-Tolerated’, Phase II Begins; Probiotec: ‘Unaudited Sales Revenue Up 25% To $78m’; Sirtex CEO Andrew McLean To US On $852k, 12-Month Clause; CE Mark For Reva Motiv Peripheral Artery Stent; US Patent For Prescient PTX-200 For Ovarian Cancer; Telix, JFE Partner For TLX-250 Japan Kidney Cancer Trials; Innate Name Change To Amplia, 1.4m Director Options AGM

Jul 25, 2018
Telix: FDA Approves Drug File, Prostate Cancer Imaging Trials; FDA: Medical Developments Penthrox Trial ‘On Hold’; Somnomed Receipts Up 26% To $60.5m; Immuron Sales Revenue Up 29% To $2m; Medadvisor Operating Revenue Up 56% To $6.6m; Medlab Starts Phase IIa NRGBiotic For Depression Trial; Nuheara, Melbourne Uni To Study Iqbuds For Autism; Redhill Recruits 400 Patients For RHB-105 Helicobacter Study; IDT Discusses Remediation Plan With FDA, Products On-Market; David Phillips Replaces Suda BDM Nick Woolf
 
Jul 24, 2018
Cardiex: Blumio Sensor ‘Good For Cardiovascular Monitoring’; Orthocell: Celgro On Track For FDA 510(K); MMJ: ‘Satipharm Marijuana CBD Reduces Paediatric Epilepsy’; Hydroponics Completes Marijuana Property Lease; Brain, Tlex Partner For ‘Ancient Wisdom’; Creso: Adam Blumenthal Converts 1.5m Performance Shares; Edinburgh Uni Below 5% In Actinogen; MMJ ‘Less Than Two Quarters Cash, $1m Coming’
 
Jul 23, 2018
Imugene Key-Vaxx ‘Superior’ For Cancer In Mice; Prof Zielinski; Euro Patent For Innate’s AMP-886 For Cancer, Fibrosis; Impedimed Receipts Down 16% To $4.6m; Dorsavi Receipts Up 19% To $4.25m; Resonance Receipts Up 16% To $2.65m, Q4 Cash Flow Positive; Creso $2.7m Options Rights Offer; Mayne Pharma Buys Efudex For Up To $40m; Creso, Kunna Reduce Purchase Price; 1-Page: From Re-Listing For Medical Marijuana To De-Listing; Regeneus Pleads Schultz To ASX 27% Query; CVC Takes 7% Of Universal Biosensors; Platinum Takes 10% Of Adalta; Wentworth Williamson Takes 5% Of TPI; Antisense Appoints Nuket Desem For Clinical, Regulatory
 
Jul 20, 2018
Dr Boreham’s Crucible: Prana Biotechnology; Sienna Raises $1.6m; $3.6m Rights Issue; Novita Raises $2.8m, To Sell Newly To Healthcarelink; Cogstate Expects Revenue Up 9.6% To $39m, $2.6m Loss; Orthocell Additional Celgro Euro Patent; Kazia Files $136m US Sec ‘Shelf’ Registration; Alcidion One Quarter Cash, ‘Substantial’ Revenue Expected; Renaissance Below 5% In Genetic Technologies; Avita Hires 3 For US Recell Launch; Promotes Dr Katie Bush; Nanosonics Joint Co Sec Robert Waring Retires
 
Jul 19, 2018
Universal Biosensors H1 Revenue Down 6% To $13.5m; Osprey H1 Revenue Up 89% To $1.5m; 15 Quarters Of Growth; Alcidion Signs 3-Year, $2.6m NT Health Extension; Botanix, UQ Collaborate On BTX1801 For Skin Infections; Memphasys To Test Felix For IVF In Europe, Middle East; Nuheara Secures Production For Iqbuds Boost; Auscann Tells ASX: ‘Not Aware Of Funding At Price Drop’; Novita Takes Capital Raising Trading Halt To Suspension
 
Jul 18, 2018
Mesoblast China Cardiac MPC Deal - $54m Cash, Stock Upfront; Dorsavi: Stryker Leibinger Evaluates Vimove2; Federal $50m For Cancer Genome Analyses; Dimerix: Ethics Approval For 2 DMX-200, Phase II Trials; Race Wins Bisantrene FDA Rare Paediatric Disease Designation; Sienna Requests Capital Raising Trading Halt; Anatara To Partner Bromelain Gut Product; Zoetis Detail
 
Jul 17, 2018
Kazia Ready For 1st GDC-0084 Glioblastoma Dosing; Federal $6m For South Australian Research; Actinogen Shortfall Raises $560k; Total $16.6m; Proteomics: Biosanapharma $350k Contract, Near Break-Even; Orthocell 1st Italian Celgro Dental Sale, Use; ITL Expects $24.3m Revenue, $3.5m Ebitda; Recce Designs Phase I Recce-327 Antibiotic For Sepsis Trial; Novita Requests ‘Bookbuild For Newly’ Trading Halt; Creso Lists On Frankfurt Exchange, Hires German Advisor
 
Jul 16, 2018
Auscann Share Plan For $8m, To Take Total To $42.4m; Microba ‘Meta-Genomic Gut Microbiome Sequencing Kit’ Launch; Antisense Begins ATL1102 Duchenne Phase II Trial; Immuron: US Army Travelan Studies; CSIRO Shigella Vaccines; Reva Appoints Bio Vascular For Italy, 1st Fantom Italy Implant; Medical Developments: Spain Approves Penthrox; Factor Completes VF001 Leg Ulcer Trial Recruitment; Medibio Heart Rhythm Depression Test FDA Application; FIRB, US FTC Approve CDH Sirtex Acquisition; Genetic Technologies: Breast, Colorectal Cancer Tests; Race Requests ‘FDA Decision’ Trading Halt; Suda To Focus On US; 12 Term Sheets In Negotiation; MMJ: ‘$153k For 2.5% Of Embark For Marijuana Extraction’; Dr Richard Hopkins Starts As Zelda M-D
 
Jul 13, 2018
Dr Boreham’s Crucible: Cardiex (Formerly Atcor Medical); Federal $22m For Biomedical Translation Bridge Program; Adalta Placement Raises $4.25m, Share Plan; Sirtex Pays Varian $15.8m Break Fee; Kazia Sells Anti-Tropomyosin To Newly-Formed Trobio; Stemcell $13.5m Dragon’s Blood Deal With Rainbow Medical; Founder Dr Bruce Gray Corrects Sirtex Substantial; MGC European Marijuana Facility ‘GMP Certified’; MMJ: ‘Harvest Recreational Marijuana For BC Liquor’; Renaissance Reduces To 5% In Genetic Technologies
 
Jul 12, 2018
Actinogen Plan Raises $952k Of Hoped For $2m, Total $16m; Suda Increases Anagrelide Solubility For Oral Cancer Spray; Resapp Sleep Apnoea Diagnostic Trial ‘On-Track’; Bard1 Granted US Breast, Ovarian Cancer Test Patent; ACCC Starts ‘Cartel’ Proceedings Against Cryosite; JP Morgan Chase, Highbridge Below 5% Of Benitec
 
Jul 11, 2018
Resonance Ferrismart Wins CE Mark, TGA Approval; Admedus Implants First Aortic Heart Valve In Sheep; Founder Dr Bruce Gray Back To 5% Of Sirtex; Immuron Granted European Nash Patent; Adherium: Connecticut Children’s Trials Hailie; Cellmid: New Évolis Products In Japan, Australia, US; Hydroponics $2.5m Southport Facility ‘Worth $14.6m’; Noxopharm To Release 15.9m Escrow Shares; Adalta Requests Capital Raising Trading Halt; MGC Requests ‘Euro Marijuana GMP’ Trading Halt; Stemcell United Requests ‘Entry Into Contract’ Trading Halt; Mesoblast Appoints Shawn Tomasello Director; Hydroponics Appoints Ken Charteris CEO, Starts On $280k; Ellex Appoints Joaquin Wolff Itrack President
 
Jul 10, 2018
Clarity Starts Sartate For Meningioma Trial; Italy, Czech Republic Okay Medical Developments Penthrox; Orthocell Appoints Carrera UK Celgro Dental Distributor; US Patent For Regeneus Progenza Stem Cells; Oventus To Release 37m Shares, 1.2m Options From ASX Escrow; Private Portfolio Managers Take 7% Of Imugene; Anthony Barton, Associates Take 6% Of Phylogica
 
Jul 9, 2018
Benitec Up 124% On Up-To $892m Axovant Gene Therapy Deal; Admedus: Medical Instruments Adapt Italy Distributor; Gi Dynamics: Risk-Benefit Study ‘Endobarrier Safe’; Bionomics Phase II BNC210 For PTSD Trial Treated; Starpharma: FDA Accepts Vivagel BV NDA, Review Starts; Neurotech US 34-Patient Autism Trial Results ‘Positive’; Noxopharm: 3 Of 9 NOX66 Patients ‘Mild’ Adverse Events; Hydroponics Extends Endoca Marijuana Deal; Paradigm Pleads Schultz, Good News To ASX 24% Query; Invictus Appoints Lou Panaccio, Richard Estalella Directors
 
Jul 6, 2018
Dr Boreham’s Crucible: Alcidion Group; Alcidion 5-Year, $4.75m ACT Health Contract; Imugene Underwritten Rights Issue Raises $8.1m; Total $20m; Actinogen: 5 More US Xanamem For Alzheimer’s Trial Sites

Jul 5, 2018; Auscann Raises $33m, Plan For $8m More; Invion Photosoft Kills Ovarian Cancer In-Vitro; Patrys PAT-DX1 Enters Triple Negative Breast Cancer In Mice; Resonance Partners With Blackford For Imaging; Neurotech Requests ‘Trial Results’ Trading Halt; Noxopharm Idronoxil Kills Brain Cancer Cells In-Vitro; Paul Cozzi Increases, Diluted To 6% Of Cardiex (Atcor); MMJ’s Harvest One Appoints Grant Froese CEO
 
Jul 4, 2018
Prana Doses 1st Human Subject With PBT434 For Parkinson’s; GI Dynamics: ‘Endobarrier HbA1C, Weight Loss Post-Explant’; Medlab Recruiting Marijuana Nanabis Cancer Pain Trial; Haemalogix, Takeda Research Multiple Myeloma; Fatima Dickey, Richard Bayles, Lagoda Down To 7% In Clinuvel; Colin Mackinnon, Donald Kennedy Each Take 6.4% In Alcidion; Alcidion Chairman Ray Blight Increases, Diluted To 12%; Genera Takes ‘Convertible Notes Raising’ Halt To Suspension; Nuheara Loses Founder Dr Michael Ottaviano; Neuren: Dianne Angus, Patrick Davies, Jenny Harry Directors; Neurotech Appoints Dr David Cantor Director
 
Jul 3, 2018
Auscann ‘$30m Raising’ Trading Halt; MTP Connect Western Australia; Dorsavi $120k Citipower, Powercor Deal; Patrys: China, Japan Deoxymab 3E10, PAT-DX1 Patents; Memphasys 15-To-1 Consolidation; Hydroponics New Site, Supply Deal Due Diligence Extended; Cardiex: Zihan Lin, Rhonda Welch In, Duncan Ross Out
 
Jul 2, 2018
June BDI-40 Up 1%, ASX200 3%, Big Caps 4% NBI 1%; Y-T-D BDI-40 Up 18%, ASX200 8%, Big Caps 38% NBI 7%; Y-T-D: Volpara Up 303%, Oncosil 206%; Airxpanders Down 86%, Reva 75%; Mesoblast Novaquest $54m Loan, $14m Shares Finance; Orthocell Begins South Africa Celgro Shoulder Study; Opthea: Phase IIb Opt-302 For Wet AMD Trial Half-Way; Cynata, RCSI Partner For Stem Cells For Sepsis; Immutep Files IMP-321 Tacti-002 IND To FDA; Botanix BTX1801 Skin Infection, BTX1308 Psoriasis Trials; Probiotec Buys Next-Door Facility For $3.6m; Suda To Pay HC Berlin $2.6m; Rights Offer For $6m; Genera Requests ‘Convertible Notes Capital Raising’ Halt; Dimerix: Further US Patent For DMX-200; Pharmaust: Epichem Wins NATA Accreditation; Race 10m ‘Performance’ Shares For Chair, CSO, Update Pharma; Dr John McBain Takes 6.5% Of Rhinomed; Botanix To Release 156m Shares, 13m Options From ASX Escrow; Creso To Sell Cannaqix In New Zealand; MMJ Invests $5m In Medipharm Labs; Ellex Appoints Mike Southard, Mike Mangano Directors; OBJ Appoints Cameron Reynolds Director; IDT Appoints Interim CEO Dr David Sparling CEO On $348k; Phylogica CEO Dr Rohan Hockings Starts On $395k; Immuron Loses Joint Co Sec Peter Vaughan; Steven Wood Replaces G Medical Co Sec Stephen Buckley
 
Jun 29, 2018
Dr Boreham’s Crucible: ITL Health; CSL’s Seqirus Joins Human Vaccine Project For Influenza; Raleigh Takes $1m 5-Year Mach7 Licence; LBT: ‘1st Apas Sale Delayed’; Elixinol Welcomes US Hemp Farming Act; MMJ, Dutch Passion Partner; One Funds Increases, Diluted To 6.4% Of Avita; Hybrid Holdings Takes 5% Of Pharmaust; Benitec Appoints Oliver Kidd Company Secretary
 
Jun 28, 2018
Pro Medicus: $15m US Mercy Archive Contract; Compumedics, Fukuda Denshi $3.6m Japan Distribution Deal; Avita ‘Buys’ US Facility; Trading Halt; Changes To ‘Leases’; Resapp Child, Adult Australian Trials On-Track; CDH Genetech, China Grand $49m Takes Sirtex Deposit To $220m; Regeneus Up-To $2m Paddington St R&D Tax Incentive Loan; Hydroponics, Ascent Exchange Marijuana Strains; Esense Wins Israeli Marijuana Permit; Suda Requests ‘HC Berlin, Capital Raising’ Trading Halt; Shenasaby Increases In Botanix, Diluted To 9%; Mayne Pharma Appoints Patrick Blake As Director; Neurotech Founder Dr Adrian Attard Trevisan Retires
 
Jun 27, 2018
Prana Back In The Clinic With PBT434 For Parkinson’s; Starpharma, Mundipharma Take Vivagel BV To Europe; Invitrocue Raises $3.6m; Nanosonics Trophon2 Wins CE Mark; Admedus, Star Bright Closer To Vaccines Deal; Botanix Recruits 1st Patients For BTX1503 Acne Trial; Nuheara: Liveiq Completes Engineering Validation Test; Cann To Build Melbourne Airport Marijuana Facility; SG Hiscock Takes 9% Of Neurotech; Eyepoint Appoints Dr Göran Ando Director; CFO Solution Replaces Brain Resource Co Sec Robert Waring 
 
Jun 26, 2018
Dorsavi Launches Professional Suite In The US; Factor Closing Leg Ulcer Recruitment, Results On-Track; Optiscan Receives $980k Federal R&D Tax Incentive; Visioneering Expands Multifocal Contact Lens Range; Australian Ethical Takes 7.5% Of Somnomed; W Whitney George Takes 20.6% Of Rhinomed; Immuron Appoints New York’s Richard Berman Director; Hydroponics Appoints Katy Day For Marijuana Regulation
 
Jun 25, 2018
Clinuvel Files US Scenesse For EPP NDA; 2019 Response; Telix Appoints Isologic To Manufacture TLX-250; Medical Developments: Penthrox In Switzerland, Portugal; CVC Takes 6.25% Of IDT; Immuron Requests ‘New Director’ Trading Halt; Race To Release 27m Escrow Shares, 10m Performance Shares; OBJ Appoints Cameron Reynolds Director; Orthocell Appoints Dr Jonathan Bell To Advisory Board; Auscann Appoints ‘Master Grower’; Jade Research Agreement; Hydroponics: 1st Marijuana Products From Endoca; MMJ To Sell Phytotech To Harvest One; Creso, Joint Venture Release 2 Marijuana Beers
 
Jun 22, 2018
Dr Boreham’s Crucible: Immuron; Cochlear Launches Nucleus 7 Android Phone Application; OBJ: ‘2 More Procter & Gamble Products’; Clinuvel Requests ‘Regulatory Submission’ Trading Halt; Australian Ethical Takes 5.5% Of Somnomed; Bard1 Releases 230m Escrow, 217m Performance Shares; MMJ Appoints CFO Jim Hallam Joint Co Sec
 
Jun 21, 2018
Mesoblast 75% Day-100 Paediatric GvHD Survival; Cynata 2nd Cohort 86% Day-28 Adult GvHD Improvement; Race Wins UK ‘Unlicensed Medicine’ For Bisantrene For AML; Rhinomed Up 28% As Columbia Takes It To Cannabis Corner; Queensland Bauxite Buys Medcan Australia, Medical Cannabis; European Patent For Uscom Blood Flow, Pressure Monitor; Esense: ‘Marijuana Terpenes Arrest Cell Growth In-Vitro’; Auscann Pleads Schultz To ASX 14.5% Fall Query
 
Jun 20, 2018
Botanix ‘Oversubscribed’ Placement Raises $8m; Medadvisor Appoints PDX For US Pharmacy Entry; Canada Approves Recreational Marijuana; MMJ; Lifespot: Marijuana For Australasia And North America; Race Requests ‘UK Regulatory Developments’ Trading Halt; Rhinomed Requests ‘Product Partner’ Trading Halt; Australian Super Increases To 7% In Osprey
 
Jun 19, 2018
Microbiotica, Adelaide Uni Faecal Drug For Colitis; Kazia Cantrixil: ‘1 Ovarian Cancer Response, 3 Stable’; Immutep Aipac Breast Cancer Trial Enrolment Half-Way; Bard1 Ovarian Test: ‘95% Accurate’; Reva CE Mark For All Fantom Encore Products; TGA Approves Medibio Depression, Mental Health Tests; Genetic Technologies, Swisstec Blockchain J-V; US Patent For Dorsavi Knee Sensor Technology; Correction: Suda; Rhinomed: CVS To Stock Mute Snoring Nasal Dilators; Canada Narcotics ‘Dealer’ Licence For MMJ’s Harvest One; Jencay, Brett Rock Increase To 6% Of Universal Biosensors; Joseph Swedish Replaces Mesoblast’s Dr Ben-Zion Weiner; Telix Appoints Jann Skinner Director
 
Jun 18, 2018
Telix Consortium Wins $1m Bio-Manufacturing Grant; Cynata, Uni Of NSW Work On Coronary Artery Disease; Proteomics Licences Promarkerd To Patia For Mexico; Canada Grants Suda Sildenafil Products Patent; James Mirams, Paradigm Wealth Take 5% Of Sienna; Tim Robertson, Farjoy Take 6% Of Nuheara; Botanix Requests ‘Capital Raising’ Trading Halt
 
Jun 15, 2018
Dr Boreham’s Crucible: Imugene; Sirtex Drops $1.6b Varian Offer For CDH, China Grand $1.9b Bid; All Change As Benitec Loses CEO Greg West, CSO Dr David Suhy; Paradigm: ‘75 OA Patients Report Average 50% Pain Reduction’; Suda Hails Aytu US, Canada Zolpimist For Insomnia Licence; Medadvisor 3-Year Deal With Ebos Zest; JCP Reduces To 8.4% Of Nanosonics; Private Portfolio Managers Below 5% In Bionomics; JP Morgan Chase Decreases, Diluted To 6% Of Benitec; Analytica Chair Dr Michael Monsour Increases, Diluted To 23%; Peter Corr, Inov8 Increase, Diluted To 11% Of Analytica; Merchant Group Takes 7% Of Rhythm; TDM Increases To 19.97% Of Somnomed
 
Jun 14, 2018
US Approves MDGH Moxidectin For River Blindness, Certara; Pharmaxis LOXL2 Fibrosis Drugs ‘Potential Partner Briefings’; Prana Starts Phase I PBT434 Parkinson’s Trial; Antisense Has ATL1103 For 12 Acromegaly Patients; Painchek National Rollout; Orthocell: ‘88% Of Ortho-ATI Patients Return To Work’; Merchant Below 5% In Polynovo; CVC, Stinoc Reduces To 12% Of Cyclopharm; Investment Administration Services Takes 5% Of Sienna; MMJ Invests $510k In Bevcanna Marijuana Drink Manufacturer; Creso Appoints John Griese COO For The Americas; Clunies Ross Award For WEHI’s Venetoclax Researchers; Respiri Appoints Mark Ziirsen Chairman
 
Jun 13, 2018
Cogstate: ‘No Impact From Eli Lilly Alzheimer’s Trial Close’; Australia Approves Botanix Phase II BTX1503 Acne Trial; Optiscan: Slow Viewnvivo Sales, Revenue $250k; Australian Ethical Takes 10% Of Cyclopharm; SG Hiscock Below 5% Of Somnomed
 
Jun 12, 2018
Resonance Reduces MRI Times, Expects Return To Profit; Cardiex ‘Oversubscribed’ Rights Raise $1.1m, Total $5m; Analytica Placement Options Raise $1.5m; Biotron $1.5m Rights Offer ‘Oversubscribed’; Cynata: ‘CYP-001 GvHD 6-Month Follow-Up Positive’; Alcidion: MKM Signs NSW Ehealth Contract; Bioxyne To Sell Rice Cooker In China, Taiwan, Malaysia; Creso’s Kunna Wins Columbian Marijuana License; MGC Marijuana Cosmetics At Harvey Nichols London Shops; Adam Leitzes, Karst Peak Take 15% Of Avita; Merchant Group Takes 5% Of Rhythm; Airxpanders CEO Frank Grillo Starts On $591k
 
Jun 8, 2018
Dr Boreham’s Crucible: Factor Therapeutics; S&P Promotes Cochlear Into ASX50; Nuheara Raises $6m; IDT Responds To FDA Facility Concerns; Imugene Answers ASX Selective Briefing Query; Biotech Daily Comment; US Patent For Oventus Snoring, Sleep Apnoea Airway; Monash Uni, Biotech Resources US Malaria Diagnostic Patent; Sandon Capital Takes 6.6% Of IDT; Lazard Below 5% In Mayne Pharma; Bard1 Releases Escrow Shares; OBJ Elects Antonio Varano Chairman
 
Jun 7, 2018
Imugene $20m For Kaumaya B-Cell Cancer Platform; BDI-40: Viralytics Out, LBT Up, Imugene In; Federal Government To Reduce Clinical Trial Red Tape; Genetic Technologies Signs Omix, Shivom Genetic Database; Third Study Backs Painchek Technology; Pharmaust, Epichem Extend $2.2m Unity Contract To 2020; Admedus Ends Go Medical Relationship; Auscann Joint Venture Harvests 620kg Marijuana Crop; Stemcell Partner Yunnan Hua Fang China Marijuana Licence; Correction: Starpharma; FIL Takes 10% Of Cynata; Marjan Mikel Replaces Memphasys Director John Periera; Melanie Leydin Replaces Medibio Co Sec Robert Lees
 
Jun 6, 2018
Avita Raising $16m For Recell US Launch; Orthocell: Positive Interim Cellgro Shoulder Trial Results; Zelda: ‘Marijuana Extracts Reduce Brain Cancer In-Vitro’; Nanosonics: US Ultrasound Decontamination Non-Compliance; LBT Review Axes Woundvue For APAS Focus; Atomo, Owen Mumford Partner For Rapid HIV Tests; Botanix: ‘Synthetic Cannabidiol BTX1204 For Eczema Safe, Efficacy’; Cann, La Trobe Uni Expand Marijuana R&D; Esense Marijuana E-Liquid For Vaporizing; US Allows Resapp Diagnostic Patent; Admedus Requests ‘Supply Termination’ Trading Halt; Nuheara Requests Capital Raising Trading Halt; Fil Reduces To 7% Of Starpharma; Clarity Appoints Michelle Parker For Clinical Operations; Cameron Petricevic Replaces Alchemia Director David Lamm
 
Jun 5, 2018
Federal, Brandon, Uniseed $25m For Certa Kidney Therapy; Adalta Hires Selexis, KBI For AD-214 Manufacture; Race: ‘Bisantrene 30-Year Efficacy For AML’; FDA Provides Recce ‘Clarity’ For Clinical Trial; CE Mark For Cogstate Cognigram; Noxopharm NOX66 Trial: 1 Partial Response; Imugene Requests ‘Acquisition, Capital Raising’ Halt; Botanix Requests Results Trading Halt
 
Jun 4, 2018
Clinical Genomics Raises $33m For Colorectal Cancer Test; WEHI ‘Sees’ SOCS1 Switch-Off Cell Signals For Cancer Drugs; Goodbye Viralytics; US Patent For Redhill Ebola Drug; Admedus Share Plan Raises $2.8m, Total $8.8m; Applications Open For Federal Global Connections Grants; Italcert Approves Neurotech Mente Autism Upgrade; Avita Requests ‘Capital Raising’ Trading Halt; Painchek Appoints Prof Jennifer Abbey Advisor 
 
Jun 1, 2018
May BDI-40 Up 3%, ASX200 0.5%, Big Caps 8% NBI 5%; Dr Boreham’s Crucible: Genetic Signatures; Cynata Stem Cells ‘Effective For Diabetic Ulcers In Mice’; Benitec Rights Raise $6.2m Of Hoped-For $17.4m; Total $8.8m; Optiscan CE Mark, Delivery Delays, Darren Lurie On $1k/Day; TPI 25% Remuneration Report 1st Strike; Oncosil Pleads Schultz To ASX 34.5% Query; MMJ Takes 13% Of Bien For Marijuana Food, Drink Powder; Paul, Eleanor Stephens Take 8% Of Rhinomed; Robert Peters Takes 13% Of Memphasys; Imagion To Release 3.5m ASX Escrow Shares; BTC Loses Director Bruce Hancox
 
May 31, 2018
Compumedics, China Health 100 ‘$133m Revenue’ JV; Biotech Daily, Commsec, Iress, Chi-X Market Report Changes; Patrys PAT-DX1-Np Kills Brain Cancer Stem Cells In-Vitro; Victoria Government Partners For 5 Conferences; Mesoblast 9-Month Revenue Up 767% To $21m; Orthocell Celgro In Poland; Value Trade Distributes Nuheara Iqbuds In Japan; Resapp Smartcough-C-2 Trial ‘On Track’ With 74% Recruited; Regal Funds Takes 9% Of Opthea; MMJ Invests $600k In Martha Jane For Marijuana Extraction; Neuren Buys-Back $1.56m Dr Richard Treagus Loaned Shares; Josh Muntner Replaces Mesoblast CFO Paul Hodgkins; All Change At Respiri, ‘Significant Milestone’
 
May 30, 2018
Immutep: ‘Keytruda, IMP321 61% Overall Response Rate’; Cynata Places $5.2m With Fidelity; Imagion Nanoparticles Bind To HER2+ Tumor Cells In Mice; Telix, Osaka University $173k Grant; Nuheara Appoints Force Australia, New Zealand Distributor; Atcor Changes Name To Cardiex, New Code CDX From Friday; Court Okays Perkinelmer RHS Acquisition, Delists Today; Blackrock Reduces To 6% Of Cochlear; Mayne Appoints Frank Condella Director; Esense Appoints Kobi Zecharia Director
 
May 29, 2018
Volpara Revenue Up 53% To $2.6m, $8m Loss; $5m Plan; Viralytics 99% Back Merck Takeover, ‘5.5-Bagger’ In 5 Years; Mesoblast, Cartherics Unite For Ovarian, Gastric Cancer; Compumedics Requests ‘China Contract’ Trading Halt; IDT Receives FDA Warning; Oventus Combination Improves Sleep Apnoea; Medical Developments In Iran; 4 Countries Approve Penthrox; Medigard, Bio-Link New Products Agreement
 
May 28, 2018
Immutep IMP321 Melanoma Interim Safety, Efficacy Results; Sirtex Scheme Meeting Delayed Until July; TGA Approves Novita’s Tali Train For Attention Disorders; Proteomics Signs Prismhealthdx For US Promarkerd Launch; Rhinomed Signs Unnamed US Pharmacy Retailer For Mute; Pharmaust: ‘BRI Monepantel Palatable For Dogs, Humans’; Cynata Requests ‘Placement’ Trading Halt; JCP Increases To 9.4% Of Nanosonics; CVC Takes 5.6% Of Universal Biosensors; Dr Dax Marcus Calder Diluted To 11% Of Patrys; Macquarie Group Takes 5% Of Patrys; Dr Warwick Tong, Cancer CRC Take 11% Of Innate; Innate Appoints Dr Warwick Tong Chairman; Uscom: Teresa Guo China Head, Curt Grosse Nth America Sales; Simon Moore Replaced TPI Chairman Peter Robinson On May 1
 
May 25, 2018
Dr Boreham’s Crucible: Antisense Therapeutics; Bio-Melbourne Celebrates 10th ‘Connecting Women’ Lunch; Compumedics $16.5m China Deals; Bob Peters Invests $1m In Memphasys For Horse IVF; Jacobs Adopts Medibio Mental Health Check-In; Factor Survives 24% Remuneration Report Dissent; Phosphagenics Passes Remuneration Report, No 2nd Strike; Director Michael Stork Diluted To 9% In Patrys; CEO Richard Hannebery Takes 11% Of Genera; Queensland Bauxite 4th Marijuana Suspension Extension; Phosphagenics Loses Director Peter Lankau
 
May 24, 2018
Reva Fantom 24-Month Low Mace Rate; Cynata Treats Last Phase I CYP-001 GvHD Patient; Russia Approves Benitec BB-401 Head Neck Cancer Trial; Somnomed Expects 2017-’18 Revenue Up 13%; European Patent For Orthocell Celgro; US Patent For Uscom Spirosonic Lung Function Monitor; Admedus 34% Remuneration Report 1st Strike; Uscom Loses Shanghai Director David He
 
May 23, 2018
CDH Sirtex Bid, Varian Won’t Match; Profit Warning; Actinogen $15m Placement, $2m Share Plan; DSMB Backs Trial; UK NHS Not Nice To Clinuvel Scenesse Reimbursement; Prota Probiotic, Peanut Immunotherapy Trial Enrolled; Australia, US Approve $502m Merck Viralytics Acquisition; Bionomics Starts Phase II BNC210 For Agitation Trial; Admedus Files 3 More US TAVR Provisional Patents; ASX Delists QRX; Imagion Pays MD Anderson $793k Fees As 10.5m Shares; MMJ Sells Cannabis Wheaton For Profit, Esense For Loss; Investors Mutual Takes 6% Of Ellex; JPS, Raff Family Take 9% Of Genera; Mason Stevens Takes 5.5% Of Patrys; Compumedics Appoints Tucson Dunn Director; Admedus Appoints Co Sec, CFO Catherine Costello Director; Adherium Appoints David Allinson CFO
 
May 22, 2018
Orthocell Claims 1st UK, EU Celgro Dental Sales, Use; Oventus: ‘Statistically Significant Apnoea Improvement’; Dorsavi Signs 2-Year Deal With Insurer AIG; Admedus Aortic Valve Replacement Sheep Trials; Victoria, J&J $300,000 Quickfire Device Challenge; Sirtex Requests ‘CDH Bid Developments’ Trading Halt; Sienna Receives $632k Federal R&D Tax Incentive; RHS Votes 99.97% For Perkinelmer Acquisition; Airxpanders 43% Oppose 1.3m Director Options; Minderoo (Metal) Group Below 5% Of Admedus; Zelda Appoints Pharmaust CEO Dr Richard Hopkins M-D On